var images_info;if (!images_info) images_info =[]; images_info["91"]={"91001":{"type":"graphic_figure","displayName":"Video bronchoscope","title":"Diagram of the components of a video bronchoscope","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Diagram of the components of a video bronchoscope</div><div class=\"cntnt\"><img style=\"width:498px; height:744px;\" src=\"images/PULM/91001_Video_bronchoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission. Copyright &copy; 2013 Olympus America Inc.</div><div id=\"graphicVersion\">Graphic 91001 Version 1.0</div></div></div>"},"91003":{"type":"graphic_table","displayName":"Differential diagnosis of concussion in children and adolescents","title":"Differential diagnosis of sports-related concussion in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of sports-related concussion in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute conditions</td> </tr> <tr> <td class=\"indent1\">Intracranial injury (eg, subdural or epidural hematoma, cerebral contusion, or diffuse axonal injury)</td> </tr> <tr> <td class=\"indent1\">Heat illness</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> </tr> <tr> <td class=\"indent1\">Syncope (cardiogenic, orthostatic, or vasovagal syncope)</td> </tr> <tr> <td class=\"subtitle1_single\">Subacute conditions</td> </tr> <tr> <td class=\"indent1\">Primary headache (eg, cervicogenic, migraine, tension, or other posttraumatic types)</td> </tr> <tr> <td class=\"indent1\">Psychiatric disorder (eg, depression, attention deficit hyperactivity disorder, anxiety or acute stress disorder, or substance abuse)</td> </tr> <tr> <td class=\"indent1\">Overtraining/burnout</td> </tr> <tr> <td class=\"indent1\">Chronic infection</td> </tr> <tr> <td class=\"indent1\">Chronic fatigue syndrome <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">(CFS, also known as systemic exertion intolerance disease [SEID])</span></td> </tr> <tr> <td class=\"indent1\">Uncorrected vision</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91003 Version 2.0</div></div></div>"},"91005":{"type":"graphic_table","displayName":"Signs and symptoms of concussion in children and adolescents","title":"Symptoms of concussion recorded by the High School Reporting Information Online injury surveillance system (HS RIO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of concussion recorded by the High School Reporting Information Online injury surveillance system (HS RIO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom recorded</td> <td class=\"subtitle1\">No. of concussions resulting in symptom</td> <td class=\"subtitle1\">Percentage of concussions resulting in symptom*</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">508</td> <td class=\"centered\">93</td> </tr> <tr> <td>Dizziness/unsteadiness</td> <td class=\"centered\">406</td> <td class=\"centered\">75</td> </tr> <tr> <td>Difficulty concentrating</td> <td class=\"centered\">308</td> <td class=\"centered\">57</td> </tr> <tr> <td>Confusion/disorientation</td> <td class=\"centered\">250</td> <td class=\"centered\">46</td> </tr> <tr> <td>Vision changes/sensitivity to light</td> <td class=\"centered\">204</td> <td class=\"centered\">38</td> </tr> <tr> <td>Nausea</td> <td class=\"centered\">157</td> <td class=\"centered\">29</td> </tr> <tr> <td>Drowsiness</td> <td class=\"centered\">144</td> <td class=\"centered\">27</td> </tr> <tr> <td>Amnesia</td> <td class=\"centered\">132</td> <td class=\"centered\">24</td> </tr> <tr> <td>Sensitivity to noise</td> <td class=\"centered\">103</td> <td class=\"centered\">19</td> </tr> <tr> <td>Tinnitus</td> <td class=\"centered\">58</td> <td class=\"centered\">11</td> </tr> <tr> <td>Irritability</td> <td class=\"centered\">50</td> <td class=\"centered\">9</td> </tr> <tr> <td>Loss of consciousness</td> <td class=\"centered\">25</td> <td class=\"centered\">5</td> </tr> <tr> <td>Hyperexcitability</td> <td class=\"centered\">12</td> <td class=\"centered\">2</td> </tr> <tr> <td>Other</td> <td class=\"centered\">41</td> <td class=\"centered\">8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percentages do not total 100, as athletes could report more than 1 symptom.</div><div class=\"graphic_reference\">Reproduced with permission from: Meehan WP 3rd, d'Hemecourt P, Comstock RD. High school concussions in the 2008-2009 academic year: mechanism, symptoms, and management. Am J Sports Med 2010; 38:2405. Copyright &copy; 2010 SAGE Publications Inc.</div><div id=\"graphicVersion\">Graphic 91005 Version 2.0</div></div></div>"},"91016":{"type":"graphic_table","displayName":"Causes and key features of chronic knee pain in active adults","title":"Chronic musculoskeletal knee pain in active adults: Causes and distinguishing features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic musculoskeletal knee pain in active adults: Causes and distinguishing features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Mechanism &#38; historical features</td> <td class=\"subtitle1\">Common symptoms</td> <td class=\"subtitle1\">Key examination findings</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anterior and medial knee pain</td> </tr> <tr> <td class=\"indent1\">Patellofemoral pain&nbsp;</td> <td>History of overuse, often involving running</td> <td> <p>Diffuse, anterior peri-patellar pain</p> <p>Knee may feel \"unstable\"</p> Pain increases with squatting, prolonged sitting, running (especially downhill), climbing or descending stairs</td> <td> <p>Patellar undersurface may be tender (medial or lateral)</p> <p>Weak terminal knee extension and VMO atrophy common</p> <p>Weak hip flexion, abduction, &#38; external rotation common</p> <p>Hamstring tightness common</p> <p>Patellofemoral compression test may be positive</p> <p>Normal knee motion</p> Effusion rare</td> <td> <p>PFPS accounts for over 70 percent of outpatient visits for knee pain</p> <p>Structural intra-articular damage must be ruled out if recurrent effusions or unusual findings (eg, abnormal knee motion or laxity detected) present</p> <p>Patient may describe knee weakness (or \"giving out\"), likely due to reflex inhibition of quadriceps from pain</p> <p>Chondromalacia patella presents with similar history and examination, but advanced imaging reveals pathologic changes</p> </td> </tr> <tr> <td class=\"indent1\">Patellar tendinopathy</td> <td> <p>History of overuse, typically involving sports with jumping or sudden direction change</p> Gradual onset of pain that steadily increases over time if ballistic activity continues</td> <td>Pain at tendon or inferior pole of patella&nbsp;with ballistic movements (eg, jumping, sprinting, cutting)</td> <td> <p>Tendon tender at inferior pole of patella (most common), along tendon, or at tibial tuberosity</p> <p>Tendon may feel thick compared to normal (contralateral) one</p> <p>Often associated with tight quadriceps and/or hip flexors</p> <p>Knee motion normal</p> Squat or hop reproduces pain</td> <td> <p>US shows characteristic changes of tendinopathy</p> <p>Much more common than quadriceps tendinopathy</p> In skeletally immature, consider apophysitis</td> </tr> <tr> <td class=\"indent1\">Chronic patella subluxation</td> <td>History of patella dislocation or hypermobility syndrome</td> <td> <p>Pain around medial border of patella</p> <p>Knee or knee-cap \"gives way\" or feels unstable</p> \"Clicking\" from superolateral part of patella with movement</td> <td> <p>VMO atrophy and weakness common</p> Patellar apprehension test usually positive</td> <td>Plain&nbsp;radiographs may show patella alta (high-riding patella) or shallow femoral sulcus</td> </tr> <tr> <td class=\"indent1\">Pes anserine tendinopathy and bursitis</td> <td> <p>Insidious onset of medial-anterior knee pain</p> Associated with repeated valgus strain (eg, breast stroke), genu valgus (\"knock knees\"), or medial knee instability</td> <td>Pain around area of pes anserine insertion</td> <td> <p>Swelling at proximal medial-anterior tibia</p> <p>Area of pes anserine insertion often tender</p> Resisted knee flexion or hip adduction elicits pain</td> <td>US may reveal characteristic changes of tendinopathy or fluid around bursa</td> </tr> <tr> <td class=\"indent1\">Prepatellar or infrapatellar bursitis</td> <td> <p>Swelling develops over days just inferior to the patella</p> History of continual pressure on affected area (eg, laborer working while kneeling)</td> <td>Pain and swelling just below patella</td> <td> <p>Swollen boggy bursa: early swelling below distal patella tendon insertion &#38; around tibial tubercle; gradually swelling increases to cover tubercle &#38; surrounding area</p> <p>Overlying skin erythematous</p> Knee motion normal</td> <td> <p>Not truly a chronic condition, but does not cause acute onset of pain and not associated with sudden trauma</p> <p>US shows fluid under distal patellar tendon; fluid extends further into soft tissue as swelling increases</p> <p>Aspiration may be needed to rule out septic bursitis</p> </td> </tr> <tr> <td class=\"indent1\">Osteoarthritis flare</td> <td> <p>Generally occurs in&nbsp;adults over 50 years</p> <p>Pain develops with activity; joint stiffness present with inactivity</p> </td> <td> <p>Delayed swelling (12 to 24 hours post activity)</p> Pain around joint line or diffuse</td> <td> <p>Effusion</p> <p>Joint line tenderness (may not be prominent)</p> <p>Ligaments stable; meniscus testing negative or equivocal</p> Inability to fully extend or flex knee common</td> <td> <p>Standing knee x-rays show arthritic changes (eg, sclerosis, joint narrowing)</p> US shows narrow joint, bone spurring, and fluid extending into suprapatellar pouch</td> </tr> <tr> <td class=\"indent1\">Degenerative medial&nbsp;meniscus tear&nbsp;</td> <td>Develops over years and presents in older adults without inciting trauma&nbsp;</td> <td> <p>Symptoms often mild but may complain of baseline discomfort</p> <p>Pain with pivoting or knee twisting</p> <p>Knee may catch or lock</p> </td> <td> <p>Medial joint line tenderness</p> <p>Knee motion may not be smooth and range may be limited</p> <p>Provocative tests (eg, Thesaly, McMurray) usually positive</p> <p>Pain increases with deep squat</p> </td> <td>US may show calcifications, fraying of peripheral meniscus, and cysts in regions of swelling&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tibial tuberosity or infrapatellar apophysitis</td> <td> <p>Common in athletes in early to mid teens whose sports involve cutting and jumping</p> <p>Often occurs during growth spurt while athlete is very active</p> Pain increases with activity and decreases with rest</td> <td>Pain around tibial tubercle or inferior patellar pole</td> <td> <p>Tenderness at tibial tubercle or inferior patellar pole</p> <p>Focal swelling &#38; warmth directly over apophysis</p> Knee stable and motion normal</td> <td> <p>Osgood Schlatter, apophysitis at tibial tubercle, is far more common than Sinding Larsen Johansson, apophysitis at inferior pole of patella</p> <p>Plain x-rays show open apophysis, often with fragmentation</p> US shows open apophysis &#38; fluid over tuberosity</td> </tr> <tr> <td class=\"indent1\">Quadriceps tendinopathy</td> <td> <p>Patient often a runner or active in sport involving jumping or sprinting</p> Pain steadily increases over time if ballistic activity continues</td> <td>Pain around superior pole of patella with jumping, running, squatting, and other ballistic activities</td> <td> <p>Focal tenderness between superior patellar border &#38; body of quadriceps</p> <p>Pain with resisted knee flexion</p> <p>Quadriceps and hip flexor tightness may be present</p> VMO atrophy may be present</td> <td> <p>US often shows characteristic changes to tendon, and bone spurs &#38; calcifications</p> Patellar tendinopathy much more common</td> </tr> <tr> <td class=\"indent1\">Medial plica syndrome</td> <td> <p>History of trauma to medial peripatellar area or dislocation/subluxation of patella</p> Runners with genu valgus (\"knock knees\") at risk</td> <td>Pain around medial patella that increases with movement (knee flexion and extension)</td> <td> <p>Thickened plica palpable under medial patella</p> <p>Patella tracks abnormally during knee flexion-extension</p> Audible pop from medial patella area during flexion-extension</td> <td>US shows thickened plica</td> </tr> <tr> <td class=\"indent1\">Patella stress fracture&nbsp;</td> <td> <p>History may be unclear</p> <p>Most common in active people training in ballistic sports</p> <p>Athletes who have increased training volume and/or intensity over past weeks to months</p> </td> <td>Anterior knee pain&nbsp;made worse by activity, particularly ballistic movements (jumping)&nbsp;</td> <td> <p>Patella tenderness (depends on severity of fracture)</p> <p>Normal knee motion</p> </td> <td>Fracture may not&nbsp;be apparent in plain radiographs; MRI may be required for diagnosis&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lateral and posterior knee pain</td> </tr> <tr> <td class=\"indent1\">Iliotibial band syndrome</td> <td> <p>Insidious onset of lateral knee pain related to overuse</p> <p>Occurs primarily in runners but also in cyclists</p> <p>In runners, pain can vary with pace &#38; increases on sloped surfaces</p> Pain increases over time if activity continues</td> <td> <p>Pain where ITB crosses lateral femoral condyle</p> Pain increases with prolonged exercise but may persist afterwards</td> <td> <p>Tender ITB where it crosses lateral femoral condyle</p> Weak hip abduction is common</td> <td> <p>Generally two patient types:</p> <p>Novice or female runner with weak hip abduction and internal knee rotation (genu valgum)</p> <p>OR</p> Advanced runner with reduced hip adduction and external knee rotation (genu varum)</td> </tr> <tr> <td class=\"indent1\">Popliteus tendinopathy</td> <td> <p>Gradual onset of posterolateral knee pain</p> Often caused by excessive running (especially downhill) or sprinting, also by hiking downhill</td> <td> <p>Posterior knee pain</p> <p>Pain increases when runner is \"braking\" or trying to prevent acceleration while running downhill</p> </td> <td> <p>Tenderness at posterior aspect of lateral femoral condyle (palpate popliteal tendon with patient in figure-of-4 position)</p> Resisted tibial external rotation may elicit pain</td> <td>US reveals characteristic changes of tendinopathy</td> </tr> <tr> <td class=\"indent1\">Biceps femoris (lateral hamstring) tendinopathy</td> <td> <p>Gradual onset of posterolateral knee pain</p> Often caused by excessive downhill running or sprinting</td> <td>Posterolateral knee pain around tendon insertion</td> <td> <p>Tenderness at tendon insertion</p> Pain increases with resisted knee flexion (perform with foot externally rotated)</td> <td>US reveals characteristic changes of tendinopathy</td> </tr> <tr> <td class=\"indent1\">Semimembranosus (medial hamstring) tendinopathy</td> <td> <p>Gradual onset of posteromedial knee pain</p> Often caused by sprinting or downhill running</td> <td>Posteromedial knee pain around tendon insertion</td> <td> <p>Tenderness at tendon insertion</p> Pain increases with resisted knee flexion (perform with foot internally rotated)</td> <td>US reveals characteristic changes of tendinopathy</td> </tr> <tr> <td class=\"indent1\">Semimembranosus-gastrocnemius bursitis</td> <td> <p>Associated with overuse</p> Pain increases when climbing stairs, running hills, or sprinting</td> <td> <p>Pain and tightness at proximal medial calf</p> Swelling around posterior knee &#38; proximal calf that increases after activity</td> <td> <p>Swelling and tenderness at medial-posterior knee</p> Resisted knee flexion and eccentric testing of gastrocnemius (lowering heel while standing on step) may elicit pain</td> <td> <p>Can be mistaken for joint effusion of deep vein thrombosis</p> US shows enlarged bursa</td> </tr> <tr> <td class=\"indent1\">Degenerative lateral&nbsp;meniscus tear</td> <td>Develops over years and presents in older adults, typically without inciting trauma</td> <td> <p>Symptoms often mild but may complain of baseline discomfort</p> <p>Pain with pivoting or knee twisting</p> Knee may catch or lock</td> <td> <p>Lateral joint line tenderness</p> <p>Knee motion may not be smooth and range may be limited</p> <p>Provocative tests (eg, Thesaly, McMurray) usually positive</p> Pain increases with deep squat</td> <td>US may show calcifications, fraying of peripheral meniscus, and cysts in regions of swelling</td> </tr> <tr> <td class=\"indent1\">Popliteal (Baker's) cyst</td> <td>Damaged protruding posterior knee capsule with many potential causes</td> <td>Posterior knee pain and tightness</td> <td>Palpable swollen cystic structure in popliteal fossa</td> <td> <p>Often associated with intra-articular pathology or knee osteoarthritis</p> <p>If cyst ruptures, knee pain &#38; tightness typically resolve; fluid may track into calf causing swelling</p> US shows compressible fluid-filled mass, typically medial to vascular bundle</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ITB: iliotibial band; PFPS: patellofemoral pain syndrome; US: ultrasound; VMO: vastus medialis oblique.</div><div id=\"graphicVersion\">Graphic 91016 Version 5.0</div></div></div>"},"91018":{"type":"graphic_table","displayName":"Musculoskeletal causes acute nontraumatic knee pain adult*","title":"Musculoskeletal causes of acute nontraumatic knee pain in active adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Musculoskeletal causes&nbsp;of acute nontraumatic knee pain in active adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <p>No acute trauma, but abrupt onset or increase in pain</p> <p>Presence of ligamentous instability strongly suggests traumatic injury and is NOT consistent with the diagnoses listed below</p> Effusion may be present</td> </tr> <tr> <td class=\"subtitle1\">Anterior knee pain</td> <td class=\"subtitle1\">Medial knee pain</td> <td class=\"subtitle1\">Generalized knee pain</td> <td class=\"subtitle1\">Lateral knee pain</td> <td class=\"subtitle1\">Posterior knee pain</td> </tr> <tr> <td>Patellofemoral pain syndrome</td> <td>Pes anserine bursitis or tendinopathy</td> <td>Osteoarthritis flare</td> <td>Iliotibial band syndrome</td> <td>Ruptured popliteal (Bakers) cyst</td> </tr> <tr> <td>Patellar tendinopathy</td> <td>Degenerative meniscus</td> <td>Degenerative meniscus</td> <td>Degenerative meniscus</td> <td>Semimembranosus-gastrocnemius bursitis</td> </tr> <tr> <td>Quadriceps tendinopathy</td> <td>Medial hamstring tendinopathy or bursitis</td> <td>&nbsp;</td> <td>Lateral hamstring (biceps femoris) tendinopathy</td> <td>&nbsp;</td> </tr> <tr> <td>Prepatellar or infrapatellar bursitis</td> <td>Medial plica syndrome</td> <td>&nbsp;</td> <td>Popliteus tendinopathy</td> <td>&nbsp;</td> </tr> <tr> <td>Osgood Schlatter or Sinding Larsen Johansson syndrome</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acute pain is generally defined as less than six weeks duration; chronic pain is generally defined as greater than six weeks duration.</div><div class=\"graphic_footnotes\">*Acute knee pain in an adult without inciting trauma or a history of overuse&nbsp;raises concerns for&nbsp;non-musculoskeletal causes (eg, crystal arthopathy, septic joint)&nbsp;and a more extensive evaluation is often required, particularly if the pain is associated with constitutional symptoms, such as fever.&nbsp;</div><div id=\"graphicVersion\">Graphic 91018 Version 3.0</div></div></div>"},"91019":{"type":"graphic_table","displayName":"Differential dx of chronic knee pain associated with overuse","title":"Common causes of chronic knee pain associated with overuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of chronic knee pain associated with overuse</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>Pain develops after reaching specific intensity of activity</p> <p>Pain progresses over time, becoming increasingly disabling</p> Pain generally has been present for six weeks or longer</td> </tr> <tr> <td class=\"subtitle1\">Anterior knee pain or poorly localized pain</td> <td class=\"subtitle1\">Medial knee pain</td> <td class=\"subtitle1\">Posterior knee pain</td> <td class=\"subtitle1\">Lateral knee pain</td> </tr> <tr> <td>Patellofemoral pain syndrome</td> <td>Pes anserine bursitis &#38; tendinopathy</td> <td>Hamstring tendinopathy</td> <td>Iliotibial band syndrome</td> </tr> <tr> <td>Patellar tendinopathy</td> <td>Degenerative meniscus</td> <td>Baker's cyst</td> <td>Degenerative meniscus</td> </tr> <tr> <td>Osteoarthritis</td> <td>Medial hamstring tendinopathy</td> <td>&nbsp;</td> <td>Biceps femoris (lateral hamstring) tendinopathy</td> </tr> <tr> <td>Prepatellar &#38; infrapatellar bursitis</td> <td>Medial plica syndrome</td> <td>&nbsp;</td> <td>Popliteus tendinopathy</td> </tr> <tr> <td>Osgood Schlatter syndrome</td> <td>MCL laxity</td> <td>&nbsp;</td> <td>LCL laxity</td> </tr> <tr> <td>Quadriceps tendinopathy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Chronic patella subluxation</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Intra-articular stress fracture</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>ACL or PCL laxity</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACL: anterior cruciate ligament; LCL: lateral collateral ligament; MCL: medial collateral ligament; PCL: posterior cruciate ligament.</div><div id=\"graphicVersion\">Graphic 91019 Version 2.0</div></div></div>"},"91020":{"type":"graphic_table","displayName":"Consensus recommendations GVHD","title":"Consensus recommendations for the prophylaxis and treatment of GVHD in allogeneic transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consensus recommendations for the prophylaxis and treatment of GVHD in allogeneic transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Prevention of GVHD</td> </tr> <tr> <td class=\"subtitle2_single\">GVHD prophylaxis: myeloablative conditioning</td> </tr> <tr> <td class=\"indent2\">&#8226; The standard prophylaxis is cyclosporine plus a short course of methotrexate. Tacrolimus plus methotrexate is regarded as equivalent, but experience in Europe is too limited to support recommendations. Institutions using tacrolimus plus methotrexate should establish institutional guidelines* and follow them.</td> </tr> <tr> <td class=\"indent2\">&#8226; Antithymocyte globulin has been shown to reduce chronic GVHD and improve the quality of life in transplantations from an unrelated donor. Therefore, antithymocyte globulin can be included in the prophylaxis regimen for unrelated donor transplantations. Institutions using antithymocyte globulin should follow the EBMT/ELN recommendations or establish institutional guidelines and follow them.</td> </tr> <tr> <td class=\"indent2\"><strong>Cyclosporine</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The initial dose is 3 mg/kg/day.</td> </tr> <tr> <td class=\"indent3\">&#8226; The administration is initiated on the day preceding the infusion of the graft (day &ndash;1). In case of two or more graft products given on more than one day, the day of the first product is counted as day 0.</td> </tr> <tr> <td class=\"indent3\">&#8226; The drug is given as short intravenous (IV) bolus infusion in two daily doses.</td> </tr> <tr> <td class=\"indent3\">&#8226; The administration is changed to oral route when oral intake is possible.</td> </tr> <tr> <td class=\"indent3\">&#8226; The first oral dose is twice the IV dose, administered in two daily doses.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose is adapted according to whole blood cyclosporine concentration or toxicity (renal insufficiency, microangiopathy, neurological problems) necessitating change of dosage.</td> </tr> <tr> <td class=\"indent3\">&#8226; The cyclosporine target concentration is 200 to 300 micrograms/L during the first three to four weeks, then 100 to 200 micrograms/L until three months after transplantation if there is no GVHD or toxicity.</td> </tr> <tr> <td class=\"indent3\">&#8226; Cyclosporine concentrations are measured from whole blood at 12 hours after a dose (trough level before the next infusion/dose).</td> </tr> <tr> <td class=\"indent3\">&#8226; The duration of cyclosporine prophylaxis is six months in the absence of GVHD.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose is tapered from three months onwards if no GVHD is present. The dose is not tapered as long as there are signs of acute GVHD or signs of chronic GVHD exceeding mild skin disease.</td> </tr> <tr> <td class=\"indent2\"><strong>Methotrexate</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The initial dose is 15 mg/m<sup>2</sup> given on day +1.</td> </tr> <tr> <td class=\"indent3\">&#8226; Three additional doses of 10 mg/m<sup>2</sup> are given, on days +3, +6 and +11. The day +11 dose is omitted in case of any toxicity of WHO grade II or higher.</td> </tr> <tr> <td class=\"indent3\">&#8226; The drug is given as bolus IV injection.</td> </tr> <tr> <td class=\"indent3\">&#8226; No dose adaptation is made except for possible omission of day +11 dose (see above).</td> </tr> <tr> <td class=\"indent3\">&#8226; Leucovorin rescue is given to all patients.</td> </tr> <tr> <td class=\"indent3\">&#8226; Leucovorin administration is started 24 hours after each methotrexate dose. The dosage is 15 mg x 3 given every six hours after methotrexate administration on day +1, the same dose x 4 given every six hours after methotrexate doses on days +3, +6 and +11.</td> </tr> <tr> <td class=\"indent3\">&#8226; Leucovorin is administered orally, in case of severe mucositis IV route is used.</td> </tr> <tr> <td class=\"indent2\"><strong>Antithymocyte globulin (rabbit)</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The brand of antithymocyte globulin is ATG-Fresenius (ATG-F) or Thymoglobulin.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose of ATG-F is 10 mg/kg on three days (total 30 mg/kg) and that of Thymoglobulin is 2.5 mg/kg on three days (total 7.5 mg/kg).</td> </tr> <tr> <td class=\"indent3\">&#8226; Antithymocyte globulin is administered on days &ndash;3, &ndash;2 and &ndash;1.</td> </tr> <tr> <td class=\"subtitle2_single\">GVHD prophylaxis: reduced intensity conditioning</td> </tr> <tr> <td class=\"indent2\">&#8226; The standard prophylaxis is cyclosporine plus mycophenolate mofetil.</td> </tr> <tr> <td class=\"indent2\">&#8226; Antithymocyte globulin has been shown to reduce chronic GVHD and improve the quality of life in transplantations from an unrelated donor. Therefore, antithymocyte globulin can be included in the regimen for unrelated donor transplantations. Institutions using antithymocyte globulin should follow the EBMT/ELN recommendations or establish institutional guidelines and follow them.</td> </tr> <tr> <td class=\"indent2\"><strong>Cyclosporine</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; Depending on the intensity of conditioning, the prophylaxis can be given either IV or PO. If the IV route is used, the recommendation for the initial dosing of cyclosporine is the same as for transplantations with myeloablative conditioning.</td> </tr> <tr> <td class=\"indent3\">&#8226; If the oral route is used, the initial dose is 12 mg/kg/day.</td> </tr> <tr> <td class=\"indent3\">&#8226; The administration is started on day &ndash;1.</td> </tr> <tr> <td class=\"indent3\">&#8226; The daily dose is given in two doses with a 12-hour interval.</td> </tr> <tr> <td class=\"indent3\">&#8226; The doses are adapted according to whole blood cyclosporine concentrations, toxicity (renal insufficiency, microangiopathy, neurological problems) necessitating change of dosage or decreasing chimerism.</td> </tr> <tr> <td class=\"indent3\">&#8226; The target concentrations are 200 to 300 micrograms/L during the first three to four weeks, then 100 to 200 micrograms/L until three months (if no GVHD, toxicity or decrease in chimerism).</td> </tr> <tr> <td class=\"indent3\">&#8226; The cyclosporine concentrations are measured from whole blood at 12 hours after a cyclosporine dose (trough levels before next infusion/dose).</td> </tr> <tr> <td class=\"indent3\">&#8226; The duration of prevention is six months, if there are no signs of GVHD. In case of persistent disease or relapse (sub-population chimerism or other sensitive method) prevention should be reduced earlier.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose is tapered from three months onwards if there are no signs of GVHD. The dose is not tapered as long as there are signs of acute GVHD or signs of chronic GVHD exceeding mild skin disease.</td> </tr> <tr> <td class=\"indent2\"><strong>Mycophenolate mofetil</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The dose is 30 mg/kg/day, given orally in two doses.</td> </tr> <tr> <td class=\"indent3\">&#8226; The administration is started on day +1.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose is adapted according to toxicity.</td> </tr> <tr> <td class=\"indent3\">&#8226; The duration of mycophenolate mofetil prophylaxis is one month in sibling transplantations, three months in transplantations from unrelated or mismatched donor.</td> </tr> <tr> <td class=\"indent3\">&#8226; In case of persistent disease or relapse (sub-population chimerism or other sensitive method) prevention should be reduced earlier.</td> </tr> <tr> <td class=\"indent2\"><strong>Antithymocyte globulin (rabbit)</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The brand is ATG-F or Thymoglobulin.</td> </tr> <tr> <td class=\"indent3\">&#8226; The dose of ATG-F is 10 mg/kg on three days (total 30 mg/kg) and that of Thymoglobulin is 2.5 mg/kg on three days (total 7.5 mg/kg).</td> </tr> <tr> <td class=\"indent3\">&#8226; Antithymocyte globulin is administered on days &ndash;3, &ndash;2 and &ndash;1.</td> </tr> <tr> <td class=\"indent2\"><strong>Prophylaxis in cord blood transplantation</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The recommended prophylaxis is cyclosporine plus mycophenolate mofetil, with dosing and duration of administration as described above for transplantations with reduced intensity conditioning.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of GVHD</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment of acute GVHD</td> </tr> <tr> <td class=\"indent2\"><strong>First-line treatment</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The first-line treatment of acute GVHD is methylprednisolone.</td> </tr> <tr> <td class=\"indent3\">&#8226; Treatment is initiated for acute GVHD of grade II or higher.</td> </tr> <tr> <td class=\"indent3\">&#8226; The initial methylprednisolone dose is 2 mg/kg/day.</td> </tr> <tr> <td class=\"indent3\">&#8226; Methylprednisolone is given in two divided doses per day.</td> </tr> <tr> <td class=\"indent3\">&#8226; The initial dose is continued for seven days. Treatment can be changed in case of clear progression after five days, but there is no evidence that change in treatment will affect the outcome.</td> </tr> <tr> <td class=\"indent3\">&#8226; No reduction of the dose is done during the first seven days.</td> </tr> <tr> <td class=\"indent3\">&#8226; Tapering of the dose is done slowly and depending on the response. No marked dose reductions are done in the early phase. Methylprednisolone is not discontinued before all signs of GVHD have disappeared.</td> </tr> <tr> <td class=\"indent3\">&#8226; Failure of treatment (corticosteroid resistance) is defined as no response after seven days of treatment or clear progression after five days.</td> </tr> <tr> <td class=\"indent3\">&#8226; Non-absorbable oral steroid (budesonide) is given, along with systemic corticosteroid, for GI GVHD in the dose of 9 mg/kg/day in one daily dose orally.</td> </tr> <tr> <td class=\"indent3\">&#8226; Topical steroids are used for skin GVHD according to center policy.</td> </tr> <tr> <td class=\"indent3\">&#8226; The decision to initiate treatment is based on clinical signs. Skin biopsy before initiation of treatment is recommended, but the decision to treat should not depend on the biopsy result. The same recommendation applies to upper GI or sigmoid biopsy if GI manifestation is suspected.</td> </tr> <tr> <td class=\"indent2\"><strong>Second-line treatment</strong></td> </tr> <tr> <td class=\"indent3\">&#8226; The indication for second-line treatment is failure of methylprednisolone treatment as defined above.</td> </tr> <tr> <td class=\"indent3\">&#8226; There is no standard second-line treatment for acute GVHD. Widely used components are mycophenolate mofetil, anti-TNF-antibodies, other monoclonal antibodies, antithymocyte globulin, extracorporeal photopheresis, methotrexate and mesenchymal stem cells. Continuation of calcineurin inhibitors and corticosteroids with optimal supportive care is considered a valid option. Centers should have and follow their institutional guidelines, and the patients should be treated in trials as far as possible.</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment of chronic GVHD</td> </tr> <tr> <td class=\"indent2\">&#8226; Indication for starting treatment of chronic GVHD depends on the type and severity of symptoms and the speed of symptom progression in the context of other relevant variables, such as disease risk, chimerism, and minimal residual disease results.</td> </tr> <tr> <td class=\"indent2\">&#8226; Evaluation of chronic GVHD according to the NIH consensus guidelines is recommended.</td> </tr> <tr> <td class=\"indent2\">&#8226; The first-line treatment of newly diagnosed chronic GVHD in patients not on any immunosuppressive drug, or receiving cyclosporine (or tacrolimus) only, is corticosteroid.</td> </tr> <tr> <td class=\"indent2\">&#8226; If the patient is already on corticosteroid treatment (for example, following treatment of acute GVHD), cyclosporine is added to the treatment and the dose of corticosteroid is increased.</td> </tr> <tr> <td class=\"indent2\">&#8226; If the patient is already receiving corticosteroid and cyclosporine at the time of the onset of chronic GVHD, no standard treatment is available.</td> </tr> <tr> <td class=\"indent2\">&#8226; Continuation of corticosteroid and cyclosporine with optimal supportive measures is a valid option. Alternatively, the patient should be treated in a clinical trial if possible.</td> </tr> <tr> <td class=\"indent2\">&#8226; The time needed to preliminarily assess the efficacy of the first-line treatment of chronic GVHD is at least one month.</td> </tr> <tr> <td class=\"indent2\">&#8226; There is no standard second-line treatment for chronic GVHD. The most widely used components of second-line treatment, in addition to corticosteroids, are extracorporeal photopheresis, mycophenolate mofetil, rituximab, calcineurin inhibitors and mTOR inhibitors. Centers should have and follow their institutional guidelines, and the patients should be treated in trials as far as possible.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Consensus recommendations for standard practice in the prophylaxis and treatment of GVHD in allogeneic transplantation for standard risk malignant diseases in adult patients using matched sibling or unrelated donor.</div><div class=\"graphic_footnotes\">GVHD: graft-versus-host disease; EBMT: European Group for Blood and Marrow Transplantation; ELN: European LeukemiaNet; GI: gastrointestinal; mTOR: mammalian target of rapamycin; WHO: World Health Organization.<br />* The expression \"institutional guidelines\" is used here in a strict sense, according to the principles of the JACIE/FACT criteria. Institutional guidelines should include a written document (standard operating procedure) with as specified details as those in the EBMT-ELN recommendations and specify in a \"change control2\" document on how the institutional guidelines will be validated compared with the standardized approach.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Bone Marrow Transplantation, advanced online publication, 29 July 2013. Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT&ndash;ELN working group recommendations for a standardized practice. DOI:10.1038/bmt.2013.107. Copyright &copy; 2013. <a href=\"http://www.nature.com/bmt\" target=\"_blank\">www.nature.com/bmt</a>.</div><div id=\"graphicVersion\">Graphic 91020 Version 1.0</div></div></div>"},"91022":{"type":"graphic_waveform","displayName":"EEG of typical absence seizure","title":"EEG showing generalized 3Hz spike wave activity during a typical absence seizure","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">EEG showing generalized 3Hz spike wave activity during a typical absence seizure</div><div class=\"cntnt\"><img style=\"width:570px; height:311px;\" src=\"images/NEURO/91022_EEG_show_3Hz_spike_wav.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91022 Version 2.0</div></div></div>"},"91025":{"type":"graphic_picture","displayName":"Musculoskeletal knee anatomy anterior view","title":"Knee musculoskeletal anatomy: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Knee musculoskeletal anatomy: Anterior view</div><div class=\"cntnt\"><img style=\"width:509px; height:589px;\" src=\"images/EM/91025_Extrnlknantmantrrvw.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91025 Version 3.0</div></div></div>"},"91039":{"type":"graphic_picture","displayName":"Scleredema histopathology","title":"Scleredema","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Scleredema</div><div class=\"cntnt\"><img style=\"width:487px; height:365px;\" src=\"images/DERM/91039_Scleredema_histopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic findings of scleredema include a thickened reticular dermis, large collagen bundles in the dermis that are separated from one another, and mucin.</div><div id=\"graphicVersion\">Graphic 91039 Version 1.0</div></div></div>"},"91041":{"type":"graphic_picture","displayName":"Turner syndrome","title":"Clinical features of Turner syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical features of Turner syndrome</div><div class=\"cntnt\"><img style=\"width:178px; height:375px;\" src=\"images/PEDS/91041_Turnersyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eleven-year-old with classical appearance of 45,X Turner syndrome, including short stature, lack of breast development, and shield chest with widely spaced nipples. Additional features may include webbed neck, cubitus valgus, and shortened fourth metatarsals.</div><div class=\"graphic_reference\">Reproduced with permission from: Rebar RW, Paupoo AAV. Puberty. In: Berek and Novak's Gynecology, Berek, JS (Ed), Philadelphia: Lippincott Williams &amp; Wilkins, 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 91041 Version 7.0</div></div></div>"},"91042":{"type":"graphic_picture","displayName":"Child with TSC and hypomelanotic macules","title":"Child with tuberous sclerosis complex and hypomelanotic macules","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Child with tuberous sclerosis complex and hypomelanotic macules</div><div class=\"cntnt\"><img style=\"width:513px; height:206px;\" src=\"images/PEDS/91042_Child_TSC_hypomel_macu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-year-old child with tuberous sclerosis complex and hypomelanotic macules involving the leg (A)&nbsp;and abdomen (B).</div><div id=\"graphicVersion\">Graphic 91042 Version 2.0</div></div></div>"},"91045":{"type":"graphic_picture","displayName":"TSC shagreen patches","title":"Shagreen patches in a patient with tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Shagreen patches in a patient with tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:514px; height:424px;\" src=\"images/PEDS/91045_TSC_shagreen_patches.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shagreen patches are most commonly found over the lower trunk in patients with tuberous sclerosis complex.</div><div id=\"graphicVersion\">Graphic 91045 Version 1.0</div></div></div>"},"91046":{"type":"graphic_picture","displayName":"TSC ungual fibromas","title":"Ungual fibromas in a patient with tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ungual fibromas in a patient with tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:436px; height:389px;\" src=\"images/PEDS/91046_TSC_ungual_fibromas.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91046 Version 1.0</div></div></div>"},"91047":{"type":"graphic_picture","displayName":"Pathology subependymal giant cell tumors","title":"Pathology of subependymal giant cell tumors in tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Pathology of subependymal giant cell tumors in tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:460px; height:426px;\" src=\"images/PEDS/91047_Path_subependyma_giant_tum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91047 Version 3.0</div></div></div>"},"91049":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of normal eye","title":"Ultrasound of normal eye","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Ultrasound of normal eye</div><div class=\"cntnt\"><img style=\"width:545px; height:303px;\" src=\"images/EM/91049_Ultrasound_normal_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Panel A: Reproduced with permission from Keith Boniface, George Washington University Department of Emergency Medicine.<br />Panel B: Reproduced from National Eye Institute, National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 91049 Version 1.0</div></div></div>"},"91050":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of retinal detachment","title":"Ultrasound of retinal detachment","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound of retinal detachment</div><div class=\"cntnt\"><img style=\"width:598px; height:280px;\" src=\"images/EM/91050_US_retinal_detachment.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Panel A: Image provided with permission by Keith Boniface, George Washington University Department of Emergency Medicine.<br />Panel B: Image provided by Dr. James Rippey. Reproduced with permission from: Ultrasound Village (<a href=\"http://www.ultrasoundvillage.com/\" target=\"_blank\">www.ultrasoundvillage.com</a>). Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 91050 Version 1.0</div></div></div>"},"91053":{"type":"graphic_picture","displayName":"Nodular cutaneous mastocytosis","title":"Nodular cutaneous mastocytosis in a child","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Nodular cutaneous mastocytosis in a child</div><div class=\"cntnt\"><img style=\"width:527px; height:652px;\" src=\"images/ALLRG/91053_Nodular_cutane_mastocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">American Journal of Clinical Dermatology, Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations, Vol. 12, 2011, p. 259, Castells M, Metcalfe DD, Escribano L, © Adis Data Information BV 2011. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 91053 Version 5.0</div></div></div>"},"91054":{"type":"graphic_table","displayName":"VRd for multiple myeloma","title":"Bortezomib (Velcade), lenalidomide (Revlimid), and \"low dose\" dexamethasone (VRd) for multiple myeloma<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bortezomib (Velcade), lenalidomide (Revlimid), and \"low dose\" dexamethasone (VRd) for multiple myeloma<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bortezomib</td> <td>1.3 mg/m<sup>2</sup> subcutaneously (SC) or intravenously (IV)*</td> <td>Given as a single SC<sup>[4]</sup> injection or as a rapid IV bolus over 3 to 5 seconds.</td> <td>Days 1, 8, and 15<sup>[3,5]</sup></td> </tr> <tr> <td>Lenalidomide<sup>&#182;</sup></td> <td>25 mg by mouth</td> <td>Administer with water. Swallow capsule whole; do not break, open, or chew.</td> <td>Daily, on days 1 through 14</td> </tr> <tr class=\"divider_bottom\"> <td>Dexamethasone</td> <td>40 mg by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, and 15<sup>[3]</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MINIMAL TO LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine premedication is not indicated. If a hypersensitivity reaction (not including local reactions) occurs with bortezomib or lenalidomide, then neither drug should be readministered. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Antithrombotic prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine antithrombotic prophylaxis is warranted. Thromboembolism was reported in 2 to 6% of patients in clinical trials receiving VRd despite antithrombotic prophylaxis.<sup>[1,2]</sup> The risk of thromboembolism was over 10% with another lenalidomide and high dose dexamethasone (RD) regimen.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VRd. Some clinicians also administer prophylactic trimethoprim-sulfamethoxazole (eg, one double strength tablet once daily on Mondays, Wednesdays, and Fridays) during treatment.<sup>[1,2]</sup> Primary prophylaxis with G-CSF is not indicated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib is an irritant. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li><strong>Bortezomib:</strong> No dosage adjustment for bortezomib secondary to renal insufficiency is necessary.<sup>[7]</sup> For patients undergoing hemodialysis, bortezomib should be administered after dialysis. Patients with moderate or severe hepatic impairment (serum bilirubin level &#62;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, with further dose modifications based upon patient tolerance. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> <li><strong>Lenalidomide:</strong> Patients with renal insufficiency experience more neutropenia with lenalidomide.<sup>[8]</sup> Dose adjustment is recommended for patients with CrCl &#60;60 mL/min.<sup>[9]</sup> At this time, studies have not been conducted in patients with hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential, electrolytes, renal function, liver function, and M protein level prior to starting each cycle. A CBC should also be performed prior to the day 8 and 15 doses of bortezomib during induction therapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Weekly assessment for peripheral neuropathy and/or neuropathic pain. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hypotension during bortezomib therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A cycle of VRd should not be started unless the ANC is &#8805;1000 cells/microL and the platelet count is &#8805;70,000/microL.<sup>[1,2,7]</sup> If platelets are &#60;50,000/microL or the ANC is &#60;1000 cells/microL on day 15, hold day 15 bortezomib dose. If several doses are held, reduce bortezomib dose by one level (from 1.5 mg/m<sup>2</sup> to 1.3 mg/m<sup>2</sup> or from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup> or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>) and decrease the daily dose of lenalidomide by 5 mg. Growth factor support can be given on day 8 of the second and subsequent cycles for ANC &#60;500/m<sup>2</sup> lasting &#62;7 days or for an episode of febrile neutropenia.<sup>[1,2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib dose should be reduced in patients who develop symptomatic peripheral neuropathy.<sup>[7]</sup> Rates of neuropathy appear to be lower with subcutaneous administration of bortezomib.<sup>[4]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other nonhematological toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or 4 nonhematologic toxicity other than neuropathy, hold lenalidomide and bortezomib. Once symptoms have resolved to grade 1 or baseline, reinitiate therapy with lower doses. Reduce dexamethasone dose for grade 2 muscle weakness, grade 3 gastrointestinal tract toxicity, hyperglycemia, confusion, or mood alterations. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. The dosing suggested uses lower doses of bortezomib and dexamethasone than used in the original studies testing the regimen, and are based on other data that suggest similar efficacy with lower adverse events with weekly dosing of bortezomib and dexamethasone. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Subcutaneous administration is preferred due to a lower risk of neuropathy.<br />¶ In the United States, the use of lenalidomide is subject to the REVLIMID REMS program (<A href=\"http://www.revlimidrems.com/\" target=_blank>www.REVLIMIDREMS.com</A>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Richardson PG, et al. Blood 2010; 116:679.</LI>&#xD;&#xA;<LI>Kumar S, et al. Blood 2012; 119:4375.</LI>&#xD;&#xA;<LI>Rajkumar S, et al. Am J Hematol 2011; 86:57.</LI>&#xD;&#xA;<LI>Moreau P, et al. Lancet Oncol 2011; 12:431.</LI>&#xD;&#xA;<LI>Rajkumar S, et al. Lancet Oncol 2010; 11:909.</LI>&#xD;&#xA;<LI>Rajkumar S, et al. Lancet Oncol 2010; 11:29.</LI>&#xD;&#xA;<LI>Bortezomib injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 24, 2013).</LI>&#xD;&#xA;<LI>Niesvizky R, et al. Br J Haematol 2007; 138:640.</LI>&#xD;&#xA;<LI>Lenalidomide capsule. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 24, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 91054 Version 11.0</div></div></div>"},"91056":{"type":"graphic_figure","displayName":"International adoptions US","title":"International adoptions to the United States, 2000-2015","html":"<div class=\"graphic\"><div style=\"width: 706px\" class=\"figure\"><div class=\"ttl\">International adoptions to the United States, 2000-2015</div><div class=\"cntnt\"><img style=\"width:686px; height:308px;\" src=\"images/PEDS/91056_International_adoptions_US.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Bureau of Consular Affairs, US Department of State. Intercountry adoption. <a href=\"http://adoption.state.gov/about_us/statistics.php\" target=\"_blank\">http://adoption.state.gov/about_us/statistics.php</a> (Accessed on April 19, 2016).</div><div id=\"graphicVersion\">Graphic 91056 Version 3.0</div></div></div>"},"91058":{"type":"graphic_table","displayName":"International adoption resources","title":"International adoption resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International adoption resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Centers for Disease Control and Prevention<br /> International Adoption: Health Guidance and the Immigration Process</p> <a href=\"http://www.cdc.gov/immigrantrefugeehealth/adoption/index.html\" target=\"_blank\">www.cdc.gov/immigrantrefugeehealth/adoption/index.html</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Eastern European Adoption Coalition</p> <a href=\"http://www.eeadopt.org/\" target=\"_blank\">www.eeadopt.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Families for Russian and Ukrainian Adoption</p> <a href=\"http://www.frua.org/\" target=\"_blank\">www.frua.org</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Massachusetts General Hospital Pre-travel Providers' Rapid Evaluation Portal (Pre-Travel PREP)</p> <a href=\"http://gten.travel/prep/prep\" spellcheck=\"true\" target=\"_blank\">http://gten.travel/prep/prep</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>National Adoption Information Clearinghouse</p> <a href=\"http://www.adoption.org/adopt/national-adoption-information-clearinghouse.php\" target=\"_blank\">www.adoption.org/adopt/national-adoption-information-clearinghouse.php</a></td> </tr> <tr class=\"divider_bottom\"> <td> <p>North American Council on Adoptable Children</p> <a href=\"http://www.nacac.org/\" target=\"_blank\">www.nacac.org</a></td> </tr> <tr> <td> <p>The US State Department Bureau of Consular Affairs Information on Intercountry Adoption</p> <a href=\"http://adoption.state.gov/\" target=\"_blank\">adoption.state.gov</a></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91058 Version 4.0</div></div></div>"},"91059":{"type":"graphic_picture","displayName":"BCG scarification","title":"Bacille Calmette-Guérin vaccination scarification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacille Calmette-Guérin vaccination scarification</div><div class=\"cntnt\"><img style=\"width:370px; height:504px;\" src=\"images/PEDS/91059_BCG_scarification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bacille Calmette-Gu&eacute;rin scarification (arrow) on deltoid.</div><div id=\"graphicVersion\">Graphic 91059 Version 1.0</div></div></div>"},"91072":{"type":"graphic_picture","displayName":"McMurray test for meniscus injury","title":"McMurray test for meniscus injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">McMurray test for meniscus injury</div><div class=\"cntnt\"><img style=\"width:426px; height:484px;\" src=\"images/EM/91072_Mcmrrytstmnscsinjry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The McMurray test is used to assess both knee motion and meniscal injury. To perform the maneuver, the examiner places their thumb and index finger on the medial and lateral joint lines while the knee is passively flexed and extended several times in a smooth back and forth motion. Flexion and extension is performed with the tibia internally rotated for several repetitions (A and B), and then with the tibia externally rotated for several repetitions (C and D). While performing the maneuver, the clinician feels for a popping sensation along the joint line. The test is positive when there is pain at the joint line, with or without a \"clunk,\" and possibly limited range of motion. A positive test suggests meniscal injury.</div><div class=\"graphic_reference\">Adapted with permission from: Knee injuries. In: ACSM's Primary Care Sports Medicine, 2nd ed, McKeag DB, Moeller JL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91072 Version 5.0</div></div></div>"},"91083":{"type":"graphic_figure","displayName":"BMI curves for boys with severe obesity","title":"BMI curves for boys with severe obesity","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">BMI curves for boys with severe obesity</div><div class=\"cntnt\"><img style=\"width:738px; height:894px;\" src=\"images/PEDS/91083_BMI_curv_boys_sev_obesity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe obesity in pediatric patients is defined as a body mass index (BMI) that is either &ge;120% of the 95<sup>th</sup> percentile curve, or BMI &ge;35 kg/m<sup>2</sup> (whichever is lower). The area defining severe obesity is shaded in red in the figure above. A BMI of 40 kg/m<sup>2</sup> is typically used as a threshold for weight loss surgery in adults and adolescents without major comorbidities. Note that this threshold is well above the curve representing 120% of the 95<sup>th</sup> percentile at all ages.<br />The black curves (50 through 97) represent the standard BMI growth reference from the CDC, published in 2000. The blue curves (110% through 190%) are derived by multiplying the 95<sup>th</sup> percentile values by 1.1 through 1.9, respectively.</div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Source: Kelly AS, Barlow SE, Rao G, Inge TH, et al. Severe obesity in children and adolescents: Identification, associated health risks, and treatment approaches. A scientific statement from the American Heart Association. Circulation 2013; 128:1689.</div><div id=\"graphicVersion\">Graphic 91083 Version 3.0</div></div></div>"},"91084":{"type":"graphic_diagnosticimage","displayName":"CT carcinoma tongue","title":"Carcinoma of the tongue by CT scan","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Carcinoma of the tongue by CT scan</div><div class=\"cntnt\"><img style=\"width:573px; height:327px;\" src=\"images/RADIOL/91084_CT_carcinoma_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the neck in the axial plane (A) shows an infiltrating mass with homogeneous enhancement (arrow). A small ipsilateral regional node is present (arrowhead). The coronal reconstruction shows the mass in the lateral aspect of the tongue.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91084 Version 1.0</div></div></div>"},"91085":{"type":"graphic_figure","displayName":"PALM-COEIN fibroid terminology","title":"PALM-COEIN subclassification system for leiomyomas","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">PALM-COEIN subclassification system for leiomyomas</div><div class=\"cntnt\"><img style=\"width:659px; height:468px;\" src=\"images/OBGYN/91085_PALM_COEIN_fibroid_terminol.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Munro MG. Abnormal Uterine Bleeding. Cambridge: Cambridge University Press, 2010. Copyright &copy; 2010 M. Munro. Reprinted with the permission of Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 91085 Version 1.0</div></div></div>"},"91086":{"type":"graphic_picture","displayName":"Pleural KS ","title":"Kaposi's sarcoma of the visceral pleura","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma of the&nbsp;visceral pleura</div><div class=\"cntnt\"><img style=\"width:540px; height:523px;\" src=\"images/PULM/91086_Pleural_KS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macroscopic image of pleural Kaposi's sarcoma showing multiple lesions on the&nbsp;visceral pleura. Thoracoscopic views would appear similar to these lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Pulmonary Kaposi sarcoma. Human Pathology 2012. Copyright © 2013. http://www.humpath.com/spip.php?article17900 (Accessed on October 11, 2013).</div><div id=\"graphicVersion\">Graphic 91086 Version 3.0</div></div></div>"},"91087":{"type":"graphic_figure","displayName":"Body composition and survival in COPD","title":"Effect of body composition on survival in COPD","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Effect of body composition on survival in COPD</div><div class=\"cntnt\"><img style=\"width:588px; height:514px;\" src=\"images/PULM/91087_Body_comp_survival_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plot of survival in different body-composition categories. Category 1 (cachexia; n = 117), solid blue line; category 2 (semistarvation; n = 23), solid green line; category 3 (muscle atrophy; n = 40), dashed green line; category 4 (no impairment; n = 232), dashed blue line. Median survival was significantly (p = 0.001) less in patients with cachexia (26 months, 95% CI&nbsp;21-31) and muscle atrophy (24&nbsp;months, 95% CI&nbsp;15-33) than in patients with semistarvation (36&nbsp;months, 95% CI 28-44) or no impairment (47 months, 95% CI 37-57). The survival plot of the semistarvation category did not differ significantly from that of the no-impairment category during the first three years.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82:53. Copyright © 2005 American Society for Nutrition.</div><div id=\"graphicVersion\">Graphic 91087 Version 1.0</div></div></div>"},"91091":{"type":"graphic_picture","displayName":"Light microscopy showing atheroembolic renal disease","title":"Light microscopy showing atheroembolic renal disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing atheroembolic renal disease</div><div class=\"cntnt\"><img style=\"width:230px; height:264px;\" src=\"images/NEPH/91091_Light_atheroembolic_renal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photomicrograph shows an atheroembolus in a muscular renal artery (arrow) with cleft-like spaces due to washout of the cholesterol crystals during histologic processing.</div><div id=\"graphicVersion\">Graphic 91091 Version 1.0</div></div></div>"},"91092":{"type":"graphic_figure","displayName":"Metabolism of pyruvate to lactate","title":"Metabolism of pyruvate to lactate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metabolism of pyruvate to lactate</div><div class=\"cntnt\"><img style=\"width:426px; height:214px;\" src=\"images/NEPH/91092_Metabolism_pyruvate_lactate.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91092 Version 1.0</div></div></div>"},"91098":{"type":"graphic_table","displayName":"Ophthalmic medications for treatment of allergic conjunctivitis","title":"Ophthalmic medications for the treatment of allergic conjunctivitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ophthalmic medications for the treatment of allergic conjunctivitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pharmacologic class</td> <td class=\"subtitle1\">Usual adult dosing</td> <td class=\"subtitle1\">Pediatric dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antihistamines with mast cell-stabilizing properties: Decreased itching should be evident within 24 to 72 hours; may result in dry eye sensation or burning</td> </tr> <tr> <td class=\"indent1\">Olopatadine 0.1% (Patanol), 0.2% (Pataday), 0.7% (Pazeo)</td> <td>One drop per eye twice daily (Patanol); one drop per eye once daily (Pataday and Pazeo)</td> <td>&#8805;2 years: One drop per eye twice daily (Patanol); one drop per eye once daily (Pataday and Pazeo)</td> </tr> <tr> <td class=\"indent1\">Alcaftadine 0.25% (Lastacaft)</td> <td>One drop per eye once daily</td> <td>&#8805;2 years: One drop per eye once daily</td> </tr> <tr> <td class=\"indent1\">Bepotastine 1.5% (Bepreve)</td> <td>One drop per eye twice daily</td> <td>&#8805;2 years: One drop per eye twice daily</td> </tr> <tr> <td class=\"indent1\">Epinastine 0.05% (Elestat, generics)</td> <td>One drop per eye twice daily</td> <td>&#8805;2 years: One drop per eye twice daily</td> </tr> <tr> <td class=\"indent1\">Ketotifen 0.025% (multiple OTC products)</td> <td>One drop per eye every eight hours</td> <td>&#8805;3 years: One drop per eye every 8 to 12 hours</td> </tr> <tr> <td class=\"indent1\">Azelastine 0.05% (Optivar, generics)</td> <td>One drop per eye twice daily</td> <td>&#8805;3 years: One drop per eye twice daily</td> </tr> <tr> <td class=\"indent1\">Emedastine 0.05% (Emadine)</td> <td>One drop per eye up to four times daily</td> <td>&#8805;3 years: One drop per eye up to four times daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vasoconstrictor/antihistamine combination: Increased redness can occur temporarily when medication is stopped</td> </tr> <tr> <td class=\"indent1\"> <p>Naphazoline 0.25% and pheniramine 0.3% (OTC Naphcon-A, generics)</p> Naphazoline 0.27% and pheniramine 0.325% (OTC Opcon-A, generics)</td> <td>One to two drops per eye up to four times daily</td> <td>&#8805;6 years: One to two drops per eye up to four times daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mast cell stabilizers: Decreased itching may be evident within a few days or may take up to four weeks</td> </tr> <tr> <td class=\"indent1\">Cromolyn sodium 4% (Opticrom, generics)</td> <td>One to two drops per eye up to six times daily</td> <td>&#62;4 years: One to two drops per eye up to six times daily</td> </tr> <tr> <td class=\"indent1\">Nedocromil 2% (Alocril)</td> <td>One to two drops per eye twice daily</td> <td>&#8805;3 years: One to two drops per eye twice daily</td> </tr> <tr> <td class=\"indent1\">Lodoxamide 0.1% (Alomide)</td> <td>One to two drops per eye four times daily for up to three months</td> <td>&#62;2 years: One to two drops per eye four times daily for up to three months (approved for seasonal allergies, which usually last &#8804;3 months)</td> </tr> <tr> <td class=\"indent1\">Pemirolast 0.1%* (Alamast)</td> <td>One to two drops per eye up to four times daily</td> <td>&#8805;3 years: One to two drops per eye up to four times daily for up to four weeks</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">United States trade names are shown in parentheses following generic name.</div><div class=\"graphic_footnotes\">OTC: over-the-counter.<br />* Not available in the&nbsp;United States. Available in some other countries.</div><div id=\"graphicVersion\">Graphic 91098 Version 8.0</div></div></div>"},"91100":{"type":"graphic_picture","displayName":"Rounded hunched shoulder posture PI","title":"Posture with rounded and hunched shoulders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posture with rounded and hunched shoulders</div><div class=\"cntnt\"><img style=\"width:426px; height:504px;\" src=\"images/PI/91100_Round_pro_shoulder_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People who spend a lot of time at a desk tend to sit with their head forward and shoulders hunched. This posture can increase the chances of developing shoulder impingement syndrome.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 91100 Version 1.0</div></div></div>"},"91101":{"type":"graphic_figure","displayName":"Throwing phases PI","title":"Phases of throwing","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Phases of throwing</div><div class=\"cntnt\"><img style=\"width:542px; height:266px;\" src=\"images/PI/91101_Throwing_phases_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Throwing athletes can get a unique form of shoulder impingement syndrome (SIS), called posterior SIS. That's because the repeated action of \"cocking\" for a throw can cause the tissues inside the back part of the shoulder joint to get compressed.</div><div id=\"graphicVersion\">Graphic 91101 Version 1.0</div></div></div>"},"91102":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for conversion disorder","title":"DSM-5 diagnostic criteria for conversion disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for conversion disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> One or more symptoms of altered voluntary motor or sensory function.</td> </tr> <tr> <td><strong>B.</strong> Clinical findings provide evidence of incompatibility between the symptom and recognized neurological or medical conditions.</td> </tr> <tr> <td><strong>C.</strong> The symptom or deficit is not better explained by another medical or mental disorder.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>D.</strong> The symptom or deficit causes clinically significant distress or impairment in social, occupational, or other important areas of functioning or warrants medical evaluation.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> symptom type:</td> </tr> <tr> <td class=\"indent1\">With weakness or paralysis</td> </tr> <tr> <td class=\"indent1\">With abnormal movement (eg, tremor, dystonic movement, myoclonus, gait disorder)</td> </tr> <tr> <td class=\"indent1\">With swallowing symptoms</td> </tr> <tr> <td class=\"indent1\">With speech symptoms (eg, dysphonia, slurred speech)</td> </tr> <tr> <td class=\"indent1\">With attacks or seizures</td> </tr> <tr> <td class=\"indent1\">With anesthesia or sensory loss</td> </tr> <tr> <td class=\"indent1\">With special sensory symptoms (eg, visual, olfactory, or hearing disturbance)</td> </tr> <tr> <td class=\"indent1\">With mixed symptoms</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91102 Version 5.0</div></div></div>"},"91103":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for anorexia nervosa","title":"DSM-5 diagnostic criteria for anorexia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for anorexia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. <em>Significantly low weight</em> is defined as a weight that is less than minimally normal or, for children and adolescents, less than that minimally expected.</td> </tr> <tr> <td><strong>B.</strong> Intense fear of gaining weight or of becoming fat or persistent behavior that interferes with weight gain, even though at a significantly low weight.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>C.</strong> Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> whether:</td> </tr> <tr> <td class=\"indent1\"><strong>Restricting type:</strong> During the last three months, the individual has not engaged in recurrent episodes of binge eating or purging behavior (ie, self-induced vomiting or the misuse of laxatives, diuretics, or enemas). This subtype describes presentations in which weight loss is accomplished primarily through dieting, fasting, and/or excessive exercise.</td> </tr> <tr> <td class=\"indent1\"><strong>Binge eating/purging type:</strong> During the last three months, the individual has engaged in recurrent episodes of binge eating or purging behavior (ie, self-induced vomiting or the misuse of laxatives, diuretics, or enemas).</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\"><strong>In partial remission:</strong> After full criteria for anorexia nervosa were previously met, criterion A (low body weight) has not been met for a sustained period, but either criterion B (intense fear of gaining weight or becoming fat or behavior that interferes with weight gain) or criterion C (disturbances in self-perception of weight and shape) is still met.</td> </tr> <tr> <td class=\"indent1\"><strong>In full remission:</strong> After full criteria for anorexia nervosa were previously met, none of the criteria have been met for a sustained period of time.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> current severity:</td> </tr> <tr> <td class=\"indent1\">The minimum level of severity is based, for adults, on current BMI (see below) or, for children and adolescents, on BMI percentile*. The ranges below were derived from World Health Organization categories for thinness in adults; for children and adolescents, corresponding BMI percentiles should be used. The level of severity may be increased to reflect clinical symptoms, the degree of functional disability, and the need for supervision.</td> </tr> <tr> <td class=\"indent2\"><strong>Mild:</strong> BMI &#8805;17 kg/m<sup>2</sup><sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Moderate:</strong> BMI 16 to 16.99 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Severe:</strong> BMI 15 to 15.99 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent2\"><strong>Extreme:</strong> BMI &#60;15 kg/m<sup>2</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; BMI: body mass index.<br />* See \"Calculator: Body mass index (BMI; Quetelet's index)\".<br />¶ UpToDate defines mild severity as BMI 17 to 18.4 kg/m<SUP>2</SUP>; BMI ≥18.5 kg/m<SUP>2</SUP> and &lt;25 kg/m<SUP>2</SUP> is a healthy weight.</div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91103 Version 6.0</div></div></div>"},"91105":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for bulimia nervosa","title":"DSM-5 diagnostic criteria for bulimia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for bulimia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:</td> </tr> <tr> <td class=\"indent1\">1) Eating, in a discrete period of time (eg, within any two-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances.</td> </tr> <tr> <td class=\"indent1\">2) A sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating).</td> </tr> <tr> <td><strong>B.</strong> Recurrent inappropriate compensatory behavior to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; fasting; or excessive exercise.</td> </tr> <tr> <td><strong>C.</strong> The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for three months.</td> </tr> <tr> <td><strong>D.</strong> Self-evaluation is unduly influenced by body shape and weight.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>E.</strong> The disturbance does not occur exclusively during episodes of anorexia nervosa.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\"><strong>In partial remission:</strong> After full criteria for bulimia nervosa were previously met, some, but not all, of the criteria have been met for a sustained period of time.</td> </tr> <tr> <td class=\"indent1\"><strong>In full remission:</strong> After full criteria for bulimia nervosa were previously met, none of the criteria have been met for a sustained period of time.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> current severity: The minimum level of severity is based on the frequency of inappropriate compensatory behaviors (see below). The level of severity may be increased to reflect other symptoms and the degree of functional disability.</td> </tr> <tr> <td class=\"indent1\"><strong>Mild:</strong> An average of 1 to 3 episodes of inappropriate compensatory behaviors per week.</td> </tr> <tr> <td class=\"indent1\"><strong>Moderate:</strong> An average of 4 to 7 episodes of inappropriate compensatory behaviors per week.</td> </tr> <tr> <td class=\"indent1\"><strong>Severe:</strong> An average of 8 to 13 episodes of inappropriate compensatory behaviors per week.</td> </tr> <tr> <td class=\"indent1\"><strong>Extreme:</strong> An average of 14 or more episodes of inappropriate compensatory behaviors per week.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91105 Version 5.0</div></div></div>"},"91106":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for manic episode","title":"DSM-5 diagnostic criteria for manic episode","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for manic episode</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least one week and present most of the day, nearly every day (or any duration if hospitalization is necessary).</td> </tr> <tr> <td class=\"sublist1_start\"><strong>B.</strong> During the period of mood disturbance and increased energy or activity, three (or more) of the following symptoms (four if the mood is only irritable) are present to a significant degree and represent a noticeable change from usual behavior:</td> </tr> <tr> <td class=\"indent1\">1) Inflated self-esteem or grandiosity.</td> </tr> <tr> <td class=\"indent1\">2) Decreased need for sleep (eg, feels rested after only three hours of sleep).</td> </tr> <tr> <td class=\"indent1\">3) More talkative than usual or pressure to keep talking.</td> </tr> <tr> <td class=\"indent1\">4) Flight of ideas or subjective experience that thoughts are racing.</td> </tr> <tr> <td class=\"indent1\">5) Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.</td> </tr> <tr> <td class=\"indent1\">6) Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation (ie, purposeless non-goal-directed activity).</td> </tr> <tr> <td class=\"indent1\">7) Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).</td> </tr> <tr> <td><strong>C.</strong> The mood disturbance is sufficiently severe to cause marked impairment in social or occupational functioning or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features.</td> </tr> <tr> <td><strong>D.</strong> The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, other treatment) or to another medical condition.</td> </tr> <tr> <td class=\"indent1\"><strong>NOTE:</strong> A full manic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a manic episode and, therefore, a bipolar I diagnosis.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>NOTE:</strong> Criteria A through D constitute a manic episode. At least one lifetime manic episode is required for the diagnosis of bipolar I disorder.</div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91106 Version 5.0</div></div></div>"},"91107":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for hypomanic episode","title":"DSM-5 diagnostic criteria for hypomanic episode","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for hypomanic episode</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least four consecutive days and present most of the day, nearly every day.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>B.</strong> During the period of mood disturbance and increased energy and activity, three (or more) of the following symptoms (four if the mood is only irritable) have persisted, represent a noticeable change from usual behavior, and have been present to a significant degree:</td> </tr> <tr> <td class=\"indent1\">1) Inflated self-esteem or grandiosity.</td> </tr> <tr> <td class=\"indent1\">2) Decreased need for sleep (eg, feels rested after only three hours of sleep).</td> </tr> <tr> <td class=\"indent1\">3) More talkative than usual or pressure to keep talking.</td> </tr> <tr> <td class=\"indent1\">4) Flight of ideas or subjective experience that thoughts are racing.</td> </tr> <tr> <td class=\"indent1\">5) Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli), as reported or observed.</td> </tr> <tr> <td class=\"indent1\">6) Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation.</td> </tr> <tr> <td class=\"indent1\">7) Excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments).</td> </tr> <tr> <td><strong>C.</strong> The episode is associated with an unequivocal change in functioning that is uncharacteristic of the individual when not symptomatic.</td> </tr> <tr> <td><strong>D.</strong> The disturbance in mood and the change in functioning are observable by others.</td> </tr> <tr> <td><strong>E.</strong> The episode is not severe enough to cause marked impairment in social or occupational functioning or to necessitate hospitalization. If there are psychotic features, the episode is, by definition, manic.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>F.</strong> The episode is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication, or other treatment).</td> </tr> <tr> <td class=\"indent1\"><strong>NOTE:</strong> A full hypomanic episode that emerges during antidepressant treatment (eg, medication, electroconvulsive therapy) but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a hypomanic episode diagnosis. However, caution is indicated so that one or two symptoms (particularly increased irritability, edginess, or agitation following antidepressant use) are not taken as sufficient for a diagnosis of a hypomanic episode, nor necessarily indicative of a bipolar diathesis.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>NOTE:</strong> Criteria A through F constitute a hypomanic episode. Hypomanic episodes are common in bipolar I disorder but are not required for the diagnosis of bipolar I disorder.</div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91107 Version 4.0</div></div></div>"},"91108":{"type":"graphic_picture","displayName":"Plasma cell cheilitis histo","title":"Histologic features of plasma cell cheilitis","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Histologic features of plasma cell cheilitis</div><div class=\"cntnt\"><img style=\"width:460px; height:504px;\" src=\"images/DERM/91108_Plasma_cell_cheilitis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In plasma cell cheilitis, there is spongiosis and epithelial hyperplasia with atrophy of the suprapapillary epithelium. The lamina propria is filled with sheets of polyclonal plasma cells, sometimes with Russell bodies.</div><div class=\"graphic_reference\">Courtesy of Tammie Ferringer, MD.</div><div id=\"graphicVersion\">Graphic 91108 Version 2.0</div></div></div>"},"91114":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for dysthymia","title":"DSM-5 diagnostic criteria for persistent depressive disorder (dysthymia)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for persistent depressive disorder (dysthymia)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Depressed mood for most of the day, for more days than not, as indicated either by subjective account or observation by others, for at least&nbsp;two years.</td> </tr> <tr> <td class=\"indent1\"><strong>NOTE:</strong> In children and adolescents, mood can be irritable and duration must be at least one year.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>B.</strong> Presence, while depressed, of two (or more) of the following:</td> </tr> <tr> <td class=\"indent1\">1) Poor appetite or overeating.</td> </tr> <tr> <td class=\"indent1\">2) Insomnia or hypersomnia.</td> </tr> <tr> <td class=\"indent1\">3) Low energy or fatigue.</td> </tr> <tr> <td class=\"indent1\">4) Low self-esteem.</td> </tr> <tr> <td class=\"indent1\">5) Poor concentration or difficulty making decisions.</td> </tr> <tr> <td class=\"indent1\">6) Feelings of hopelessness.</td> </tr> <tr> <td><strong>C.</strong> During the two-year period (one year for children or adolescents) of the disturbance, the individual has never been without the symptoms in Criteria A and B for more than two months at a time.</td> </tr> <tr> <td><strong>D.</strong> Criteria for a major depressive disorder may be continuously present for two years.</td> </tr> <tr> <td><strong>E.</strong> There has never been a manic episode or a hypomanic episode, and criteria have never been met for cyclothymic disorder.</td> </tr> <tr> <td><strong>F.</strong> The disturbance is not better explained by a persistent schizoaffective disorder, schizophrenia, delusional disorder, or other specified or unspecified schizophrenia spectrum and other psychotic disorder.</td> </tr> <tr> <td><strong>G.</strong> The symptoms are not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication) or another medical condition (eg, hypothyroidism).</td> </tr> <tr> <td><strong>H.</strong> The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>NOTE:</strong> Because the criteria for a major depressive episode include four symptoms that are absent from the symptom list for persistent depressive disorder (dysthymia), a very limited number of individuals will have depressive symptoms that have persisted longer than two years but will not meet criteria for persistent depressive disorder. If full criteria for a major depressive episode have been met at some point during the current episode of illness, they should be given a diagnosis of major depressive disorder. Otherwise, a diagnosis of other specified depressive disorder or unspecified depressive disorder is warranted.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\">With anxious distress</td> </tr> <tr> <td class=\"indent1\">With mixed features</td> </tr> <tr> <td class=\"indent1\">With melancholic features</td> </tr> <tr> <td class=\"indent1\">With atypical features</td> </tr> <tr> <td class=\"indent1\">With mood-congruent psychotic features</td> </tr> <tr> <td class=\"indent1\">With mood-incongruent psychotic features</td> </tr> <tr> <td class=\"indent1\">With peripartum onset</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\">In partial remission</td> </tr> <tr> <td class=\"indent1\">In full remission</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if:</td> </tr> <tr> <td class=\"indent1\"><strong>Early onset:</strong> If onset is before 21 years.</td> </tr> <tr> <td class=\"indent1\"><strong>Late onset:</strong> If onset is at age 21 years or older.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> if (for most recent two years of persistant depressive disorder):</td> </tr> <tr> <td class=\"indent1\"><strong>With pure dysthymic syndrome:</strong> Full criteria for a major depressive episode have not been met in at least the preceding two years.</td> </tr> <tr> <td class=\"indent1\"><strong>With persistent major depressive episode:</strong> Full criteria for a major depressive episode have been met throughout the preceding two-year period.</td> </tr> <tr> <td class=\"indent1\"><strong>With intermittent major depressive episodes, with current episode:</strong> Full criteria for a major depressive episode are currently met, but there have been periods of at least eight weeks in at least the preceding two years with symptoms below the threshold for a full major depressive episode.</td> </tr> <tr> <td class=\"indent1\"><strong>With intermittent major depressive episodes, without current episode:</strong> Full criteria for a major depressive episode are not currently met, but there has been one or more major depressive episodes in at least the preceding two years.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em> current severity:</td> </tr> <tr> <td class=\"indent1\">Mild</td> </tr> <tr> <td class=\"indent1\">Moderate</td> </tr> <tr> <td class=\"indent1\">Severe</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright © 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91114 Version 5.0</div></div></div>"},"91115":{"type":"graphic_table","displayName":"Antibiotics used for the treatment of P. aeruginosa infections","title":"Antibiotics used for the treatment of <EM>Pseudomonas aeruginosa </EM>infections in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics used for the treatment of <EM>Pseudomonas aeruginosa </EM>infections in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Penicillins*</td> <td>Ticarcillin-clavulanate (not available in the United States or Canada)</td> <td>3.1 g every four hours</td> </tr> <tr class=\"divider_bottom\"> <td>Piperacillin-tazobactam</td> <td> <p>4.5 g every six hours<sup>&#182;</sup></p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Cephalosporins</td> <td>Ceftazidime</td> <td>2 g every eight hours</td> </tr> <tr> <td>Cefepime</td> <td>2 g every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td>Cefoperazone</td> <td>2 g every 12 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cephalosporin-beta-lactamase inhibitor combinations<sup>&#916;</sup></td> <td>Ceftazidime-avibactam</td> <td>2.5 g every&nbsp;eight hours</td> </tr> <tr class=\"divider_bottom\"> <td>Ceftolozane-tazobactam</td> <td>1.5 g every&nbsp;eight hours</td> </tr> <tr class=\"divider_bottom\"> <td>Monobactams</td> <td>Aztreonam</td> <td>2 g every eight hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Fluoroquinolones<sup>&#9674;</sup></td> <td>Ciprofloxacin</td> <td>400 mg every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td>Levofloxacin</td> <td>750 mg once daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Carbapenems<sup>&#167;</sup></td> <td>Imipenem</td> <td>500 mg every eight hours<sup>&#165;</sup></td> </tr> <tr> <td>Meropenem</td> <td>1 g every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td>Doripenem</td> <td>500 mg every eight hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Aminoglycosides<sup>&#135;</sup></td> <td>Gentamicin</td> <td class=\"divider_bottom\" rowspan=\"3\">Dosing of aminoglycosides is discussed in detail in a dedicated topic</td> </tr> <tr> <td>Tobramycin</td> </tr> <tr class=\"divider_bottom\"> <td>Amikacin</td> </tr> <tr> <td rowspan=\"2\">Polymyxins<sup>&#134;</sup></td> <td>Colistin</td> <td rowspan=\"2\">Dosing of&nbsp;polymyxins is discussed in detail in a dedicated topic</td> </tr> <tr> <td>Polymyxin B</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses refer to intravenous administration.</div><div class=\"graphic_footnotes\">* Ticarcillin (3 g every four hours) and piperacillin (4 g every four hours) each have antipseudomonal activity, but are not available in the United States as single agents without the beta-lactamase inhibitor.<br />¶ Piperacillin-tazobactam is generally infused over 30 minutes. Some evidence suggests that an extended infusion (eg, 3.375 g or 4.5 g over four hours every eight hours) may be associated with better outcomes among critically ill patients. Refer to other UpToDate content on prolonged infusions of beta-lactam antibiotics.<br />Δ Combination cephalosporin and beta-lactamase inhibitor agents are generally reserved for specific types of infections (such as complicated intra-abdominal or complicated urinary tract infection) resistant to other agents.<br /><FONT class=lozenge>◊</FONT> Fluoroquinolones are the only class of antibiotics with antipseudomonal activity that have an oral formulation.<br />§ Carbapenems have the propensity to induce resistance during treatment.<br />¥ Imipenem can be given up to a dose of 1 g every eight hours for severe infection.<br />‡ Aminoglycosides are generally used in combination with a beta-lactam and should NOT be used as a single agent for infections other than those of the lower urinary tract.<br />† Polymyxins&nbsp;are generally reserved for the treatment of serious infections caused by<EM> Pseudomonas</EM> isolates resistant to other agents. In such cases, they are often administered in combination with other antimicrobial agents and with a loading dose preceding the standing dose. Refer to other UpToDate content for more details on polymyxin dosing. </div><div id=\"graphicVersion\">Graphic 91115 Version 7.0</div></div></div>"},"91117":{"type":"graphic_picture","displayName":"Scleromyxedema hands","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:281px;\" src=\"images/DERM/91117_Scleromyxedema_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Firm, waxy, closely spaced papules of 2 to 3 mm diameter involving the hands.</div><div id=\"graphicVersion\">Graphic 91117 Version 1.0</div></div></div>"},"91118":{"type":"graphic_picture","displayName":"Scleromyxedema lower extremity","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:458px; height:504px;\" src=\"images/DERM/91118_Scleromyxedema_low_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerodermoid skin with papules and erythema on the thighs.</div><div id=\"graphicVersion\">Graphic 91118 Version 1.0</div></div></div>"},"91119":{"type":"graphic_picture","displayName":"Scleromyxedema papules","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:389px; height:504px;\" src=\"images/DERM/91119_Scleromyxedema_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules often are arranged in a strikingly linear array.</div><div id=\"graphicVersion\">Graphic 91119 Version 1.0</div></div></div>"},"91120":{"type":"graphic_picture","displayName":"Scleromyxedema glabella","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:307px;\" src=\"images/DERM/91120_Scleromyxedema_glabella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The glabella typically is involved with deep longitudinal furrows that produce the characteristic leonine facies.</div><div id=\"graphicVersion\">Graphic 91120 Version 1.0</div></div></div>"},"91121":{"type":"graphic_picture","displayName":"Scleromyxedema Shar-Pei sign","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/DERM/91121_Scleromyxedema_shar_pei.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep furrowing is often evident on the trunk (\"Shar-Pei sign\").</div><div id=\"graphicVersion\">Graphic 91121 Version 1.0</div></div></div>"},"91122":{"type":"graphic_picture","displayName":"Scleromyxedema doughnut sign","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/91122_Scleromyxedema_doughnut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the proximal interphalangeal joints, a central depression surrounded by an elevated rim (due to skin thickening) can be seen (\"doughnut sign\").</div><div id=\"graphicVersion\">Graphic 91122 Version 1.0</div></div></div>"},"91123":{"type":"graphic_picture","displayName":"Scleromyxedema histopathology","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:474px;\" src=\"images/DERM/91123_Scleromyxedema_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic findings in scleromyxedema. Mucin deposition, increased fibroblasts, and mucin in the upper/mid dermis.</div><div id=\"graphicVersion\">Graphic 91123 Version 1.0</div></div></div>"},"91124":{"type":"graphic_picture","displayName":"Scleromyxedema histopathology fibroblasts","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/DERM/91124_Scleromyxedem_histo_fibro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The histopathologic triad of scleromyxedema: mucin deposition, increase in collagen, and marked proliferation of irregularly arranged fibroblasts in the dermis.</div><div id=\"graphicVersion\">Graphic 91124 Version 1.0</div></div></div>"},"91125":{"type":"graphic_picture","displayName":"Scleromyxedema histopathology Alcian blue stain","title":"Scleromyxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleromyxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:347px;\" src=\"images/DERM/91125_Sclerom_histo_Alcian_blue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of scleromyxedema. A diffuse deposit of mucin comprised primarily of hyaluronic acid in the upper- and mid-reticular dermis confirmed with Alcian blue stain at pH 2.5.</div><div id=\"graphicVersion\">Graphic 91125 Version 1.0</div></div></div>"},"91126":{"type":"graphic_picture","displayName":"Actinic cheilitis histo","title":"Histologic features of actinic cheilitis","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Histologic features of actinic cheilitis</div><div class=\"cntnt\"><img style=\"width:502px; height:377px;\" src=\"images/DERM/91126_Actinic_cheilitis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In actinic cheilitis, keratinocyte atypia and disorder of the lower portions of the epithelium are accompanied by solar elastosis in the dermis.</div><div class=\"graphic_reference\">Courtesy of Tammie Ferringer, MD.</div><div id=\"graphicVersion\">Graphic 91126 Version 1.0</div></div></div>"},"91127":{"type":"graphic_picture","displayName":"Discoid lupus lips","title":"Discoid lupus ","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Discoid lupus </div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/91127_Discoid_lupus_lips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques with scale involving the lips and perioral area in a patient with discoid lupus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91127 Version 1.0</div></div></div>"},"91151":{"type":"graphic_diagnosticimage","displayName":"Parastomal hernia on CT","title":"Parastomal hernia on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Parastomal hernia on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:332px;\" src=\"images/RADIOL/91151_Parastomal_hernia_on_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the lower abdomen (A) shows a loop of small bowel herniating through a colostomy defect (arrow). Contrast is seen in the colostomy bag (arrowhead). Image B is a coronal reconstruction and shows the herniated small bowel in the subcutaneous tissues (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91151 Version 3.0</div></div></div>"},"91152":{"type":"graphic_figure","displayName":"ECG patterns of Brugada syndrome","title":"ECG patterns of Brugada syndrome in leads V1-V2","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">ECG patterns of Brugada syndrome in leads V1-V2</div><div class=\"cntnt\"><img style=\"width:528px; height:255px;\" src=\"images/CARD/91152_ECG_patt_BrS_V1V2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This typical <STRONG>coved pattern</STRONG> present in V1-V2 shows the following:<br /><OL>&#xD;&#xA;<LI>At the end of QRS, an ascending and quick slope with a high take-off ≥2 mm followed by concave or rectilinear downsloping ST. There are few cases of coved pattern with a high take-off between 1 and 2 mm.</LI></LI>&#xD;&#xA;<LI>There is no clear r' wave.</LI>&#xD;&#xA;<LI>The high take-off often does not correspond with the J point.</LI>&#xD;&#xA;<LI>At 40 ms of high take-off, the decrease in amplitude of ST is ≤4 mm. In RBBB and athletes, it is much higher.</LI>&#xD;&#xA;<LI>ST at high take-off N ST at 40 ms N ST at 80 ms.</LI>&#xD;&#xA;<LI>ST is followed by negative and symmetric T wave.</LI>&#xD;&#xA;<LI>The duration of QRS is longer than in RBBB, and there is a mismatch between V1 and V6.</LI></OL>(B) This typical <STRONG>saddle-back pattern</STRONG> present in V1-V2 shows&nbsp;the following:<br /><OL>&#xD;&#xA;<LI>High take-off of r' (that often does not coincide with J point) ≥2 mm.</LI>&#xD;&#xA;<LI>Descending arm of r' coincides with beginning of ST (often is not well seen).</LI>&#xD;&#xA;<LI>Minimum ST ascent ≥0.5 mm.</LI>&#xD;&#xA;<LI>ST is followed by positive T wave in V2 (T peak N ST minimum N 0) and of variable morphology in V1.</LI>&#xD;&#xA;<LI>The characteristics of triangle formed by r' allow to define different criteria useful for diagnosis. &#xD;&#xA;<UL>&#xD;&#xA;<LI>β angle.</LI>&#xD;&#xA;<LI>Duration of the base of the triangle of r' at 5 mm from the high take-off greater than 3.5 mm.</LI></UL>&#xD;&#xA;<LI>The duration of QRS is longer in BrP type 2 than in other cases with r' in V1, and there is a mismatch between V1 and V6.</LI></OL></div><div class=\"graphic_reference\">Reproduced from: Bayés de Luna A, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol 2012; 45:433. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91152 Version 1.0</div></div></div>"},"91154":{"type":"graphic_table","displayName":"Summary of PPV-23-deficient response phenotypes","title":"Summary of PPV-23-deficient response phenotypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of PPV-23-deficient response phenotypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phenotype*</td> <td class=\"subtitle1\">PPV-23 response, age &#62;6 years</td> <td class=\"subtitle1\">PPV-23 response, age &#60;6 years</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Severe</td> <td>&#8804;2 protective titers (&#8805;1.3 mcg/mL)</td> <td>&#8804;2 protective titers (&#8805;1.3 mcg/mL)</td> <td>Protective titers present are low (&#60;1.3 to 2.0 mcg/mL)</td> </tr> <tr> <td>Moderate</td> <td>&#60;70% of serotypes are protective (&#8805;1.3 mcg/mL)</td> <td>&#60;50% of serotypes are protective (&#8805;1.3 mcg/mL)</td> <td>Protective titers present to &#8805;3 serotypes</td> </tr> <tr> <td>Mild</td> <td>Failure to generate protective titers to multiple serotypes or failure of a twofold increase in 70% of serotypes</td> <td>Failure to generate protective titers to multiple serotypes or failure of a twofold increase in 50% of serotypes</td> <td>Twofold increases assume a prevaccination titer of less than the values noted below<sup>&#182;</sup></td> </tr> <tr> <td>Memory</td> <td>Loss of response within six months</td> <td>Loss of response within six months</td> <td>Adequate initial response to &#8805;50% of serotypes in children &#60;6 years of age and &#8805;70% in those &#62;6 years of age. Might respond to a second dose of PPV-23 after&nbsp;one year.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV-23: 23-valent pneumococcal polysaccharide vaccine.<br />* All phenotypes assume a history of infection.<br />¶ Twofold increases assume a preimmunization titer of between 4.4 and 10.3 mcg/mL, depending on the pneumococcal serotype.</div><div class=\"graphic_reference\">Reproduced from: Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the basic and clinical immunology interest section of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2012; 130:S1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91154 Version 8.0</div></div></div>"},"91155":{"type":"graphic_diagnosticimage","displayName":"CT sleeve gastrectomy","title":"Sleeve gastrectomy on CT scan","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Sleeve gastrectomy on CT scan</div><div class=\"cntnt\"><img style=\"width:596px; height:438px;\" src=\"images/RADIOL/91155_CT_sleeve_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper abdomen (A) shows the tubular appearance of the stomach (arrow) following sleeve gastrectomy. Image B shows the normal shape of the empty stomach (arrow) in axial projection. Image C is a sagittal reconstruction of the CT scan and shows the tubular appearance of the stomach following sleeve gastrectomy (arrow). Image D is a sagittal reconstruction of a normal almost empty stomach (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91155 Version 1.0</div></div></div>"},"91157":{"type":"graphic_diagnosticimage","displayName":"CT reflux aspiration sleeve gastrectomy","title":"Reflux and aspiration following sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Reflux and aspiration following sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:598px; height:251px;\" src=\"images/RADIOL/91157_CT_reflux_aspir_sleeve_gast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reconstructed in the sagittal plane (A) shows gastroesophageal reflux (arrow). Image B is a CT scan through the lower chest and shows bilateral aspiration pneumonia (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91157 Version 1.0</div></div></div>"},"91158":{"type":"graphic_diagnosticimage","displayName":"MRI pleomorphic undifferentiated sarcoma","title":"Pleomorphic undifferentiated sarcoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Pleomorphic undifferentiated sarcoma on MRI</div><div class=\"cntnt\"><img style=\"width:573px; height:372px;\" src=\"images/RADIOL/91158_MRI_pleom_undiff_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1-weighted MRI in the coronal projection prior to contrast (A) shows a mass in the vastus lateralis muscle of the right thigh. There are surrounding soft tissue changes (arrow). The mass enhances following gadolinium administration (arrow B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91158 Version 1.0</div></div></div>"},"91159":{"type":"graphic_diagnosticimage","displayName":"CT pleomorphic undifferentiated sarcoma","title":"Pleomorphic undifferentiated sarcoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Pleomorphic undifferentiated sarcoma on CT scan</div><div class=\"cntnt\"><img style=\"width:597px; height:386px;\" src=\"images/RADIOL/91159_CT_pleomo_undiff_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reformatted in the coronal plane following contrast administration (A) shows an enhancing heterogeneous mass in the vastus lateralis muscle of the right thigh. An axial image (B) shows the mass as well as the edema in the surrounding soft tissues (short arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91159 Version 1.0</div></div></div>"},"91160":{"type":"graphic_diagnosticimage","displayName":"PET pleomorphic undifferentiated sarcoma","title":"Pleomorphic undifferentiated sarcoma on PET scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleomorphic undifferentiated sarcoma on PET scan</div><div class=\"cntnt\"><img style=\"width:421px; height:329px;\" src=\"images/RADIOL/91160_PET_pleomo_undif_sarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A PET scan projected in the coronal plane (A) shows a hypermetabolic mass in the vastus lateralis muscle of the right thigh. The central portion of the mass has diminished FDG uptake. A 3D reconstruction of the head, chest, and abdomen (B) shows no evidence of metastatic disease. Normal accumulation of FDG is seen in the brain, heart, kidneys, and bladder.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; FDG: fluorodeoxyglucose; 3D: three dimensional.</div><div id=\"graphicVersion\">Graphic 91160 Version 2.0</div></div></div>"},"91161":{"type":"graphic_diagnosticimage","displayName":"CT and VC sigmoid colon diverticulosis","title":"Diverticulosis of sigmoid colon with CT and VC","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Diverticulosis of sigmoid colon with CT and VC</div><div class=\"cntnt\"><img style=\"width:580px; height:221px;\" src=\"images/RADIOL/91161_CT_VC_sigmo_col_divert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the pelvis (A) shows multiple air filled diverticula (arrows) of the sigmoid colon. Image B is a virtual colonoscopy of the sigmoid colon showing the necks of sigmoid colon diverticula (arrows) from a luminal perspective.</div><div class=\"graphic_footnotes\">3D: three-dimensional; CT: computed tomography; VC: virtual colonoscopy.</div><div id=\"graphicVersion\">Graphic 91161 Version 1.0</div></div></div>"},"91162":{"type":"graphic_algorithm","displayName":"Diagnostic approach to splenomegaly in children","title":"Diagnostic approach to the child with unexplained splenomegaly*","html":"<div class=\"graphic\"><div style=\"width: 1303px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the child with unexplained splenomegaly*</div><div class=\"cntnt\"><img style=\"width:1283px; height:2324px;\" src=\"images/PEDS/91162_Evaluatsplenomegalychild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content. For detailed discussion of the diagnostic approach to the conditions listed in this algorithm, refer to separate UpToDate content on the specific disorder(s).</div><div class=\"graphic_footnotes\">EBV: Epstein-Barr virus; CMV: cytomegalovirus; CXR: chest radiograph; LCH: Langerhans cell histiocytosis; HLH: hematophagocytic lymphohistiocytosis; ALPS: autoimmune lymphoproliferative syndrome; POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; CT: computed tomography; ALL: acute lymphoblastic leukemia; AML: acute myelogenous leukemia; CBC: complete blood count; TB: tuberculosis; HIV: human immunodeficiency virus; IV: intravenous; SLE: systemic lupus erythematosus; ANA: antinuclear antibody; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CVID: common variable immunodeficiency; LFTs: liver function tests; U/S: ultrasound; RBC: red blood cell; G6PD: glucose-6-phosphate dehydrogenase;&nbsp;LDH: lactate dehydrogenase; MRI: magnetic resonance imaging.<br />* The evaluation of a child with unexplained splenomegaly generally includes history, physical examination, CBC (with platelet count and differential), reticulocyte count, review of the peripheral smear, LFTs, serologies for EBV and CMV, CXR, and abdominal U/S (with Doppler imaging). The diagnosis may be apparent from the initial evaluation (eg, physical examination may reveal clear signs mononucleosis; CBC may reveal peripheral blasts; abdominal U/S may reveal portal hypertension, portal thrombosis, or discrete splenic lesion). In most cases, additional testing is needed to confirm the specific diagnosis. If the work-up for the suspected etiology is negative, additional evaluation for other etiologies is generally warranted.</div><div id=\"graphicVersion\">Graphic 91162 Version 3.0</div></div></div>"},"91163":{"type":"graphic_table","displayName":"Drugs associated with SJS-TEN","title":"Drugs associated with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Strongly associated*</td> </tr> <tr> <td class=\"indent1\">Allopurinol</td> </tr> <tr> <td class=\"indent1\">Amifostine</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Etoricoxib<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Lamotrigine</td> </tr> <tr> <td class=\"indent1\">Meloxicam</td> </tr> <tr> <td class=\"indent1\">Nevirapine</td> </tr> <tr> <td class=\"indent1\">Oxcarbazepine</td> </tr> <tr> <td class=\"indent1\">Phenobarbital, primidone</td> </tr> <tr> <td class=\"indent1\">Phenytoin, fosphenytoin</td> </tr> <tr> <td class=\"indent1\">Piroxicam, tenoxicam<sup>​&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Sulfadiazine, sulfadoxine, sulfamethoxazole, sulfasalazine</td> </tr> <tr> <td class=\"subtitle1_single\">Associated<sup>​&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Amoxicillin, ampicillin</td> </tr> <tr> <td class=\"indent1\">Azithromycin, clarithromycin, erythromycin</td> </tr> <tr> <td class=\"indent1\">Cefadroxil, cefixime, ceftriaxone, cefuroxime</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin, levofloxacin, pefloxacin<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> </tr> <tr> <td class=\"indent1\">Dipyrone (metamizole)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Pipemidic acid<sup>​&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Rifampin (rifampicin)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.<br />* Significant association in case-control studies with a lower limit of the confidence interval ≥5 and unpublished data from the International Registry of&nbsp;Severe Cutaneous Adverse Reactions&nbsp;(RegiSCAR).<br />¶ Etoricoxib, tenoxicam, and dipyrone are NSAIDs available in some countries outside North America.<br />Δ&nbsp;Significant association in case-control studies with a lower limit of the confidence interval &lt;5.<br />◊ Pefloxacin and pipemidic acid are antimicrobials available in some countries outside North America.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.</li>&#xD;&#xA;    <li>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35.</li>&#xD;&#xA;    <li>Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis. Clin Pharmacol Ther 2010; 88:60.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 91163 Version 5.0</div></div></div>"},"91165":{"type":"graphic_table","displayName":"Definitions from ACR and EULAR criteria for SSc","title":"Definitions of items in the ACR/EULAR criteria for the classification of SSc","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of items in the ACR/EULAR criteria for the classification of SSc</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td>Skin thickening</td> <td>Skin thickening or hardening not due to scarring after injury, trauma, etc.</td> </tr> <tr class=\"divider_bottom\"> <td>Puffy fingers</td> <td>Swollen digits&#8212;a diffuse, usually nonpitting increase in soft tissue mass of the digits extending beyond the normal confines of the joint capsule. Normal digits are tapered distally with the tissues following the contours of the digital bone and joint structures. Swelling of the digits obliterates these contours. Not due to other causes such as inflammatory dactylitis.</td> </tr> <tr class=\"divider_bottom\"> <td>Fingertip ulcers or pitting scars</td> <td>Ulcers or scars distal to or at the proximal interphalangeal joint not thought to be due to trauma. Digital pitting scars are depressed areas at digital tips as a result of ischemia, rather than trauma or exogenous causes.</td> </tr> <tr class=\"divider_bottom\"> <td>Telangiectasia</td> <td>Telangiectasiae are visible macular dilated superficial blood vessels, which collapse upon pressure and fill slowly when pressure is released. Telangiectasiae in a scleroderma-like pattern are round and well demarcated and found on hands, lips, and&nbsp;inside of the mouth, and/or are large mat-like telangiectasiae. Distinguishable from rapidly filling spider angiomas with central arteriole and from dilated superficial vessels.</td> </tr> <tr class=\"divider_bottom\"> <td>Abnormal nailfold capillary pattern consistent with systemic sclerosis</td> <td>Enlarged capillaries and/or capillary loss with or without pericapillary hemorrhages at the nailfold. May also be seen on the cuticle.</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary arterial hypertension</td> <td>Pulmonary arterial hypertension diagnosed by right-sided heart catheterization according to standard definitions.</td> </tr> <tr class=\"divider_bottom\"> <td>Interstitial lung disease</td> <td>Pulmonary fibrosis seen on high-resolution computed tomography or chest radiography, most pronounced in the basilar portions of the lungs, or occurrence of \"Velcro\" crackles on auscultation, not due to another cause such as congestive heart failure.</td> </tr> <tr class=\"divider_bottom\"> <td>Raynaud's phenomenon</td> <td>Self-reported or reported by a physician, with at least a two-phase color change in finger(s) and often toe(s) consisting of pallor, cyanosis, and/or reactive hyperemia in response to cold exposure or emotion; usually one phase is pallor.</td> </tr> <tr> <td>SSc-related autoantibodies</td> <td>Anticentromere antibody or centromere pattern seen on antinuclear antibody testing, anti-topoisomerase I antibody (also known as anti-Scl-70 antibody), or anti-RNA polymerase III antibody. Positive according to local laboratory standards.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Definitions of the items/sub-items in the ACR/EULAR criteria for the classification of systemic sclerosis.</div><div class=\"graphic_footnotes\">ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; SSc: systemic sclerosis.</div><div class=\"graphic_reference\">From: van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65:2737. Copyright &copy; 2013 by the American College of Rheumatology. Reproduced with permission from John Wiley &amp; Sons, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91165 Version 2.0</div></div></div>"},"91166":{"type":"graphic_table","displayName":"The ACR and EULAR criteria for the classification of SSc","title":"The ACR/EULAR criteria for the classification of SSc*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The ACR/EULAR criteria for the classification of SSc*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Sub-item(s)</td> <td class=\"subtitle1\">Weight/score<sup>&#182;</sup></td> </tr> <tr> <td>Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints <em>(sufficient criterion)</em></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">9</td> </tr> <tr> <td rowspan=\"2\">Skin thickening of the fingers <em>(only count the higher score)</em></td> <td>Puffy fingers</td> <td class=\"centered\">2</td> </tr> <tr> <td>Sclerodactyly of the fingers (distal to the metacarpophalangeal joints but proximal to the proximal interphalangeal joints)</td> <td class=\"centered\">4</td> </tr> <tr> <td rowspan=\"2\">Fingertip lesions <em>(only count the higher score)</em></td> <td>Digital tip ulcers</td> <td class=\"centered\">2</td> </tr> <tr> <td>Fingertip pitting scars</td> <td class=\"centered\">3</td> </tr> <tr> <td>Telangiectasia</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">2</td> </tr> <tr> <td>Abnormal nailfold capillaries</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">2</td> </tr> <tr> <td rowspan=\"2\">Pulmonary arterial hypertension and/or interstitial lung disease <em>(maximum score is 2)</em></td> <td>Pulmonary arterial hypertension</td> <td class=\"centered\">2</td> </tr> <tr> <td>Interstitial lung disease</td> <td class=\"centered\">2</td> </tr> <tr> <td>Raynaud's phenomenon</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">3</td> </tr> <tr> <td>SSc-related autoantibodies (anticentromere, anti-topoisomerase I [anti-Scl-70], anti-RNA polymerase III) <em>(maximum score is 3)</em></td> <td> <p>Anticentromere</p> <p>Anti-topoisomerase I</p> Anti-RNA polymerase III</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ACR/EULAR criteria for the classification of systemic sclerosis.</div><div class=\"graphic_footnotes\">ACR: American College of Rheumatology; EULAR: European League Against Rheumatism; SSc: systemic sclerosis.<br />* These criteria are applicable to any patient considered for inclusion in an SSc study. The criteria are not applicable to patients with skin thickening sparing the fingers or to patients who have a scleroderma-like disorder that better explains their manifestations (eg, nephrogenic sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, scleredema diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft-versus-host disease, diabetic cheiroarthropathy).<br />¶ The total score is determined by adding the maximum weight (score) in each category. Patients with a total score of ≥9 are classified as having definite SSc.</div><div class=\"graphic_reference\">From: van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65:2737. Copyright &copy; 2013 by the American College of Rheumatology. Reproduced with permission from John Wiley &amp; Sons, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91166 Version 3.0</div></div></div>"},"91167":{"type":"graphic_table","displayName":"Clinical manifestations of cutaneous and systemic mastocytosis","title":"Clinical manifestations of cutaneous and systemic mastocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of cutaneous and systemic mastocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ system affected</td> <td class=\"subtitle1\">Symptoms due to acute and/or chronic mast cell-mediator release</td> <td class=\"subtitle1\">Symptoms, physical findings, and abnormalities of routine laboratories due to organ infiltration</td> </tr> <tr> <td>Skin</td> <td>Flushing, pruritus</td> <td><strong>Multiple</strong>: Urticaria pigmentosa, plaque-like or nodular lesions, diffuse skin involvement, bullous eruptions, isolated mastocytoma, or telangiectasias</td> </tr> <tr> <td>Gastrointestinal tract</td> <td>Nausea, bloating, chronic diarrhea, hyperacidity, gastroduodenal ulcer disease, chronic abdominal pain, vomiting</td> <td> <p><strong>Stomach and duodenal infiltration</strong>: Gastroduodenal ulcers (possibly, although more clearly related to mediator release), steatorrhea, malabsorption</p> <strong>Liver infiltration</strong>: Elevated transaminases, portal hypertension, and ascites (only in advanced forms of the disease)</td> </tr> <tr> <td>Musculoskeletal*</td> <td> <p>Adults: Fibromyalgia-like diffuse musculoskeletal pain, pain in long bones, osteoporosis, osteopenia, pathologic fractures</p> </td> <td>In mast cell sarcoma of the bone (rare), local symptoms (eg, pain, deformity, pathologic fracture) occur at the involved site</td> </tr> <tr> <td>Cardiovascular</td> <td>Adults: Episodes of vasodilation, tachycardia, hypotension, collapse<br /> Infants: Apneic spells, cyanosis</td> <td>&nbsp;</td> </tr> <tr> <td>Hematologic (lymph nodes, spleen, bone marrow)</td> <td>&nbsp;</td> <td> <p><strong>Lymph nodes and spleen</strong>: Lymphadenopathy, splenomegaly (with hematologic findings of hypersplenism: nonimmune hemolytic anemia)</p> <strong>Bone marrow</strong>: Anemia (mild-to-moderate, in approximately 50%), thrombocytopenia (usually asymptomatic), eosinophilia (approximately 25%), myeloproliferative or myelodysplastic findings, fibrosis</td> </tr> <tr> <td>Neurologic, psychiatric</td> <td>Adults: Anxiety, depression, headache, mood changes, inability to concentrate, hypersomnolence, irritability, \"mixed organic brain syndrome\"<br /> Children: Aggressive behavior</td> <td>&nbsp;</td> </tr> <tr> <td>Systemic*</td> <td>Adults: Fatigue, cachexia</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Signs and symptoms of both acute and chronic release of mast cell mediators are seen in patients with cutaneous and systemic forms of mastocytosis. Episodic symptoms tend to occur in patterns that are characteristic for a given patient, but not all patients demonstrate all of the signs and symptoms described in the table. In patients with cutaneous mastocytosis, mast cells infiltrate the skin. In patients with systemic mastocytosis, mast cells may infiltrate the skin, gastrointestinal tract and liver, lymph nodes, spleen, and bone marrow.</div><div class=\"graphic_footnotes\">* Rare in children.</div><div id=\"graphicVersion\">Graphic 91167 Version 10.0</div></div></div>"},"91170":{"type":"graphic_table","displayName":"Ethanol dosing for the treatment of toxic alcohol poisoning","title":"Ethanol dosing for the treatment of toxic alcohol poisoning*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ethanol dosing for the treatment of toxic alcohol poisoning*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\"> <p>Prepare 10 percent infusion<sup>&#182;</sup><sup>[1,2]</sup></p> </td> </tr> <tr> <td class=\"indent1\"><strong>1.</strong> Withdraw 100 mL of fluid from 1 liter of 5 percent dextrose water (D5W)</td> </tr> <tr> <td class=\"indent1\"><strong>2.</strong> Replace with 100 mL of 98 percent dehydrated alcohol (ethanol) injection solution, USP (preservative- and bacteriostat-free) to create a 10 percent ethanol solution</td> </tr> <tr> <td class=\"indent1\"><strong>3.</strong> <strong>Check vials/ampules.</strong> In some countries, pharmaceutical grade 95 percent ethanol is available. Do <strong>NOT</strong> use denatured alcohol or any other type of alcohol<sup>&#916;</sup>.</td> </tr> <tr> <td class=\"indent1\"><strong>4.</strong> Prior to dilution, dehydrated alcohol injection should be purified through a 0.22 micron filter because these solutions may not be pyrogen-free</td> </tr> <tr> <td class=\"subtitle1_single\">Loading dose</td> </tr> <tr> <td class=\"indent1\">Infuse 10 mL/kg of 10 percent ethanol over 60 minutes to raise serum ethanol concentration by about 100 mg/dL (22 mmol/L)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Maintenance dose</td> </tr> <tr> <td class=\"indent1\"><strong>1.</strong> Following administration of the loading dose, begin maintenance infusion of 10 percent ethanol solution at 1 mL/kg per hour</td> </tr> <tr> <td class=\"indent1\"><strong>2.</strong> Titrate infusion rate to maintain serum ethanol concentration of approximately 100 mg/dL (22 mmol/L) based on serial ethanol concentrations measured initially every 1 to 2 hours</td> </tr> <tr> <td class=\"indent1\"><strong>3.</strong> Actual maintenance dose requirements vary from 0.8 mL/kg per hour to 2 mL/kg per hour (and higher still during hemodialysis)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>4.</strong> Once serial measurements demonstrate stable ethanol serum levels of &#8776; 100 mg/dL (22 mmol/L), frequency of measurements may be decreased to every 2 to 4 hours</td> </tr> <tr> <td class=\"indent1\"><strong>5.</strong> Larger toxic ingestions may warrant targeting a higher serum ethanol concentration goal of up to 150 mg/dL (33 mmol/L)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>6.</strong> Continue maintenance infusion until either serum methanol or ethylene glycol concentration is undetectable (in patients with end-organ toxicity) <strong>OR</strong> &#60;20 mg/dL (SI units: methanol &#60;6.2 mmol/L; ethylene glycol &#60;3.2 mmol/L) and patient is asymptomatic and with a normal pH. Two or more days of ethanol infusion may be required, depending upon amount of ingestion, toxicity, and use of hemodialysis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* NOTE: Fomepizole is preferred antidotal therapy. Ethanol shown in this table is an alternate option when fomepizole is unavailable or when there is a history of a severe adverse reaction due to fomepizole warranting its avoidance. Refer to topic.<br />¶ Prepared as above, a 10 percent (volume to volume) ethanol solution provides approximately 0.8 grams of ethanol per 10 mL. A 10 mL/kg loading dose therefore provides ≈ 0.8 grams ethanol/kg. 10 percent ethanol solution is hyperosmolar (1700 mosm/L) and can cause phlebitis. Central venous catheter administration using an infusion pump is therefore preferred when feasible.<br />Δ When pharmaceutical grade ethanol is not available, alcoholic beverages can be substituted; a 20 percent ethanol solution (eg, 80 proof or 40 percent [volume to volume] diluted in an equal volume of D5W) can be administered orally or via a nasogastric tube at&nbsp;half the volumes recommended herein for a 10 percent intravenous infusion.<br /><FONT class=lozenge>◊</FONT> Rate of elimination of ethanol is subject to wide inter-individual variability and is generally increased in male patients and those who consume alcohol chronically. Typical clearance rates are 15 to 20 mg/dL/hour (3.3 to 4.3 mmol/L per hour). The half-life of ethanol increases as serum levels rise such that small adjustments to dose can produce disproportionate changes in ethanol serum concentrations. Ethanol dose requirement are increased by about 50 percent during hemodialysis.<br />§ The targeted ethanol serum concentration should be at least one quarter of the serum methanol or ethylene glycol concentration as measured in conventional (mg/dL) units. Refer to topic for empiric adjustment.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Barceloux DG, Krenzelok EP, Olson K, et al. American academy of clinical toxicology practice guidelines on the treatment of ethylene glycol poisoning. J Toxicol Clin Toxicol 1999; 37:537. </LI>&#xD;&#xA;<LI>Barceloux DG, Bond GR, Krenzelok EP, et al. American academy of clinical toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol 2002; 40:415.</LI></OL></div><div id=\"graphicVersion\">Graphic 91170 Version 4.0</div></div></div>"},"91173":{"type":"graphic_figure","displayName":"The adenoma carcinoma sequence in small bowel adenocarcinomas","title":"The adenoma carcinoma sequence in small bowel adenocarcinomas","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">The adenoma carcinoma sequence in small bowel adenocarcinomas</div><div class=\"cntnt\"><img style=\"width:529px; height:623px;\" src=\"images/ONC/91173_Adenoma_carc_seq_adenocarc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">APC:&nbsp;adenomatous polyposis coli; TGF: transforming growth factor.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Clinical Oncology. Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013; 10:534. Copyright &copy; 2013. <a href=\"http://www.nature.com/nrclinonc\" target=\"_blank\">www.nature.com/nrclinonc</a>.</div><div id=\"graphicVersion\">Graphic 91173 Version 1.0</div></div></div>"},"91180":{"type":"graphic_diagnosticimage","displayName":"Limited amniochorionic separation before amniocentesis","title":"Limited amniochorionic separation before amniocentesis","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Limited amniochorionic separation before amniocentesis</div><div class=\"cntnt\"><img style=\"width:587px; height:398px;\" src=\"images/OBGYN/91180_Limit_amniochorionic_separa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to area of limited amniochorionic separation present before amniocentesis at 16 weeks of gestation.</div><div id=\"graphicVersion\">Graphic 91180 Version 2.0</div></div></div>"},"91182":{"type":"graphic_picture","displayName":"Full face NIPPV mask","title":"Full face mask for the application of noninvasive ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full face mask for the application of noninvasive ventilation</div><div class=\"cntnt\"><img style=\"width:233px; height:237px;\" src=\"images/PULM/91182_Full_face_NIPPV_mask.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a typical full face mask that is applied over the nose and mouth. Straps secure the mask in place and help to secure its position. A tight fit ensures that air leaks, which can occur at the interface between the skin and mask, are minimized.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Philips Healthcare.</div><div id=\"graphicVersion\">Graphic 91182 Version 1.0</div></div></div>"},"91184":{"type":"graphic_diagnosticimage","displayName":"Peri-implantitis","title":"Peri-implantitis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Peri-implantitis</div><div class=\"cntnt\"><img style=\"width:511px; height:195px;\" src=\"images/PC/91184_Peri_implantitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph on the left side shows a dental implant placed on the maxillary posterior left side and then restored subsequently. This same implant is seen on the right radiograph eight years later, now with peri-implantitis, with severe angular alveolar bone loss evidenced by the extended radiolucency seen both at the mesial and distal aspects.</div><div class=\"graphic_reference\">Courtesy of Antonio Moretti, DDS, MS.</div><div id=\"graphicVersion\">Graphic 91184 Version 1.0</div></div></div>"},"91186":{"type":"graphic_algorithm","displayName":"Optimal donor selection for allo-HCT","title":"Optimal donor selection for allogeneic HCT","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Optimal donor selection for allogeneic HCT</div><div class=\"cntnt\"><img style=\"width:608px; height:369px;\" src=\"images/HEME/91186_Opti_don_select_alloge_HCT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">allo-HCT: allogeneic hematopoietic cell transplantation; HLA: human leukocyte antigen; NIMA: non-inherited maternal antigen.<br />* Haploidentical donors or umbilical cord blood may be preferred if an urgent transplant is necessary.</div><div id=\"graphicVersion\">Graphic 91186 Version 1.0</div></div></div>"},"91187":{"type":"graphic_table","displayName":"Wheezing due to extrathoracic upper airway diseases","title":"Evaluation of wheezing due to extrathoracic upper airway diseases in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of wheezing due to extrathoracic upper airway diseases in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory</td> <td class=\"subtitle1\">Pulmonary function testing</td> <td class=\"subtitle1\">Chest imaging</td> <td class=\"subtitle1\">Other testing that may be useful in selected patients</td> </tr> <tr class=\"divider_bottom\"> <td>Anaphylaxis with laryngeal edema</td> <td>Abrupt onset of wheezing with urticaria, angioedema, and hypotension</td> <td> <p>Serum or plasma tryptase</p> <p>Plasma histamine</p> <p>Urinary histamine or histamine metabolites</p> Immunoassay to identify culprit</td> <td>&nbsp;</td> <td>Generally not needed unless patient fails to respond to therapy</td> <td>Laryngoscopy to identify swelling of vocal folds (cords) and surrounding tissue</td> </tr> <tr class=\"divider_bottom\"> <td>Cricoarytenoid arthritis</td> <td>Hoarseness and stridor in a patient with rheumatoid arthritis; onset may be acute</td> <td>Rheumatoid factor; anti-cyclic citrullinated peptide antibodies</td> <td>Flow volume loop likely to show variable extrathoracic airflow limitation, but patient may not be able to perform testing</td> <td>&nbsp;</td> <td>Laryngoscopy showing fixation of vocal folds in a midline position</td> </tr> <tr class=\"divider_bottom\"> <td>Vocal&nbsp;fold edema, hematoma, or paralysis</td> <td> <p>Dyspnea and wheeze or stridor</p> History of neck or thyroid surgery or intubation</td> <td>&nbsp;</td> <td>Flow volume loop likely to show variable extrathoracic airflow limitation</td> <td>&nbsp;</td> <td>Laryngoscopy</td> </tr> <tr class=\"divider_bottom\"> <td>Paradoxical vocal&nbsp;fold motion</td> <td>Patients may present with significant respiratory distress and dramatic inspiratory stridor. They may complain of throat tightness, choking sensation, dysphonia, or cough. They may also describe worsening of stridor or wheeze with vigorous exercise.</td> <td>&nbsp;</td> <td>Flow volume loops show variable inspiratory slowing, but may be normal between episodes when patient is asymptomatic</td> <td>&nbsp;</td> <td>Laryngoscopy at time of symptoms shows paradoxical inspiratory and/or early expiratory adduction of vocal folds; glottic aperture may be obliterated except for a posterior diamond-shaped passage</td> </tr> <tr class=\"divider_bottom\"> <td>Laryngeal stenosis</td> <td>History of neck trauma, irradiation, or endotracheal intubation</td> <td>&nbsp;</td> <td>FV loop may show fixed or variable inspiratory slowing</td> <td>Neck radiograph</td> <td>Laryngoscopy</td> </tr> <tr class=\"divider_bottom\"> <td>Laryngocele</td> <td>Usually asymptomatic but may present with hoarseness, dyspnea, dysphagia, inspiratory stridor</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>CT imaging</td> <td>Laryngoscopy showing smooth swelling near false vocal&nbsp;fold and aryepiglottic fold</td> </tr> <tr class=\"divider_bottom\"> <td>Epiglottitis (supraglottitis)</td> <td> <p>Acute onset of severe sore throat out of proportion to pharyngitis; dysphagia</p> Tenderness of neck in area of hyoid bone</td> <td> <p>Complete blood count and differential</p> <p>Blood cultures</p> Epiglottal cultures ONLY after airway is secure</td> <td>&nbsp;</td> <td> <p>Lateral neck radiograph (if obtained) shows enlarged epiglottis protruding from anterior wall of the hypopharynx, \"thumb sign\"</p> Ultrasound shows: \"alphabet P sign\", formed by an acoustic shadow of the swollen epiglottis and hyoid bone</td> <td>Depending on severity of respiratory compromise, flexible laryngoscopy</td> </tr> <tr class=\"divider_bottom\"> <td>Goiter</td> <td>Slowly enlarging thyroid mass</td> <td>TSH</td> <td>Flow volume loop may show airflow limitation depending on location/severity of compression</td> <td>Neck/chest radiograph may show extrinsic airway compression, but CT usually needed to assess degree of narrowing. Thyroid tissue has characteristic appearance on CT.</td> <td>Laryngoscopy or bronchoscopy may be needed to assess airway narrowing</td> </tr> <tr class=\"divider_bottom\"> <td>Postnasal drip syndrome</td> <td>Nasal congestion and rhinorrhea, may have seasonal symptoms</td> <td>&nbsp;</td> <td>FV loop may show extrathoracic variable upper airway obstruction and normal bronchoprovocation</td> <td>May need sinus CT to evaluate cause of postnasal drip if skin testing negative</td> <td> <p>Trial of therapy (eg, older antihistamine if not histamine mediated, intranasal steroids)</p> Allergy skin testing</td> </tr> <tr class=\"divider_bottom\"> <td>Relapsing polychondritis causing larynx, glottis, subglottic inflammation and narrowing</td> <td> <p>Wheeze can be expiratory or inspiratory depending on location of cartilaginous damage</p> Usually has associated involvement of cartilage of ears, nose, ribs, eyes</td> <td> <p>No available diagnostic tests</p> <p>Need to exclude tuberculosis, syphilis</p> Autoantibodies may be positive (eg, ANA, ANCA, RF)</td> <td>Flow volume loop shows variable intrathoracic or extrathoracic airflow limitation</td> <td> <p>Chest x-ray may show tracheal narrowing</p> <p>Lateral neck radiograph may show calcification of tracheal or laryngeal cartilage</p> MRI may differentiate inflammation from fibrosis</td> <td>Patients with relapsing polychondritis should also be evaluated for involvement of cardiac valve cartilage with Doppler echocardiography</td> </tr> <tr class=\"divider_bottom\"> <td>Retropharyngeal abscess</td> <td>Subacute (hours to days) onset of stiff neck, sore throat, fever, history of penetrating trauma to posterior pharynx</td> <td> <p>Complete blood count and differential blood cultures</p> Culture of abscess fluid, if drained</td> <td>&nbsp;</td> <td>Lateral neck radiograph or CT imaging may demonstrate cervical lordosis with retropharyngeal space swelling and gas collections. Imaging is used to determine whether a loculated abscess has developed that can be surgically drained.</td> <td>Direct visualization</td> </tr> <tr class=\"divider_bottom\"> <td>Tonsillar hypertrophy</td> <td>Typically presents in children and adolescents rather than adults</td> <td>&nbsp;</td> <td>Flow volume loop may show inspiratory slowing</td> <td>&nbsp;</td> <td>Enlarged tonsils visible on oropharyngeal exam</td> </tr> <tr> <td>Tumor of pharynx, larynx, upper trachea</td> <td>Hoarseness, dyspnea, stridor</td> <td>&nbsp;</td> <td>Flow volume loop may show inspiratory slowing</td> <td>CT scan of neck</td> <td>Laryngoscopy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FV: flow volume; CT: computed tomography; TSH: thyroid stimulating hormone; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; RF: rheumatoid factor; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91187 Version 3.0</div></div></div>"},"91188":{"type":"graphic_table","displayName":"Wheezing due to central airway diseases","title":"Evaluation of wheezing due to central airway diseases in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of wheezing due to central airway diseases in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory</td> <td class=\"subtitle1\">Pulmonary function testing</td> <td class=\"subtitle1\">Chest imaging</td> <td class=\"subtitle1\">Other</td> </tr> <tr class=\"divider_bottom\"> <td>Goiter</td> <td>Slowly enlarging thyroid mass</td> <td>TSH</td> <td>Flow volume loop may show airflow limitation depending on location/severity of compression</td> <td>Neck/chest radiograph may show extrinsic airway compression, but CT usually needed to assess degree of narrowing. Thyroid tissue has characteristic appearance on CT.</td> <td>Laryngoscopy or bronchoscopy may be needed to assess airway narrowing</td> </tr> <tr class=\"divider_bottom\"> <td>Compression from mediastinal mass/lymphadenopathy</td> <td>Usually gradual onset of dyspnea and wheeze, although can be more rapid with germ cell tumors and aggressive lymphomas</td> <td>Testing may be helpful (eg, complete blood count, beta-HCG, alpha fetoprotein)</td> <td>Flow volume loop likely to show irreversible expiratory airflow limitation</td> <td>Mediastinal mass/lymphadenopathy may be visible on chest radiograph; chest CT usually needed to determine origin of mass and degree of compression</td> <td>Biopsy of mass/lymphadenopathy via EBUS, EUS, mediastinoscopy, Chamberlain procedure, VATS</td> </tr> <tr class=\"divider_bottom\"> <td>Relapsing polychondritis</td> <td> <p>Wheeze can be expiratory or inspiratory depending on location of cartilaginous damage</p> Usually has associated involvement of cartilage of ears, nose, ribs, eyes</td> <td> <p>No available diagnostic tests</p> <p>Need to exclude tuberculosis, syphilis</p> Autoantibodies may be positive (eg, ANA, ANCA, RF)</td> <td>Flow volume loop shows variable intrathoracic or extrathoracic airflow limitation</td> <td> <p>Chest&nbsp;radiograph may show tracheal narrowing; lateral neck radiograph may show calcification of tracheal or laryngeal cartilage; inspiratory and expiratory chest CT views of trachea needed</p> <p>Three dimensional reconstruction of CT may also help with diagnosis</p> MRI may differentiate inflammation from fibrosis</td> <td>Patients with relapsing polychondritis should also be evaluated for involvement of cardiac valve cartilage with Doppler echocardiography</td> </tr> <tr class=\"divider_bottom\"> <td>Respiratory papillomatosis</td> <td> <p>Typically presents in infancy but may recur in adulthood; gradual onset of dyspnea</p> May affect larynx, vocal cords, trachea</td> <td>&nbsp;</td> <td>Flow volume loop likely to show intrathoracic airflow limitation</td> <td>Chest imaging</td> <td>Bronchoscopy, biopsy if not previously done</td> </tr> <tr class=\"divider_bottom\"> <td>Tracheobronchomalacia</td> <td>Predisposing factors (eg, congenital, emphysema, recurrent or prolonged intubation, external compression on the trachea, relapsing polychondritis)</td> <td>&nbsp;</td> <td>Flow volume loop shows variable intrathoracic airflow limitation</td> <td>Inspiratory and expiratory multidetector CT imaging</td> <td>Bronchoscopy to visualize airway</td> </tr> <tr class=\"divider_bottom\"> <td>Tracheal stenosis</td> <td>History of cannulation of trachea by endotracheal or tracheostomy tube; history of lung transplantation or blunt chest trauma</td> <td>&nbsp;</td> <td>Flow volume loops if patient stable</td> <td>Multidetector CT with three dimensional reconstruction may help characterize length and severity of obstruction</td> <td>Bronchoscopy</td> </tr> <tr class=\"divider_bottom\"> <td>Tracheal and bronchial tumors</td> <td>Gradual onset of dyspnea; bronchial tumor may cause focal/unilateral wheeze</td> <td>Serum 5HIAA if bronchial carcinoid suspected</td> <td>Flow volume loop likely to show fixed airflow limitation</td> <td>Chest&nbsp;radiograph and chest CT</td> <td>Bronchoscopy with biopsy</td> </tr> <tr> <td>Vascular ring or aneurysm</td> <td>Slowly progressive dyspnea; dyspnea may be positional or associated with exertion</td> <td>&nbsp;</td> <td>Spirometry likely to show irreversible expiratory airflow limitation</td> <td> <p>Chest&nbsp;radiograph may show right sided aortic arch</p> <p>Chest CT with intravenous contrast</p> MRI</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid stimulating hormone; CT: computed tomography; beta-HCG: beta-human chorionic gonadotrophin; EBUS: endobronchial bronchoscopic ultrasound; EUS: endoscopic ultrasound; VATS: video-assisted thoracoscopic biopsy; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; RF: rheumatoid factor; 5HIAA: 5-hydroxyindoleacetic acid; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91188 Version 3.0</div></div></div>"},"91189":{"type":"graphic_table","displayName":"Wheezing due to lower airway diseases","title":"Evaluation of wheezing due to lower airway diseases other than asthma in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of wheezing due to lower airway diseases other than asthma in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory</td> <td class=\"subtitle1\">Pulmonary function testing</td> <td class=\"subtitle1\">Chest imaging</td> <td class=\"subtitle1\">Other</td> </tr> <tr class=\"divider_bottom\"> <td>Bronchiectasis</td> <td>History of recurrent episodes of productive cough or pneumonia; may also have chronic or recurrent sinusitis; sometimes digital clubbing</td> <td> <p>Quantitative immunoglobulins</p> <p>Immunoglobulin subclasses</p> <p>Assess response to polysaccharide vaccines</p> <p>Testing for cystic fibrosis if not previously done</p> Cultures for bacteria and mycobacteria (MAC, TB)</td> <td>Often shows airflow limitation; may show mixed obstruction and restriction</td> <td> <p>Chest radiograph may show tram tracks or increased bronchovascular markings</p> HRCT with 1 to 1.5 mm slices every 10 mm or multidetector chest CT with 1 to 1.5 mm contiguous slices (preferred)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bronchiolitis</td> <td>History of respiratory infection, rheumatic disease, transplantation, ulcerative colitis, development of chronic airflow obstruction over months to few years</td> <td> <p>Serologic studies for rheumatic diseases suspected on basis of clinical findings (eg, rheumatoid factor)</p> Cultures and immunoassays for infection (eg, respiratory syncytial virus)</td> <td>Spirometry with lung volumes: mixed obstructive and restrictive pattern</td> <td> <p>Chest radiograph: hyperinflation and fine nodular opacities</p> HRCT: may show mosaic pattern; expiratory views may show patchy airtrapping</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Carcinoid syndrome due to extrathoracic carcinoid tumor or bronchial carcinoid</td> <td>History of episodes of flushing, wheezing, and watery diarrhea</td> <td>Elevated 5-hydroxyindoleacetic acid level in a 24 hour urine specimen</td> <td>&nbsp;</td> <td>Chest CT may show nodule in case of bronchial carcinoid, but may be negative in carcinoid of gastrointestinal origin</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)</td> <td>Wheeze, dyspnea, and cough in middle-aged woman</td> <td>Serum chromogranin A may be elevated</td> <td>Airflow limitation without bronchodilator reversibility</td> <td>HRCT shows patchy mosaic attenuation due to constrictive bronchiolitis and multiple small (4 to 10 mm) pulmonary nodules</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Heart failure</td> <td> <p>Orthopnea, peripheral edema</p> Crackles in addition to wheeze</td> <td>Elevated brain natriuretic peptide</td> <td>&nbsp;</td> <td>Chest radiograph may show cephalization of flow, enlarged heart</td> <td>Echocardiogram: systolic or diastolic left ventricular dysfunction</td> </tr> <tr class=\"divider_bottom\"> <td>Noncardiogenic pulmonary edema</td> <td>Acute onset of dyspnea in setting of risk factors for ARDS</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Chest imaging shows diffuse reticular or ground glass opacities</td> <td> <p>Echocardiogram: normal left ventricular function</p> Pulmonary artery catheterization: normal pulmonary capillary wedge pressure</td> </tr> <tr class=\"divider_bottom\"> <td>Parasitic infection with VLM (eg, Ascaris Strongyloides, filaria)</td> <td>Travel or residence in endemic area</td> <td>Elevated eosinophil count; stools for ova and parasites for non-filarial causes; serologic immunoassay for filaria/strongyloides/ascaris antibodies</td> <td>&nbsp;</td> <td>Chest imaging may show migratory opacities</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary thromboembolism (uncommon cause of wheeze)</td> <td>History of risk factors for thromboembolic disease</td> <td>Elevated D-dimer</td> <td>Not usually obtained, but DLCO is reduced</td> <td>CT pulmonary angiogram shows intraluminal defects and/or cut-offs</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Reactive airways dysfunction syndrome</td> <td>History of an inhalational exposure to a high concentration of an irritant gas or aerosol</td> <td>&nbsp;</td> <td> <p>Spirometry may show airflow limitation</p> <p>Post bronchodilator spirometry often shows irreversibility</p> Bronchoprovocation challenge usually shows airways hyperresponsiveness</td> <td>Chest radiograph is usually normal or shows hyperinflation</td> <td>&nbsp;</td> </tr> <tr> <td>Tracheobronchomalacia</td> <td>Dyspnea</td> <td>&nbsp;</td> <td>Flow volume loop may show expiratory slowing consistent with intrathoracic variable obstruction</td> <td>Inspiratory and expiratory multidetector CT images show airway collapse during expiration</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MAC: Mycobacterium avium complex; TB: Mycobacteria tuberculosis; HRCT: high resolution computed tomography; CT: computed tomography; ARDS: acute respiratory distress syndrome; VLM: visceral larva migrans; DLCO: diffusing capacity for carbon monoxide.</div><div id=\"graphicVersion\">Graphic 91189 Version 3.0</div></div></div>"},"91192":{"type":"graphic_diagnosticimage","displayName":"Brain metastases in melanoma MRI","title":"Brain metastases in melanoma (MRI)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain metastases in melanoma (MRI)</div><div class=\"cntnt\"><img style=\"width:425px; height:500px;\" src=\"images/ONC/91192_Brain_met_melanoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91192 Version 2.0</div></div></div>"},"91197":{"type":"graphic_diagnosticimage","displayName":"CT lung cancer mediastinal invasion","title":"Invasion of lung cancer into the mediastinum on CT scan","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Invasion of lung cancer into the mediastinum on CT scan</div><div class=\"cntnt\"><img style=\"width:601px; height:208px;\" src=\"images/RADIOL/91197_CT_lng_cn_med_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan in axial projection (A) and with coronal reconstruction (B) shows a paramediastinal lung carcinoma invading the mediastinum (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91197 Version 1.0</div></div></div>"},"91199":{"type":"graphic_table","displayName":"Advantages and disadvantages of oral anticoagulants","title":"Advantages and disadvantages of oral anticoagulants (warfarin versus direct oral anticoagulants*)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of oral anticoagulants (warfarin versus direct oral anticoagulants*)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Warfarin</td> <td class=\"subtitle1\">Direct&nbsp;oral anticoagulants*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dosing</strong></td> <td>Once-daily dosing may be more convenient</td> <td>May require more frequent dosing</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dietary restrictions</strong></td> <td>Need to ensure relatively constant level of vitamin K intake</td> <td>None. Rivaroxaban should be taken with food when used for atrial fibrillation thromboprophylaxis. Betrixaban should be taken with food when used for VTE prophylaxis.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Monitoring therapy</strong></td> <td>PT/INR monitoring is required, which entails regular visits to a facility for most patients (point of care devices may be an option for some)</td> <td>Not required; however, noncompliance will not be as readily apparent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drug interactions</strong></td> <td>Many</td> <td>Rivaroxaban interacts with CYP-3A4 and P-glycoprotein inhibitors; other factor Xa inhibitors interact with P-glycoprotein; dabigatran may be affected by P-glycoprotein inducers or inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time in therapeutic range</strong></td> <td>Approximately 65% based on clinical trials</td> <td>Expected to be superior to warfarin, although therapeutic ranges have not been established</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Reversal agent(s)</strong></td> <td>Several available (eg, vitamin K, FFP, PCC, rFVIIa)</td> <td>Idarucizumab is available to reverse dabigatran. Specific reversal agents are not available for direct factor Xa inhibitors but several are in development. Activated charcoal; antifibrinolytic agents; PCC may be used for life-threatening bleeding. Hemodialysis could be used in severe cases for dabigatran (but not rivaroxaban or apixaban).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Monitoring reversal</strong></td> <td>PT/INR can be used</td> <td>TT can be used for dabigatran; anti-factor Xa can be used for apixaban</td> </tr> <tr> <td><strong>Effect of comorbid conditions</strong></td> <td>&nbsp;</td> <td>Renal function affects pharmacokinetics; dosing unclear in those with obesity</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The factors listed may be considered in making decisions regarding choice of oral anticoagulant, but these must be considered together with clinical information regarding efficacy and toxicity in specific medical conditions. Refer to the UpToDate topic reviews on specific medical conditions for clinical data and expert opinion regarding the choice of oral anticoagulants. Refer to UpToDate topics on warfarin and direct thrombin and factor Xa inhibitors for further details on administration of these agents and management of bleeding associated with their use. Refer to UpToDate tables on drug interactions for all agents described herein.</div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; PT: prothrombin time; INR: international normalized ratio; FFP: fresh frozen plasma; PCC: prothrombin complex concentrates; rFVIIa: recombinant activated factor VII;&nbsp;TT: thrombin time.<br />*&nbsp;Direct oral anticoagulants include direct thrombin inhibitors (eg, dabigatran) and direct factor Xa inhibitors (eg, rivaroxaban, apixaban, edoxaban, betrixaban).</div><div id=\"graphicVersion\">Graphic 91199 Version 8.0</div></div></div>"},"91200":{"type":"graphic_diagnosticimage","displayName":"BE and CT colonography diverticulosis","title":"Diverticulosis of colon on BE and CT colonography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Diverticulosis of colon on BE and CT colonography</div><div class=\"cntnt\"><img style=\"width:599px; height:351px;\" src=\"images/RADIOL/91200_BE_CT_colonogr_divert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single contrast barium enema (A) shows diverticulosis of the ascending colon (arrowheads) and descending colon (double arrow). Source images for a virtual colonoscopy reconstructed in the coronal plane show diverticula in the ascending colon (arrowhead) and extensive diverticulosis of the descending colon (double arrow).</div><div class=\"graphic_footnotes\">BE: barium enema; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91200 Version 2.0</div></div></div>"},"91201":{"type":"graphic_diagnosticimage","displayName":"BE and CT colonography diverticulosis narrowing","title":"Diverticulosis muscle thickening and narrowing on BE and CT colonography","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Diverticulosis muscle thickening and narrowing on BE and CT colonography</div><div class=\"cntnt\"><img style=\"width:597px; height:344px;\" src=\"images/RADIOL/91201_BE_CT_colon_divert_narr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single contrast barium enema (A) shows diverticulosis (arrowhead) with circular muscle thickening and luminal narrowing of the distal descending colon (double arrow). Source images for a CT virtual colonoscopy reconstructed in the coronal plane show extensive diverticulosis of the descending colon (arrow) with circular muscle thickening and luminal narrowing (arrowhead).</div><div class=\"graphic_footnotes\">BE: barium enema; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91201 Version 2.0</div></div></div>"},"91203":{"type":"graphic_diagnosticimage","displayName":"CT pylephlebitis","title":"Pylephlebitis on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pylephlebitis on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:230px;\" src=\"images/RADIOL/91203_CT_pylephlebitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan (A) shows thrombosis of the left portal vein (arrow) in a 41-year-old patient presenting with pain and fever five months following pancreaticojejunostomy. There are multiple low density foci in the right lobe of the liver (arrowheads). Image B is a CT scan performed one week later and shows a large left upper quadrant abscess (short arrow) and enlarging multicentric intrahepatic fluid collections along the distribution of the portal vein (arrowheads). Left portal vein thrombosis persists (arrow). A drain was placed into the largest abscess (dashed arrow) in the&nbsp;right lobe of the liver.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91203 Version 1.0</div></div></div>"},"91211":{"type":"graphic_figure","displayName":"Anesthesia demographics","title":"Anesthesia demographics","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Anesthesia demographics</div><div class=\"cntnt\"><img style=\"width:586px; height:272px;\" src=\"images/ANEST/91211_Anesthesia_demographics.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data include all cases performed by anesthesiologists, including obstetric analgesia, in 180 practices in the United States.</div><div class=\"graphic_reference\">Data from the National Anesthesia Clinical Outcomes Registry, November 1, 2013. Used with permission of the Anesthesia Quality Institute.</div><div id=\"graphicVersion\">Graphic 91211 Version 3.0</div></div></div>"},"91212":{"type":"graphic_picture","displayName":"Cheilitis granulomatosa","title":"Cheilitis granulomatosa (Mischer's cheilitis)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cheilitis granulomatosa (Mischer's cheilitis)</div><div class=\"cntnt\"><img style=\"width:576px; height:390px;\" src=\"images/DERM/91212_Cheilitis_granulomatosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent swelling of the lips in a 29-year-old patient with cheilitis granulomatosa.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <a href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</a>. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91212 Version 1.0</div></div></div>"},"91213":{"type":"graphic_picture","displayName":"Melkersson-Rosenthal syndrome","title":"Melkersson-Rosenthal syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melkersson-Rosenthal syndrome</div><div class=\"cntnt\"><img style=\"width:431px; height:576px;\" src=\"images/DERM/91213_Melkersson_rosenthal_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fissured tongue and persistently swollen upper lip in a patient with Melkersson-Rosenthal syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91213 Version 1.0</div></div></div>"},"91214":{"type":"graphic_table","displayName":"Frailty criteria","title":"Frailty criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frailty criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Shrinking (weight loss)</td> <td>&#62;10 pound weight loss during previous year</td> </tr> <tr> <td>Weakness (grip strength)</td> <td>Lowest 20th percentile measured by hand-held dynamometer</td> </tr> <tr> <td>Exhaustion</td> <td>Feeling \"I can't get going\" or \"everything is an effort\" 3 or more days per week</td> </tr> <tr> <td>Activity level</td> <td>Kilocalorie expenditure less than 20th percentile for gender</td> </tr> <tr> <td>Walking speed</td> <td>Lowest 20th percentile walking 15 feet at normal pace</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each criteria is scored with a 0 or a 1. Intermediately frail was defined by meeting two or three criteria, while frail patients were defined by meeting four or five frailty criteria.</div><div class=\"graphic_reference\">Source: Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010; 210:901.</div><div id=\"graphicVersion\">Graphic 91214 Version 2.0</div></div></div>"},"91219":{"type":"graphic_figure","displayName":"Survival based on HLA matching","title":"Survival following allogeneic hematopoietic cell transplantation based on the degree of HLA matching","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival following allogeneic hematopoietic cell transplantation based on the degree of HLA matching</div><div class=\"cntnt\"><img style=\"width:296px; height:532px;\" src=\"images/HEME/91219_Survival_based_HLA_match.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival of patients with early, intermediate, and advanced disease depending on degree of HLA matching (8/8, 7/8, and 6/8) for HLA-A, -B, -C, and -DRB1.<br />(A) Early-stage disease for 8/8, 7/8, and 6/8, respectively: one-year survival 63, 52, and 39 percent; five-year survival 50, 39, and 28 percent.<br />(B) Intermediate-stage disease for 8/8, 7/8, and 6/8, respectively: one-year survival 48, 40, and 32 percent; five-year survival 32, 27, and 22 percent.<br />(C) Advanced-stage disease for 8/8, 7/8, and 6/8, respectively: one-year survival 31, 29, and 24 percent; five-year survival 17, 15, and 10 percent.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 91219 Version 7.0</div></div></div>"},"91222":{"type":"graphic_picture","displayName":"High-grade serous carcinoma 1","title":"High-grade serous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">High-grade serous carcinoma</div><div class=\"cntnt\"><img style=\"width:599px; height:221px;\" src=\"images/ONC/91222_High_grade_serous_carcin_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The exterior surface of the ovary and the numerous friable surface papillae.<br />(B) Cut surface of ovary demonstrating cystic areas, papillary areas, and more solid areas. The solid areas are grossly worrisome for invasive carcinoma.</div><div id=\"graphicVersion\">Graphic 91222 Version 2.0</div></div></div>"},"91223":{"type":"graphic_picture","displayName":"High-grade serous carcinoma 2","title":"High-grade serous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">High-grade serous carcinoma</div><div class=\"cntnt\"><img style=\"width:598px; height:227px;\" src=\"images/ONC/91223_High_grade_serous_carcin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) High-grade serous carcinoma is composed of cells with pleomorphic nuclei and numerous mitotic figures as seen here (400x hematoxilin and eosin staining).<br />(B) In most high-grade serous carcinomas, p53 immunohistochemical staining is diffusely and strongly positive. However, a subset of high-grade serous carcinomas are negative for p53 immunohistochemical staining.</div><div id=\"graphicVersion\">Graphic 91223 Version 2.0</div></div></div>"},"91224":{"type":"graphic_picture","displayName":"Low-grade serous carcinoma","title":"Low-grade serous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Low-grade serous carcinoma</div><div class=\"cntnt\"><img style=\"width:598px; height:228px;\" src=\"images/ONC/91224_Low_grade_serous_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nests of low-grade serous carcinoma invading the stroma with accompanying desmoplastic response and psammoma bodies. Note the lack of nuclear pleomorphism and low mitotic rate (200x hematoxilin and eosin staining).<br />(B) High-power view of low-grade serous carcinoma. Although there is some nuclear pleomorphism, there are no mitotic figures identified (400x hematoxilin and eosin).</div><div id=\"graphicVersion\">Graphic 91224 Version 2.0</div></div></div>"},"91225":{"type":"graphic_picture","displayName":"Endometrioid adenocarcinoma of the ovary","title":"Endometrioid adenocarcinoma of the ovary","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Endometrioid adenocarcinoma of the ovary</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/ONC/91225_Endometrioid_adenocar_ovary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex glandular architecture without intervening stroma. Glands are lined by tall, stratified columnar cells.</div><div id=\"graphicVersion\">Graphic 91225 Version 1.0</div></div></div>"},"91226":{"type":"graphic_picture","displayName":"Clear cell adenocarcinoma","title":"Clear cell adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Clear cell adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:598px; height:448px;\" src=\"images/ONC/91226_Clear_cell_adenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Solid variant with irregular nuclei and clear, koilocyte-like appearance.<br />(B) Clear cell carcinoma with a tubulocystic appearance with flattened neoplastic cells.<br />(C) Clear cell carcinoma with \"hobnail\" cells.<br />(D) Clear cell carcinoma with papillary architecture. Papillae are generally short and rounded and often have an eosinophilic, hyalinized stroma.</div><div id=\"graphicVersion\">Graphic 91226 Version 1.0</div></div></div>"},"91227":{"type":"graphic_picture","displayName":"Mucinous adenocarcinoma","title":"Mucinous adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Mucinous adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:598px; height:450px;\" src=\"images/ONC/91227_Mucinous_adenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gastrointestinal-type mucinous adenocarcinoma. Note the destructive stromal invasion and irregular, angulated glands.<br />(B) Gastrointestinal-type mucinous adenocarcinoma with prominent goblet cells.<br />(C) High-grade intraepithelial neoplasia in gastrointestinal-type mucinous adenocarcinoma. The high cytologic grade and mitotic activity are characteristic of high-grade intraepithelial neoplasia, but no invasive carcinoma is seen in this field.</div><div id=\"graphicVersion\">Graphic 91227 Version 2.0</div></div></div>"},"91228":{"type":"graphic_picture","displayName":"Serous borderline neoplasm","title":"Serous borderline neoplasm","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Serous borderline neoplasm</div><div class=\"cntnt\"><img style=\"width:590px; height:292px;\" src=\"images/ONC/91228_Serous_borderline_neoplasm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photo demonstrating cystic ovary with numerous friable papillary excrescences. Note the lack of solid or necrotic areas that would suggest serous carcinoma.</div><div id=\"graphicVersion\">Graphic 91228 Version 2.0</div></div></div>"},"91229":{"type":"graphic_picture","displayName":"Serous borderline neoplasm 2","title":"Serous borderline neoplasm","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Serous borderline neoplasm</div><div class=\"cntnt\"><img style=\"width:598px; height:449px;\" src=\"images/ONC/91229_Serous_borderline_neoplasm2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Serous borderline neoplasm with an epithelial proliferation of low-grade cells with serous morphology. Note the epithelial stratification and the hierarchical branching of successively smaller papillae arising from larger, more centrally located papillae.<br />(B) Higher power of serous borderline neoplasm. Note lack of any invasion.<br />(C) Serous borderline neoplasm with proliferative epithelium and low-grade nuclei lining papillae.</div><div id=\"graphicVersion\">Graphic 91229 Version 2.0</div></div></div>"},"91230":{"type":"graphic_picture","displayName":"Mucinous borderline neoplasm","title":"Mucinous borderline neoplasm","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Mucinous borderline neoplasm</div><div class=\"cntnt\"><img style=\"width:598px; height:227px;\" src=\"images/ONC/91230_Mucinou_borderline_neoplasm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mucinous glands with prominent epithelial proliferation, tufting, and stratification.<br />(B) Higher power demonstrating goblet cell differentiation and prominent stratification.</div><div id=\"graphicVersion\">Graphic 91230 Version 1.0</div></div></div>"},"91231":{"type":"graphic_picture","displayName":"Endometrioid borderline neoplasm","title":"Endometrioid borderline neoplasm","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Endometrioid borderline neoplasm</div><div class=\"cntnt\"><img style=\"width:597px; height:227px;\" src=\"images/ONC/91231_Endomet_borderline_neoplasm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Complex glandular architecture with fibrous background and intervening stroma reminiscent of complex atypical hyperplasia in the uterus.<br />(B) Higher power demonstrating higher gland to stroma ratio but with intervening stroma. Note prominent squamous morules.</div><div id=\"graphicVersion\">Graphic 91231 Version 1.0</div></div></div>"},"91232":{"type":"graphic_table","displayName":"Criteria to aid in determination of primary site of endometrioid","title":"Criteria to aid in determination of primary site of endometrioid carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria to aid in determination of primary site of endometrioid carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Favors ovarian primary</td> <td class=\"subtitle1\">Favors endometrial primary</td> <td class=\"subtitle1\">Favors synchronous primaries</td> </tr> <tr> <td>Minimal to no myometrial invasion</td> <td>Deep myometrial invasion (&#62;1/3 of myometrium)</td> <td>Minimal to no myometrial invasion</td> </tr> <tr> <td>No vascular lymphovascular invasion in uterus</td> <td>Uterine lymphovascular invasion present</td> <td>No vascular lymphovascular invasion in uterus or ovary</td> </tr> <tr> <td>Unilateral mass in ovary</td> <td>Bilateral masses in ovaries</td> <td>Unilateral mass in ovary</td> </tr> <tr> <td>No ovarian surface involvement</td> <td>Ovarian surface involvement present</td> <td>No ovarian surface involvement</td> </tr> <tr> <td>Large ovarian mass with expansile growth pattern</td> <td>Smaller ovarian mass with multinodular growth pattern</td> <td>Large ovarian mass with expansile growth pattern</td> </tr> <tr> <td>Background endometriois or endometrioid borderline neoplasm</td> <td>Complex atypical hyperplasia present in uterus</td> <td>Background endometriosis or endometrioid borderline neoplasm in ovary in addition to complex atypical hyperplasia present in uterus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91232 Version 1.0</div></div></div>"},"91233":{"type":"graphic_table","displayName":"Clinical features of right and left atrial isomerism","title":"Clinical features of right and left atrial isomerism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of right and left atrial isomerism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Right atrial isomerism</td> <td class=\"subtitle1\">Left atrial isomerism</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Situs</strong></td> <td>Bilateral right-sidedness</td> <td>Bilateral left-sidedness</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Spleen</td> <td>No spleen (asplenia)</td> <td>More than one spleen (polysplenia)</td> </tr> <tr> <td class=\"indent1\">Liver</td> <td>Symmetrical and horizontal</td> <td>Bilobed, may be symmetrical, but more often to one side</td> </tr> <tr> <td class=\"indent1\">Stomach</td> <td>Near midline (right or left)</td> <td>Usually right-sided</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Heart and vessels</td> </tr> <tr> <td class=\"indent1\">Cardiac position</td> <td>Mesocardia common; can be on either side</td> <td>Mesocardia rare; generally on either side</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Systemic venous vessels</td> </tr> <tr> <td class=\"indent2\">Superior vena cava</td> <td>Bilateral: One to each atrium</td> <td>May be bilateral: One to each atrium (can be via coronary sinus)</td> </tr> <tr> <td class=\"indent2\">Coronary sinus</td> <td>Absent</td> <td>Generally present</td> </tr> <tr> <td class=\"indent2\">Inferior vena cava</td> <td>Present; can connect to either atria but is always on the same side as DAo</td> <td>Usually interrupted with azygos continuation</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Atria</td> </tr> <tr> <td class=\"indent2\">General</td> <td>Bilateral right atria</td> <td>Bilateral left atria</td> </tr> <tr> <td class=\"indent2\">Sinoatrial node</td> <td>Bilateral with one dominant (usually inferior P wave axis)</td> <td>Absent coronary sinus rhythm</td> </tr> <tr> <td class=\"indent2\">Septum</td> <td>Usually large primum and secundum ASD</td> <td>Highly variable, from intact septum to common atrium</td> </tr> <tr> <td class=\"indent2\">Atrioventricular valves</td> <td>Single (AVSD type) or atresia of one</td> <td>Two valves or AVSD type</td> </tr> <tr> <td class=\"indent2\">Pulmonary veins</td> <td>Generally extracardiac TAPVR</td> <td>Directly to atria</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Ventricles</td> </tr> <tr> <td class=\"indent2\">Position</td> <td>Inverted</td> <td>D-looping</td> </tr> <tr> <td class=\"indent2\">Ventricular septal defect type</td> <td>Canal type (inlet)</td> <td>Membranous or canal type</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Great arteries</td> </tr> <tr> <td class=\"indent2\">Position</td> <td>Malposed (approximately 95 percent); DORV (approximately 5 percent)</td> <td>Generally normal, occasional DORV and rare malposition</td> </tr> <tr> <td class=\"indent2\">Pulmonary outflow obstruction</td> <td>Severe pulmonary stenosis or atresia in &#62;90 percent</td> <td>Pulmonic stenosis is unusual</td> </tr> <tr> <td class=\"indent2\">Left-sided obstruction</td> <td>Rare</td> <td>Common (MS, AS, CoA)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other thoracic organs</td> </tr> <tr> <td class=\"indent1\">Bronchi</td> <td>Both are eparterial</td> <td>Both are hyparterial</td> </tr> <tr> <td class=\"indent1\">Lungs</td> <td>Bilateral trilobed</td> <td>Bilateral bilobed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DAo: descending aorta; ASD: atrial septal defect; AVSD: atrioventricular septal defect; TAPVR: total anomalous pulmonary venous return; DORV: double outlet right ventricle; MS: mitral stenosis; AS: aortic stenosis; CoA: coarctation of the aorta.</div><div id=\"graphicVersion\">Graphic 91233 Version 5.0</div></div></div>"},"91234":{"type":"graphic_diagnosticimage","displayName":"Heterotaxy: Right atrial isomerism with AV canal defect ","title":"Heterotaxy: Right atrial isomerism with AV canal defect ","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Heterotaxy: Right atrial isomerism with AV canal defect </div><div class=\"cntnt\"><img style=\"width:501px; height:586px;\" src=\"images/PEDS/91234_HeteroRisoAVcandef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transthoracic apical four chamber in a patient with right atrial isomerism&nbsp;demonstrating an L-looped ventricle, as the left ventricle (LV) is on the right side of the patient and the right ventricle (RV) is on the left side of the patient. A complete atrioventricular (AV) canal defect is also noted with the very large atrial septal defect (ASD) and large, inlet ventricular septal defect (VSD). There is no true tricuspid or mitral valve. Instead, a common atrioventricular valve (CAVV) is shown, which supplies equal flow to each ventricular mass, consistent with a relatively balanced complete atrioventricular canal.</div><div id=\"graphicVersion\">Graphic 91234 Version 3.0</div></div></div>"},"91235":{"type":"graphic_figure","displayName":"Heterotaxy sinus node abnormalities","title":"Sinus node abnormalities associated with heterotaxy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus node abnormalities associated with heterotaxy</div><div class=\"cntnt\"><img style=\"width:338px; height:685px;\" src=\"images/PEDS/91235_Heterot_sinus_node_abnormal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus node and atrial depolarization in:<br />(A) Normal patients.<br />(B) Patients with heterotaxy due to right atrial isomerism.<br />(C) Patients with heterotaxy due to left atrial isomerism.</div><div id=\"graphicVersion\">Graphic 91235 Version 2.0</div></div></div>"},"91236":{"type":"graphic_algorithm","displayName":"Sample massive transfusion algorithm","title":"Sample massive transfusion algorithm","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Sample massive transfusion algorithm</div><div class=\"cntnt\"><img style=\"width:566px; height:756px;\" src=\"images/OBGYN/91236_Samp_mass_transfus_protocol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Texas Children's Pavilion for Women massive transfusion protocol.</div><div class=\"graphic_footnotes\">MTP: massive transfusion protocol; PRBC: packed red blood cells; PCA: patient-controlled analgesia; RRT: rapid response team; BB: blood bank; Hg: hemoglobin; Hct: hematocrit; DIC: disseminated intravascular coagulation; PT: prothrombin time; INR: international normalized ratio; PTT: partial thromboplastin time; ABG: arterial blood gas; RBC: red blood cells; FFP: fresh frozen plasma; OB: Obstetrics; Anes: Anesthesia; OR: operating room; CRNA: certified registered nurse anesthetist; Chrg: charge; RN: registered nurse; Lab: laboratory; Tech: technician; MD: medical doctor; L&amp;D: labor and delivery; iCa: ionized calcium; K: potassium; Glu: glucose; PCA: patient care assistant.<br />* Every two packages or based on lab results.</div><div class=\"graphic_reference\">Reproduced with permission. Accessed on February 19, 2013. Copyright &copy; Evidence-Based Outcomes Center, 2013. Quality and Outcomes Center, Texas Children's Hospital. This guideline was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children's Hospital Pavilion for Women. Development of this guideline supports the TCH Quality and Patient Safety Program initiative to promote clinical guidelines and outcomes that build a culture of quality and safety within the organization. Guideline recommendations are made from the best evidence, clinical expertise and consensus, in addition to thoughtful consideration for the patients and families cared for within the Integrated Delivery System. When evidence was lacking or inconclusive, content experts made consensus recommendations. Expert consensus is implied when a reference is not otherwise indicated. The guideline is not intended to impose standards of care preventing selective variation in practice that is necessary to meet the unique needs of individual patients. The physician must consider each patient and family's circumstance to make the ultimate judgment regarding best care.</div><div id=\"graphicVersion\">Graphic 91236 Version 4.0</div></div></div>"},"91237":{"type":"graphic_picture","displayName":"Cheilitis granulomatosa histo","title":"Histologic features of cheilitis granulomatosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of cheilitis granulomatosa</div><div class=\"cntnt\"><img style=\"width:436px; height:502px;\" src=\"images/DERM/91237_Cheilitis_granulo_hist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cheilitis granulomatosa is characterized by non-necrotizing granulomas in the lamina propria (arrows). Granulomas may be focal, subtle, or poorly formed. An erivascular infiltrate of lymphocytes and plasma cells is commonly present.</div><div class=\"graphic_reference\">Courtesy of Tammie Ferringer, MD.</div><div id=\"graphicVersion\">Graphic 91237 Version 1.0</div></div></div>"},"91240":{"type":"graphic_diagnosticimage","displayName":"Ultrasound appearance of normal and injured hamstring","title":"Ultrasound appearance of normal and injured hamstring muscle","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Ultrasound appearance of normal and injured hamstring muscle</div><div class=\"cntnt\"><img style=\"width:547px; height:309px;\" src=\"images/EM/91240_Hamstr_inj_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Acutely strained hamstring muscle. Note the disorganized, disrupted fibers.<br />(B) Normal hamstring from unaffected side. Note the organized linear muscle fibers.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 91240 Version 1.0</div></div></div>"},"91241":{"type":"graphic_diagnosticimage","displayName":"Hamstring avulsion injury on ultrasound","title":"Ultrasound appearance of hamstring avulsion injury","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Ultrasound appearance of hamstring avulsion injury</div><div class=\"cntnt\"><img style=\"width:588px; height:427px;\" src=\"images/EM/91241_Hamstring_avuls_ultra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ultrasound image of&nbsp;a hamstring avulsion injury is shown above. The \"X\" indicates the ischial tuberosity; the downward arrow points to a bony fragment avulsed from the tuberosity; and the \"+\" indicates the proximal tendon. Note the \"hypoechoic\" area between the tendon and the tuberosity consistent with acute swelling.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 91241 Version 1.0</div></div></div>"},"91244":{"type":"graphic_table","displayName":"NCI CTCAE v5 sinus bradycardia","title":"NCI CTCAE v5.0 sinus bradycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 sinus bradycardia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Sinus bradycardia</td> <td>Asymptomatic, intervention not indicated</td> <td>Symptomatic, intervention not indicated; change in medication initiated</td> <td>Symptomatic, intervention indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Sinus bradycardia is characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91244 Version 3.0</div></div></div>"},"91245":{"type":"graphic_table","displayName":"NCI CTCAE v5 dysphagia","title":"NCI CTCAE v5.0 dysphagia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 dysphagia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Dysphagia</td> <td>Symptomatic, able to eat regular diet</td> <td>Symptomatic and altered eating/swallowing</td> <td>Severely altered eating/swallowing; tube feeding or TPN or hospitalization indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dysphagia is characterized by difficulty in swallowing.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91245 Version 4.0</div></div></div>"},"91247":{"type":"graphic_table","displayName":"NCI CTCAE v5 gastroparesis","title":"NCI CTCAE v5.0 gastroparesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 gastroparesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Gastroparesis</td> <td>Mild nausea, early satiety and bloating, able to maintain caloric intake on regular diet</td> <td>Moderate symptoms; able to maintain nutrition with dietary and lifestyle modifications; may need pharmacologic intervention</td> <td>Weight loss &#8805;20% from baseline; tube feeding or TPN indicated; elective operative intervention indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Gastroparesis is characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91247 Version 3.0</div></div></div>"},"91248":{"type":"graphic_table","displayName":"NCI CTCAE v5 infusion site extravasation","title":"NCI CTCAE v5.0 infusion site extravasation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 infusion site extravasation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Infusion site extravasation</td> <td>Painless edema</td> <td>Erythema with associated symptoms (eg, edema, pain, induration, phlebitis)</td> <td>Ulceration or necrosis, severe tissue damage; operative intervention indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Infusion site extravasation is characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms include induration, erythema, swelling, burning sensation, and marked discomfort at the infusion site.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91248 Version 3.0</div></div></div>"},"91249":{"type":"graphic_table","displayName":"NCI CTCAE v5 allergic reaction and anaphylaxis","title":"NCI CTCAE v5.0 allergic reaction and anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 allergic reaction and anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Allergic reaction</td> <td>Systemic intervention not indicated</td> <td>Oral intervention indicated</td> <td>Bronchospasm; hospitalization indicated for clinical sequelae; intravenous intervention indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> <tr> <td>Anaphylaxis</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Allergic reactions are characterized by adverse local or general responses from exposure to an allergen. NOTE: If related to a drug infusion, use the grading scheme for infusion-related reaction.<br />Anaphylaxis is characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis, and loss of consciousness and may lead to death.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NSAIDS: non-steroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91249 Version 5.0</div></div></div>"},"91251":{"type":"graphic_table","displayName":"NCI CTCAE v5 electrocardiogram QT corrected interval prolonged","title":"NCI CTCAE v5.0 electrocardiogram QT corrected interval prolonged","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 electrocardiogram QT corrected interval prolonged</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Corrected QT interval prolongation on the electrocardiogram</td> <td>Average QTc 450 to 480 milliseconds</td> <td>Average QTc 481 to 500 milliseconds</td> <td>Average QTc &#8805;501 milliseconds; &#62;60 milliseconds change from baseline</td> <td>Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Prolongation of the corrected QT interval is a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; QTc: corrected QT interval.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91251 Version 5.0</div></div></div>"},"91252":{"type":"graphic_table","displayName":"NCI CTCAE v5 electrolyte abnormalities","title":"NCI CTCAE v5.0 electrolyte abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 electrolyte abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Hypercalcemia</td> <td>Corrected serum calcium &#62;ULN to 11.5 mg/dL; &#62;ULN to 2.9 mmol/L; ionized calcium &#62;ULN to 1.5 mmol/L</td> <td>Corrected serum calcium &#62;11.5 to 12.5 mg/dL; &#62;2.9 to 3.1 mmol/L; ionized calcium &#62;1.5 to 1.6 mmol/L; symptomatic</td> <td>Corrected serum calcium &#62;12.5 to 13.5 mg/dL; &#62;3.1 to 3.4 mmol/L; ionized calcium &#62;1.6 to 1.8 mmol/L; hospitalization indicated</td> <td>Corrected serum calcium &#62;13.5 mg/dL; &#62;3.4 mmol/L; ionized calcium &#62;1.8 mmol/L; life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hyperkalemia</td> <td>&#62;ULN to 5.5 mmol/L (mEq/L)</td> <td>&#62;5.5 to 6.0 mmol/L (mEq/L)</td> <td>&#62;6.0 to 7.0 mmol/L (mEq/L); hospitalization indicated</td> <td>&#62;7.0 mmol/L (mEq/L); life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hypermagnesemia</td> <td>&#62;ULN to 3.0 mg/dL; &#62;ULN to 1.23 mmol/L</td> <td>&nbsp;</td> <td>&#62;3.0 to 8.0 mg/dL; &#62;1.23 to 3.30 mmol/L</td> <td>&#62;8.0 mg/dL; &#62;3.30 mmol/L; life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hypernatremia</td> <td>&#62;ULN to 150 mmol/L (mEq/L)</td> <td>&#62;150 to 155 mmol/L (mEq/L)</td> <td>&#62;155 to 160 mmol/L (mEq/L); hospitalization indicated</td> <td>&#62;160 mmol/L (mEq/L); life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hyperuricemia</td> <td>&#62;ULN without physiologic consequences</td> <td>&nbsp;</td> <td>&#62;ULN with physiologic consequences</td> <td>Life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hypocalcemia</td> <td>Corrected serum calcium &#60;LLN to 8.0 mg/dL; &#60;LLN to 2.0 mmol/L; ionized calcium &#60;LLN to 1.0 mmol/L</td> <td>Corrected serum calcium &#60;8.0 to 7.0 mg/dL; &#60;2.0 to 1.75 mmol/L; ionized calcium &#60;1.0 to 0.9 mmol/L; symptomatic</td> <td>Corrected serum calcium &#60;7.0 to 6.0 mg/dL; &#60;1.75 to 1.5 mmol/L; ionized calcium &#60;0.9 to 0.8 mmol/L; hospitalization indicated</td> <td>Corrected serum calcium &#60;6.0 mg/dL; &#60;1.5 mmol/L; ionized calcium &#60;0.8 mmol/L; life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hypokalemia</td> <td>&#60;LLN to 3.0 mmol/L (mEq/L)</td> <td>&#60;LLN to 3.0 mmol/L (mEq/L); symptomatic; intervention indicated</td> <td>&#60;3.0 to 2.5 mmol/L (mEq/L); hospitalization indicated</td> <td>&#60;2.5 mmol/L (mEq/L); life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hypomagnesemia</td> <td>&#60;LLN to 1.2 mg/dL; &#60;LLN to 0.5 mmol/L</td> <td>&#60;1.2 to 0.9 mg/dL; &#60;0.5 to 0.4 mmol/L</td> <td>&#60;0.9 to 0.7 mg/dL; &#60;0.4 to 0.3 mmol/L</td> <td>&#60;0.7 mg/dL; &#60;0.3 mmol/L; life-threatening consequences</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Hyponatremia</td> <td>&#60;LLN to 130 mmol/L (mEq/L)</td> <td>125 to 129 mmol/L (mEq/L) and asymptomatic</td> <td>125 to 129 mmol/L (mEq/L) symptomatic; 120 to 124 mmol/L regardless of symptoms</td> <td>&#60;120 mmol/L (mEq/L); life-threatening consequences</td> <td>Death</td> </tr> <tr> <td>Hypophosphatemia</td> <td>Laboratory finding only and intervention not indicated</td> <td>Oral replacement therapy indicated</td> <td>Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated</td> <td>Life-threatening consequences</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Electrolyte abnormalities are all graded as Investigations. Serum calcium is corrected for albumin. Additional electrolyte abnormalities are included in the source document. A calculator for converting between standard and SI units is available in UpToDate.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ULN: upper limit of normal; LLN: lower limit of normal.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91252 Version 6.0</div></div></div>"},"91253":{"type":"graphic_table","displayName":"NCI CTCAE v5 acute kidney injury, creatinine increased","title":"NCI CTCAE v5.0 acute kidney injury, creatinine increased","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 acute kidney injury, creatinine increased</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Acute kidney injury</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hospitalization indicated</td> <td>Life-threatening consequences; dialysis indicated</td> <td>Death</td> </tr> <tr> <td>Creatinine increased</td> <td>&#62;ULN to 1.5 x ULN</td> <td>&#62;1.5 to 3.0 x baseline; &#62;1.5 to 3.0 x ULN</td> <td>&#62;3.0 x baseline; &#62;3.0 to 6.0 x ULN</td> <td>&#62;6.0 x ULN</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acute kidney injury is characterized by the acute loss of renal function (within two weeks) and is traditionally classified as pre-renal (low blood flow into the kidney), renal (kidney damage), and post-renal causes (ureteral or bladder outflow obstruction). Creatinine increased is a laboratory test result of increased creatinine in a biological specimen (graded under \"Investigations\").</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ULN: upper limit of normal.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91253 Version 4.0</div></div></div>"},"91254":{"type":"graphic_table","displayName":"NCI CTCAE v5 cystitis noninfective","title":"NCI CTCAE v5.0 cystitis noninfective","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 cystitis noninfective</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Cystitis noninfective</td> <td>Microscopic hematuria; minimal increase in frequency, urgency, dysuria, or nocturia; new onset of incontinence</td> <td>Moderate hematuria; moderate increase in frequency, urgency, dysuria, nocturia, or incontinence; urinary catheter placement or bladder irrigation indicated; limiting instrumental activities of daily living</td> <td>Gross hematuria; transfusion, intravenous medications, or hospitalization indicated; elective invasive intervention indicated</td> <td>Life-threatening consequences; urgent invasive intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Noninfective cystitis is characterized by inflammation of the bladder that is not caused by an infection of the urinary tract.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91254 Version 4.0</div></div></div>"},"91255":{"type":"graphic_table","displayName":"NCI CTCAE v5 proteinuria","title":"NCI CTCAE v5.0 proteinuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 proteinuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td rowspan=\"2\">Proteinuria</td> <td rowspan=\"2\">1+ proteinuria on dipstick; urinary protein &#60;1.0 g/24 hours</td> <td>Adult: 2+ and 3+ proteinuria on dipstick; urinary protein 1.0 to 3.4 g/24 hours</td> <td>Adult: Urinary protein &#8805;3.5 g/24 hours</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Pediatric: Urine protein/creatinine (P/C) ratio 0.5 to 1.9</td> <td>Pediatric: Urine protein/creatinine (P/C) ratio &#62;1.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Proteinuria is characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but can also include globulin. A 24-hour urine collection to quantify the degree of proteinuria takes precedence over a dipstick result.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91255 Version 6.0</div></div></div>"},"91256":{"type":"graphic_table","displayName":"NCI CTCAE v5 alopecia","title":"NCI CTCAE version 5.0 alopecia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE version 5.0 alopecia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Alopecia</td> <td>Hair loss of &#60;50% normal for that individual that is not obvious from a distance but only on close inspection; a different hairstyle may be required to cover the hair loss, but it does not require a wig or hair piece to camouflage</td> <td>Hair loss of &#8805;50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Alopecia is characterized by a decrease in density of hair compared with normal for a given individual at a given age and body location.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91256 Version 5.0</div></div></div>"},"91257":{"type":"graphic_table","displayName":"NCI CTCAE v5 radiation dermatitis","title":"NCI CTCAE v5.0 radiation dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 radiation dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Radiation dermatitis</td> <td>Faint erythema or dry desquamation</td> <td>Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema</td> <td>Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion</td> <td>Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Radiation dermatitis is a finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" spellcheck=\"true\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91257 Version 3.0</div></div></div>"},"91258":{"type":"graphic_algorithm","displayName":"Sample algorithm for management of PPH","title":"Texas Children's Hospital algorithm for approach to postpartum hemorrhage (PPH) due to uterine atony","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Texas Children's Hospital algorithm for approach to postpartum hemorrhage (PPH) due to uterine atony</div><div class=\"cntnt\"><img style=\"width:666px; height:2106px;\" src=\"images/OBGYN/91258_Smpl_algo_apprch_PPH_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages are based on the California Maternal Quality Care Collaborative OB Hemorrhage Protocol (<A href=\"http://www.cmqcc.org/qi-initiatives/obstetric-hemorrhage\">www.cmqcc.org/qi-initiatives/obstetric-hemorrhage</A>):<br />Stage 0: Blood loss &lt;500 mL with vaginal delivery or &lt;1000 mL with cesarean delivery. Stable vital signs.&nbsp;&nbsp;<br />Stage 1: Blood loss &gt;500 mL vaginal delivery or &gt;1000 mL cesarean delivery or change in vital signs (by &gt;15 percent or heart rate ≥110 beats/minute, blood pressure ≤85/45 mmHg, O<SUB>2</SUB> saturation &lt;95%).<br />Stage 2: Continued bleeding with total blood loss &lt;1500 mL.<br />Stage 3: Continued bleeding with total blood loss &gt;1500 mL or transfusion of more than 2 units packed red blood cells or unstable vital signs or suspicion of disseminated intravascular coagulation.</div><div class=\"graphic_footnotes\">LR: Lactated Ringers; IM: intramuscular; QBL: quantified blood loss; NRBM: non-re-breather mask; IV: intravenous; RRT: rapid response team; OR: operating room; S&amp;S: signs and symptoms; VS: vital signs; IMM: intramyometrially; PRBCs: packed red blood cells; ABG: arterial blood gas; H&amp;H: hemoglobin and hematocrit; DIC: disseminated intravascular coagulation; PT: prothrombin time; INR: international normalized ratio; PTT: partial thromboplastin time; MTP: massive transfusion protocol; IR: interventional radiology; ICU: intensive care unit; HR: heart rate.<br />* Lowering systolic blood pressure, HR &gt;120 beats/minute, relative risk &gt;30, O<sub>2</sub> saturation &lt;95%.<br />&para; Most rapid onset with prolonged duration.</div><div class=\"graphic_reference\">Modified with permission. Accessed on August 30, 2017. Copyright © Evidence-Based Outcomes Center, 2017. Quality and Outcomes Center, Texas Children's Hospital. This guideline was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children's Hospital Pavilion for Women. Development of this guideline supports the TCH Quality and Patient Safety Program initiative to promote clinical guidelines and outcomes that build a culture of quality and safety within the organization. Guideline recommendations are made from the best evidence, clinical expertise and consensus, in addition to thoughtful consideration for the patients and families cared for within the Integrated Delivery System. When evidence was lacking or inconclusive, content experts made consensus recommendations. Expert consensus is implied when a reference is not otherwise indicated. The guideline is not intended to impose standards of care preventing selective variation in practice that is necessary to meet the unique needs of individual patients. The physician must consider each patient and family's circumstance to make the ultimate judgment regarding best care.</div><div id=\"graphicVersion\">Graphic 91258 Version 8.0</div></div></div>"},"91261":{"type":"graphic_picture","displayName":"Terry nails","title":"Terry nails","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Terry nails</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/91261_Terry_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with cirrhosis may have a finding known as Terry nails. In patients with Terry nails, the proximal two-thirds of the nail plate appears white, whereas the distal one-third is red. This finding is believed to be secondary to a low serum albumin. Terry nails may also be seen in patients with renal failure, diabetes, and heart failure.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91261 Version 1.0</div></div></div>"},"91267":{"type":"graphic_table","displayName":"Anticoagulant drug effects on coagulation tests","title":"Expected effects of anticoagulant drugs on commonly used coagulation tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected effects of anticoagulant drugs on commonly used coagulation tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Brand name(s)</td> <td class=\"subtitle1\">PT</td> <td class=\"subtitle1\">aPTT</td> <td class=\"subtitle1\">Anti-factor Xa activity</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Vitamin K antagonists</td> <td>Warfarin</td> <td>Coumadin, Jantoven</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;/&ndash;*</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Acenocoumarol</td> <td>Sintrom</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;/&ndash;*</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Heparins</td> <td>Unfractionated heparin</td> <td>&nbsp;</td> <td class=\"centered\">&ndash;<sup>&#182;</sup></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td> <p>LMW heparins</p> <p>&nbsp; Enoxaparin</p> <p>&nbsp; Dalteparin</p> <p>&nbsp; Nadroparin</p> </td> <td> <p>&nbsp;</p> <p>Lovenox</p> <p>Fragmin</p> <p>Fraxiparine</p> </td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;</td> </tr> <tr class=\"divider_bottom\"> <td>Fondaparinux</td> <td>Arixtra</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Direct thrombin inhibitors</td> <td>Argatroban</td> <td>Acova</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Dabigatran</td> <td>Pradaxa</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td rowspan=\"4\">Direct factor Xa inhibitors</td> <td>Rivaroxaban</td> <td>Xarelto</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;<sup>&#916;</sup></td> </tr> <tr> <td>Apixaban</td> <td>Eliquis</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;/&ndash;</td> <td class=\"centered\">&#8593;<sup>&#916;</sup></td> </tr> <tr> <td>Edoxaban</td> <td>Lixiana, Savaysa</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8593;<sup>&#916;</sup>&nbsp;</td> </tr> <tr> <td>Betrixaban</td> <td>Bevyxxa</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8593;<sup>&#916;</sup>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PT and aPTT are measured in seconds; anti-factor Xa activity is measured in units/mL. Upward arrow (&uarr;) signifies an increase above normal due to the anticoagulant (prolongation of PT or aPTT; increase in anti-factor Xa activity). The effect magnitude will vary depending on the reagent formulation and instrument used. Dash (&ndash;) signifies no appreciable effect. Normal ranges for the PT, aPTT, and anti-factor Xa activity vary among laboratories and should be reported from the testing laboratory along with the patient result. Refer to the UpToDate topic on coagulation testing for details.</div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time; LMW heparin: low molecular weight heparin.<br />* Warfarin has a weak effect on most aPTT reagents. However, warfarin use will increase the sensitivity of the aPTT to heparin effect.<br />¶ While heparin, LMW heparin, and fondaparinux should, in theory, prolong the PT as indirect thrombin inhibitors, in practice most PT reagents contain heparin-binding chemicals that block any heparin effect below a concentration of 1 unit/mL. Above concentrations of 1 unit/mL, heparin effect on the PT may be observed.<br />Δ Anti-factor Xa activity testing must be calibrated for the specific anticoagulant; this information should be verified with the clinical laboratory. Data are not available for betrixaban but would be expected to be similar to other direct factor Xa inhibitors.</div><div class=\"graphic_reference\">Some of the data are&nbsp;from: Samuelson BT, Cuker A, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: A systematic review. Chest 2017; 151:127.</div><div id=\"graphicVersion\">Graphic 91267 Version 7.0</div></div></div>"},"91270":{"type":"graphic_algorithm","displayName":"Recommended algorithm for HIV diagnosis","title":"Recommended algorithm for HIV diagnosis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Recommended algorithm for HIV diagnosis</div><div class=\"cntnt\"><img style=\"width:550px; height:332px;\" src=\"images/ID/91270_New_HIV_diag_test_algo_13.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Modified from: CDC and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://stacks.cdc.gov/view/cdc/23447. Published June 27, 2014.</div><div id=\"graphicVersion\">Graphic 91270 Version 2.0</div></div></div>"},"91271":{"type":"graphic_table","displayName":"Heparin and fondaparinux doses for VTE prevention in cancer","title":"Doses of heparins and fondaparinux for VTE prevention in adults with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of&nbsp;heparins and fondaparinux&nbsp;for VTE prevention in adults with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td rowspan=\"3\">LMW heparin</td> <td>Enoxaparin, 40 mg&nbsp;subcutaneously&nbsp;once daily</td> </tr> <tr> <td>Dalteparin, 5000 units subcutaneously once daily</td> </tr> <tr> <td>Tinzaparin, 4500 units&nbsp;subcutaneously once daily or 75 units/kg subcutaneously once daily</td> </tr> <tr> <td>&nbsp;</td> <td>Nadroparin, 38 units/kg subcutaneously once daily for 3 days followed by 57 units/kg daily</td> </tr> <tr> <td>Unfractionated heparin</td> <td>5000 units subcutaneously every&nbsp;8 hours or 5000&nbsp;to 10,000 units&nbsp;subcutaneously every 12 hours</td> </tr> <tr> <td>Fondaparinux</td> <td>2.5 mg&nbsp;subcutaneously once daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Prophylactic doses are for primary VTE prevention in hospitalized medical or surgical patients with cancer who have normal renal function. Dose adjustments may be needed for renal insufficiency or obesity.&nbsp;Refer to UpToDate topics on on VTE prevention in patients with cancer for details on indications and duration of therapy. Tinzaparin and nadroparin are not available in the United States.</div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; LMW: low molecular weight.</div><div id=\"graphicVersion\">Graphic 91271 Version 2.0</div></div></div>"},"91272":{"type":"graphic_table","displayName":"NCI CTCAE v5 glucose abnormalities","title":"NCI CTCAE v5.0 glucose abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 glucose abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Hyperglycemia</td> <td>Abnormal glucose above baseline with no medical intervention</td> <td>Change in daily management from baseline for a diabetic; oral antiglycemic agent initiated; workup for diabetes</td> <td>Insulin therapy initiated; hospitalization indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> <tr> <td>Hypoglycemia</td> <td>&#60;LLN to 55 mg/dL; &#60;LLN to 3 mmol/L</td> <td>&#60;55 to 40 mg/dL; &#60;3.0 to 2.2 mmol/L</td> <td>&#60;40 to 30 mg/dL; &#60;2.2 to 1.7 mmol/L</td> <td>&#60;30 mg/dL; &#60;1.7 mmol/L; life-threatening consequences; seizures</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hyperglycemia and hypoglycemia indicate an elevation or a reduction in blood sugar, respectively.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; LLN: lower limit of normal.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91272 Version 6.0</div></div></div>"},"91275":{"type":"graphic_figure","displayName":"Heart failure with breast cancer therapy","title":"Incidence of heart failure with breast cancer therapy ","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Incidence of heart failure with breast cancer therapy </div><div class=\"cntnt\"><img style=\"width:647px; height:633px;\" src=\"images/ONC/91275_Hrtfailbreastcancrther.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104(17):1293-1305. By permission of Oxford University Press. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 91275 Version 8.0</div></div></div>"},"91276":{"type":"graphic_table","displayName":"DSM-IV and DSM-5 criteria for dementia","title":"DSM-IV and DSM-5 criteria for dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV and DSM-5 criteria for dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">DSM-IV criteria for dementia</td> <td class=\"subtitle1\">DSM-5 criteria for major neurocognitive disorder<br /> (previously dementia)</td> </tr> <tr> <td><strong>A1.</strong> Memory impairment</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p><strong>A.</strong> Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains*:</p> <p>- Learning and memory</p> <p>- Language</p> <p>- Executive function</p> <p>- Complex attention</p> <p>- Perceptual-motor</p> - Social cognition</td> </tr> <tr> <td class=\"divider_bottom\"> <p><strong>A2.</strong> At least one of the following:</p> <p>- Aphasia</p> <p>- Apraxia</p> <p>- Agnosia</p> - Disturbance in executive functioning</td> </tr> <tr class=\"divider_bottom\"> <td><strong>B.</strong> The cognitive deficits in A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning</td> <td><strong>B.</strong> The cognitive deficits interfere with independence in everyday activities. At a minimum, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>C.</strong> The cognitive deficits do not occur exclusively during the course of delirium</td> <td><strong>C.</strong> The cognitive deficits do not occur exclusively in the context of a delirium</td> </tr> <tr> <td>&nbsp;</td> <td><strong>D.</strong> The cognitive deficits are not better explained by another mental disorder (eg, major depressive disorder, schizophrenia)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For diagnostic criteria of dementia subtypes such as Alzheimer disease or frontotemporal dementia, please refer to UpToDate topics on the clinical manifestations and diagnosis of individual dementia subtypes.</div><div class=\"graphic_footnotes\">DSM: diagnostic and statistical manual.<br />* Evidence of decline is based on: Concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and a substantial impairment in cognitive performance, preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>American Psychiatric Association Diagnostic and Statistical Manual, 4th ed, APA Press, Washington, DC 1994.</LI>&#xD;&#xA;<LI>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</LI></OL></div><div id=\"graphicVersion\">Graphic 91276 Version 4.0</div></div></div>"},"91277":{"type":"graphic_figure","displayName":"SCFE severity","title":"SCFE severity","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">SCFE severity</div><div class=\"cntnt\"><img style=\"width:600px; height:519px;\" src=\"images/EM/91277_SCFE_severity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification of severity of slipped capital femoral epiphysis:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Mild: Displacement of epiphysis &lt;1/3 of the diameter of the femoral neck on anteroposterior (AP) projection or &lt;30 degrees of displaced on true lateral projection</li>&#xD;&#xA;    <li>Moderate: Displacement of epiphysis &gt;1/3 but &lt;1/2 of diameter of femoral neck on AP projection or 30 to 50 degrees displaced on true lateral projection</li>&#xD;&#xA;    <li>Severe: Displacement of epiphysis &gt;1/2 of diameter of femoral neck on AP projection or &gt;50 degrees displaced on true lateral projection</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 91277 Version 2.0</div></div></div>"},"91278":{"type":"graphic_figure","displayName":"Thyroid hormone biosynthesis","title":"Thyroid hormone biosynthesis","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Thyroid hormone biosynthesis</div><div class=\"cntnt\"><img style=\"width:658px; height:416px;\" src=\"images/PEDS/91278_Thyroidhormonebiosynthes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thyroid hormone synthesis includes the following steps, marked by numbers in the diagram above:<br /><OL>&#xD;&#xA;<LI>Iodide (I<SUP>–</SUP>) trapping by the thyroid follicular cells </LI>&#xD;&#xA;<LI>Diffusion of iodide to the apex of the cells</LI>&#xD;&#xA;<LI>Transport of iodide into the colloid </LI>&#xD;&#xA;<LI>Oxidation of inorganic iodide to iodine by thyroid peroxidase (TPO), and incorporation of iodine into tyrosine residues with thyroglobulin molecules in the colloid. DUOX2 and DUOXA2 are required for generation of hydrogen peroxide, a substrate for thyroid peroxidase.</LI>&#xD;&#xA;<LI>Combination of two diiodotyrosine (DIT) molecules to form tetraiodothyronine (thyroxine, T4) or of monoiodotyrosine (MIT) with DIT to form triiodothyronine (T3)</LI>&#xD;&#xA;<LI>Uptake of thyroglobulin from the colloid into the follicular cell by endocytosis, fusion of the thyroglobulin with a lysosome, and proteolysis and release of T4, T3, DIT, and MIT</LI>&#xD;&#xA;<LI>Release of T4 and T3 into the circulation</LI>&#xD;&#xA;<LI>Deiodination of DIT and MIT to yield tyrosine </LI></OL><br />T3 is also formed from monodeiodination of T4 in the thyroid and in peripheral tissues.</div><div class=\"graphic_reference\">Illustration created by Mikael H&auml;ggstr&ouml;m. Used under the Creative Commons CC0 1.0 Universal Public Domain Dedication.</div><div id=\"graphicVersion\">Graphic 91278 Version 2.0</div></div></div>"},"91279":{"type":"graphic_picture","displayName":"Allergic contact cheilitis 1","title":"Allergic contact cheilitis ","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Allergic contact cheilitis </div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/91279_Allerg_contact_cheilitis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scaling involving the lips and perioral skin in a patient with allergic contact cheilitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91279 Version 1.0</div></div></div>"},"91280":{"type":"graphic_picture","displayName":"Allergic contact cheilitis 2","title":"Allergic contact cheilitis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Allergic contact cheilitis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/91280_Allerg_contact_cheilitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, edema, and vesiculation involving the lips and the perioral area in a patient with allergic contact cheilitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91280 Version 1.0</div></div></div>"},"91283":{"type":"graphic_figure","displayName":"Normal heart anatomy","title":"Graphic depiction of the normal anatomy of the heart indicating the correct positioning of right and left structures","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Graphic depiction of the normal anatomy of the heart indicating the correct positioning of right and left structures</div><div class=\"cntnt\"><img style=\"width:583px; height:723px;\" src=\"images/PEDS/91283_Normal_heart_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal anatomy demonstrating the identifying characteristics of each chamber.<br />(A) Anterior view.<br />(B) Posterior view.</div><div class=\"graphic_footnotes\">IVC: inferior vena cava.</div><div class=\"graphic_reference\">Printed with permission from: Anita Impagliazzo.</div><div id=\"graphicVersion\">Graphic 91283 Version 1.0</div></div></div>"},"91284":{"type":"graphic_figure","displayName":"Lateralization and lung lobulation","title":"Lung lobulation due to abdominal and thoracic organ arrangement and lateralization","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Lung lobulation due to abdominal and thoracic organ arrangement and lateralization</div><div class=\"cntnt\"><img style=\"width:536px; height:672px;\" src=\"images/PEDS/91284_Lateralizatlunglobulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung lobulation based on:<br />(A) Normal (situs solitus) arrangement of abdominal and thoracic organs with a trilobar right lung and bilobar left lung. <br />(B) Inverse (solitus inversus) with a mirror image of the normal arrangement of abdominal and thoracic organs.<br />(C) Abnormal lateralization (solitus ambiguus) with right isomerism: Bilateral right lung with three lobes each, symmetrical liver, and absent spleen.<br />(D) Abnormal lateralization (solitus ambiguus) with&nbsp;left isomerism: Bilateral left lungs with two lobes each, symmetrical&nbsp;liver, right-sided stomach, and polysplenia.</div><div id=\"graphicVersion\">Graphic 91284 Version 2.0</div></div></div>"},"91285":{"type":"graphic_figure","displayName":"Heterotaxy bronchial and pulmonary artery anatomy","title":"Relation between bronchial and pulmonary artery anatomy in heterotaxy","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Relation between bronchial and pulmonary artery anatomy in heterotaxy</div><div class=\"cntnt\"><img style=\"width:530px; height:689px;\" src=\"images/PEDS/91285_Hetero_bronch_pulm_art_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of the relationship of bronchi to pulmonary arteries.<br />(A) Normal: Anterior view with a right mainstem bronchus to its first branch (right upper lobar bronchi) located above the right pulmonary artery (eparterial bronchus), whereas the left bronchus has a longer course from the carina to its first branch point below the left pulmonary artery (hyparterial bronchus).<br />(B) Right atrial isomerism: Anterior view with bilateral short eparterial bronchi with pulmonary arterial branches located anterior to bronchi.<br />(C) Left atrial isomerism: Anterior view of bilateral long hyparterial bronchi.<br />(D) Left atrial isomerism (posterior):&nbsp;Posterior view with pulmonary arteries superior to bronchi.</div><div id=\"graphicVersion\">Graphic 91285 Version 4.0</div></div></div>"},"91286":{"type":"graphic_table","displayName":"DSM-5 criteria for major vascular neurocognitive disorder","title":"DSM-5 criteria for major vascular neurocognitive disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 criteria for major vascular neurocognitive disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains:</td> </tr> <tr> <td class=\"indent1\">Learning and memory.</td> </tr> <tr> <td class=\"indent1\">Language.</td> </tr> <tr> <td class=\"indent1\">Executive function.</td> </tr> <tr> <td class=\"indent1\">Complex attention.</td> </tr> <tr> <td class=\"indent1\">Perceptual-motor.</td> </tr> <tr> <td class=\"indent1\">Social cognition.</td> </tr> <tr> <td><strong>B.</strong> The cognitive deficits interfere with independence in everyday activities. At a minimum, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.</td> </tr> <tr> <td><strong>C.</strong> The cognitive deficits do not occur exclusively in the context of a delirium.</td> </tr> <tr> <td><strong>D.</strong> The cognitive deficits are not better explained by another mental disorder (eg, major depressive disorder, schizophrenia).</td> </tr> <tr> <td class=\"sublist1_start\"><strong>E.</strong> The clinical features are consistent with a vascular etiology, as suggested by either of the following:</td> </tr> <tr> <td class=\"indent1\">Onset of the cognitive deficits is temporally related to one or more cerebrovascular events.</td> </tr> <tr> <td class=\"indent1\">Evidence for decline is prominent in complex attention (including processing speed) and frontal-executive function.</td> </tr> <tr> <td><strong>F.</strong> There is evidence of the presence of cerebrovascular disease from history, physical examination, and/or neuroimaging considered sufficient to account for the neurocognitive deficits.</td> </tr> <tr> <td><strong>G.</strong> The deficits are not better explained by another brain disease or systemic disorder.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DSM: diagnostic and statistical manual.</div><div class=\"graphic_reference\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</div><div id=\"graphicVersion\">Graphic 91286 Version 3.0</div></div></div>"},"91287":{"type":"graphic_figure","displayName":"Heterotaxy bronchial anatomy","title":"Bronchial anatomy in right and left atrial isomerism (heterotaxy)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchial anatomy in right and left atrial isomerism (heterotaxy)</div><div class=\"cntnt\"><img style=\"width:375px; height:716px;\" src=\"images/PEDS/91287_Heterotaxy_bronchial_anatom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchial anatomy with anterior views of trachea and bronchi. Arrows point to upper lobe bronchi.<BR>(A) Normal bronchial situs with asymmetrical main bronchi with a right short bronchus to a trilobar right lung and&nbsp;a longer main bronchus to a&nbsp;left bilobar lung.<BR>(B) Right atrial isomerism with symmetrical bilateral short main bronchi to bilateral trilobar lungs.<BR>(C) Left atrial isomerism with symmetrical bilateral long main bronchi to bilateral bilobar lungs.</div><div id=\"graphicVersion\">Graphic 91287 Version 1.0</div></div></div>"},"91288":{"type":"graphic_table","displayName":"DSM-5 criteria for major neurocognitive disorder due to AD","title":"DSM-5 criteria for major neurocognitive disorder due to Alzheimer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 criteria for major neurocognitive disorder due to Alzheimer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>A.</strong> Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains*:</td> </tr> <tr> <td class=\"indent1\">Learning and memory.</td> </tr> <tr> <td class=\"indent1\">Language.</td> </tr> <tr> <td class=\"indent1\">Executive function.</td> </tr> <tr> <td class=\"indent1\">Complex attention.</td> </tr> <tr> <td class=\"indent1\">Perceptual-motor.</td> </tr> <tr> <td class=\"indent1\">Social cognition.</td> </tr> <tr> <td><strong>B.</strong> The cognitive deficits interfere with independence in everyday activities. At a minimum, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.</td> </tr> <tr> <td><strong>C.</strong> The cognitive deficits do not occur exclusively in the context of a delirium.</td> </tr> <tr> <td><strong>D.</strong> The cognitive deficits are not better explained by another mental disorder (eg, major depressive disorder, schizophrenia).</td> </tr> <tr> <td><strong>E.</strong> There is insidious onset and gradual progression of impairment in at least two cognitive domains.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>F.</strong> Either of the following:</td> </tr> <tr> <td class=\"indent1\">Evidence of a causative Alzheimer disease genetic mutation from family history or genetic testing.</td> </tr> <tr> <td class=\"indent1\">All three of the following are present:</td> </tr> <tr> <td class=\"indent2\">1) Clear evidence of decline in memory and learning and at least one other cognitive domain.</td> </tr> <tr> <td class=\"indent2\">2) Steadily progressive, gradual decline in cognition, without extended plateaus.</td> </tr> <tr> <td class=\"indent2\">3) No evidence of mixed etiology (ie, absence of other neurodegenerative disorders or cerebrovascular disease, or another neurological, mental, or systemic disease or condition likely contributing to cognitive decline).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DSM: diagnostic and statistical manual.<br />* Evidence of decline is based on: Concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and a substantial impairment in cognitive performance, preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment.</div><div class=\"graphic_reference\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</div><div id=\"graphicVersion\">Graphic 91288 Version 3.0</div></div></div>"},"91291":{"type":"graphic_diagnosticimage","displayName":"Echocardiography - Normal abdomen","title":"Echocardiography of normal arrangement (situs solitus) of abdominal organs and great vessels","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Echocardiography of normal arrangement (situs solitus) of abdominal organs and great vessels</div><div class=\"cntnt\"><img style=\"width:590px; height:589px;\" src=\"images/PEDS/91291_Echonormalabdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram showing abdominal situs solitus (normal arrangement of organs and great vessels) with a left-sided stomach and right-sided liver. The normal position of the inferior vena cava (IVC) and descending aorta (DAo) relative to the spine is also shown. The hepatic veins connect to the IVC, which then joins the right atrium. The IVC is located to the right of the spine, and the aorta travels in the paravertebral gutter, to the left of the spine.</div><div id=\"graphicVersion\">Graphic 91291 Version 2.0</div></div></div>"},"91293":{"type":"graphic_diagnosticimage","displayName":"Abdominal echocardiography - Left isomerism","title":"Echocardiography of a patient with left atrial isomerism (heterotaxy)","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Echocardiography of a patient with left atrial isomerism (heterotaxy)</div><div class=\"cntnt\"><img style=\"width:539px; height:492px;\" src=\"images/PEDS/91293_AbdominalechoLisomerism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subcostal abdominal view of a transthoracic echocardiogram&nbsp;in a patient with&nbsp;left atrial isomerism. No vena cava is seen, and a prominent azygos vein is observed adjacent to the spine posterior to the descending aorta.</div><div class=\"graphic_footnotes\">DAo: descending aorta.</div><div id=\"graphicVersion\">Graphic 91293 Version 2.0</div></div></div>"},"91294":{"type":"graphic_table","displayName":"Use of bedaquiline in adults","title":"Use of bedaquiline in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of bedaquiline in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Treatment of multidrug-resistant tuberculosis (MDR-TB) should be provided in consultation with an expert in the management of MDR-TB. Bedaquiline should be used only for patients who have no other treatment options.</td> </tr> <tr> <td>Dosing consists of 400 mg orally once daily for two weeks, followed by 200 mg orally three times weekly taken with food (to maximize absorption) for a total treatment duration of 24 weeks. Patients should be advised to avoid drinking alcohol.</td> </tr> <tr> <td>If a dose is missed during the first two weeks of treatment, patients should not make up the missed dose but continue the usual dosing schedule. If a dose is missed from the third week onward, patients should take the missed dose as soon as possible and then resume the established regimen.</td> </tr> <tr> <td>The use of bedaquiline with rifamycins or other drugs that induce or suppress CYP3A4 should be avoided if possible. A separate table of CYP3A4 inhibitors/inducers is available. If bedaquiline is administered with these drugs, monitoring of serum drug levels should be performed; the United States Centers for Disease Control and Prevention (CDC) may be contacted for assistance.</td> </tr> <tr> <td>Bedaquiline has a very long terminal half-life (four to five months); providers should consider discontinuation of bedaquiline four to five months before scheduled discontinuation of other drugs to avoid an extended period of exposure to low levels of bedaquiline as a single drug.</td> </tr> <tr> <td>Bedaquiline should be administered only by directly observed therapy (DOT) as part of a case management strategy. Patients should be monitored weekly for nausea, headache, hemoptysis, chest pain, arthralgia, and rash.</td> </tr> <tr> <td>Bedaquiline should be avoided in patients with severe hepatic impairment (Child-Pugh C) but may be administered to patients with mild to moderate impairment (Child-Pugh A or B). Serum aminotransferases should be monitored at baseline, monthly, and if symptomatic. An increase to more than three times the upper limit of normal should be managed as discussed separately.* More frequent aminotransferase monitoring should be considered in patients receiving other hepatotoxic drugs or in those with underlying liver disease.</td> </tr> <tr> <td>Bedaquiline should be administered with caution in patients with severe renal impairment requiring dialysis. Dose adjustment is not required in patients with mild to moderate renal impairment.</td> </tr> <tr> <td>An electrocardiogram (ECG) should be obtained at baseline and repeated at least 2, 12, and 24 weeks after starting treatment, as well as in the setting of syncope. Serum potassium, calcium, and magnesium should be obtained at baseline and monitored until fully corrected. Weekly ECGs are warranted in patients with persistent low electrolyte concentrations, patients taking other QTc prolonging drugs<sup>&#182;</sup>, and patients with history of torsade de pointes, congenital long QT syndrome, hypothyroidism and bradyarrhythmia, or uncompensated heart failure.</td> </tr> <tr> <td>Discontinuation of bedaquiline is warranted in the setting of clinically significant ventricular arrhythmia or QTc F &#62;500 ms.</td> </tr> <tr> <td>A registry for individuals treated with bedaquiline in the United States is being established by the manufacturer through its United States distributor to track its use and patient outcomes. Serious adverse events that may be attributed to bedaquiline should be reported to the US Food and Drug Administration (FDA) Medwatch (<a href=\"http://www.fda.gov/Safety/MedWatch\" target=\"_blank\">http://www.fda.gov/Safety/MedWatch</a> or 1-800-332-1088) and the CDC (1-770-488-7100).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to the UpToDate topic review on the treatment of pulmonary tuberculosis in HIV-negative patients.<br />¶ QTc prolonging drugs include fluoroquinolones, macrolides, and clofazimine. For additional information, refer to the UpToDate topic review on acquired long QT syndrome.</div><div class=\"graphic_reference\">Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recomm Rep 2013; 62:1. (Available at: <a href=\"http://www.cdc.gov/mmwr/pdf/rr/rr6209.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/pdf/rr/rr6209.pdf</a>).</div><div id=\"graphicVersion\">Graphic 91294 Version 5.0</div></div></div>"},"91303":{"type":"graphic_picture","displayName":"Lacrimal gland enlargement in sarcoidosis","title":"Lacrimal gland enlargement in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lacrimal gland enlargement in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/PULM/91303_Lacrim_gland_enlrg_sarcoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eversion of upper eyelid showing lacrimal gland enlargement in a patient with sarcoidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91303 Version 1.0</div></div></div>"},"91304":{"type":"graphic_picture","displayName":"Sarcoid papules and lacrimal gland enlargement","title":"Cutaneous papules and lacrimal gland enlargement in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cutaneous papules and lacrimal gland enlargement in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/PULM/91304_Sarc_pap_acrim_glnd_enlrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with sarcoidosis, cutaneous yellow-brown papules are seen inferomedially to the eye. Prominence of lacrimal gland is evident above upper eyelid.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91304 Version 1.0</div></div></div>"},"91306":{"type":"graphic_diagnosticimage","displayName":"X-ray branch arterial calcification","title":"Branch calcification of popliteal artery on x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Branch calcification of popliteal artery on x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:436px;\" src=\"images/RADIOL/91306_X_branch_arter_calcifi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A focused image from an A-P x-ray over the left tibia (A) shows calcification of the below knee popliteal artery just before it branches into the anterior tibial artery laterally and the tibioperoneal trunk medially. Image B is a magnification view and shows the branch point (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 91306 Version 1.0</div></div></div>"},"91307":{"type":"graphic_diagnosticimage","displayName":"X-ray and angiogram SFA atherosclerosis","title":"Atherosclerosis of the SFA on x-ray and arteriogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atherosclerosis of the SFA on x-ray and arteriogram</div><div class=\"cntnt\"><img style=\"width:349px; height:529px;\" src=\"images/RADIOL/91307_X_angiogram_SFA_athero.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An x-ray of the left distal thigh (A) in the A-P projection shows atherosclerotic calcification of the distal SFA (arrowhead) as well as the above knee popliteal artery (arrow). Image B is a corresponding angiogram and shows a focal high grade stenosis (arrow) with collateral flow around the stenosis (arrowhead).</div><div class=\"graphic_footnotes\">SFA: superficial femoral artery; A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 91307 Version 1.0</div></div></div>"},"91308":{"type":"graphic_diagnosticimage","displayName":"X-ray aneurysm of SFA","title":"Aneurysm of SFA on x-ray","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Aneurysm of SFA on x-ray</div><div class=\"cntnt\"><img style=\"width:594px; height:418px;\" src=\"images/RADIOL/91308_X_ray_aneurysm_SFA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An x-ray of the right distal thigh (A) in the A-P projection shows atherosclerotic calcification of the distal SFA (arrow) as well as an aneurysm of the SFA at Hunter's canal (arrowhead). Image B is a magnified view and shows the calcified aneurysm (between arrows).</div><div class=\"graphic_footnotes\">SFA: superficial femoral artery; A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 91308 Version 1.0</div></div></div>"},"91309":{"type":"graphic_diagnosticimage","displayName":"X-ray SFA stent tibial atherosclerosis","title":"Atherosclerosis tibial arteries and SFA stent","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Atherosclerosis tibial arteries and SFA stent</div><div class=\"cntnt\"><img style=\"width:598px; height:458px;\" src=\"images/RADIOL/91309_X_SFA_stent_tib_athero.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An x-ray of the right knee (A) in the A-P projection shows a stent in the distal SFA (arrowhead) and atherosclerotic calcification of the tibial arteries (double arrow). Image B is a lateral view and shows the stent in the SFA extending into the above knee popliteal artery (arrowhead) and the tibial artery calcifications (arrow).</div><div class=\"graphic_footnotes\">SFA: superficial femoral artery; A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 91309 Version 1.0</div></div></div>"},"91310":{"type":"graphic_diagnosticimage","displayName":"US loculated bile leak","title":"Bile leak following cholecystectomy on US","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Bile leak following cholecystectomy on US</div><div class=\"cntnt\"><img style=\"width:588px; height:406px;\" src=\"images/RADIOL/91310_US_loculated_bile_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse ultrasound image through the gallbladder bed following cholecystectomy shows a complex fluid collection (arrow).</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91310 Version 1.0</div></div></div>"},"91311":{"type":"graphic_diagnosticimage","displayName":"CT loculated bile leak","title":"Bile leak following cholecystectomy on CT","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Bile leak following cholecystectomy on CT</div><div class=\"cntnt\"><img style=\"width:586px; height:450px;\" src=\"images/RADIOL/91311_CT_loculated_bile_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the upper abdomen following cholecystectomy shows a low density fluid collection in the region of the gastrohepatic ligament (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91311 Version 1.0</div></div></div>"},"91312":{"type":"graphic_diagnosticimage","displayName":"CT guided drainage bile leak","title":"Percutaneous drainage of bile leak using CT guidance","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Percutaneous drainage of bile leak using CT guidance</div><div class=\"cntnt\"><img style=\"width:598px; height:242px;\" src=\"images/RADIOL/91312_CT_guid_drain_bil_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In image A, a CT scan through the upper abdomen shows part of a pigtail catheter (arrow) in a decompressed post cholecystectomy biloma. Image B shows contrast in the irregular collection (arrowhead) following injection through the catheter (arrow) There is no communication to the biliary system.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91312 Version 1.0</div></div></div>"},"91313":{"type":"graphic_diagnosticimage","displayName":"HIDA large bile leak status post cholecystectomy ","title":"Large bile leak following cholecystectomy using HIDA scan","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Large bile leak following cholecystectomy using HIDA scan</div><div class=\"cntnt\"><img style=\"width:588px; height:372px;\" src=\"images/RADIOL/91313_HIDA_lrg_bile_cholcyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A HIDA scan following cholecystectomy shows an early bile leak at 15 minutes (arrow) enlarging significantly over the following 15 minutes (arrowhead).</div><div class=\"graphic_footnotes\">HIDA: hepatobiliary iminodiacetic acid.</div><div id=\"graphicVersion\">Graphic 91313 Version 1.0</div></div></div>"},"91314":{"type":"graphic_diagnosticimage","displayName":"HIDA scan bile leak type A","title":"Type A bile leak on HIDA scan","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Type A bile leak on HIDA scan</div><div class=\"cntnt\"><img style=\"width:573px; height:405px;\" src=\"images/RADIOL/91314_HIDA_scan_bile_leak_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A HIDA scan shows a small accumulation of radiotracer along the inferomedial aspect of the liver (arrow) at 40 minutes.</div><div class=\"graphic_footnotes\">HIDA: hepatobiliary iminodiacetic acid.</div><div id=\"graphicVersion\">Graphic 91314 Version 1.0</div></div></div>"},"91315":{"type":"graphic_diagnosticimage","displayName":"ERCP bile leak","title":"Bile leak by ERCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bile leak by ERCP</div><div class=\"cntnt\"><img style=\"width:410px; height:499px;\" src=\"images/RADIOL/91315_ERCP_bile_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ERCP shows a bile leak (arrow) in the expected location of the amputated cystic duct.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91315 Version 1.0</div></div></div>"},"91316":{"type":"graphic_diagnosticimage","displayName":"MRCP bile leak","title":"Bile leak by MRCP","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Bile leak by MRCP</div><div class=\"cntnt\"><img style=\"width:600px; height:293px;\" src=\"images/RADIOL/91316_MRCP_bile_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An MRCP (A) shows the origin of the bile leak near the cystic duct amputation site (arrow) following cholecystectomy. The bile duct is mildly dilated (arrowhead). Image B is a T2 weighted sequence through the kidneys and shows free fluid in Morrison's pouch (arrow).</div><div class=\"graphic_footnotes\">MRCP: magnetic resonance cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91316 Version 2.0</div></div></div>"},"91317":{"type":"graphic_diagnosticimage","displayName":"MRCP and ERCP bile duct transection injury","title":"Transection injury of the bile duct status post cholecystectomy by MRCP and ERCP","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Transection injury of the bile duct status post cholecystectomy by MRCP and ERCP</div><div class=\"cntnt\"><img style=\"width:598px; height:309px;\" src=\"images/RADIOL/91317_MRCP_ERCP_bil_trns_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An MRCP (A) following cholecystectomy shows a transition zone (arrow) separating a dilated upstream biliary system and normal caliber downstream system. The obstruction is approximately 2.5 cm beyond the bifurcation. Image B is an ERCP and shows total obstruction of the biliary system in the region of the cholecystectomy clips.</div><div class=\"graphic_footnotes\">MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91317 Version 1.0</div></div></div>"},"91318":{"type":"graphic_diagnosticimage","displayName":"ERCP bile leak type A with stent","title":"Type A bile leak treated with a retrograde stent by ERCP ","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Type A bile leak treated with a retrograde stent by ERCP </div><div class=\"cntnt\"><img style=\"width:596px; height:299px;\" src=\"images/RADIOL/91318_Type_A_bile_stent_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ERCP (A) shows a small bile leak (arrow) in the expected location of the amputated cystic duct. Image B shows a plastic stent in place above the leak (arrow).</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91318 Version 1.0</div></div></div>"},"91319":{"type":"graphic_diagnosticimage","displayName":"ERCP intraoperative repair of type A bile leak","title":"Type A bile leak repaired intraoperatively with a clip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type A bile leak repaired intraoperatively with a clip</div><div class=\"cntnt\"><img style=\"width:445px; height:461px;\" src=\"images/RADIOL/91319_Typ_A_bil_rep_intr_clip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ERCP shows a small clip (arrow) in the expected location of the gallbladder fossa. The bile leak was observed intraoperatively and treated with a clip.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91319 Version 1.0</div></div></div>"},"91320":{"type":"graphic_diagnosticimage","displayName":"CT and ERCP Type A bile leak","title":"Type A bile leak from minor hepatic duct treated with stent","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Type A bile leak from minor hepatic duct treated with stent</div><div class=\"cntnt\"><img style=\"width:573px; height:644px;\" src=\"images/RADIOL/91320_Typ_A_bile_hp_duct_stnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan showing a small biloma (arrow) complicating laparoscopic cholecystectomy. Image B is an ERCP showing an accessory right hepatic duct leaking into the post operative bed (arrow). Image C is an ERCP performed 4 weeks after stent placement and shows resolution of the leak.</div><div class=\"graphic_footnotes\">CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91320 Version 1.0</div></div></div>"},"91322":{"type":"graphic_picture","displayName":"Atopic cheilitis","title":"Atopic cheilitis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Atopic cheilitis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/91322_Atopic_cheilitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dryness and scaling of the lips in a child with atopic dermatitis. Note the blurred vermilion border of the upper lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91322 Version 1.0</div></div></div>"},"91324":{"type":"graphic_table","displayName":"Selection of etiology-based antiemetics in palliative care","title":"Selection of etiology-based antiemetics in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of etiology-based antiemetics in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Situation</td> <td class=\"subtitle1\">Associated neurotransmitters</td> <td class=\"subtitle1\">Recommended antiemetic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer patients</td> </tr> <tr> <td class=\"indent1\">No definite etiology (not related to chemotherapy or radiation, constipation,&nbsp;central nervous system disease, metabolic abnormalities/drugs, or bowel obstruction)</td> <td>Dopamine, serotonin (type 3 receptor [5HT3] and type 4 receptor [5HT4]), acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Metoclopramide 10 mg every four hours orally or intravenously initially; increase to 5 mg per hour infusion (120 mg/day) if needed for relief</p> <strong>Second line:</strong> Add 5HT3-receptor antagonist* or substitute dopamine receptor antagonist (chlorpromazine 10 to 25 mg every four to eight hours orally, intravenously, or subcutaneously; or prochlorperazine 5 to 25 mg every six to eight hours orally, intramuscularly, or rectally; or haloperidol 0.5 to 2 mg every six to eight hours orally, intravenously, or subcutaneously) or olanzapine 2.5 to 5 mg every 12 hours orally or sublingually.</td> </tr> <tr> <td class=\"indent1\">Chemotherapy-induced nausea and vomiting (CINV)</td> <td>5HT3, neurokinin-1</td> <td><strong>First line:</strong> <ol class=\"decimal_heading\"> <li>5HT3 receptor antagonist*</li> <li>Neurokinin-1 antagonist<sup>&#182;</sup></li> <li>Dexamethasone</li> </ol> <strong>Second line:</strong> Other drugs with a lower therapeutic index, including dopamine receptor antagonist<sup>&#916;</sup>, metoclopramide, nabilone, or dronabinol.</td> </tr> <tr> <td class=\"indent1\">Radiation therapy-induced nausea and vomiting</td> <td>5HT3, dopamine</td> <td><strong>First line:</strong> <ol class=\"decimal_heading\"> <li>5HT3 receptor antagonists*</li> <li>Dexamethasone</li> </ol> <strong>Second line:</strong> Dopamine receptor antagonist<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Gastroparesis</td> <td>Dopamine, 5HT3, 5HT4, acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Metoclopramide 5 to 10 mg four times daily intravenously, orally, or subcutaneously</p> <p><strong>Second line:</strong> Erythromycin</p> <strong>Third line:</strong> Domperidone (outside United States) or cisapride (direct from manufacturer)</td> </tr> <tr> <td class=\"indent1\">Bowel obstruction</td> <td>Dopamine, somatostatin, acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Haloperidol 0.5 to 2 mg every six to eight hours orally, intravenously, or subcutaneously and titrate up to 20 mg per day if needed; also add dexamethasone 4 mg every 12 hours intravenously or subcutaneously; and octreotide 0.1 mg every eight hours intravenously or subcutaneously up to 0.3 mg every eight hours depending on response; or hyoscine (scopolamine) hydrobromide 0.2 to 0.4 mg every six to eight hours subcutaneously; or transdermal scopolamine</p> <strong>Second line:</strong> Chlorpromazine, prochlorperazine, or cyclizine subcutaneously or rectally, or intravenously</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nausea due to intracranial malignancy (primary or secondary brain tumor)</td> <td>Unknown</td> <td><strong>First line:</strong> Dexamethasone 10 mg loading dose, followed by 4 mg every six hours or 8 mg every 12 hours orally or intravenously</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nausea due to non-cancer conditions</td> </tr> <tr> <td class=\"indent1\">Kidney failure</td> <td>&nbsp;</td> <td>Haloperidol (decrease dose by 50 percent)</td> </tr> <tr> <td class=\"indent1\">Liver failure</td> <td>&nbsp;</td> <td>Metoclopramide at 60 mg/24 hours appears to be safe and does not increase sedation in mild encephalopathy</td> </tr> <tr> <td class=\"indent1\">Chronic obstructive pulmonary disorder (COPD)</td> <td>&nbsp;</td> <td>No specific recommendations, but in view of association with GERD, a prokinetic such as metoclopramide is reasonable</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> <td>&nbsp;</td> <td>No specific recommendation; however, use ondansetron or metoclopramide with caution</td> </tr> <tr> <td class=\"indent1\">HIV</td> <td>&nbsp;</td> <td> <p>Often related to antiretroviral medication. No specific antiemetic recommendation; however, patients with HIV on metoclopramide may be at increased risk of EPS.</p> Consider the cannabinoid dronabinol in patients who also have a poor appetite (initial dose 2.5 mg twice daily before lunch and dinner and titrate up to a maximum of 20 mg/day)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; GERD: gastroesophageal reflux disease; EPS: extrapyramidal symptoms.<br />* 5HT3 receptor antagonists: granisetron, ondansetron, palonosetron, dolasetron, tropisetron, ramosetron.<br />¶ Neurokinin-1 antagonists: aprepitant, fosaprepitant.<br />Δ Dopamine receptor antagonists: chlorpromazine, haloperidol, prochlorperazine.</div><div class=\"graphic_reference\">Adapted and expanded from: Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.</div><div id=\"graphicVersion\">Graphic 91324 Version 2.0</div></div></div>"},"91326":{"type":"graphic_table","displayName":"Immunization schedule by birth country","title":"Immunization schedules of common countries of origin for international adoption to the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunization schedules of common countries of origin for international adoption to the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\"><span class=\"blue\">United States</span></td> <td class=\"subtitle1\">China</td> <td class=\"subtitle1\">Ethiopia</td> <td class=\"subtitle1\">Ukraine&nbsp;</td> <td class=\"subtitle1\">The Republic of Korea (South Korea)</td> <td class=\"subtitle1\">Uganda&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bacille Calmette-Gu&#233;rin</td> <td><span class=\"blue\">--</span></td> <td>Birth</td> <td>Birth</td> <td> <p>3 to&nbsp;5 days</p> <p>7 years</p> </td> <td>Birth to 1 month</td> <td>Birth</td> </tr> <tr class=\"divider_bottom\"> <td>Diphtheria, tetanus, pertussis</td> <td> <p><strong><span class=\"blue\">DTaP</span></strong></p> <p><span class=\"blue\">2 months</span></p> <p><span class=\"blue\">4 months</span></p> <p><span class=\"blue\">6 months</span></p> <p><span class=\"blue\">15 to 18 months</span></p> <p><span class=\"blue\">4 to 6 years</span></p> <br /> <p><span class=\"blue\"><strong>Tdap</strong></span></p> <span class=\"blue\">11 years</span></td> <td> <p><strong>DTaP</strong></p> <p>3 months</p> <p>4 months</p> <p>5 months</p> <p>18 to 24 months (2 doses)</p> <br /> <p><strong>DT</strong></p> 6 years</td> <td> <p><strong>DTwP</strong></p> <p>6 weeks</p> <p>10 weeks</p> 14 weeks</td> <td> <p><strong>DTaP</strong></p> <p>3 months</p> <p>4 months</p> <p>&nbsp;</p> <p><strong>DTwP</strong></p> <p>3 months</p> <p>4 months</p> <p>5 months </p> <p>18 months</p> <p><strong>&nbsp;</strong></p> <p><strong>DT</strong></p> <p>6 years</p> <p>&nbsp;</p> <p><strong>Td</strong></p> <p>14 years</p> <p>18 years</p> </td> <td> <p><strong>DTaP</strong></p> <p>2 months</p> <p>4 months</p> <p>6 months</p> <p>15 to 18 months</p> <p>4 to 6 years</p> <p>&nbsp;</p> <p><strong>Td</strong></p> <p>11 to 12 years (two doses)</p> <p>&nbsp;</p> <p><strong>Tdap </strong></p> <p>11 to 12 years (two doses)</p> </td> <td> <p><strong>&nbsp;DTwP</strong></p> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> </td> </tr> <tr class=\"divider_bottom\"> <td><em>Haemophilus influenzae</em> type b</td> <td> <p><span class=\"blue\">2 months</span></p> <p><span class=\"blue\">4 months</span></p> <p><span class=\"blue\">6 months</span></p> <span class=\"blue\">12 to 15 months</span></td> <td>--</td> <td> <p>6 weeks</p> <p>10 weeks</p> 14 weeks</td> <td> <p>3 months</p> <p>4 months</p> <p>18 months</p> </td> <td> <p>2&nbsp;months</p> <p>4 months</p> <p>6&nbsp;months</p> <p>&nbsp;</p> </td> <td> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis A</td> <td><span class=\"blue\">12 to 23 months (second dose 6 months after first)</span></td> <td>18 months</td> <td>--</td> <td>--</td> <td> <p>12 to 23 months(second dose 6 to 12 months after first)</p> </td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis B</td> <td> <p><span class=\"blue\">Birth</span></p> <p><span class=\"blue\">1 to 2 months</span></p> <span class=\"blue\">6 to 18 months</span></td> <td> <p>Birth</p> <p>1 month</p> 6 months</td> <td> <p>6 weeks</p> <p>10 weeks</p> 14 weeks</td> <td> <p>Birth</p> <p>1 month</p> <p>6 months</p> </td> <td> <p>Birth</p> <p>1 month</p> <p>6 months</p> </td> <td> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Human papillomavirus</td> <td><span class=\"blue\">3-dose series beginning at 11 years</span></td> <td>--</td> <td>--</td> <td>--</td> <td>--</td> <td> <p>10 years</p> <p>6 months after first dose</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Influenza</td> <td><span class=\"blue\">Annually for those &#8805;6 months</span></td> <td>Annually for those &#8805;6 months to 8 years (two doses)</td> <td>--</td> <td>--</td> <td>Annually for those 6 through 59 months and children &#8805;6 months with chronic illness</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td>Japanese encephalitis</td> <td><span class=\"blue\">--</span></td> <td> <p><strong>Live, attenuated</strong></p> <p>8 months</p> <p>2 years</p> <br /> <p><strong>Inactivated</strong></p> <p>8 months</p> <p>7 days after first dose</p> <p>2 years</p> 6 years</td> <td>--</td> <td>--</td> <td> <p><strong>Live attenuated</strong></p> <p>12 to 23 months</p> <p>34 to 35 months</p> <p>&nbsp;</p> <p><strong>Inactivated</strong></p> <p>12 to 23 months</p> <p>7 to 30 days after first dose</p> <p>12 months after second dose</p> <p>6 years</p> <p>12 years</p> </td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td>Measles, mumps, rubella</td> <td> <p><span class=\"blue\"><strong>MMR</strong>&nbsp;</span></p> <p><span class=\"blue\">12 to 15 months</span></p> <span class=\"blue\">4 to 6 years</span></td> <td> <p><strong>MR</strong></p> <p>8 months</p> <br /> <p><strong>MMR</strong></p> 18 to 24 months</td> <td> <p><strong>Measles</strong></p> 9 months</td> <td> <p><strong>MMR</strong></p> <p>18 months</p> <p>6 years</p> </td> <td> <p><strong>MMR</strong></p> <p>12 to 15 months</p> <p>4 to 6 years</p> </td> <td> <p><strong>Measles</strong></p> <p>9 months</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Meningococcal</td> <td> <p><strong><span class=\"blue\">MCV4</span></strong></p> <p><span class=\"blue\">11 to 12 years</span></p> <span class=\"blue\">16 to 18 years</span></td> <td> <p><strong>MenA</strong></p> <p>6 to 18 months (two doses)</p> <br /> <p><strong>MenAC</strong></p> <p>3 years</p> 6 years</td> <td>--</td> <td>--</td> <td>--</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td>Pneumococcal conjugate vaccine</td> <td> <p><span class=\"blue\">2 months</span></p> <p><span class=\"blue\">4 months</span></p> <p><span class=\"blue\">6 months</span></p> <span class=\"blue\">12 to 15 months</span></td> <td>--</td> <td> <p>6 weeks</p> <p>10 weeks</p> 14 weeks</td> <td>--</td> <td> <p>2&nbsp;months</p> <p>4 months </p> <p>6 months</p> <p>12 to 15 months</p> </td> <td> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Poliovirus</td> <td> <p><strong><span class=\"blue\">IPV</span></strong></p> <p><span class=\"blue\">2 months</span></p> <p><span class=\"blue\">4 months</span></p> <p><span class=\"blue\">6 to 18 months</span></p> <span class=\"blue\">4 to 6 years</span></td> <td> <p><strong>OPV</strong></p> <p>2 months</p> <p>3 months</p> <p>4 months</p> <p>4 years</p> <p>&nbsp;</p> <p><strong>IPV </strong></p> <p>2 months</p> </td> <td> <p><strong>OPV</strong></p> <p>Birth</p> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> <p>&nbsp;</p> <p><strong>IPV </strong></p> 14 weeks</td> <td> <p><strong>OPV</strong></p> <p>5 months</p> <p>18 months</p> <p>6 years</p> <p>14 years</p> </td> <td> <p><strong>IPV</strong></p> <p>2&nbsp;months</p> <p>4 months</p> <p>6 months</p> <p>4 to 6 years</p> </td> <td> <p><strong>OPV</strong></p> <p>Birth</p> <p>6 weeks</p> <p>10 weeks</p> <p>14 weeks</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Rotavirus</td> <td> <p><span class=\"blue\">2 months</span></p> <p><span class=\"blue\">4 months</span></p> <span class=\"blue\">6 months (depending on vaccine)</span></td> <td>--</td> <td> <p>6 weeks</p> 10 weeks</td> <td>--</td> <td>--</td> <td>--&nbsp;</td> </tr> <tr> <td>Varicella</td> <td> <p><span class=\"blue\">12 to 15 months</span></p> <span class=\"blue\">4 to 6 years</span></td> <td>--</td> <td>--</td> <td>--</td> <td>12 to 15 months</td> <td>--</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DTaP: diphtheria, tetanus, acellular pertussis vaccine; DTwP: diphtheria, tetanus, whole cell pertussis vaccine; Tdap: tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine; DT: diphtheria and tetanus toxoids; Td: reduced diphtheria toxoid and tetanus toxoid vaccine; MMR: measles, mumps, rubella vaccine; MR: measles and rubella vaccine; MCV4: quadrivalent meningococcal conjugate vaccine; MenA: meningococcal serotype A conjugate vaccine; MenAC: meningococcal serotypes A and C polysaccharide vaccine; IPV: inactivated poliovirus vaccine; OPV: oral poliovirus vaccine.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>The BCG World Atlas. <A href=\"http://www.bcgatlas.org/\" target=_blank>www.bcgatlas.org</A> (Accessed on July 11, 2016).</LI>&#xD;&#xA;<LI>World Health Organization Vaccine Preventable Diseased Monitoring System. <A href=\"http://apps.who.int/immunization_monitoring/globalsummary\" target=_blank>http://apps.who.int/immunization_monitoring/globalsummary</A> (Accessed on July 11, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 91326 Version 7.0</div></div></div>"},"91329":{"type":"graphic_table","displayName":"Approach to immunizations received outside the US","title":"Approaches to evaluation and vaccination of persons vaccinated outside the United States who have no (or questionable) vaccination records","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches to evaluation and vaccination of persons vaccinated outside the United States who have no (or questionable) vaccination records</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Recommended approach</td> <td class=\"subtitle1\">Alternative approach*</td> </tr> <tr> <td>MMR</td> <td>Revaccination with MMR</td> <td>Serologic testing for IgG antibodies to measles, mumps, and rubella</td> </tr> <tr> <td>Hib</td> <td>Age-appropriate revaccination</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Hepatitis A</td> <td>Age-appropriate revaccination</td> <td>Serologic testing for IgG antibodies to hepatitis A</td> </tr> <tr> <td>Hepatitis B</td> <td>Age-appropriate revaccination and serologic testing for HBsAg<sup>&#182;</sup></td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Poliovirus</td> <td>Revaccination with inactivated poliovirus vaccine</td> <td>Serologic testing not recommended</td> </tr> <tr> <td>DTaP</td> <td>Revaccination with DTaP, with serologic testing for specific IgG antibody to tetanus and diphtheria toxins in the event of a severe local reaction</td> <td>Persons whose records indicate receipt of &#8805;3 doses: Serologic testing for specific IgG antibody to diphtheria and tetanus toxins before administering additional doses, or administer a single booster dose of DTaP, followed by serological testing after&nbsp;one month for specific IgG antibody to diphtheria and tetanus toxins with revaccination as appropriate<sup>&#916;</sup></td> </tr> <tr> <td>Tdap</td> <td>Age-appropriate vaccination of persons who are candidates for Tdap vaccine</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Varicella</td> <td>Age-appropriate vaccination of persons who lack evidence of varicella immunity</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Pneumococcal conjugate</td> <td>Age-appropriate vaccination</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Rotavirus</td> <td>Age-appropriate vaccination</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>HPV</td> <td>Age-appropriate vaccination</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Meningococcal conjugate (MenACWY)</td> <td>Age-appropriate vaccination&nbsp;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMR: measles, mumps, and rubella; IgG: immunoglobulin G; Hib: <EM>Haemophilus influenzae </EM>type b; HBsAg: hepatitis B surface antigen; DTaP: diphtheria and tetanus toxoids and acellular pertussis; Tdap: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; HPV: human papillomavirus; MenACWY: quadrivalent meningococcal conjugate vaccine.<br />* There is a recommended approach for all vaccines and an alternative approach for some vaccines.<br />¶ In rare instances, hepatitis B vaccine can give a false-positive HBsAg result up to 18 days after vaccination; therefore, blood should be drawn to test for HBsAg before vaccinating (Source: Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices [ACIP]; Part I: Immunization in infants, children, and adolescents. MMWR 2005; 54[No. RR-16.]).<br />Δ&nbsp;If the child has a protective concentration, recorded doses are considered valid, and the vaccination series should be completed as age appropriate. Clinicians should contact the laboratory performing the test for interpretive standards and limitations. Protective concentrations for antibody to diphtheria and tetanus toxins are defined as &gt;0.1 international unit/mL.</div><div class=\"graphic_reference\">Reproduced and adapted from: Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>. Accessed on April 27, 2017. </div><div id=\"graphicVersion\">Graphic 91329 Version 7.0</div></div></div>"},"91331":{"type":"graphic_algorithm","displayName":"Treatment chronic nonchemotherapy nausea in palliative care","title":"Summary of the treatment approach to chronic nausea and/or vomiting in palliative care patients with cancer","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Summary of the treatment approach to chronic nausea and/or vomiting in palliative care patients with cancer</div><div class=\"cntnt\"><img style=\"width:708px; height:752px;\" src=\"images/PALC/91331_Tx_chronic_nonchemo_nausea.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy.<br />* Sodium, calcium, liver function and renal tests, serum cortisol.</div><div id=\"graphicVersion\">Graphic 91331 Version 1.0</div></div></div>"},"91344":{"type":"graphic_picture","displayName":"Serum sickness lesions on the chest","title":"Serum sickness lesions on the chest","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Serum sickness lesions on the chest</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/ALLRG/91344_Serum_sickness_lesion_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91344 Version 1.0</div></div></div>"},"91345":{"type":"graphic_picture","displayName":"Serum sickness lesions","title":"Serum sickness lesions","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Serum sickness lesions</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/ALLRG/91345_Serum_sickness_lesions_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91345 Version 1.0</div></div></div>"},"91346":{"type":"graphic_picture","displayName":"Serum sickness lesions detail","title":"Serum sickness lesions detail","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Serum sickness lesions detail</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/ALLRG/91346_Ser_sickness_lesions_detail.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91346 Version 1.0</div></div></div>"},"91347":{"type":"graphic_picture","displayName":"Fetal milk line development","title":"Fetal milk line development","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Fetal milk line development</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/SURG/91347_Fetal_milk_line_development.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The milk line develops in utero as an epidermal-derived structure from the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: The Anatomy and Histology of the Normal Human Breast. Images and text by Dr. Hanne Jensen. </div><div id=\"graphicVersion\">Graphic 91347 Version 3.0</div></div></div>"},"91348":{"type":"graphic_picture","displayName":"Breast - Normal terminal ductal lobular units","title":"Breast - Normal terminal ductal lobular units","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Breast - Normal terminal ductal lobular units</div><div class=\"cntnt\"><img style=\"width:598px; height:604px;\" src=\"images/SURG/91348_Breast_norm_term_duct_lobu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology of normal female breast ducts and terminal ductal lobular units (TDLU):<br />(A) Major duct at low magnification (6.3x) (slide 11).<br />(B) Several TDLU at low magnification (10x) (slide 16).<br />(C) Sharp interphase between dense extralobular connective tissue and each TDLU (25x magnification) (slide 17).<br />(D) Loose intralobular stroma investing ductules (63x magnification) (slide 18).<br />(E) Single duct cut transversely revealing an inner layer of secretory cells with abundant mitochndria and an outer sparse cell layer of myoepithelium with sparse cytoplasm (25x magnification).</div><div class=\"graphic_reference\">Reproduced with permission from: The Anatomy and Histology of the Normal Human Breast. Images and text by Dr. Hanne Jensen.</div><div id=\"graphicVersion\">Graphic 91348 Version 2.0</div></div></div>"},"91349":{"type":"graphic_picture","displayName":"Breast lobules - Normal atrophy with time","title":"Breast lobules - Normal atrophy with time","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Breast lobules - Normal atrophy with time</div><div class=\"cntnt\"><img style=\"width:596px; height:400px;\" src=\"images/SURG/91349_Breast_lobules_norm_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal breast lobules atrophy with the age of the woman.<br />(A) Normal breast lobule in premenopausal woman age 43 years. Note thickened basement membrane around ductules and early sclerotic changes of the lobule. (63x magnification).<br />(B) Normal breast in postmenopausal woman showing moderate atrophy of the lobules. (8x magnification).<br />(C) Normal breast in postmenopausal woman showing complete atrophy of the terminal ductal lobular unit. (1x magnification).<br />(D) Higher power magnification of normal breast in postmenopausal woman showing complete atrophy of the terminal ductal lobular unit. (4x magnification).</div><div class=\"graphic_reference\">Reproduced with permission from: The Anatomy and Histology of the Normal Human Breast. Images and text by Dr. Hanne Jensen. </div><div id=\"graphicVersion\">Graphic 91349 Version 2.0</div></div></div>"},"91351":{"type":"graphic_picture","displayName":"Breast morphological changes with the menstrual cycle","title":"Breast morphological changes with the menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Breast morphological changes with the menstrual cycle</div><div class=\"cntnt\"><img style=\"width:547px; height:367px;\" src=\"images/SURG/91351_Brst_mrph_chg_mnst_cyc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in normal breast morphology with normal menstrual cycle stages (left panel low magnification, right panel high magnification):<br />(A) Stage 1 of menstrual cycle. A, low magnification of lobule showing acini clustered with barely perceptible epithelial and myoepithelial layer. Nuclei are round to oval with basophilic cytoplasm and sparse stromal infiltrate, with occasional sprinkling of mast cells seen. Eosinophilic secretions are noted within the lumina.<br />(B) Stage 2 of menstrual cycle. A, low magnification of lobule showing appearance of vacuolation in the myoepithelial layer with prominent distinction between the two layers of the acini.<br />(C) Stage 3 of menstrual cycle. A, low magnification of lobule showing prominent myoepithelial vacuolation with edema of the stroma. The eosinophilic secretions within the lumina are present.<br />(D) Stage 4 of menstrual cycle. A, low magnification of lobule showing extensive stromal edema and infiltrate with myoepithelial vacuolization.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Modern Pathology. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002; 15:1348, Copyright &copy; 2002. <a href=\"http://www.nature.com/modpathol\" target=\"_blank\">www.nature.com/modpathol</a>.</div><div id=\"graphicVersion\">Graphic 91351 Version 2.0</div></div></div>"},"91352":{"type":"graphic_picture","displayName":"Breast morphological changes with pregnancy and lactation ","title":"Breast morphological changes with pregnancy and lactation   ","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Breast morphological changes with pregnancy and lactation   </div><div class=\"cntnt\"><img style=\"width:515px; height:551px;\" src=\"images/SURG/91352_Brst_mrph_chng_prg_lct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The breast terminal ductule and lobular units (TDLU) undergo marked physiologic changes during pregnancy and lactation as shown in the following images:<br />(A) Pregnancy hormones induce hyperplasia of TDLU. This image depicts the changes in a woman who is five months pregnant. Note the enlarged lobules have crowded out the extralobular connective tissue.<br />(B) Low magnification image of a lactating mammary gland of a young woman. Note that the alveoli fill the entire mammary gland without evidence of residual fat cells.<br />(C) TDLU of the lactating mammary gland of a young woman. Medium magnification.<br />(D) Lactating mammary gland of a young woman. Note that the lumens are filled with a proteinaceous fluid with clear lipid vacuoles. The epithelium is attenuated.<br />(E) Lactating mammary gland of a young woman showing lumens filled with fluid and the tall columnar cells have clear lipid vacuoles.</div><div class=\"graphic_reference\">Reproduced with permission from: The Anatomy and Histology of the Normal Human Breast. Images and text by Dr. Hanne Jensen. Copyright © 1999.</div><div id=\"graphicVersion\">Graphic 91352 Version 3.0</div></div></div>"},"91372":{"type":"graphic_table","displayName":"Etiology-based classification of gastropathy and gastritis","title":"Etiology-based classification of gastropathy and gastritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology-based classification of gastropathy and gastritis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastropathy</td> </tr> <tr> <td class=\"subtitle2_left\">Reactive (chemical) gastropathy</td> </tr> <tr> <td class=\"indent1\">Bile reflux</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">NSAIDs</td> </tr> <tr> <td class=\"indent1\">Iron salts</td> </tr> <tr> <td class=\"indent1\">Other agents (eg, alendronate, sodium phosphate)&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Vascular gastropathy</td> </tr> <tr> <td class=\"indent1\">Portal hypertensive (congestive) gastropathy</td> </tr> <tr> <td class=\"indent1\">Gastric antral vascular ectasia</td> </tr> <tr> <td class=\"subtitle2_left\">Ischemic gastropathy</td> </tr> <tr> <td class=\"indent1\">Trauma, prolapse</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Hypovolemia</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastritis</td> </tr> <tr> <td class=\"subtitle2_left\">Infectious gastritis</td> </tr> <tr> <td class=\"indent1\"><em>Helicobacter pylori</em></td> </tr> <tr> <td class=\"indent1\">Other bacteria (phlegmonous gastritis)</td> </tr> <tr> <td class=\"indent1\">Mycobacterial</td> </tr> <tr> <td class=\"indent1\">Syphilitic</td> </tr> <tr> <td class=\"indent1\">Viral</td> </tr> <tr> <td class=\"indent1\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Fungal</td> </tr> <tr> <td class=\"subtitle2_left\">Autoimmune gastritis</td> </tr> <tr> <td class=\"subtitle2_left\">Granulomatous disease</td> </tr> <tr> <td class=\"indent1\">Crohn disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle2_left\">Uncertain etiology</td> </tr> <tr> <td class=\"indent1\">Lymphocytic gastritis</td> </tr> <tr> <td class=\"indent1\">Collagenous gastritis</td> </tr> <tr> <td class=\"indent1\">Eosinophilic gastritis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 91372 Version 3.0</div></div></div>"},"91373":{"type":"graphic_table","displayName":"Findings possible cardiac syncope in children","title":"Findings suggesting possible cardiac syncope in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings suggesting possible cardiac syncope in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Past medical history</td> <td class=\"subtitle1\">Family history</td> <td class=\"subtitle1\">Physical examination</td> <td class=\"subtitle1\">Electrocardiogram</td> </tr> <tr class=\"divider_bottom\"> <td>Syncope during exertion (including swimming)*</td> <td>Congenital heart disease (corrected or uncorrected)*</td> <td>Early cardiac death or sudden death in close relatives younger than 50 years of age*<sup>&#182;</sup></td> <td>Pathologic murmur (eg, systolic ejection murmur with a click [aortic stenosis] or an outflow murmur that decreases with&nbsp; squatting&nbsp;or increases with Valsalva [HCM])*</td> <td>Abnormal QT intervals*<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Chest pain, or palpitations prior to or during the event*</td> <td>Acquired heart disease with residual abnormal function*<sup>&#9674;</sup></td> <td>Familial arrhythmias*<sup>&#182;</sup></td> <td>Signs of heart failure (eg, gallop, rales, hepatomegaly)*</td> <td>Delta wave (ventricular preexcitation or Wolff-Parkinson-White syndrome)*</td> </tr> <tr class=\"divider_bottom\"> <td>Triggered by fright, anger, or auditory stimulus</td> <td>&nbsp;</td> <td>Familial cardiomyopathy*<sup>&#182;</sup></td> <td>Four limb blood pressure with systolic gradient (arm &#62; leg) in patients with possible coarctation of aorta*<sup>&#167;</sup></td> <td>Excessive bradycardia or AV block*</td> </tr> <tr class=\"divider_bottom\"> <td>Brief posturing or \"seizure-like\" event</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Tachycardia (&#62;95th percentile for age)</td> <td>Left axis deviation, prominent Q waves (leads II, III, and aVF), atrial enlargement with left ventricular hypertrophy, and/or deep inverted T waves (V<sub>2</sub> through V<sub>4</sub>) indicating HCM*</td> </tr> <tr class=\"divider_bottom\"> <td>No identifiable prodrome (eg, no lightheadedness, visual changes, or nausea)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Bradycardia (&#60;5th percentile for age)</td> <td>Brugada syndrome (eg, pseudo-RBBB and ST elevation in V<sub>1</sub> to V<sub>3</sub> leads)*</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Irregular rhythm</td> <td>Epsilon wave (arrhythmogenic right ventricular cardiomyopathy)*</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Signs of myocardial ischemia (eg, ST-T wave changes, Q waves)*<sup>&#165;</sup></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Findings of atrial enlargement and ventricular hypertrophy with ST segment and T wave abnormalities*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; AV: atrioventricular; RBBB: right bundle branch block.<br />* Patients with any one of these findings are more likely to have a cardiac cause for syncope. If present, consultation with a cardiologist with pediatric expertise is warranted. Findings without an asterisk are less specific and, by themselves, may not indicate a need for pediatric cardiology consultation if all other findings are normal.<br />&#182; Applies to first degree (parents and siblings) and second degree (grandparents, uncle, aunt, half siblings) relatives.<br />&Delta; Prolonged hand-calculated corrected QT interval (eg, QTc &gt;0.44 in males or &gt;0.45 in adolescent females) or a short QT interval (&le;0.30 sec).<br /><span class=\"lozenge\">&loz;</span> Eg, Kawasaki disease, rheumatic heart disease, myocarditis with cardiomyopathy.<br />&sect; A difference in the systolic measurement of 20 mmHg (arm greater than leg) is significant and suggests coarctation of the aorta.<br />&yen; Refer to UpToDate topics on electrocardiogram in the diagnosis of myocardial ischemia and infarction.</div><div class=\"graphic_reference\">Adapted and expanded from: Friedman KG, Alexander ME. Chest pain and syncope in children: a practical approach to the diagnosis of cardiac disease. J Pediatr 2013; 163:896.</div><div id=\"graphicVersion\">Graphic 91373 Version 6.0</div></div></div>"},"91374":{"type":"graphic_waveform","displayName":"Fractional flow reserve pressure tracing - normal","title":"Fractional flow reserve pressure tracing - normal","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Fractional flow reserve pressure tracing - normal</div><div class=\"cntnt\"><img style=\"width:551px; height:386px;\" src=\"images/CARD/91374_Fract_flow_press_norm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FFR tracing demonstrating non-hemodynamically significant value of 0.87. The corresponding stress test was negative.</div><div id=\"graphicVersion\">Graphic 91374 Version 1.0</div></div></div>"},"91375":{"type":"graphic_waveform","displayName":"Fractional flow reserve pressure tracing - abnormal 2","title":"Fractional flow reserve pressure tracing - abnormal 2","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Fractional flow reserve pressure tracing - abnormal 2</div><div class=\"cntnt\"><img style=\"width:582px; height:339px;\" src=\"images/CARD/91375_Fract_flow_press_abnorm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FFR tracing demonstrating a hemodynamically significant value of 0.77. The corresponding stress test was positive.</div><div id=\"graphicVersion\">Graphic 91375 Version 1.0</div></div></div>"},"91376":{"type":"graphic_waveform","displayName":"Pressure and coronary Doppler tracings","title":"Pressure and coronary Doppler tracings","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Pressure and coronary Doppler tracings</div><div class=\"cntnt\"><img style=\"width:497px; height:489px;\" src=\"images/CARD/91376_Press_coron_dopp_trace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure and coronary doppler display. Signals show ECG at top, aortic guide pressure (red), coronary pressure wire (yellow), and doppler coronary velocity signal.</div><div class=\"graphic_footnotes\">FFR: fractional flow reserve is computed from ratio of aortic and coronary pressures; CFR: coronary flow reserve is computed from ratio of hyperemic to rest average peak velocity. Using both pressure and flow; HSR: hyperemic stenosis resistance; HMR: hyperemic myocardial resistance can also be calculated; Pa: pressure, aortic; Pd: pressure distal (guidewire).</div><div id=\"graphicVersion\">Graphic 91376 Version 2.0</div></div></div>"},"91377":{"type":"graphic_waveform","displayName":"Fractional flow reserve pressure tracing - abnormal","title":"Fractional flow reserve pressure tracing - abnormal","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Fractional flow reserve pressure tracing - abnormal</div><div class=\"cntnt\"><img style=\"width:577px; height:314px;\" src=\"images/CARD/91377_Fractfloprestracab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure tracings used to calculate FFr. Aortic pressure (red) and sensor-wire pressure (green) at rest (left) and after adensoine IV (at yellow arrow) show maximal separation at hyperemia where FFR is calculated as Pd/Pa = 65/90 = 0.72.</div><div class=\"graphic_reference\">Reproduced with permission from: Kern MJ, Lim MJ. Evaluation of myocardial and coronary blood flow and metabolism. In: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention, 8th ed, Moscucci M (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 91377 Version 5.0</div></div></div>"},"91380":{"type":"graphic_picture","displayName":"Transition zone nevus histo","title":"Histologic features of melanocytic nevi of the glabrous/nonglabrous skin transition zone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of melanocytic nevi of the glabrous/nonglabrous skin transition zone</div><div class=\"cntnt\"><img style=\"width:379px; height:598px;\" src=\"images/DERM/91380_Transitionzonenevushisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical and histopathologic features of a melanocytic nevus located on a transition area (the fourth interdigital area of the right foot) of a 23-year-old woman.<br />(A-C) In all of the histopathologic photographs (hematoxylin-eosin), we see that melanocytes proliferate mainly as solitary units within the epidermis, and many of them are situated above the dermoepidermal junction, mimicking histopathologic features of melanoma in situ. However, overall distribution of melanocytes within the lesion is mostly symmetrical and orderly. The nuclei of melanocytes are relatively large but not hyperchromatic; instead, they are vesicular. In addition, there is virtually no inflammatory cell infiltrate in the dermis. The original magnifications are x12, x38, and x84 for panels A, B, and C, respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Saida T, Kawachi S, Koga H. Anatomic transitions and the histopathologic features of melanocytic nevi. Arch Dermatol 2008; 144:1232. Copyright &copy; 2008 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91380 Version 9.0</div></div></div>"},"91398":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for bipolar major depression","title":"DSM-5 diagnostic criteria for bipolar major depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for bipolar major depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Five (or more) of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>NOTE:</strong> Do not include symptoms that are clearly attributable to another medical condition.</td> </tr> <tr> <td class=\"indent1\">1) Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad, empty, hopeless) or observations made by others (eg, appears tearful). (NOTE: In children and adolescents can be irritable mood.)</td> </tr> <tr> <td class=\"indent1\">2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).</td> </tr> <tr> <td class=\"indent1\">3) Significant weight loss when not dieting or weight gain (eg, a change of more than 5 percent of body weight in a month), or decrease or increase in appetite nearly every day. (NOTE: In children, consider failure to make expected weight gain.)</td> </tr> <tr> <td class=\"indent1\">4) Insomnia or hypersomnia nearly every day.</td> </tr> <tr> <td class=\"indent1\">5) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).</td> </tr> <tr> <td class=\"indent1\">6) Fatigue or loss of energy nearly every day.</td> </tr> <tr> <td class=\"indent1\">7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).</td> </tr> <tr> <td class=\"indent1\">8) Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by their subjective account or as observed by others).</td> </tr> <tr> <td class=\"indent1\">9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.</td> </tr> <tr> <td><strong>B.</strong> The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr> <td><strong>C.</strong> The episode is not attributable to the direct physiological effects of a substance or to another medical condition.</td> </tr> <tr> <td><strong>NOTE:</strong> Criteria A through C represent a major depressive episode.</td> </tr> <tr> <td><strong>NOTE:</strong> Responses to a significant loss (eg, bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgement based on the individual's history and the cultural norms for the expression of distress in the context of loss.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>D.</strong> The occurence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.</td> </tr> <tr> <td class=\"sublist1_start\"><em>Specify</em>:</td> </tr> <tr> <td class=\"indent1\">With anxious distress</td> </tr> <tr> <td class=\"indent1\">With mixed features</td> </tr> <tr> <td class=\"indent1\">With rapid cycling</td> </tr> <tr> <td class=\"indent1\">With melancholic features</td> </tr> <tr> <td class=\"indent1\">With atypical features</td> </tr> <tr> <td class=\"indent1\">With psychotic features</td> </tr> <tr> <td class=\"indent1\">With catatonia</td> </tr> <tr> <td class=\"indent1\">With peripartum onset</td> </tr> <tr> <td class=\"indent1\">With seasonal pattern</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 91398 Version 6.0</div></div></div>"},"91405":{"type":"graphic_picture","displayName":"Pseudomonas aeruginosa green nail syndrome 1","title":"Pseudomonas aeruginosa green nail syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonas aeruginosa green nail syndrome</div><div class=\"cntnt\"><img style=\"width:407px; height:399px;\" src=\"images/ID/91405_Pseudo_aerug_gr_nail_synd_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Maurice Dahdah</div><div id=\"graphicVersion\">Graphic 91405 Version 1.0</div></div></div>"},"91406":{"type":"graphic_picture","displayName":"Pseudomonas aeruginosa green nail syndrome 2","title":"Pseudomonas aeruginosa green nail syndrome","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Pseudomonas aeruginosa green nail syndrome</div><div class=\"cntnt\"><img style=\"width:514px; height:248px;\" src=\"images/ID/91406_Pseud_ae_gr_nail_syn_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Green nail syndrome in a patient with underlying nail psoriasis before (A) and after (B) treatment with nadifloxacin cream for two weeks.</div><div class=\"graphic_reference\">Courtesy of Maurice Dahdah.</div><div id=\"graphicVersion\">Graphic 91406 Version 1.0</div></div></div>"},"91407":{"type":"graphic_picture","displayName":"Pseudomonas aeruginosa green nail syndrome 3","title":"Pseudomonas aeruginosa green nail syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomonas aeruginosa green nail syndrome</div><div class=\"cntnt\"><img style=\"width:354px; height:404px;\" src=\"images/ID/91407_Pseudo_aerug_gr_nail_synd_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Maurice Dahdah</div><div id=\"graphicVersion\">Graphic 91407 Version 1.0</div></div></div>"},"91409":{"type":"graphic_table","displayName":"ILAE classification of seizure types","title":"International League Against Epilepsy (ILAE) classification of seizure types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International League Against Epilepsy (ILAE)&nbsp;classification of seizure types</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Generalized onset seizures</td> </tr> <tr> <td class=\"subtitle2\">Motor</td> <td class=\"subtitle2\">Nonmotor (absence)</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Tonic-clonic </li> <li>Clonic </li> <li>Tonic </li> <li>Myoclonic </li> <li>Myoclonic-tonic-clonic </li> <li>Myoclonic-atonic </li> <li>Atonic </li> <li>Epileptic spasms </li> </ul> </td> <td> <ul> <li>Typical </li> <li>Atypical </li> <li>Myoclonic </li> <li>Eyelid myoclonia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Focal onset seizures</td> </tr> <tr> <td class=\"subtitle2\">Motor onset</td> <td class=\"subtitle2\">Nonmotor onset</td> </tr> <tr> <td> <ul> <li>Aware </li> <li>Impaired awareness </li> <li>Unknown awareness </li> </ul> </td> <td> <ul> <li>Aware </li> <li>Impaired awareness </li> <li>Unknown awareness </li> </ul> </td> </tr> <tr> <td> <ul> <li>Automatisms </li> <li>Atonic* </li> <li>Clonic </li> <li>Epileptic spasms* </li> <li>Hyperkinetic </li> <li>Myoclonic </li> <li>Tonic </li> </ul> </td> <td> <ul> <li>Autonomic </li> <li>Behavior arrest </li> <li>Cognitive </li> <li>Emotional </li> <li>Sensory </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Focal to bilateral tonic-clonic </li> </ul> </td> <td> <ul> <li>Focal to bilateral tonic-clonic </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Unknown onset seizures</td> </tr> <tr> <td class=\"subtitle2\">Motor</td> <td class=\"subtitle2\">Nonmotor</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Tonic-clonic </li> <li>Epileptic spasms </li> </ul> </td> <td> <ul> <li>Behavior arrest </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td style=\"font-size: 1.2em; text-align: center;\" colspan=\"2\"><strong>Unclassified seizures</strong><sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ILAE: International League Against Epilepsy.<br />* Degree of awareness usually is not specified.<br />​¶ Due to inadequate information or inability to place in other categories.</div><div class=\"graphic_reference\">Adapted from: Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017.</div><div id=\"graphicVersion\">Graphic 91409 Version 4.0</div></div></div>"},"91410":{"type":"graphic_table","displayName":"Epilepsy syndromes by age","title":"Examples of epilepsy syndromes and other epilepsies arranged according to age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of epilepsy syndromes and other epilepsies arranged according to age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Neonatal period</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign neonatal seizures </li> <li>Benign familial neonatal epilepsy </li> <li>Early myoclonic encephalopathy (EME) </li> <li>Ohtahara syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Infancy (onset under 2 years)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Febrile seizures </li> <li>Febrile seizures plus (FS+)</li> <li>Epilepsy of infancy with migrating focal seizures </li> <li>West syndrome </li> <li>Myoclonic epilepsy in infancy (MEI) </li> <li>Benign infantile epilepsy </li> <li>Benign familial infantile epilepsy </li> <li>Dravet syndrome </li> <li>Myoclonic encephalopathy in non-progressive disorders </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Childhood</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Febrile seizures </li> <li>Febrile seizures plus (FS+) </li> <li>Early onset childhood occipital epilepsy (Panayiotopoulos type) </li> <li>Epilepsy with myoclonic atonic (previously astatic) seizures </li> <li>Benign epilepsy with centrotemporal spikes (BECTS) </li> <li>Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) </li> <li>Late onset childhood occipital epilepsy (Gastaut type) </li> <li>Childhood absence epilepsy (CAE) </li> <li>Epilepsy with myoclonic absences </li> <li>Lennox-Gastaut syndrome </li> <li>Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) </li> <li>Landau-Kleffner syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Adolescent to adult</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Juvenile absence epilepsy (JAE) </li> <li>Juvenile myoclonic epilepsy (JME) </li> <li>Epilepsy with generalized tonic-clonic seizures alone (GTCA) </li> <li>Autosomal dominant epilepsy with auditory features (ADEAF) </li> <li>Other familial temporal lobe epilepsies </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Familial epilepsy syndromes</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Familial focal epilepsy with variable foci (FFEVF) </li> <li>Genetic epilepsy with febrile seizures plus (GEFS+) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ILAE: International League Against Epilepsy.</div><div class=\"graphic_reference\">Adapted from: Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676. <A href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2010.02522.x/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2010.02522.x/abstract</A>. Copyright © 2010 International League Against Epilepsy. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 91410 Version 2.0</div></div></div>"},"91415":{"type":"graphic_picture","displayName":"Draining tympanic membrane perforation","title":"Draining tympanic membrane perforation","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Draining tympanic membrane perforation</div><div class=\"cntnt\"><img style=\"width:501px; height:375px;\" src=\"images/ALLRG/91415_Drain_tympanic_memb_perfor.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 91415 Version 2.0</div></div></div>"},"91418":{"type":"graphic_picture","displayName":"Dry subtotal tympanic membrane perforation","title":"Dry subtotal tympanic membrane perforation","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Dry subtotal tympanic membrane perforation</div><div class=\"cntnt\"><img style=\"width:500px; height:432px;\" src=\"images/ALLRG/91418_Dry_subtot_tymp_mem_perfor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91418 Version 1.0</div></div></div>"},"91420":{"type":"graphic_table","displayName":"Additives and excipients in commonly available insulin products","title":"Additives and excipients in commonly available insulin products*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Additives and excipients in commonly available insulin products*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Insulin</td> <td class=\"subtitle1\">Trade name in United States</td> <td class=\"subtitle1\">Protamine<br /> (yes/no)</td> <td class=\"subtitle1\">Other</td> <td class=\"subtitle1\">Availability outside of United States</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Rapid-acting (duration two to four hours)</td> </tr> <tr> <td class=\"indent1\">Aspart</td> <td>NovoLog</td> <td>No</td> <td>Metacresol, glycerin, phenol, zinc</td> <td>Yes (NovoRapid)</td> </tr> <tr> <td class=\"indent1\">Lispro</td> <td>Humalog</td> <td>No</td> <td>Metacresol, glycerin, zinc</td> <td>Yes (Humalog, Liprolog)</td> </tr> <tr> <td class=\"indent1\">Glulisine</td> <td>Apidra</td> <td>No</td> <td>Metacresol, tromethamine, polysorbate 20</td> <td>Yes (Apidra)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Short-acting (duration five to eight hours)</td> </tr> <tr> <td class=\"indent1\">Regular</td> <td>Humulin R, Novolin R, Novolin R ReliOn</td> <td>No</td> <td>Metacresol, glycerin, zinc</td> <td>Yes (Actraphane, Actrapid Human, Humulin, others)</td> </tr> <tr> <td class=\"indent1\">U-500 concentrated</td> <td>Humulin R Regular U-500</td> <td>No</td> <td>Metacresol, glycerin, zinc</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate-acting (duration 14 to 24 hours)</td> </tr> <tr> <td class=\"indent1\">NPH (human insulin isophane suspension)</td> <td>Humulin N, Novolin N, Novolin N ReliOn</td> <td>Yes</td> <td>Metacresol, glycerin, phenol, zinc</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate-acting mixtures (duration 14 to 24 hours with a more rapid peak)</td> </tr> <tr> <td class=\"indent1\">75 percent lispro protamine and 25 percent lispro</td> <td>Humalog Mix 75/25</td> <td>Yes</td> <td>Metacresol, glycerin, phenol, zinc</td> <td>Yes (Humalog Mix, Humalog Mix 25, Humalog NPL)</td> </tr> <tr> <td class=\"indent1\">70 percent aspart protamine and 30 percent aspart</td> <td>NovoLog Mix 70/30</td> <td>Yes</td> <td>Metacresol, glycerin, phenol, zinc</td> <td>Yes (NovoMix 30)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate to long-acting (duration 6 to 24 hours, dose dependent)</td> </tr> <tr> <td class=\"indent1\">Detemir</td> <td>Levemir</td> <td>No</td> <td>Metacresol, glycerin, phenol, zinc</td> <td>Yes (Levemir)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Long acting (duration 20 to &#62;24 hours)</td> </tr> <tr> <td class=\"indent1\">Glargine</td> <td>Lantus</td> <td>No</td> <td>Metacresol, glycerin, zinc, (polysorbate 20 in 10 mL vial, not in 3 mL cartridge)</td> <td>Yes (Basalin, Lantus, Optisulin)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Insulin products listed are produced by recombinant DNA technology utilizing <em>Saccharomyces cerevisiae</em> (baker's yeast) or nonpathogenic strain of <em>Escherichia coli</em>.</div><div class=\"graphic_footnotes\">NPH: neutral protamine Hagedorn.<br />* According to product information in United States. Check local prescribing information. Glycerol is an international nonproprietary name for glycerin (United States name). Metacresol (m-cresol) is a phenol-type preservative. Products are pH adjusted.</div><div id=\"graphicVersion\">Graphic 91420 Version 8.0</div></div></div>"},"91424":{"type":"graphic_diagnosticimage","displayName":"Angiogram critical pulmonic stenosis","title":"Angiogram of critical pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Angiogram of critical pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:598px; height:296px;\" src=\"images/PEDS/91424_Angiogr_crit_pulm_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram in a neonate with critical pulmonic stenosis that shows minimal contrast passing from the right ventricle through the pulmonary valve into the main pulmonary artery. A wire is seen crossing through the pulmonary valve. Panel (A) is a frontal image, and panel (B) is a lateral image at higher magnification.</div><div class=\"graphic_footnotes\">RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 91424 Version 1.0</div></div></div>"},"91425":{"type":"graphic_movie","displayName":"Angiography of valvar pulmonic stenosis","title":"Angiography of valvar pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Angiography of valvar pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91425_Angiovalvapulmstenvideo.mp4\" style=\"width:496px;height:512px\"></div><img style=\"width:598px; height:295px;\" src=\"images/PEDS/91425_Angiovalvapulmstenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram of a patient with valvar pulmonic stenosis. Panels (A) and (B) are still frame images from the angiogram that demonstrate the classical dome-shaped pulmonary valve. Panel (B) also shows the post-stenotic dilation within the main pulmonary artery (thick arrow).</div><div id=\"graphicVersion\">Graphic 91425 Version 1.0</div></div></div>"},"91426":{"type":"graphic_diagnosticimage","displayName":"Balloon valvuloplasty pulmonic stenosis","title":"Percutaneous balloon valvuloplasty in pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Percutaneous balloon valvuloplasty in pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:598px; height:301px;\" src=\"images/PEDS/91426_Balloonvalvuloplpulmsten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiographic images of percutaneous balloon valvuloplasty.<br />(A) Demonstrates the waist of the balloon at the pulmonary valve.<br />(B) Shows the inflation of the balloon at the pulmonary valve.</div><div id=\"graphicVersion\">Graphic 91426 Version 1.0</div></div></div>"},"91427":{"type":"graphic_diagnosticimage","displayName":"Continuous wave Doppler severe valvar pulmonic stenosis","title":"Echocardiogram Doppler of pulmonic stenosis pre- and post-balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Echocardiogram Doppler of pulmonic stenosis pre- and post-balloon dilation</div><div class=\"cntnt\"><img style=\"width:585px; height:817px;\" src=\"images/PEDS/91427_Cont_wave_Doppl_sev_valvar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the different scales used to measure velocity on the y-axis. In panel (A): m/s on the y-axis on the left; panel (B): cm/s on the y-axis on the right.<br />(A) Pre-balloon dilation; this demonstrates the velocity across the pulmonary valve of 6.33 m/s, which correlates to a peak gradient of 160 mmHg across the pulmonary valve.<br />(B) Post-balloon dilation; this demonstrates the velocity across the pulmonary valve of 2.2 m/s, which correlates to a peak gradient of 19 mmHg across the pulmonary valve.</div><div id=\"graphicVersion\">Graphic 91427 Version 2.0</div></div></div>"},"91428":{"type":"graphic_movie","displayName":"Echo critical pulmonic stenosis","title":"Echocardiographic image of critical pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiographic image of critical pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91428_Echocritpulmstenvideo.mp4\" style=\"width:512px;height:384px\"></div><img style=\"width:408px; height:683px;\" src=\"images/PEDS/91428_Echocritpulmstenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Still echocardiographic images</strong> of a patient with critical pulmonic stenosis pre- and post-balloon dilation. Panel (A) is a pre-balloon echocardiographic image of a patient with critical pulmonic stenosis that shows virtually no antegrade flow from the right ventricle through the pulmonary valve into the main pulmonary artery. Panel (B) is a post-dilation echocardiographic image that shows virtually unobstructed pulmonary blood flow across the pulmonary valve.<br />The <strong>movie clip</strong> is a pre-balloon dilatation echocardiography showing minimal antegrade flow from the right ventricle through the critical pulmonic stenosis.</div><div class=\"graphic_footnotes\">RV: right ventricle; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 91428 Version 2.0</div></div></div>"},"91430":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram critical pulmonic stenosis","title":"Echocardiographic image of critical pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Echocardiographic image of critical pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:565px; height:349px;\" src=\"images/PEDS/91430_Echocard_crit_pulm_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic image of a patient with critical pulmonic stenosis that shows virtually no antegrade flow from the right ventricle through the pulmonary valve into the main pulmonary artery.</div><div class=\"graphic_footnotes\">RV: right ventricle; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 91430 Version 1.0</div></div></div>"},"91431":{"type":"graphic_movie","displayName":"Echocardiogram of valvar pulmonic stenosis","title":"Echocardiogram of valvar pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of valvar pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91431_Echovalvarpulmstenvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:560px; height:400px;\" src=\"images/PEDS/91431_Echovalvarpulmstenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of a patient with pulmonary valvar stenosis, showing thickened and domed pulmonary valve leaflets, and post-stenotic dilatation.</div><div class=\"graphic_footnotes\">RV: right ventricle; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 91431 Version 1.0</div></div></div>"},"91432":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram of pulmonic stenosis","title":"Echocardiogram of pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:513px; height:218px;\" src=\"images/CARD/91432_Echocard_img_pulm_sten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Parasternal transthoracic image of right ventricular outflow tract showing a dysplastic pulmonic valve.<br />(B) Color Doppler demonstrates turbulent flow through the stenotic pulmonic valve.</div><div class=\"graphic_footnotes\">PV: pulmonic valve; RVOT: right ventricular outflow tract; PA: pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Karen Stout, MD.</div><div id=\"graphicVersion\">Graphic 91432 Version 2.0</div></div></div>"},"91433":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram valvar pulmonic stenosis pre- and post-dilation","title":"Echocardiogram of valvar pulmonic stenosis pre- and post-balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of valvar pulmonic stenosis pre- and post-balloon dilation</div><div class=\"cntnt\"><img style=\"width:598px; height:344px;\" src=\"images/PEDS/91433_Echovalvarprepostdilat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of a patient with valvar pulmonic&nbsp;stenosis pre- and post-balloon dilation, with color.<BR>(A) Shows turbulent pulmonary blood flow across a pulmonary valve with severe stenosis.<BR>(B) Shows unobstructed color flow across the pulmonary valve after dilation.</div><div class=\"graphic_footnotes\">RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 91433 Version 2.0</div></div></div>"},"91434":{"type":"graphic_movie","displayName":"Echocardiogram of valvar pulmonic stenosis with color flow","title":"Color echocardiogram of valvar pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Color echocardiogram of valvar pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91434_Echovalvastencolorvideo.mp4\" style=\"width:512px;height:352px\"></div><img style=\"width:480px; height:420px;\" src=\"images/PEDS/91434_Echovalvastencolorimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of a patient with pulmonary valvar stenosis, showing turbulent blood flow across the pulmonary valve.</div><div class=\"graphic_footnotes\">RV: right ventricle; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 91434 Version 1.0</div></div></div>"},"91436":{"type":"graphic_algorithm","displayName":"Treatment algorithm non-metastatic exocrine pancreatic cancer","title":"Treatment algorithm for non-metastatic exocrine pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for non-metastatic exocrine pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:756px; height:796px;\" src=\"images/ONC/91436_Treat_algo_no_meta_pan_can.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PS: performance status; ULN: upper limit of normal; CRT: chemoradiotherapy; FOLFIRINOX: leucovorin plus short-term infusional fluorouracil plus oxaliplatin and irinotecan; RT: radiation therapy.<br />* For patients whose tumors harbor a known <EM>BRCA</EM> mutation, a platinum-based chemotherapy regimen is preferred.<br />¶ At some institutions, patients with a very good response to neoadjuvant chemotherapy would be taken directly to surgical exploration. Fluorouracil-based chemoradiotherapy (or stereotactic body RT, refer to text) should be considered if further tumor shrinkage might increase the chance of a complete (R0) resection. It is unknown whether RT contributes to the R0 resection rate after chemotherapy (especially for combination regimens like FOLFIRINOX). Another alternative is two to three months of additional chemotherapy alone.</div><div id=\"graphicVersion\">Graphic 91436 Version 5.0</div></div></div>"},"91439":{"type":"graphic_movie","displayName":"Fetal echo right atrial isomerism","title":"Fetal echocardiography of a case of right atrial isomerism (heterotaxy)","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Fetal echocardiography of a case of right atrial isomerism (heterotaxy)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91439_FetalechoRatriisovideo.mp4\" style=\"width:512px;height:480px\"></div><img style=\"width:485px; height:469px;\" src=\"images/PEDS/91439_FetalechoRatriisoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic still frame and movie (clip 1) of a fetus with right atrial isomerism at&nbsp;33 weeks' gestation with a common atrioventricular valve, and showing the juxtaposed position of the IVC and aorta together on the same (left) side of the spine. The aorta is posterior to the IVC. The confluence seen coursing behind the atrium on the left denotes the fact that there is probably total anomalous pulmonary venous connection. Movie clip 2 demonstrates another example of a complete atrioventricular canal with no apparent ventricular septum. <br />Note: The IVC and&nbsp;aorta are on the same side of the spine.</div><div class=\"graphic_footnotes\">C: confluence; IVC: inferior vena cava; CAVV: common atrioventricular valve; RV: right ventricle; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 91439 Version 3.0</div></div></div>"},"91440":{"type":"graphic_movie","displayName":"Fetal echo left atrial isomerism","title":"Fetal echocardiography of a case of left atrial isomerism (heterotaxy)","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Fetal echocardiography of a case of left atrial isomerism (heterotaxy)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91440_FetalechoLatriisovideo.mp4\" style=\"width:512px;height:320px\"></div><img style=\"width:544px; height:727px;\" src=\"images/PEDS/91440_FetalechoLatriisoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiography of a fetus with left atrial isomerism at 31 weeks' gestation. <br />(A) Still frame and movie demonstrating a prominent azygos vein to the right of the spine and the descending aorta (DAo). This fetus also has a complete atrioventricular canal defect that is demonstrated by the large primum atrial septal defect (ASD) and an inlet ventricular septal defect (VSD) at the crux of the heart.&nbsp; (B) Echocardiographic frame that shows the entry of the azygos vein into the RA and no IVC. The right diaphragm (denoted by the three *) separates the right lung and the liver.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; LV: left ventricle; RV: right ventricle; IVC: inferior vena cava; A: anterior; P: posterior; S: superior.</div><div id=\"graphicVersion\">Graphic 91440 Version 3.0</div></div></div>"},"91441":{"type":"graphic_movie","displayName":"Fetal echo left atrial isomerism color Doppler","title":"Fetal color Doppler echocardiography of a case of left atrial isomerism (heterotaxy)","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Fetal color Doppler echocardiography of a case of left atrial isomerism (heterotaxy)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91441_LatrialisoDopplervideo.mp4\" style=\"width:512px;height:336px\"></div><img style=\"width:587px; height:377px;\" src=\"images/PEDS/91441_LatrialisoDopplerimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler echocardiography of a fetus with left atrial isomerism at 31 weeks' gestation that shows the azygos vein (red color) traveling along the spine entering the posterior aspect of the superior vena cava (SVC), which enters the right atrium (RA).</div><div id=\"graphicVersion\">Graphic 91441 Version 2.0</div></div></div>"},"91442":{"type":"graphic_movie","displayName":"Echo severe AV septal defect and RA isomerism pre-Fontan","title":"Echocardiography of severely unbalanced atrioventricular septal defect in a patient with right atrial isomerism pre-Fontan procedure","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiography of severely unbalanced atrioventricular septal defect in a patient with right atrial isomerism pre-Fontan procedure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91442_EchoAVRAisopreFonvideo.mp4\" style=\"width:320px;height:448px\"></div><img style=\"width:436px; height:472px;\" src=\"images/PEDS/91442_EchoAVRAisopreFonimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 91442 Version 3.0</div></div></div>"},"91443":{"type":"graphic_table","displayName":"Maximum expected number of acquired renal cysts according to age","title":"Maximum expected number of acquired renal cysts according to age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maximum expected number of acquired renal cysts according to age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group</td> <td class=\"subtitle1\" colspan=\"2\">Number of cysts in both kidneys</td> <td class=\"subtitle1\" colspan=\"2\">Number of cysts in kidney with the most cysts</td> </tr> <tr> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> <td class=\"subtitle2\">Men</td> <td class=\"subtitle2\">Women</td> </tr> <tr> <td>18-29 years (n = 256)</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>30-39 years (n = 491)</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr> <td>40-49 years (n = 598)</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr> <td>50-59 years (n = 409)</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> <td class=\"centered\">5</td> <td class=\"centered\">2</td> </tr> <tr> <td>60-69 years (n = 171)</td> <td class=\"centered\">10</td> <td class=\"centered\">4</td> <td class=\"centered\">7</td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Upper reference limit (97.5th percentile) for number of parenchymal cysts &gt;5 mm by age and gender based on 1925 potential kidney donors.</div><div class=\"graphic_reference\">Reproduced from: Rule AD, Sasiwimonphan K, Lieske JC, et al. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis 2012; 59:611. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91443 Version 1.0</div></div></div>"},"91444":{"type":"graphic_movie","displayName":"Echo severe AV septal defect and RA isomerism post-Fontan","title":"Echocardiography of severely unbalanced atrioventricular septal defect in a patient with right atrial isomerism post-Fontan procedure","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiography of severely unbalanced atrioventricular septal defect in a patient with right atrial isomerism post-Fontan procedure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/91444_EchoRAisopostFontanvideo.mp4\" style=\"width:298px;height:448px\"></div><img style=\"width:597px; height:336px;\" src=\"images/PEDS/91444_EchoRAisopostFontanimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiography including color Doppler study following Fontan procedure in a patient with severely unbalanced atrioventricular septal defect and right atrial isomerism.</div><div class=\"graphic_footnotes\">RPV: right pulmonary vein; LPV: left pulmonary vein; C: former confluence of pulmonary veins; F: Fontan; CAVV: common atrioventricular valve; RV: right ventricle; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 91444 Version 2.0</div></div></div>"},"91445":{"type":"graphic_table","displayName":"Distribution of measured and estimated GFR in kidney donors","title":"Distribution of measured and estimated GFR in living kidney donors*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of measured and estimated GFR in living kidney donors*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"3\">Measured GFR (estimated GFR)<br /> (mL/min per 1.73 m<sup>2</sup>)</td> </tr> <tr> <td class=\"subtitle2\">Expected 5th percentile</td> <td class=\"subtitle2\">Mean expected value</td> <td class=\"subtitle2\">Expected 95th percentile</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Women</td> </tr> <tr> <td class=\"indent2\">20</td> <td class=\"centered\">89 (76)</td> <td class=\"centered\">116 (102)</td> <td class=\"centered\">144 (128)</td> </tr> <tr> <td class=\"indent2\">25</td> <td class=\"centered\">87 (73)</td> <td class=\"centered\">114 (99)</td> <td class=\"centered\">142 (125)</td> </tr> <tr> <td class=\"indent2\">30</td> <td class=\"centered\">85 (70)</td> <td class=\"centered\">113 (96)</td> <td class=\"centered\">140 (122)</td> </tr> <tr> <td class=\"indent2\">35</td> <td class=\"centered\">83 (67)</td> <td class=\"centered\">111 (93)</td> <td class=\"centered\">138 (119)</td> </tr> <tr> <td class=\"indent2\">40</td> <td class=\"centered\">81 (64)</td> <td class=\"centered\">109 (90)</td> <td class=\"centered\">136 (116)</td> </tr> <tr> <td class=\"indent2\">45</td> <td class=\"centered\">79 (61)</td> <td class=\"centered\">107 (87)</td> <td class=\"centered\">134 (113)</td> </tr> <tr> <td class=\"indent2\">50</td> <td class=\"centered\">74 (58)</td> <td class=\"centered\">101 (84)</td> <td class=\"centered\">129 (110)</td> </tr> <tr> <td class=\"indent2\">55</td> <td class=\"centered\">69 (55)</td> <td class=\"centered\">96 (81)</td> <td class=\"centered\">124 (107)</td> </tr> <tr> <td class=\"indent2\">60</td> <td class=\"centered\">64 (52)</td> <td class=\"centered\">91 (78)</td> <td class=\"centered\">119 (104)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Men</td> </tr> <tr> <td class=\"indent2\">20</td> <td class=\"centered\">86 (79)</td> <td class=\"centered\">113 (105)</td> <td class=\"centered\">141 (131)</td> </tr> <tr> <td class=\"indent2\">25</td> <td class=\"centered\">84 (76)</td> <td class=\"centered\">111 (102)</td> <td class=\"centered\">139 (127)</td> </tr> <tr> <td class=\"indent2\">30</td> <td class=\"centered\">82 (73)</td> <td class=\"centered\">109 (99)</td> <td class=\"centered\">137 (124)</td> </tr> <tr> <td class=\"indent2\">35</td> <td class=\"centered\">80 (70)</td> <td class=\"centered\">107 (96)</td> <td class=\"centered\">135 (121)</td> </tr> <tr> <td class=\"indent2\">40</td> <td class=\"centered\">78 (67)</td> <td class=\"centered\">105 (93)</td> <td class=\"centered\">133 (118)</td> </tr> <tr> <td class=\"indent2\">45</td> <td class=\"centered\">76 (64)</td> <td class=\"centered\">103 (90)</td> <td class=\"centered\">131 (115)</td> </tr> <tr> <td class=\"indent2\">50</td> <td class=\"centered\">71 (61)</td> <td class=\"centered\">98 (86)</td> <td class=\"centered\">126 (112)</td> </tr> <tr> <td class=\"indent2\">55</td> <td class=\"centered\">66 (57)</td> <td class=\"centered\">93 (83)</td> <td class=\"centered\">121 (109)</td> </tr> <tr> <td class=\"indent2\">60</td> <td class=\"centered\">60 (54)</td> <td class=\"centered\">88 (80)</td> <td class=\"centered\">116 (106)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Age-specific reference limits for measured GFR and serum creatinine-based estimated GFR (MDRD study equation) based upon 1057 potential kidney donors.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; MDRD: modification of diet in renal disease.<br />* For mGFR, all living kidney donors (n = 1057); for MDRD, all living kidney donors from 1996 to 2005 with measured serum creatinine (n = 545).</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International. Poggio ED, Rule AD, Tanchanco R, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 2009; 75:1079. Copyright &copy; 2009. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 91445 Version 2.0</div></div></div>"},"91446":{"type":"graphic_figure","displayName":"Assoc of CKD risk factors with GFR depends upon GFR assessment","title":"Association of CKD risk factors with GFR depends upon how GFR is assessed","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Association of CKD risk factors with GFR depends upon how GFR is assessed</div><div class=\"cntnt\"><img style=\"width:596px; height:392px;\" src=\"images/NEPH/91446_Asso_CKD_GFR_dep_GFR_assess.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The association of CKD risk factors with percentage decrease in GFR (&darr; GFR) by each method (mGFR, eGFR<sub>Cr</sub>, eGFR<sub>Cr-CysC</sub>, and eGFR<sub>CysC</sub>). The * identifies p&lt;0.05 for eGFR compared to mGFR. Risk factor associations with mGFR were more similar to those with eGFR<sub>Cr</sub> than with eGFR<sub>Cr-CysC</sub> or eGFR<sub>CysC</sub>. The one exception was 24-hour urine creatinine where eGFR<sub>CysC</sub> was more similar to the same association with mGFR.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International. Rule AD, Bailey KR, Lieske JC, et al. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int 2013; 83:1169. Copyright &copy; 2013. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 91446 Version 1.0</div></div></div>"},"91447":{"type":"graphic_figure","displayName":"Adjusted hazard ratio for all-cause mortality","title":"Adjusted hazard ratio for all-cause mortality","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Adjusted hazard ratio for all-cause mortality</div><div class=\"cntnt\"><img style=\"width:570px; height:556px;\" src=\"images/NEPH/91447_Adj_haz_rat_all_cause_mort.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Association of estimated GFR with all-cause mortality among individuals aged 18 to 54 years (reference group: &gt;105 mL/min/1.73 m<SUP>2</SUP>).<br />(B) Association of estimated GFR with all-cause mortality among individuals 75 years and older (reference group: 75 to 89 mL/min/1.73 m<SUP>2</SUP>).<br />Adjusted hazard ratios for all-cause mortality in individuals without albuminuria based on pooled estimates from 33 general population cohorts. Low risk is a serum creatinine-based estimated GFR of &gt;75 mL/min/1.73 m<SUP>2</SUP> in younger adults (18 to 54 years, top panel) and an estimated GFR of 45 to 104 mL/min/1.73 m<SUP>2</SUP> in older adults (&gt;75 years, bottom panel).</div><div class=\"graphic_reference\">Data from: Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308:2349.</div><div id=\"graphicVersion\">Graphic 91447 Version 2.0</div></div></div>"},"91448":{"type":"graphic_movie","displayName":"Eyelid eversion","title":"Eyelid eversion technique","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Eyelid eversion technique</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ALLRG/91448_Eyelidinversionvideo.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/91448_Eyelidinversionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: Some clinicians may prefer to wear gloves when performing lid eversion. Gloves should be worn if there is any concern about conjunctival infection.</div><div class=\"graphic_reference\">Reproduced with permission from the University of Michigan Kellogg Eye Center, <a href=\"http://www.kellogg.umich.edu/\" target=\"_blank\">http://www.kellogg.umich.edu</a>.</div><div id=\"graphicVersion\">Graphic 91448 Version 4.0</div></div></div>"},"91450":{"type":"graphic_table","displayName":"Potential adjustments for concussion symptoms in school","title":"Potential adjustments for concussion symptoms in the school setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential adjustments for concussion symptoms in the school setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sign/symptom</td> <td class=\"subtitle1\">Potential adjustments in school setting</td> </tr> <tr class=\"divider_bottom\"> <td>Headache</td> <td> <ul> <li>Permit frequent breaks </li> <li>Identify aggravators and reduce exposure to them </li> <li>Provide rests, planned or as needed, in nurses office or quiet area </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dizziness</td> <td> <ul> <li>Allow student to put head down if symptoms worsen </li> <li>Give student early dismissal from class and extra time to get from class to class to avoid crowded hallways </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Visual symptoms: light sensitivity, double vision, blurry vision</td> <td> <ul> <li>Reduce exposure to computers, smart boards, videos </li> <li>Reduce brightness on the screens </li> <li>Allow the student to wear a hat or sunglasses in school </li> <li>Permit use of audiotapes of books </li> <li>Turn off fluorescent lights as needed </li> <li>Seat student closer to the center of classroom activities (blurry vision) </li> <li>Cover&nbsp;one eye with patch/tape&nbsp;one lens if glasses are worn (double vision) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Noise sensitivity</td> <td> <ul> <li>Allow the student to have lunch in quiet area with a classmate </li> <li>Limit or avoid band, choir, or shop classes </li> <li>Avoid noisy gyms and organized sports practices/games </li> <li>Permit the use of earplugs </li> <li>Give student early dismissal from class and extra time to get from class to class to avoid crowded hallways during pass time </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Difficulty concentrating or remembering</td> <td> <ul> <li>Avoid testing or completion of major projects during recovery when possible </li> <li>Provide extra time to complete nonstandardized tests </li> <li>Postpone standardized testing (may require formal academic accommodation) </li> <li>Consider&nbsp;one test per day during exam periods, as tolerated </li> <li>Consider the use of preprinted notes, notetaker, scribe, or reader for oral test taking </li> </ul> </td> </tr> <tr> <td>Sleep disturbances</td> <td> <ul> <li>Allow for late start or shortened school day to catch up on sleep </li> <li>Allow rest breaks </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 132, Pages 948-57, Copyright &copy; 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 91450 Version 9.0</div></div></div>"},"91452":{"type":"graphic_picture","displayName":"Glomerular immunofluorescence in C3 glomerulonephritis","title":"Glomerular immunofluorescence in C3 glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Glomerular immunofluorescence in C3 glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:515px; height:209px;\" src=\"images/NEPH/91452_Glomer_immun_C3_glomer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence micrographs stained for IgG (A) and C3 (B) in a case of C3 glomerulonephritis. Note the weak or absent staining for IgG and strong glomerular capillary wall staining for C3.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD and David J Salant, MD.</div><div id=\"graphicVersion\">Graphic 91452 Version 1.0</div></div></div>"},"91453":{"type":"graphic_picture","displayName":"Electron microscopy of a glomerulus in a patient with C3GN","title":"Electron microscopy of a glomerulus in a patient with C3 glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Electron microscopy of a glomerulus in a patient with C3 glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:520px; height:378px;\" src=\"images/NEPH/91453_Elect_micro_glom_C3_gl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in C3 glomerulonephritis showing subendothelial electron-dense deposits (arrows). Mesangial deposits are also present in C3&nbsp;glomerulonephritis.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD and David J Salant, MD.</div><div id=\"graphicVersion\">Graphic 91453 Version 1.0</div></div></div>"},"91454":{"type":"graphic_diagnosticimage","displayName":"Simple silicosis radiograph","title":"Chest radiograph of simple silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of simple silicosis</div><div class=\"cntnt\"><img style=\"width:430px; height:417px;\" src=\"images/PULM/91454_Simple_silicosis_radiogrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple small nodules with a predilection for the upper lung zones, suggestive of simple silicosis. Note the intrinsic calcification of the small nodular opacities.</div><div id=\"graphicVersion\">Graphic 91454 Version 1.0</div></div></div>"},"91455":{"type":"graphic_diagnosticimage","displayName":"Simple silicosis CT","title":"Computed tomography of simple silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of simple silicosis</div><div class=\"cntnt\"><img style=\"width:430px; height:304px;\" src=\"images/PULM/91455_Simple_silicosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial computed tomography (CT) image shows sharply marginated centrilobular and perilymphatic nodules with a bias for the dorsal regions of the upper lobes.</div><div class=\"graphic_reference\">Courtesy of HG Hieckel, MD.</div><div id=\"graphicVersion\">Graphic 91455 Version 1.0</div></div></div>"},"91456":{"type":"graphic_diagnosticimage","displayName":"Early complicated silicosis","title":"Chest computed tomography (CT) in early complicated silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest computed tomography (CT) in early complicated silicosis</div><div class=\"cntnt\"><img style=\"width:430px; height:259px;\" src=\"images/PULM/91456_Early_complicated_silicosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomogram (CT) demonstrates early development of complicated silicosis with upper lobe conglomerate shadows and early scarring with loss of volume, on a background of small rounded opacities.</div><div class=\"graphic_reference\">Courtesy of HG Hieckel, MD.</div><div id=\"graphicVersion\">Graphic 91456 Version 1.0</div></div></div>"},"91457":{"type":"graphic_diagnosticimage","displayName":"Silicosis and bronchogenic carcinoma","title":"Computed tomography (CT) of silicosis and bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) of silicosis and bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:430px; height:271px;\" src=\"images/PULM/91457_Silicosis_bronchogenc_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows a left upper lobe mass due to bronchogenic carcinoma on a background of small centrilobular nodules caused by silica inhalation.</div><div class=\"graphic_reference\">Courtesy of HG Hieckel, MD.</div><div id=\"graphicVersion\">Graphic 91457 Version 1.0</div></div></div>"},"91458":{"type":"graphic_figure","displayName":"Risks benefits aspirin PI","title":"Risks and benefits of aspirin for primary prevention","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Risks and benefits of aspirin for primary prevention</div><div class=\"cntnt\"><img style=\"width:516px; height:789px;\" src=\"images/PI/91458_Risks_benefits_aspirin_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 1,000 people older than 60 who are at average risk for heart disease and cancer, daily aspirin use during a 10-year period would be expected to result in:<br /><UL>&#xD;&#xA;<LI>6 fewer deaths</LI>&#xD;&#xA;<LI>17 fewer heart attacks</LI>&#xD;&#xA;<LI>6 fewer cancers </LI>&#xD;&#xA;<LI>16 more major bleeds (this includes bleeding in the stomach or intestines, and bleeding in other sites that results in the person being hospitalized or getting a transfusion)</LI></UL></div><div id=\"graphicVersion\">Graphic 91458 Version 1.0</div></div></div>"},"91459":{"type":"graphic_diagnosticimage","displayName":"Silicotuberculosis","title":"Chest radiograph in a patient with cavitating silicotuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a patient with cavitating silicotuberculosis</div><div class=\"cntnt\"><img style=\"width:417px; height:455px;\" src=\"images/PULM/91459_Silicotuberculosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph is from a patient with silicosis complicated by tuberculosis. Bilateral upper lobe conglomerate masses are present in addition to a right upper lobe cavity with an air-liquid level.</div><div id=\"graphicVersion\">Graphic 91459 Version 1.0</div></div></div>"},"91460":{"type":"graphic_diagnosticimage","displayName":"Silicoproteinosis in surface coal miner","title":"Chest radiograph of silicoproteinosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of silicoproteinosis</div><div class=\"cntnt\"><img style=\"width:297px; height:277px;\" src=\"images/PULM/91460_Silicoproteinos_surf_mine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a surface coal miner shows bilateral, lower lobe confluent consolidations with air bronchograms, consistent with silicoproteinosis.</div><div class=\"graphic_reference\">Courtesy of Daniel Banks, MD.</div><div id=\"graphicVersion\">Graphic 91460 Version 1.0</div></div></div>"},"91461":{"type":"graphic_diagnosticimage","displayName":"Vineyard sprayer lung","title":"Chest radiograph from a patient with vineyard sprayer’s lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph from a patient with vineyard sprayer’s lung</div><div class=\"cntnt\"><img style=\"width:427px; height:474px;\" src=\"images/PULM/91461_Vineyard_sprayer_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph from a vineyard sprayer&nbsp;shows marked architectural distortion with upper lobe scarring, cyst-like cavities, and coarse scarring, as well as scattered nodules.</div><div id=\"graphicVersion\">Graphic 91461 Version 1.0</div></div></div>"},"91462":{"type":"graphic_diagnosticimage","displayName":"Talcosis radiograph","title":"Chest radiograph in talcosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in talcosis</div><div class=\"cntnt\"><img style=\"width:430px; height:412px;\" src=\"images/PULM/91462_Talcosis_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with talcosis. Multiple small nodules of the \"p\" type (≤1.5 mm) are scattered throughout both lungs.</div><div id=\"graphicVersion\">Graphic 91462 Version 1.0</div></div></div>"},"91463":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaques","title":"Calcified pleural plaques due to asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified pleural plaques due to asbestos exposure</div><div class=\"cntnt\"><img style=\"width:428px; height:380px;\" src=\"images/PULM/91463_Calcified_pleural_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph from an asbestos-exposed worker&nbsp;shows a \"candle dripping\" pattern of calcification, particularly in the right hemithorax. Bilateral linear calcifications are noted along the lateral pleural borders and right-sided mediastinal pleura.</div><div id=\"graphicVersion\">Graphic 91463 Version 1.0</div></div></div>"},"91464":{"type":"graphic_diagnosticimage","displayName":"Diaphragmatic pleural plaques","title":"Calcified diaphragmatic pleural plaques due to asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified diaphragmatic pleural plaques due to asbestos exposure</div><div class=\"cntnt\"><img style=\"width:424px; height:430px;\" src=\"images/PULM/91464_Diaphragma_pleural_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows curvilinear calcifications along both hemidiaphragms typical of asbestos exposure.</div><div id=\"graphicVersion\">Graphic 91464 Version 1.0</div></div></div>"},"91465":{"type":"graphic_diagnosticimage","displayName":"Pleural plaques and asbestosis","title":"Diffuse pleural calcification in a patient with asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse pleural calcification in a patient with asbestosis</div><div class=\"cntnt\"><img style=\"width:427px; height:441px;\" src=\"images/PULM/91465_Pleural_plaques_asbestosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with asbestosis showing&nbsp;a combination of extensively calcified pleural plaques and interstitial fibrosis.</div><div id=\"graphicVersion\">Graphic 91465 Version 1.0</div></div></div>"},"91466":{"type":"graphic_picture","displayName":"Muscles of the posterior leg - Superficial dissection","title":"Muscles of the posterior leg: Superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Muscles of the posterior leg: Superficial dissection</div><div class=\"cntnt\"><img style=\"width:451px; height:637px;\" src=\"images/EM/91466_Musclespostlegsuperdiss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of images shows the superficial muscles of the posterior leg and their relationships to one another.</div><div class=\"graphic_reference\">Reproduced with permission from: Pansky B, Gest TR. Lippincott's Concise Illustrated Anatomy: Back, Upper Limb and Lower Limb. Lippincott Williams &amp; Wilkins, Philadephia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91466 Version 6.0</div></div></div>"},"91467":{"type":"graphic_diagnosticimage","displayName":"Chest CT benign asbestos effusion","title":"Chest computed tomogram of benign asbestos exudative pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest computed tomogram of benign asbestos exudative pleural effusion</div><div class=\"cntnt\"><img style=\"width:424px; height:357px;\" src=\"images/PULM/91467_Chst_CT_benig_asbes_eff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram (CT) from a patient with a benign asbestos pleural effusion shows a \"split pleura\" sign with thickening and enhancement of the visceral and parietal pleura following injection of intravenous contrast material.</div><div id=\"graphicVersion\">Graphic 91467 Version 1.0</div></div></div>"},"91468":{"type":"graphic_diagnosticimage","displayName":"Asbestos pleural thickening and pleural effusion","title":"Asbestos-related pleural thickening and pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestos-related pleural thickening and pleural effusion</div><div class=\"cntnt\"><img style=\"width:423px; height:415px;\" src=\"images/PULM/91468_Asbestos_pleu_thick_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a shipyard pipefitter exposed to asbestos showing left-sided diffuse pleural thickening and right-sided pleural plaques with characteristic punctate calcifications in the lungs.</div><div id=\"graphicVersion\">Graphic 91468 Version 1.0</div></div></div>"},"91469":{"type":"graphic_diagnosticimage","displayName":"Retractile pleuritis","title":"Chest radiograph of retractile pleuritis after asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of retractile pleuritis after asbestos exposure</div><div class=\"cntnt\"><img style=\"width:428px; height:390px;\" src=\"images/PULM/91469_Retractile_pleuritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of asbestos-exposed patient that shows left-sided apico-lateral pleural thickening with apical capping and \"crow's feet\", typical of pleurogenic parenchymal fibrosis, also known as retractile pleuritis. Calcified pleural plaques are seen along right medial pleural reflection, and non-calcified pleural plaques are seen en face, partially obscuring the right heart border.</div><div id=\"graphicVersion\">Graphic 91469 Version 1.0</div></div></div>"},"91470":{"type":"graphic_diagnosticimage","displayName":"Endstage asbestosis","title":"Chest radiograph of endstage asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of endstage asbestosis</div><div class=\"cntnt\"><img style=\"width:414px; height:378px;\" src=\"images/PULM/91470_Endstage_asbestosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a patient with asbestosis demonstrating pulmonary fibrosis with reticular opacities and bibasal honeycombing.</div><div id=\"graphicVersion\">Graphic 91470 Version 1.0</div></div></div>"},"91471":{"type":"graphic_figure","displayName":"Sex determination and differentiation","title":"Molecular and genetic events in mammalian sex determination and differentiation","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Molecular and genetic events in mammalian sex determination and differentiation</div><div class=\"cntnt\"><img style=\"width:618px; height:446px;\" src=\"images/ENDO/91471_Sex_determination_different.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The molecular and genetic events in mammalian sex determination and differentiation. The bipotential genital ridge is established by several genes including <em>NR5A1</em> [Wilhelm, et al, 2007; Sekido and Lovell-Badge, 2009]. In the XY gonad the activation of <em>SRY</em> expression, possibly initiated by <em>GATA4/FOG2/NR5A1/WT1</em>, leads to the upregulation of <em>SOX9</em> expression via a synergy with <em>NR5A1</em> [Sekido and Lovell-Badge 2008, 2009]. In the XX gonad, the supporting cell precursors accumulate &beta;-catenin in response to <em>RSPO1/WNT4</em> signalling and repress <em>SOX9</em> activity [Schlessinger, et al, 2010]. Once <em>SOX9</em> levels reach a critical threshold, several positive regulatory loops are initiated, including autoregulation of its own expression and formation of feed-forward loops via <em>FGF9</em> or <em>PGD2</em> signalling [Sekido and Lovell-Badge, 2009]. At later stages, <em>FOXL2</em> may repress <em>SOX9</em> expression [Uhlenhaut, et al, 2009]. In the testis, <em>SOX9</em> promotes the testis pathway, including <em>AMH</em> activation, and it also probably represses the ovarian genes <em>WNT4</em> and <em>FOXL2</em> [Sekido and Lovell-Badge, 2009; Uhlenhaut, et al, 2009; Schlessinger, et al, 2010]. <em>DMRT1</em> controls sex determination in some species of fish and may be the master sex-determining switch in birds, but its role in mammalian sexual development is unclear [Wilhelm, et al, 2007; Smith, et al, 2009]. Much of this data has been generated from studies in mice.</div><div class=\"graphic_reference\">Reproduced with permission from: Bashamboo A, Ledig S, Wieacker P, et al. New technologies for the identification of novel genetic markers of disorders of sex development (DSD). Sex Dev 2010; 4:213. Copyright &copy; 2010 S. Karger AG. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91471 Version 3.0</div></div></div>"},"91472":{"type":"graphic_diagnosticimage","displayName":"Graves orbitopathy CT scan","title":"Graves’ orbitopathy: Findings on CT scan","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Graves’ orbitopathy: Findings on CT scan</div><div class=\"cntnt\"><img style=\"width:504px; height:318px;\" src=\"images/ENDO/91472_Graves_orbitopathy_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan showing enlarged extra-ocular muscles in a patient with Graves' orbitopathy and resulting proptosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Terry F Davies, MD, FRCP, FACE.</div><div id=\"graphicVersion\">Graphic 91472 Version 1.0</div></div></div>"},"91473":{"type":"graphic_movie","displayName":"Resection of pituitary macroadenoma","title":"Endoscopic transsphenoidal resection en bloc of a pituitary macroadenoma","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Endoscopic transsphenoidal resection en bloc of a pituitary macroadenoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ENDO/91473_Resectpituitmacroadvideo.mp4\" style=\"width:528px;height:320px\"></div><img style=\"width:576px; height:336px;\" src=\"images/ENDO/91473_Resectpituitmacroadimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John Lee, MD, University of Pennsylvania.</div><div id=\"graphicVersion\">Graphic 91473 Version 1.0</div></div></div>"},"91477":{"type":"graphic_picture","displayName":"Muscles of the posterior leg - Intermediate dissection","title":"Muscles of the posterior leg: Intermediate dissection","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Muscles of the posterior leg: Intermediate dissection</div><div class=\"cntnt\"><img style=\"width:604px; height:603px;\" src=\"images/EM/91477_Musclespostleginterdiss.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pansky B, Gest TR. Lippincott's Concise Illustrated Anatomy: Back, Upper Limb and Lower Limb. Lippincott Williams &amp; Wilkins, Philadephia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91477 Version 6.0</div></div></div>"},"91478":{"type":"graphic_picture","displayName":"Superficial muscles of the ankle and foot - Posterior view","title":"Superficial muscles of the ankle and foot: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the ankle and foot: Posterior view</div><div class=\"cntnt\"><img style=\"width:504px; height:633px;\" src=\"images/EM/91478_Superfmuscanklefootpost.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91478 Version 6.0</div></div></div>"},"91479":{"type":"graphic_picture","displayName":"Gastrocnemius muscle","title":"Gastrocnemius muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastrocnemius muscle</div><div class=\"cntnt\"><img style=\"width:219px; height:613px;\" src=\"images/EM/91479_Gastrocnemiusmuscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows the origin, location, and insertion of the gastrocnemius muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91479 Version 7.0</div></div></div>"},"91480":{"type":"graphic_picture","displayName":"Soleus muscle","title":"Soleus muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Soleus muscle</div><div class=\"cntnt\"><img style=\"width:219px; height:613px;\" src=\"images/EM/91480_Soleusmuscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows the origin, location, and insertion of the soleus muscle.&nbsp;The soleus lies deep to the gastrocnemius, which is not shown here.</div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91480 Version 7.0</div></div></div>"},"91481":{"type":"graphic_picture","displayName":"Plantaris muscle","title":"Plantaris muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantaris muscle</div><div class=\"cntnt\"><img style=\"width:218px; height:611px;\" src=\"images/EM/91481_Plantarismuscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows the origin, location, long distal tendon, and insertion of the plantaris muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 91481 Version 7.0</div></div></div>"},"91484":{"type":"graphic_picture","displayName":"Hand swelling and edema in PMR","title":"Hand swelling and edema in PMR","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Hand swelling and edema in PMR</div><div class=\"cntnt\"><img style=\"width:505px; height:320px;\" src=\"images/RHEUM/91484_Hand_swelling_edema_PMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling and pitting edema of the hand developing early in the course of&nbsp;PMR in an 84-year-old woman. The patient's other hand&nbsp;was similarly swollen. Swelling resolved with glucocorticoid therapy.</div><div class=\"graphic_footnotes\">PMR: polymyalgia rheumatica.</div><div class=\"graphic_reference\">Courtesy of Gene Hunder, MD.</div><div id=\"graphicVersion\">Graphic 91484 Version 3.0</div></div></div>"},"91491":{"type":"graphic_table","displayName":"Neoadjuvant therapy for borderline resectable pancreatic cancer","title":"Studies of neoadjuvant treatment in borderline resectable pancreatic cancer (2010 to present)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies of neoadjuvant treatment in borderline resectable pancreatic cancer (2010 to present)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"13%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"13%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Neoadjuvant regimen</td> <td class=\"subtitle1\">Number resected<br /> <em>&nbsp;(percent)</em></td> <td class=\"subtitle1\">Number completely (R0) resected<br /> <em>&nbsp;(percent)</em></td> <td class=\"subtitle1\">Survival</td> </tr> <tr> <td>Kim S, 2016</td> <td class=\"centered\">26</td> <td>FOLFIRINOX (n = 26)&nbsp;then RT (n = 4)</td> <td>26 (100)</td> <td>22 (92)</td> <td>Median survival not reached at median follow-up 27.6 months</td> </tr> <tr> <td>Katz M, 2016</td> <td class=\"centered\">22</td> <td>FOLFIRINOX then CRT</td> <td>15 (68)</td> <td>14 (93)</td> <td>Median 21.7 months&nbsp;</td> </tr> <tr> <td>Leone F, 2013</td> <td class=\"centered\">15</td> <td>GEMOX then Gem-RT</td> <td>9 (60)</td> <td>NR</td> <td>Median 28 months</td> </tr> <tr> <td>Tahahashi H, 2013</td> <td class=\"centered\">80</td> <td>Gem-RT</td> <td>43 (54)</td> <td>42 (98)</td> <td>5-year: 34 percent</td> </tr> <tr> <td>Kim E, 2013</td> <td class=\"centered\">39</td> <td>GEMOX-RT</td> <td>24 (62)</td> <td>NR</td> <td>Median 18.4 months</td> </tr> <tr> <td>Motoi F, 2013</td> <td class=\"centered\">16</td> <td>Gem-S-1</td> <td>NR</td> <td>NR</td> <td>2-year: 31.5 percent</td> </tr> <tr> <td>Mahaseth H, 2012</td> <td class=\"centered\">2</td> <td>FOLFIRINOX then CRT</td> <td>2 (100)</td> <td>2 (100)</td> <td>NR</td> </tr> <tr> <td>Kharofa J, 2012</td> <td class=\"centered\">12</td> <td>FOLFIRINOX then CRT</td> <td>7 (58)</td> <td>7 (100)</td> <td>Median survival not reached at 13 months</td> </tr> <tr> <td>Peddi P, 2012</td> <td class=\"centered\">4</td> <td>FOLFIRINOX</td> <td>4 (100)</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Hosein P, 2012</td> <td class=\"centered\">4</td> <td>FOLFIRINOX</td> <td>3 (75)</td> <td>3 (100)</td> <td>NR</td> </tr> <tr> <td>Lee J, 2012</td> <td class=\"centered\">18</td> <td>Gem-Cape</td> <td>11 (61)</td> <td>9 (82)</td> <td>NR</td> </tr> <tr> <td>Kang C, 2012</td> <td class=\"centered\">32</td> <td>Gem with or without Cis-RT</td> <td>32 (100)</td> <td>28 (88)</td> <td>NR</td> </tr> <tr> <td>Chuong M, 2011</td> <td class=\"centered\">14</td> <td>GTX then CRT</td> <td>14 (100)</td> <td>12 (86)</td> <td>NR</td> </tr> <tr> <td>Barugola G, 2012</td> <td class=\"centered\">27</td> <td>Various</td> <td>27 (100)</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Stokes J, 2011</td> <td class=\"centered\">40</td> <td>Cape-RT</td> <td>16 (40)</td> <td>12 (75)</td> <td>NR</td> </tr> <tr> <td>Sahora K, 2011</td> <td class=\"centered\">12</td> <td>Gem-Tax</td> <td>4 (33)</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Chun Y, 2010</td> <td class=\"centered\">74</td> <td>Various</td> <td>74 (100)</td> <td>44 (60)</td> <td>Median 21 months</td> </tr> <tr> <td>McClaine R, 2010</td> <td class=\"centered\">29</td> <td>Various</td> <td>12 (41)</td> <td>8 (75)</td> <td>NR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FOLFIRINOX: short-term infusional fluorouracil plus leucovorin, irinotecan, and oxaliplatin; RT: radiation therapy; CRT: chemoradiotherapy;&nbsp;GEMOX: gemcitabine plus oxaliplatin; Gem: gemcitabine; NR: not reported; Cape: capecitabine; Cis: cisplatin; GTX: gemcitabine, docetaxel, plus capecitabine; Tax: taxane.</div><div class=\"graphic_reference\">Table expanded from: Conroy T, Gavoille C, Samalin E, et al. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep 2013; 15:182.</div><div id=\"graphicVersion\">Graphic 91491 Version 5.0</div></div></div>"},"91492":{"type":"graphic_figure","displayName":"Knee-chest pulls","title":"Knee-chest pulls","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Knee-chest pulls</div><div class=\"cntnt\"><img style=\"width:468px; height:504px;\" src=\"images/RHEUM/91492_Knee-chest_pulls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Knee-chest pulls should be performed lying on a firm, padded surface. Grasp your upper lower leg and slowly bring your knee slowly up to your chest, holding it in place for five seconds. Relax the buttock and lower back muscles. Perform sets of 15 to 20 stretches on the right side, then the left side, and finally both legs simultaneously (curling up in the fetal position).</div><div id=\"graphicVersion\">Graphic 91492 Version 2.0</div></div></div>"},"91493":{"type":"graphic_figure","displayName":"Side bends","title":"Side bends","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Side bends</div><div class=\"cntnt\"><img style=\"width:468px; height:602px;\" src=\"images/RHEUM/91493_Side_bends.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Side bends increase the flexibility of the lower back&nbsp;and oblique abdominal muscles.&nbsp;While lying down, crawl your fingers down the side of your thigh.&nbsp;Hold this position for&nbsp;five seconds.&nbsp;Return to the neutral position.&nbsp;Repeat on the other side.&nbsp;Sets of 20 repetitions should be performed daily.&nbsp;Initially, this exercise should be performed while lying down or while floating in water.&nbsp;With improvement in flexibility and stiffness, this exercise can be performed sitting in a straight-back chair or standing.</div><div id=\"graphicVersion\">Graphic 91493 Version 1.0</div></div></div>"},"91494":{"type":"graphic_figure","displayName":"Pelvic rock exercise","title":"Pelvic rock exercise","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Pelvic rock exercise</div><div class=\"cntnt\"><img style=\"width:469px; height:344px;\" src=\"images/RHEUM/91494_Pelvic_rock_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pelvic rock exercise can be performed on all fours or while lying on the back. With the knees bent, rotate your pelvis forward then backwards.&nbsp;The abdominal muscles are used to rotate backwards, while the back muscles rotate forward (arching the back).&nbsp;Each position is held for&nbsp;five seconds and&nbsp;repeated&nbsp;in sets of&nbsp;20.&nbsp;Caution: Do not overextend when arching the back.</div><div id=\"graphicVersion\">Graphic 91494 Version 1.0</div></div></div>"},"91495":{"type":"graphic_figure","displayName":"Cross-leg pulls","title":"Cross-leg pulls","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cross-leg pulls</div><div class=\"cntnt\"><img style=\"width:468px; height:574px;\" src=\"images/RHEUM/91495_Cross-leg_pulls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The affected leg is crossed over the other leg while sitting with the spine in a neutral position in a straight-backed chair or on the floor. Grasp the knee on the affected side, and pull the leg to the opposite side. Be sure to keep the buttocks flat, avoiding twisting the back or rolling the buttocks. A gentle pulling sensation should be felt in the outer hip and buttock areas. Sharp pain suggests excessive stretching and irritation of the bursa. The stretch should be repeated 20 times.</div><div id=\"graphicVersion\">Graphic 91495 Version 3.0</div></div></div>"},"91499":{"type":"graphic_picture","displayName":"OTSC treatment of gastric ulcer","title":"Treatment of a gastric ulcer with an over-the-scope endoclip","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Treatment of a gastric ulcer with an over-the-scope endoclip</div><div class=\"cntnt\"><img style=\"width:514px; height:392px;\" src=\"images/GAST/91499_OTSC_treat_gastric_ulc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bleeding ulcer with a visible vessel in the gastric antrum.<br />(B) Placement of an over-the-scope endoclip.<br />(C) Image of the ulcer after endoclip placement.</div><div id=\"graphicVersion\">Graphic 91499 Version 1.0</div></div></div>"},"91501":{"type":"graphic_table","displayName":"Treatment of pregnant women with APS or aPL","title":"Approach to treatment of pregnant and postpartum women with APS or aPL","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to treatment of pregnant and postpartum&nbsp;women with APS or aPL</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antepartum</td> <td class=\"subtitle1\">Postpartum</td> </tr> <tr class=\"divider_bottom\"> <td><strong>APS with prior arterial or venous thrombosis, with or without <strong>APS-defining pregnancy morbidity</strong></strong></td> <td>Therapeutic-dose LMWH and low-dose ASA</td> <td>Warfarin for an indefinite period of time.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>APS based on laboratory criteria for aPL and APS-defining pregnancy morbidity of &#8805;1 fetal losses &#8805;10 weeks of gestation or &#8805;3 unexplained consecutive spontaneous pregnancy losses &#60;10 weeks of gestation and </strong><strong>NO</strong><strong> history of arterial or venous thrombosis</strong></td> <td>Prophylactic-dose LMWH and low-dose ASA</td> <td>Prophylactic-dose LMWH and low-dose ASA for six weeks regardless of route of delivery.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>APS based on laboratory criteria for aPL and APS-defining pregnancy morbidity of &#8805;1 preterm deliveries of a morphologically normal infant before 34 weeks of gestation due to severe preeclampsia, eclampsia, or other findings consistent with placental insufficiency and&nbsp;NO history of arterial or venous thrombosis</strong></td> <td>Most cases: Low-dose ASA</td> <td> <p>Vaginal delivery: Intermittent pneumatic compression and low-dose ASA while in the hospital. Graduated compression stockings and low-dose ASA&nbsp;for six weeks.</p> <p>Cesarean delivery: Prophylactic-dose LMWH and low-dose ASA&nbsp;for six weeks.</p> </td> </tr> <tr class=\"divider_bottom\"> <td>In cases of ASA failure or when placental examination shows extensive decidual inflammation and vasculopathy and/or thrombosis, prophylactic-dose LMWH with low-dose ASA</td> <td>Prophylactic-dose LMWH&nbsp;and low-dose ASA for six weeks regardless of route of delivery.</td> </tr> <tr> <td class=\"divider_bottom\"><strong>Laboratory criteria for&nbsp;APS&nbsp;but&nbsp;NO clinical criteria for APS&nbsp;(ie, NO history of venous or arterial thrombosis&nbsp;and NO history of&nbsp;APS-defining obstetric morbidity)</strong></td> <td>Low-dose ASA</td> <td> <p>Vaginal delivery: Intermittent pneumatic compression and low-dose ASA while in the hospital. Graduated compression stockings and low-dose ASA&nbsp;for six weeks.</p> <p>Cesarean delivery: Prophylactic-dose LMWH and low-dose ASA&nbsp;for six weeks.</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples of therapeutic LMWH (also referred to as weight-adjusted, full-treatment dose): enoxaparin 1 mg/kg every 12 hours, dalteparin 200 units/kg once daily, tinzaparin 175 units/kg once daily, dalteparin 100 units/kg every 12 hours.<br />Examples of prophylactic LMWH: enoxaparin 40 mg SC once daily, dalteparin 5000 units SC once daily, tinzaparin 4500 units SC once daily. These doses may need to be modified at extremes of body weight.<br />Anticoagulation can generally be resumed four to six hours after vaginal delivery or 6 to 12 hours after cesarean delivery, unless there is significant bleeding or risk for significant bleeding.<br />NOTE: Tinzaparin is not available in the United States. The role and frequency of anti-Xa testing for management of therapeutic dosing of LMWH in pregnancy are reviewed in&nbsp;the UpToDate topic on&nbsp;anticoagulation in pregnancy.</div><div class=\"graphic_footnotes\">APS: antiphospholipid syndrome; LMWH: low molecular weight heparin; ASA: aspirin; aPL: antiphospholipid antibodies; SC: subcutaneous.</div><div id=\"graphicVersion\">Graphic 91501 Version 8.0</div></div></div>"},"91502":{"type":"graphic_table","displayName":"Minimum frequency of CIED follow-up","title":"Minimum frequency of cardiac implantable electronic device (CIED) follow-up","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimum frequency of cardiac implantable electronic device (CIED) follow-up</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Delivery method</td> </tr> <tr> <td>Immediate post-implant check</td> <td>Within 72 hours</td> <td>In person</td> </tr> <tr> <td>Early post-implant check</td> <td>2 to 12 weeks</td> <td>In person</td> </tr> <tr> <td>Routine PPM/CRT-PPM check</td> <td>Every 3 to 12 months</td> <td>In person or remote</td> </tr> <tr> <td>Routine ICD/CRT-D</td> <td>Every 3 to 6 months</td> <td>In person or remote</td> </tr> <tr> <td>Following one ICD/CRT-D shock</td> <td>Within 24 to 48 hours</td> <td>In person or remote</td> </tr> <tr> <td>Following &#62;1 ICD/CRT-D shocks</td> <td>Immediately</td> <td>In person</td> </tr> <tr> <td>Any CIED until signs of battery depletion</td> <td>Annually</td> <td>In person</td> </tr> <tr> <td>Any CIED following signs of battery depletion</td> <td>Every 1 to 3 months</td> <td>In person or remote</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CIED: cardiac implantable electronic device; CRT: cardiac resynchronization therapy; ICD: implantable cardioverter-defibrillator; PPM: permanent pacemaker.</div><div class=\"graphic_reference\">Adapted from: Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm 2008; 5:907.</div><div id=\"graphicVersion\">Graphic 91502 Version 3.0</div></div></div>"},"91503":{"type":"graphic_picture","displayName":"Folliculitis decalvans active","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:502px; height:334px;\" src=\"images/DERM/91503_Folliculit_decalvan_active.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active folliculitis decalvans demonstrating smooth scarred areas, erythema, and pustules.</div><div id=\"graphicVersion\">Graphic 91503 Version 1.0</div></div></div>"},"91505":{"type":"graphic_picture","displayName":"Folliculitis decalvans tufted hairs","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:476px; height:590px;\" src=\"images/DERM/91505_Folliculit_decal_tuft_hair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Folliculitis decalvans after successful treatment demonstrating smooth scarred areas as well as numerous tufted hairs on the occipital scalp.</div><div id=\"graphicVersion\">Graphic 91505 Version 1.0</div></div></div>"},"91506":{"type":"graphic_picture","displayName":"Folliculitis decalvans tunneling of hairs","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:493px; height:387px;\" src=\"images/DERM/91506_Follic_decalv_tunnel_hairs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partially treated folliculitis decalvans demonstrating tunneling of hairs under the scalp surface and perifollicular scale. Pustules are absent.</div><div id=\"graphicVersion\">Graphic 91506 Version 1.0</div></div></div>"},"91507":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp nodule","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:516px; height:343px;\" src=\"images/DERM/91507_Dissect_cellulit_scalp_nod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolated fluctuant nodule on the scalp with overlying hair loss.</div><div id=\"graphicVersion\">Graphic 91507 Version 1.0</div></div></div>"},"91508":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp widespread","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:516px; height:387px;\" src=\"images/DERM/91508_Dissect_cellulit_scalp_wid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple alopecic plaques with crusting at sites of drainage.</div><div id=\"graphicVersion\">Graphic 91508 Version 1.0</div></div></div>"},"91509":{"type":"graphic_picture","displayName":"Lichen planopilaris late stage","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:387px; height:515px;\" src=\"images/DERM/91509_Lichn_planopilaris_lat_stg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Late stage lichen planopilaris demonstrating confluent area of scarring alopecia and&nbsp;perifollicular scale. Erythema is minimal.</div><div id=\"graphicVersion\">Graphic 91509 Version 1.0</div></div></div>"},"91510":{"type":"graphic_picture","displayName":"Discoid lupus erythematosus active","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:423px; height:514px;\" src=\"images/DERM/91510_Discoid_lup_erythemats_act.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active discoid lupus erythematosus. Large plaque on the frontal scalp in a patient with concomitant male pattern hair loss. Note the central depigmentation and peripheral scale.</div><div id=\"graphicVersion\">Graphic 91510 Version 1.0</div></div></div>"},"91511":{"type":"graphic_picture","displayName":"Central centrifugal cicatricial alopecia crown","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:514px; height:533px;\" src=\"images/DERM/91511_Cent_cicatric_alopcia_crwn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large area of incomplete hair loss on the crown of the scalp without obvious inflammation.</div><div id=\"graphicVersion\">Graphic 91511 Version 1.0</div></div></div>"},"91512":{"type":"graphic_picture","displayName":"Folliculitis decalvans before and after treatment","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:527px; height:189px;\" src=\"images/DERM/91512_Follic_declv_bna_treat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient before (A) and after (B) treatment with oral antibiotics and oral glucocorticoids. Hair will not regrow in the areas of scarring.</div><div id=\"graphicVersion\">Graphic 91512 Version 1.0</div></div></div>"},"91513":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray - Pulmonic stenosis","title":"Chest radiograph of a patient with pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a patient with pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:540px; height:590px;\" src=\"images/PEDS/91513_Chest_xray_pulmonic_stenos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a three-year-old child with pulmonic stenosis&nbsp;demonstrating enlarged&nbsp;heart and&nbsp;dilation of the main pulmonary artery (arrow).</div><div id=\"graphicVersion\">Graphic 91513 Version 1.0</div></div></div>"},"91514":{"type":"graphic_waveform","displayName":"ECG - Pulmonic stenosis","title":"Electrocardiogram of a patient with pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of a patient with pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:612px; height:518px;\" src=\"images/PEDS/91514_ECG_pulmonic_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram (ECG) of a one-month-old child with pulmonic stenosis demonstrating right axis deviation, right atrial enlargement (increased magnitude of P waves in lead II), and right ventricular hypertrophy (increased QRS waves in the right precordial leads V1, V2, and V3).</div><div id=\"graphicVersion\">Graphic 91514 Version 1.0</div></div></div>"},"91517":{"type":"graphic_table","displayName":"Preoperative CA 19-9 levels and tumor resectabilty and survival","title":"Preoperative CA 19-9 levels and tumor resectabilty and survival rates in pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative CA 19-9 levels and tumor resectabilty and survival rates in pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">CA 19-9 (U/mL)</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Resectability (%)</td> <td class=\"subtitle1\" rowspan=\"2\">R0 resection (%)</td> <td class=\"subtitle1\" colspan=\"2\">Survival after resection</td> <td class=\"subtitle1\">Survival if unresectable</td> </tr> <tr> <td class=\"subtitle2\">5-year (%)</td> <td class=\"subtitle2\">Median (months)</td> <td class=\"subtitle2\">Median (months)</td> </tr> <tr> <td>&#60;5</td> <td class=\"centered\">99</td> <td class=\"centered\">73.7</td> <td class=\"centered\">48.6</td> <td class=\"centered\">21.9</td> <td class=\"centered\">26.8</td> <td class=\"centered\">10.1</td> </tr> <tr> <td>5 to &#60;37</td> <td class=\"centered\">281</td> <td class=\"centered\">79.7</td> <td class=\"centered\">52.7</td> <td class=\"centered\">27.2</td> <td class=\"centered\">28.5</td> <td class=\"centered\">9.1</td> </tr> <tr> <td>37 to &#60;100</td> <td class=\"centered\">216</td> <td class=\"centered\">83.3</td> <td class=\"centered\">46.9</td> <td class=\"centered\">19.1</td> <td class=\"centered\">26.9</td> <td class=\"centered\">8.6</td> </tr> <tr> <td>100 to &#60;250</td> <td class=\"centered\">247</td> <td class=\"centered\">82.2</td> <td class=\"centered\">42.1</td> <td class=\"centered\">16.8</td> <td class=\"centered\">22.5</td> <td class=\"centered\">5.4</td> </tr> <tr> <td>250 to &#60;500</td> <td class=\"centered\">204</td> <td class=\"centered\">72.1</td> <td class=\"centered\">37.0</td> <td class=\"centered\">8.3</td> <td class=\"centered\">20.1</td> <td class=\"centered\">9.2</td> </tr> <tr> <td>500 to &#60;1000</td> <td class=\"centered\">184</td> <td class=\"centered\">67.4</td> <td class=\"centered\">44.7</td> <td class=\"centered\">7.0</td> <td class=\"centered\">15.4</td> <td class=\"centered\">8.9</td> </tr> <tr> <td>1000 to &#60;2000</td> <td class=\"centered\">126</td> <td class=\"centered\">61.1</td> <td class=\"centered\">32.5</td> <td class=\"centered\">0.0</td> <td class=\"centered\">12.0</td> <td class=\"centered\">6.8</td> </tr> <tr> <td>2000 to &#60;4000</td> <td class=\"centered\">92</td> <td class=\"centered\">45.7</td> <td class=\"centered\">31.0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">12.3</td> <td class=\"centered\">6.2</td> </tr> <tr> <td>&#8805;4000</td> <td class=\"centered\">94</td> <td class=\"centered\">38.3</td> <td class=\"centered\">27.8</td> <td class=\"centered\">0.0</td> <td class=\"centered\">14.4</td> <td class=\"centered\">7.2</td> </tr> <tr> <td>&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"><em>p</em>&#60;0.0001</td> <td class=\"centered\"><em>p</em> = 0.0009</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"><em>p</em>&#60;0.0001</td> <td class=\"centered\"><em>p</em> = 0.065</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Preoperative CA 19-9 levels were available for 1106 patients with resectable and for 437 patients with unresectable pancreatic adenocarcinomas. The R0 resection rate was calculated by using resectable patients only. Including all patients with CA 19-9 &ge;1000 U/mL (resectable and unresectable), a R0 resection was achieved in only 15.4% of this group. Starting in 2005, histopathologic reporting applied the refined resection margin evaluation, as detailed in a prior report (Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011; 254:311-9).</div><div class=\"graphic_reference\">Reproduced by permission from: Springer. Annals of Surgical Oncology. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20:2188. Copyright © 2013. <A spellcheck=true href=\"https://link.springer.com/journal/10434\" target=_blank>https://link.springer.com/journal/10434</A>.</div><div id=\"graphicVersion\">Graphic 91517 Version 3.0</div></div></div>"},"91531":{"type":"graphic_picture","displayName":"Kawasaki rash","title":"Diffuse rash of Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Diffuse rash of Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91531_Kawasaki_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Morbilliform confluent rash on the face and trunk of a child with Kawasaki disease. Some targetoid lesions are also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91531 Version 1.0</div></div></div>"},"91532":{"type":"graphic_picture","displayName":"Kawasaki perineal erythema","title":"Perineal erythema of Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perineal erythema of Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/91532_Kawasaki_perineal_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perineal erythema and desquamation are characteristic of Kawasaki disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91532 Version 1.0</div></div></div>"},"91533":{"type":"graphic_diagnosticimage","displayName":"Complicated silicosis chest radiograph","title":"Chest radiograph of complicated silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of complicated silicosis</div><div class=\"cntnt\"><img style=\"width:428px; height:404px;\" src=\"images/PULM/91533_Compl_silicosis_chest_radio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph from a patient with silicosis demonstrates conglomerate masses in both upper lobes on a background of residual small rounded opacities.</div><div id=\"graphicVersion\">Graphic 91533 Version 1.0</div></div></div>"},"91534":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph showing complicated silicosis with angel wings","title":"Chest radiograph of complicated silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of complicated silicosis</div><div class=\"cntnt\"><img style=\"width:358px; height:245px;\" src=\"images/PULM/91534_Chst_rd_cmp_silc_angl_wing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph from a patient with&nbsp;a history of silica exposure&nbsp;demonstrates bilateral conglomerate masses forming so-called angel wings in a case of complicated silicosis.</div><div id=\"graphicVersion\">Graphic 91534 Version 1.0</div></div></div>"},"91535":{"type":"graphic_diagnosticimage","displayName":"Silicosis with egg shell calcifications","title":"Lymph node enlargement with egg shell calcifications due to silicosis","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Lymph node enlargement with egg shell calcifications due to silicosis</div><div class=\"cntnt\"><img style=\"width:528px; height:157px;\" src=\"images/PULM/91535_Sili_egg_shell_calcific.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph from a patient with a history of silica inhalation showing coarse calcifications on a background of small rounded pulmonary opacities.<br />(B) Axial computed tomogram (CT) showing a mostly peripheral distribution of calcifications in the hilar and mediastinal lymph nodes, known as \"egg shell calcifications\".</div><div id=\"graphicVersion\">Graphic 91535 Version 1.0</div></div></div>"},"91536":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of chronic beryllium disease","title":"Chest radiograph of chronic beryllium disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of chronic beryllium disease</div><div class=\"cntnt\"><img style=\"width:430px; height:370px;\" src=\"images/PULM/91536_Chst_radio_chron_bryll_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with chronic beryllium disease that demonstrates peripheral nodules and advanced pulmonary fibrosis with traction tracheomegaly and architectural distortion.</div><div id=\"graphicVersion\">Graphic 91536 Version 1.0</div></div></div>"},"91537":{"type":"graphic_diagnosticimage","displayName":"Chronic beryllium disease chest radiograph","title":"Chest radiograph of chronic beryllium disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of chronic beryllium disease</div><div class=\"cntnt\"><img style=\"width:429px; height:377px;\" src=\"images/PULM/91537_Chron_beryll_dis_chst_rdio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with chronic beryllium disease&nbsp;demonstrates small lung volumes, diffuse fibrosis with architectural distortion, and nodules. The cardiac border is poorly marginated due to adjacent lung disease.</div><div id=\"graphicVersion\">Graphic 91537 Version 1.0</div></div></div>"},"91538":{"type":"graphic_diagnosticimage","displayName":"Pleural plaques due to asbestos exposure with one-edged lesions","title":"Pleural plaques due to asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural plaques due to asbestos exposure</div><div class=\"cntnt\"><img style=\"width:415px; height:421px;\" src=\"images/PULM/91538_Plrl_plaqu_asbest_one_edge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a patient with pleural plaques due to asbestos exposure. Features include lesions where one edge is sharp and the other indistinct, so-called one-edged lesions with incomplete border sign, consistent with pleural lesions. Some opacities have a \"holly leaf\" appearance with scalloped edges and marginal calcifications.</div><div id=\"graphicVersion\">Graphic 91538 Version 1.0</div></div></div>"},"91539":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaques due to asbestos exposure","title":"Pleural plaques due to asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural plaques due to asbestos exposure</div><div class=\"cntnt\"><img style=\"width:416px; height:429px;\" src=\"images/PULM/91539_Calc_pleur_plaq_asbest_exp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with&nbsp;pleural plaques due to asbestos&nbsp;demonstrates pleural calcifications with mottled stippled, sunburst, holly leaf, and rolled margin configuration.</div><div id=\"graphicVersion\">Graphic 91539 Version 1.0</div></div></div>"},"91540":{"type":"graphic_diagnosticimage","displayName":"Chest CT of asbestosis","title":"Chest computed tomogram of asbestosis and calcified pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest computed tomogram of asbestosis and calcified pleural plaques</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/PULM/91540_Chest_CT_asbestosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram (CT) from a patient with asbestosis shows reticular opacities, traction bronchiectases, and honeycombing. Thick calcified pleural plaques are also present.</div><div id=\"graphicVersion\">Graphic 91540 Version 1.0</div></div></div>"},"91541":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of rounded atelectasis","title":"Chest radiograph of rounded atelectasis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of rounded atelectasis</div><div class=\"cntnt\"><img style=\"width:511px; height:327px;\" src=\"images/PULM/91541_Chst_radio_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal and lateral chest radiographs showing a right posterobasal, subpleural mass with connecting strands to the hilar region, resembling a comet-tail, consistent with rounded atelectasis.</div><div id=\"graphicVersion\">Graphic 91541 Version 1.0</div></div></div>"},"91542":{"type":"graphic_diagnosticimage","displayName":"Malignant pleural mesothelioma","title":"Chest radiograph of malignant pleural mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of malignant pleural mesothelioma</div><div class=\"cntnt\"><img style=\"width:430px; height:434px;\" src=\"images/PULM/91542_Malign_pleur_mesothelioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a patient with malignant mesothelioma&nbsp;shows multiple confluent right-sided nodular pleural masses carpeting the parietal and mediastinal pleura.</div><div id=\"graphicVersion\">Graphic 91542 Version 1.0</div></div></div>"},"91543":{"type":"graphic_diagnosticimage","displayName":"Siderosis in arc welder","title":"Chest radiograph and biopsy of siderosis (iron dust pneumoconiosis) in an arc welder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and biopsy of siderosis (iron dust pneumoconiosis) in an arc welder</div><div class=\"cntnt\"><img style=\"width:429px; height:420px;\" src=\"images/PULM/91543_Siderosis_arc_welder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from an arc welder with coarse reticular opacities seen throughout both lungs. Biopsy stained with Prussian blue shows iron pigment throughout the specimen.</div><div id=\"graphicVersion\">Graphic 91543 Version 1.0</div></div></div>"},"91544":{"type":"graphic_diagnosticimage","displayName":"CT scan bronchiolitis obliterans","title":"Computed tomogram of bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomogram of bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:352px; height:239px;\" src=\"images/PULM/91544_CT_scn_bronchiolitis_oblit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) image of a patient with bronchiolitis obliterans. A mosaic pattern of attenuation is present in which higher attenuation indicates normal lung with relatively greater perfusion, whereas lower attenuation areas are caused by air trapping and hypoxic vasoconstriction in areas with narrowed small airways.</div><div id=\"graphicVersion\">Graphic 91544 Version 1.0</div></div></div>"},"91545":{"type":"graphic_diagnosticimage","displayName":"Coal workers pneumoconiosis","title":"Chest radiograph of coal workers' pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of coal workers' pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:430px; height:392px;\" src=\"images/PULM/91545_Coal_workrs_pneumoconiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a coal worker shows multiple small, rounded opacities of the p (&le;1.5 mm) and q (1.6 to 3 mm) type.</div><div id=\"graphicVersion\">Graphic 91545 Version 1.0</div></div></div>"},"91546":{"type":"graphic_diagnosticimage","displayName":"CT coal workers pneumoconiosis","title":"Computed tomography (CT) of coal worker's pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) of coal worker's pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:283px; height:363px;\" src=\"images/PULM/91546_CT_coal_wrk_pneumoconiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomogram (CT) in a patient with coal worker's pneumoconiosis showing multiple centrilobular nodules.</div><div id=\"graphicVersion\">Graphic 91546 Version 1.0</div></div></div>"},"91547":{"type":"graphic_diagnosticimage","displayName":"Benign asbestos pleural effusion","title":"Chest radiograph of benign asbestos pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of benign asbestos pleural effusion</div><div class=\"cntnt\"><img style=\"width:423px; height:437px;\" src=\"images/PULM/91547_Benig_asbest_pleural_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with a history of asbestos exposure&nbsp;shows blunting of the right costophrenic sulcus due to a pleural effusion and bilateral pleural thickening due primarily to visceral pleural fibrosis.</div><div id=\"graphicVersion\">Graphic 91547 Version 1.0</div></div></div>"},"91548":{"type":"graphic_table","displayName":"Likely DPD phenotype based on genotype and recommended FU dose","title":"Likely DPD phenotype based on genotype and recommended dosing of fluoropyrimidines by DPD phenotype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likely DPD phenotype based on genotype and recommended dosing of fluoropyrimidines by DPD phenotype</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Likely phenotype</td> <td class=\"subtitle1\">Genotypes</td> <td class=\"subtitle1\">Examples of diplotypes</td> <td class=\"subtitle1\">Implications for phenotypic measures</td> <td class=\"subtitle1\">Dosing recommendations</td> </tr> <tr> <td>Homozygous for wild-type allele or normal, high DPD activity</td> <td>An individual carrying two or more functional (*1) alleles</td> <td>*1/*1</td> <td>Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity</td> <td>Use label-recommended dosage and administration</td> </tr> <tr> <td>Heterozygote or intermediate activity (approximately 3 to 5 percent of patients); may have partial DPD deficiency; at risk for toxicity with drug exposure</td> <td>An individual carrying one functional allele (*1) plus one nonfunctional allele (*2A, *13, or *9B)</td> <td>*1/*2A; *1/*13; or *1/*9B</td> <td>Decreased DPD activity (leukocyte DPD activity at 30 to 70 percent that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td> <td>Start with at least a 50 percent reduction in starting dose, followed by titration of dose based on toxicity<sup>&#182;</sup> or pharmacokinetic test (if available)</td> </tr> <tr> <td>Homozygous variant or mutant; DPD deficiency (approximately 0.2 percent of patients); at risk for toxicity with drug exposure</td> <td>An individual carrying two nonfunctional alleles (*2A, *13, or *9B)</td> <td>*2A/*2A; *13/*13; or *9B/*9B</td> <td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td> <td>Select alternative drug</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DPD: dihydropyrimidine dehydrogenase; fluoropyrimidines: fluorouracil, capecitabine, and tegafur.<br />¶ Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Clinical pharmacology and therapeutics. Caudle KE, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94:640. Copyright &copy; 2013. <a href=\"http://www.nature.com/clpt\" target=\"_blank\">www.nature.com/clpt</a>.</div><div id=\"graphicVersion\">Graphic 91548 Version 4.0</div></div></div>"},"91549":{"type":"graphic_picture","displayName":"Shoulder pad sign and wrist amyloid deposits beta2m","title":"Shoulder pad sign and wrist and hand amyloid deposits in a patient with beta<sub>2</sub>-m amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Shoulder pad sign and wrist and hand amyloid deposits in a patient with beta<sub>2</sub>-m amyloidosis</div><div class=\"cntnt\"><img style=\"width:567px; height:722px;\" src=\"images/NEPH/91549_Shldr_sgn_wrst_amyld_bt2m.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bilateral shoulder pads in a patient with beta<sub>2</sub>-microglobulin amyloidosis who was receiving long-term hemodialysis.<br />(B) Fixed flexion contractures of the fingers due to beta<sub>2</sub>-microglobulin amyloid deposits in the hand of a patient receiving long-term hemodialysis. Amyloid deposits, appearing as soft tissue fullness around the wrist, resulted in carpal tunnel syndrome and atrophy of the thenar muscle.</div><div class=\"graphic_reference\">Reproduced from Kay J. Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. Cleve Clin J Med 1999; 66:145-147. With permission from The Cleveland Clinic Foundation. &copy; 1999 The Cleveland Clinic Foundation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91549 Version 1.0</div></div></div>"},"91550":{"type":"graphic_diagnosticimage","displayName":"beta2m amyloidosis wrist radiograph","title":"Wrist radiograph of a patient with beta<sub>2</sub>-microglobulin amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Wrist radiograph of a patient with beta<sub>2</sub>-microglobulin amyloidosis</div><div class=\"cntnt\"><img style=\"width:712px; height:702px;\" src=\"images/NEPH/91550_beta2m_amyldss_wrst_rdgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wrist radiograph of a patient with beta<sub>2</sub>-microglobulin amyloidosis who was on long-term hemodialysis, showing cysts in the carpal bones (small arrows) and the distal radius (large arrow).</div><div class=\"graphic_reference\">Reproduced from Kay J. Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. Cleve Clin J Med 1999; 66:145-147. With permission from The Cleveland Clinic Foundation. &copy; 1999 The Cleveland Clinic Foundation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91550 Version 1.0</div></div></div>"},"91554":{"type":"graphic_form","displayName":"ILO form for pneumoconiosis","title":"International Labour Organization form for classification of chest radiographs in suspected pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">International Labour Organization form for classification of chest radiographs in suspected pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:670px; height:2049px;\" src=\"images/PULM/91554_ILO_form_pneumoconiosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The International Labour Organization (ILO) form for classification of chest radiograph features in suspected pneumoconiosis has been adapted for use by the United States Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health.</div><div class=\"graphic_reference\">Reproduced from: National Institute for Occupational Safety and Health. Workplace Safety &amp; Health Topics. Chest Radiology: ILO Classification. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/niosh/topics/chestradiography/ilo.html\" target=\"_blank\">http://www.cdc.gov/niosh/topics/chestradiography/ilo.html</a> (Accessed on July 31, 2014).</div><div id=\"graphicVersion\">Graphic 91554 Version 1.0</div></div></div>"},"91555":{"type":"graphic_figure","displayName":"ILO description of radiographic features A","title":"ILO description of radiographic features of pneumoconioses A","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">ILO description of radiographic features of pneumoconioses A</div><div class=\"cntnt\"><img style=\"width:472px; height:726px;\" src=\"images/PULM/91555_ILO_descript_radiograph_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synopsis of parameters and additional symbols that are noted and graded on the International Labour Organization (ILO) pneumoconiosis form.</div><div class=\"graphic_footnotes\">R: regular; I: irregular; p, q, r, s, t, u: these designations refer to the size and shape of nodules; qq: all nodules are described by q (small, rounded nodules with diameter 1.5 up to about 3 mm); tt: all nodules are described by t (irregular nodules with diameter 1.5 up to about 3 mm); qt: mix of q and t with q predominating; tq: mix of t and q nodules with t predominating; RUZ: right upper lung zone size.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91555 Version 1.0</div></div></div>"},"91556":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph p nodules","title":"Standard chest ILO radiograph of small \"p\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard chest ILO radiograph of small \"p\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:394px;\" src=\"images/PULM/91556_ILO_radiograph_p_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating a profusion of small, rounded opacities designated \"p\" for &le;1.5 mm. The ILO description of this radiograph is \"p/p\" meaning that all or virtually all of the opacities are size \"p\"; if most of the opacities are \"p\", but some are \"q\", then the designation \"p/q\" would be used. The scale for the concentration of opacities ranges from \"0\", meaning no opacities, to \"3\", meaning profuse. The degree of profusion of the small opacities in this radiograph is designated \"3/3\", as the profusion is exactly consistent with \"3\". If the reader thought the profusion looked mostly like a standard \"3\", but also considered the possibility that it was consistent with a standard radiograph with a profusion of \"2\", the profusion would be designated \"3/2\".</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91556 Version 1.0</div></div></div>"},"91557":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph q nodules","title":"Standard chest ILO radiograph of small \"q\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard chest ILO radiograph of small \"q\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:407px;\" src=\"images/PULM/91557_ILO_radiograph_q_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating a profusion of small, rounded opacities designated \"q\" for 1.6 to 3 mm. The ILO description of this radiograph is \"q/q\" meaning that all or virtually all of the opacities are size \"q\"; if most of the opacities are \"q\", but some are \"r\", then the designation \"q/r\" would be used. The scale for the concentration of opacities ranges from \"0\", meaning no opacities, to \"3\", meaning profuse. The degree of profusion of the small opacities in this radiograph is designated \"3/3\", as the profusion is exactly consistent with \"3\". If the reader thought the profusion looked mostly like a standard \"3\", but also considered the possibility that it was consistent with a standard radiograph with a profusion of \"2\", the profusion would be designated \"3/2\".</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91557 Version 1.0</div></div></div>"},"91558":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph r nodules","title":"Standard ILO chest radiograph of small \"r\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard ILO chest radiograph of small \"r\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:408px;\" src=\"images/PULM/91558_ILO_radiograph_r_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating a profusion of small, rounded opacities designated \"r\" for &gt;3 to 10 mm. The ILO description of this radiograph is \"r/r\" meaning that all or virtually all of the opacities are size \"r\". However, if the opacities were of different sizes (eg, r and q), the first letter would reflect the most frequent size and the second letter the less frequent size. Thus, if most of the opacities are \"r\", but some are \"q\", the designation \"r/q\" would be used. The degree of profusion of the small opacities in this radiograph is designated \"3/3\", as the profusion is exactly consistent with a standard \"3\". The ILO scale for the concentration of opacities ranges from \"0\", meaning no opacities, to \"3\", meaning profuse. If the reader thought the profusion was between \"3\" and \"2\", but closest to \"3\", the designation \"3/2\" would be used for profusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91558 Version 1.0</div></div></div>"},"91559":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph A nodules","title":"Standard ILO chest radiograph of large \"A\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard ILO chest radiograph of large \"A\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:420px;\" src=\"images/PULM/91559_ILO_radiograph_A_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating a large nodular opacity designated category \"A\" for &le;50 mm.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91559 Version 1.0</div></div></div>"},"91560":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph B nodules","title":"Standard ILO chest radiograph of large \"B\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard ILO chest radiograph of large \"B\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:466px;\" src=\"images/PULM/91560_ILO_radiograph_B_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating bilateral upper lung zone large nodular opacities designated category \"B\" for &gt;50 mm but not larger than size of right upper lung zone.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91560 Version 1.0</div></div></div>"},"91561":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph C nodules","title":"Standard ILO chest radiograph of large \"C\" nodular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard ILO chest radiograph of large \"C\" nodular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:405px;\" src=\"images/PULM/91561_ILO_radiograph_C_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating bilateral large nodular opacities designated category \"C\" for larger than the size of the right upper lung zone.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91561 Version 1.0</div></div></div>"},"91562":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph s nodules","title":"Standard chest ILO radiograph of small \"s\" irregular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard chest ILO radiograph of small \"s\" irregular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:444px;\" src=\"images/PULM/91562_ILO_radiograph_s_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating small irregular opacities of the profusion and type, \"3/3\" and \"s/s\", typical for asbestosis. The scale for the concentration of opacities ranges from \"0\", meaning no opacities, to \"3\", meaning profuse. The degree of profusion of the irregular opacities in this radiograph is designated \"3/3\", as the profusion is exactly consistent with \"3\". If the reader thought the profusion looked mostly like a standard \"3\", but also considered the possibility that it was consistent with a standard radiograph with a profusion of \"2\", the profusion would be designated \"3/2\". The \"s\" designation refers to opacities with a width of ≤1.5 mm. The ILO description of \"s/s\" means that all or virtually all of the opacities are width \"s\".</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91562 Version 1.0</div></div></div>"},"91563":{"type":"graphic_diagnosticimage","displayName":"ILO radiograph t nodules","title":"Standard chest ILO radiograph of small \"t\" irregular opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard chest ILO radiograph of small \"t\" irregular opacities</div><div class=\"cntnt\"><img style=\"width:432px; height:377px;\" src=\"images/PULM/91563_ILO_radiograph_t_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a standard International Labour Organization (ILO) radiograph demonstrating small irregular opacities of the profusion and type, \"3/3 t/t\", typical for asbestosis. The degree of profusion of the irregular opacities in this radiograph is designated \"3/3\", using the ILO scale for the concentration of opacities that ranges from \"0\", meaning no opacities, to \"3\", meaning profuse. The \"t\" designation refers to irregular opacities with a width of 1.6 to 3 mm. The ILO description of \"t/t\" means that all or virtually all of the opacities are size \"t\". In contrast, if most of the opacities were \"t\", but some were \"s\", then the designation \"t/s\" would be used.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses: ILO Standard Digital Images (ILO 2011-D) in DICOM Format. Copyright &copy; 2011 International Labour Organization. Available at: <a href=\"http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm\" target=\"_blank\">http://www.ilo.org/safework/info/publications/WCMS_168337/lang--en/index.htm</a>.</div><div id=\"graphicVersion\">Graphic 91563 Version 1.0</div></div></div>"},"91565":{"type":"graphic_picture","displayName":"Direct immunofluorescence of lupus erythematosus","title":"Direct immunofluorescence of skin in lupus erythematosus (lupus band test)","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence of skin in lupus erythematosus (lupus band test)</div><div class=\"cntnt\"><img style=\"width:570px; height:576px;\" src=\"images/DERM/91565_Directimmunofllupuseryth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granular deposits of immunoglobulin G in the basement membrane zone on direct immunofluorescence of lesional skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Winfield H, Jaworsky C. Connective tissue diseases. In: Lever's Histopathology of the Skin, 10th ed, Elenitsas R, Johnson BL JR, Murphy GF, Xu X (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 91565 Version 5.0</div></div></div>"},"91570":{"type":"graphic_table","displayName":"Stretches to improve iliotibial band mobility","title":"Stretches to improve iliotibial band mobility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stretches to improve iliotibial band mobility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Iliotibial band stretches include the following:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Standing stretch: Done standing 40 to 60 cm from a wall, with affected side facing towards wall. Athlete places affected leg behind unaffected leg, then brings legs towards each other and advances hind foot so that toes are nearly aligned (\"legs tightly crossed\"). Push the hip of the affected leg towards wall. The arm of the affected side may be extended towards the wall to help maintain balance and to accentuate the stretch. </li> <li>Arms-overhead stretch: Similar to standing stretch, except both arms are raised directly overhead, then directed away from side being stretched (body roughly approximates the shape of a \"C\"). </li> <li>Forward-lean stretch: Start with legs placed in same manner as for standing stretch. Then lean forward at the waist until fingers are near ankles or toes. Reach fingers towards unaffected side to accentuate stretch. </li> </ul> </td> </tr> <tr> <td>Have the patient choose one or two of these stretches and perform two stretching sessions daily. Hold each stretch for 30-40 seconds, and repeat (ie, for each exercise chosen, perform two stretches per session, and two sessions per day). After three to four weeks, the sessions can be reduced to once daily. After recovery, continue to perform stretches at least three times per week indefinitely.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Sources:<br /><ol>&#xD;&#xA;    <li>Fredericson M, White JJ, Macmahon JM, et al. Quantitative analysis of the relative effectiveness of 3 iliotibial band stretches. Arch Phys Med Rehabil 2002; 83:589.</li>&#xD;&#xA;    <li>Fredericson M, Cookingham CL, Chaudhari AM, et al. Hip abductor weakness in distance runners with iliotibial band syndrome. Clin J Sport Med 2000; 10:169.</li>&#xD;&#xA;    <li>Fredericson M, Weir A. Practical management of iliotibial band friction syndrome in runners. Clin J Sport Med 2006; 16:261.</li>&#xD;&#xA;    <li>Baker RL, Souza RB, Fredericson M. Iliotibial band syndrome: soft tissue and biomechanical factors in evaluation and treatment. PM R. 2011; 3:550.</li>&#xD;&#xA;    <li>Jenkins J, Beazell J. Flexibility for runners. Clin Sports Med 2010; 29:365.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 91570 Version 2.0</div></div></div>"},"91571":{"type":"graphic_table","displayName":"Berlin questionnaire","title":"Berlin questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Berlin questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <p>Height (m) <sub>__________</sub> Weight (kg) <sub>__________</sub> Age <sub>__________</sub> Male/Female</p> <p>Please choose the correct response to each question.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Category 1</strong></td> <td> <p><strong>1. Do you snore?</strong></p> <p class=\"indent2\">_ a. Yes</p> <p class=\"indent2\">_ b. No</p> <p class=\"indent2\">_ c. Don't know</p> <p class=\"indent1\"><em>If you snore:</em></p> <p class=\"indent2\"><strong>2. Your snoring is:</strong></p> <p class=\"indent4\">_ a. Slightly louder than breathing</p> <p class=\"indent4\">_ b. As loud as talking</p> <p class=\"indent4\">_ c. Louder than talking</p> <p class=\"indent4\">_ d. Very loud &ndash; can be heard in adjacent rooms</p> <p class=\"indent2\"><strong>3. How often do you snore</strong></p> <p class=\"indent4\">_ a. Nearly every day</p> <p class=\"indent4\">_ b.&nbsp;Three to four&nbsp;times a week</p> <p class=\"indent4\">_ c.&nbsp;One to two&nbsp;times a week</p> <p class=\"indent4\">_ d.&nbsp;One to two&nbsp;times a month</p> <p class=\"indent4\">_ e. Never or nearly never</p> <p class=\"indent2\"><strong>4. Has your snoring ever bothered other people?</strong></p> <p class=\"indent4\">_ a. Yes</p> <p class=\"indent4\">_ b. No</p> <p class=\"indent4\">_ c. Don't know</p> <p class=\"indent2\"><strong>5. Has anyone noticed that you quit breathing during your sleep?</strong></p> <p class=\"indent4\">_ a. Nearly every day</p> <p class=\"indent4\">_ b.&nbsp;Three to four&nbsp;times a week</p> <p class=\"indent4\">_ c.&nbsp;One to two&nbsp;times a week</p> <p class=\"indent4\">_ d.&nbsp;One to two&nbsp;times a month</p> <p class=\"indent4\">_ e. Never or nearly never</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Category 2</strong></td> <td> <p><strong>6. How often do you feel tired or fatigued after your sleep?</strong></p> <p class=\"indent2\">_ a. Nearly every day</p> <p class=\"indent2\">_ b.&nbsp;Three to four&nbsp;times a week</p> <p class=\"indent2\">_ c.&nbsp;One to two&nbsp;times a week</p> <p class=\"indent2\">_ d.&nbsp;One to two&nbsp;times a month</p> <p class=\"indent2\">_ e. Never or nearly never</p> <p><strong>7. During your waking time, do you feel tired, fatigued or not up to par?</strong></p> <p class=\"indent2\">_ a. Nearly every day</p> <p class=\"indent2\">_ b.&nbsp;Three to four&nbsp;times a week</p> <p class=\"indent2\">_ c.&nbsp;One to two&nbsp;times a week</p> <p class=\"indent2\">_ d.&nbsp;One to two&nbsp;times a month</p> <p class=\"indent2\">_ e. Never or nearly never</p> <p><strong>8. Have you ever nodded off or fallen asleep while driving a vehicle?</strong></p> <p class=\"indent2\">_ a. Yes</p> <p class=\"indent2\">_ b. No</p> <p class=\"indent1\"><em>If yes:</em></p> <p class=\"indent2\"><strong>9. How often does this occur?</strong></p> <p class=\"indent4\">_ a. Nearly every day</p> <p class=\"indent4\">_ b.&nbsp;Three to four&nbsp;times a week</p> <p class=\"indent4\">_ c.&nbsp;One to two&nbsp;times a week</p> <p class=\"indent4\">_ d.&nbsp;One to two&nbsp;times a month</p> <p class=\"indent4\">_ e. Never or nearly never</p> </td> </tr> <tr> <td class=\"highlight_gray_text\"><strong>Category 3</strong></td> <td> <p><strong>10. Do you have high blood pressure?</strong></p> <p class=\"indent2\">_ Yes</p> <p class=\"indent2\">_ No</p> <p class=\"indent2\">_ Don't know</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Netzer NC, Stoohs RA, Netzer CM, et al, Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome, Vol 131, Pg 485. Copyright © 1999 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 91571 Version 6.0</div></div></div>"},"91572":{"type":"graphic_table","displayName":"Hip abductor strengthening exercises","title":"Hip abductor strengthening exercises","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hip abductor strengthening exercises</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Single shallow knee bend:</strong> Patient stands on one foot, slowly bends knee to 20 degrees flexion by \"sitting\" slightly, then returns to starting position. Limiting knee flexion keeps knee from extending beyond toes in sagittal plane, which can exacerbate patellofemoral symptoms, and works the desired muscle group (gluteal more than quadriceps). Goal is to avoid any medial movement of the knee, and to keep upper trunk in a vertical position. <ul> <li>Perform 2 sets of 20 to 30 repetitions daily</li> <li>Strengthens gluteus medius and hip external rotators and develops proprioception</li> </ul> </td> </tr> <tr> <td><strong>Contralateral pelvic drop:</strong> Patient stands with foot of affected leg on stair or ledge; unaffected leg faces away from stair and remains non-weight-bearing throughout exercise. Begin with unaffected hip elevated (pelvis tilted \"unaffected side up,\" affected hip is abducted). Slowly drop non-weighted hip so that pelvis is tilted to \"unaffected side down\" (eccentric abduction leading to adducted position of affected hip). Then slowly tilt unaffected hip back up to starting position (concentric abduction of affected hip). <ul> <li>Build to 2 to 3 sets of 20 to 30 repetitions daily</li> <li>Strengthens gluteus medius</li> </ul> </td> </tr> <tr> <td><strong>One of the following (hip abduction exercises)</strong> <ul> <li>Side-lying abduction: Patient lies on unaffected side and raises affected leg to 30 degrees abduction (avoiding hip internal/external rotation), then slowly returns to starting position. Start with abducting leg against gravity. When this is easy, add ankle-weight. <ul> <li>Perform 2 sets of 20 repetitions daily</li> <li>Strengthens gluteus medius</li> </ul> </li> </ul> <ul> <li>Standing abduction: Patient tethers exercise band to low anchor then loops other end of band around ankle of affected side. Patient abducts leg away from band anchor to 20 to 30 degrees abduction, creating moderate tension on band, then (focusing on slow, controlled motion) slowly returns to starting position. <ul> <li>Perform 2 sets of 20 repetitions daily</li> <li>Strengthens gluteus medius</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91572 Version 1.0</div></div></div>"},"91573":{"type":"graphic_picture","displayName":"Bicycle seat height and ITBS","title":"Bicycle seat height and ITBS","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Bicycle seat height and ITBS</div><div class=\"cntnt\"><img style=\"width:525px; height:312px;\" src=\"images/EM/91573_Bicycle_st_height_ITBS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An elevated seat position may exacerbate ITBS.<br />(B) A lower seat position may help patients with ITBS. Note the seat position relative to the top tube of the frame, and compare this position to that of the elevated seat.</div><div class=\"graphic_footnotes\">ITBS: Iliotibial band syndrome</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 91573 Version 1.0</div></div></div>"},"91574":{"type":"graphic_picture","displayName":"Bicycle seat position and ITBS","title":"Bicycle seat position and ITBS","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Bicycle seat position and ITBS</div><div class=\"cntnt\"><img style=\"width:522px; height:182px;\" src=\"images/EM/91574_Bicycle_st_psition_ITBS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An aft saddle position may exacerbate ITBS. Note the saddle position relative to the seat post.<br />(B) A forward seat position may help patients with ITBS. Note the saddle position relative to the seat post and compare to accompanying photo of an aft saddle position.</div><div class=\"graphic_footnotes\">ITBS: Iliotibial band syndrome</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 91574 Version 1.0</div></div></div>"},"91576":{"type":"graphic_table","displayName":"Known cardiovascular disease and similar risk","title":"Known cardiovascular disease and similar risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Known cardiovascular disease and similar risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with the following are at high risk for a second (or first) cardiovascular disease event:</td> </tr> <tr> <td class=\"indent1\">Coronary heart disease</td> </tr> <tr> <td class=\"indent2\">Myocardial infarction</td> </tr> <tr> <td class=\"indent2\">Angina</td> </tr> <tr> <td class=\"indent2\">Coronary revascularization</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular disease</td> </tr> <tr> <td class=\"indent2\">Stroke</td> </tr> <tr> <td class=\"indent2\">Transient ischemic attack</td> </tr> <tr> <td class=\"indent1\">Peripheral arterial disease</td> </tr> <tr> <td class=\"indent1\">Multiple risk factors that confer a 10-year risk of CVD &#62;20%</td> </tr> <tr> <td class=\"indent1\">Chronic kidney disease with estimated GFR &#60;45 mL/min per 1.73 m<sup>2</sup>*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CVD: cardiovascular disease; GFR: glomerular filtration rate.<br />* Statin doses may require adjustment in patients with chronic kidney disease.</div><div id=\"graphicVersion\">Graphic 91576 Version 3.0</div></div></div>"},"91577":{"type":"graphic_figure","displayName":"Iliotibial band function","title":"Iliotibial band (ITB) function","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Iliotibial band (ITB) function</div><div class=\"cntnt\"><img style=\"width:678px; height:650px;\" src=\"images/EM/91577_Iliotibialbandfunction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustrations demonstrating how the function of the iliotibial band (ITB) depends on the position of the knee.<br />(A) With the knee in extension, the ITB lies anterior to the lateral femoral epicondyle and serves as an active knee extensor.<br />(B) At 20&deg; to 30&deg; of flexion, the ITB assumes a posterior position relative to the lateral femoral epicondyle and becomes an active knee flexor.</div><div class=\"graphic_reference\">From: Strauss EJ, Kim S, Calcei JG, Park D. Iliotibial band syndrome: Evaluation and management. J Am Acad Orthop Surg 2011; 19:728. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2011 American Academy of Orthopaedic Surgeons. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91577 Version 2.0</div></div></div>"},"91578":{"type":"graphic_figure","displayName":"Hip abductor strength test","title":"Hip abductor strength test","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Hip abductor strength test</div><div class=\"cntnt\"><img style=\"width:588px; height:359px;\" src=\"images/EM/91578_Hip_abductor_strength_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weakness of the hip abductors contributes to a number of conditions, including iliotibial band syndrome. The lateral side leg raise against manual resistance is one test used to assess the strength of the hip abductors.</div><div class=\"graphic_reference\">From: Fredericson M, Cookingham CL, Chaudhari AM, et al. Hip abductor weakness in distance runners with iliotibial band syndrome. Clin J Sport Med 2000; 10:169. Copyright © 2000 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91578 Version 3.0</div></div></div>"},"91579":{"type":"graphic_figure","displayName":"ITB standing stretch","title":"Iliotibial band (ITB) standing stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iliotibial band (ITB) standing stretch</div><div class=\"cntnt\"><img style=\"width:390px; height:590px;\" src=\"images/EM/91579_ITB_standing_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The standing ITB stretch is performed by placing the&nbsp;affected leg behind the unaffected leg, then bringing the&nbsp;legs towards each other&nbsp;by advancing the&nbsp;hind foot so the toes of both feet are nearly aligned (\"legs tightly crossed\"). From this position, push the hip of the affected leg towards the wall. A stretching sensation should be appreciated over the ITB and lateral thigh of the posterior leg.</div><div class=\"graphic_reference\">From: Fredericson M, Cookingham CL, Chaudhari AM, et al. Hip abductor weakness in distance runners with iliotibial band syndrome. Clin J Sport Med 2000; 10:169. Copyright © 2000 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91579 Version 4.0</div></div></div>"},"91580":{"type":"graphic_figure","displayName":"Side lying abduction","title":"Side lying abduction","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Side lying abduction</div><div class=\"cntnt\"><img style=\"width:598px; height:494px;\" src=\"images/EM/91580_Side_lying_abduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The side-lying abduction exercise is performed with the patient laying on the unaffected side. The patient&nbsp;raises the affected leg to approximately 30 degrees of&nbsp;abduction, while avoiding hip internal or external rotation, and&nbsp;then slowly returns to starting position.&nbsp;Begin by&nbsp;abducting the&nbsp;leg against gravity, and when this becomes easy add ankle weights, increasing the resistance gradually. Photograph A above shows the start position and B the end position.</div><div class=\"graphic_reference\">From: Fredericson M, Cookingham CL, Chaudhari AM, et al. Hip abductor weakness in distance runners with iliotibial band syndrome. Clin J Sport Med 2000; 10:169. Copyright © 2000 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91580 Version 3.0</div></div></div>"},"91581":{"type":"graphic_figure","displayName":"Pelvic drop exercise","title":"Pelvic drop exercise","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Pelvic drop exercise</div><div class=\"cntnt\"><img style=\"width:455px; height:599px;\" src=\"images/EM/91581_Pelvic_drop_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the pelvic drop exercise, stand with the foot of the affected leg on a stair, ledge, or other raised surface; the unaffected leg faces away from stair and remains non-weight-bearing throughout exercise. Begin with the unaffected hip elevated (pelvis tilted \"unaffected side up\"). Slowly&nbsp;lower the unaffected&nbsp;hip until the pelvis is tilted \"unaffected side down.\" Then slowly&nbsp;raise the&nbsp;unaffected hip back to the starting position. Photograph A above shows the&nbsp;starting position and B the end position.</div><div class=\"graphic_reference\">From: Fredericson M, Cookingham CL, Chaudhari AM, et al. Hip abductor weakness in distance runners with iliotibial band syndrome. Clin J Sport Med 2000; 10:169. Copyright © 2000 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91581 Version 3.0</div></div></div>"},"91582":{"type":"graphic_picture","displayName":"ITB standing and bending stretches","title":"ITB standing and bending stretches","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">ITB standing and bending stretches</div><div class=\"cntnt\"><img style=\"width:724px; height:549px;\" src=\"images/EM/91582_ITB_stnd_strtch_bend_strtch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standing and bending stretches of the ITB are used. The positioning for each stretch&nbsp;involves placing the&nbsp;affected leg behind the unaffected leg, then&nbsp;advancing the&nbsp;hind foot so the toes of both feet are nearly aligned (\"legs tightly crossed\"). From this position, a stretch is created by gradually driving the hip of the affected leg towards&nbsp;it's own&nbsp;side. A stretching sensation should be appreciated over the ITB and lateral thigh of the posterior leg.</div><div class=\"graphic_reference\">Reproduced with permission from: Fredericson M, Guillet M, Debenedictis L. Innovative solutions for iliotibial band syndrome. Phys Sports Med. 2000;28:52. Copyright &copy; 2000 Informa PLC.</div><div id=\"graphicVersion\">Graphic 91582 Version 2.0</div></div></div>"},"91583":{"type":"graphic_figure","displayName":"Foam roll mobilization of lateral thigh","title":"Foam roll mobilization of lateral thigh","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Foam roll mobilization of lateral thigh</div><div class=\"cntnt\"><img style=\"width:475px; height:312px;\" src=\"images/EM/91583_Foam_roll_mobilization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A foam roller can be used to mobilize soft tissue and break up adhesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Fredericson M, Guillet M, Debenedictis L. Innovative solutions for iliotibial band syndrome. Phys Sports Med. 2000;28:52. Copyright &copy; 2000 Informa PLC.</div><div id=\"graphicVersion\">Graphic 91583 Version 1.0</div></div></div>"},"91584":{"type":"graphic_figure","displayName":"Standing hip abduction exercise against resistance","title":"Standing hip abduction exercise against resistance","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Standing hip abduction exercise against resistance</div><div class=\"cntnt\"><img style=\"width:488px; height:560px;\" src=\"images/EM/91584_Hip_abduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Lalonde F. Iliotibial band syndrome: Noninvasive solutions for runners. ACSM Health &amp; Fitness J 2013; 17:9. DOI: <A href=\"http://journals.lww.com/acsm-healthfitness/Abstract/2013/09000/Iliotibial_Band_Syndrome__Noninvasive_Solutions.5.aspx\" target=_blank>10.1249/FIT.0b013e3182a0671a</A>. Copyright © 2013 American College of Sports Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91584 Version 4.0</div></div></div>"},"91604":{"type":"graphic_table","displayName":"Risk factors hepatic SOS","title":"Risk factors for hepatic sinusoidal obstruction syndrome (veno-occlusive disease)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for hepatic sinusoidal obstruction syndrome (veno-occlusive disease)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient factors</td> </tr> <tr> <td class=\"indent1\">Younger age in children</td> </tr> <tr> <td class=\"indent1\">Older age in adults</td> </tr> <tr> <td class=\"indent1\">Poor performance status</td> </tr> <tr> <td class=\"indent1\">Glutathione S-transferase M1 null genotype</td> </tr> <tr> <td class=\"indent1\">Hemochromatosis C282Y allele</td> </tr> <tr> <td class=\"indent1\">Pre-existing hepatic dysfunction</td> </tr> <tr> <td class=\"indent1\">Hypoalbuminemia</td> </tr> <tr> <td class=\"indent1\">Hyperbilirubinemia</td> </tr> <tr> <td class=\"indent1\">High serum ferritin</td> </tr> <tr> <td class=\"indent1\">Positive CMV serology</td> </tr> <tr> <td class=\"indent1\">Elevated plasma transforming growth factor &#946; level</td> </tr> <tr> <td class=\"indent1\">Hepatitis B or C infection</td> </tr> <tr> <td class=\"indent1\">History of pancreatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Disease factors</td> </tr> <tr> <td class=\"indent1\">Thalassemia major</td> </tr> <tr> <td class=\"indent1\">Advanced malignancy</td> </tr> <tr> <td class=\"indent1\">Acute leukemia</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma</td> </tr> <tr> <td class=\"indent1\">Delayed platelet engraftment</td> </tr> <tr> <td class=\"indent1\">Presence of acute graft-versus-host disease</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment factors</td> </tr> <tr> <td class=\"indent1\">Interval between diagnosis and transplantation greater than 13 months</td> </tr> <tr> <td class=\"indent1\">Allogeneic HCT</td> </tr> <tr> <td class=\"indent1\">Unrelated donor HCT</td> </tr> <tr> <td class=\"indent1\">Mismatched donor</td> </tr> <tr> <td class=\"indent1\">Second or subsequent transplants</td> </tr> <tr> <td class=\"indent1\">Prior use of gemtuzumab ozogamicin</td> </tr> <tr> <td class=\"indent1\">Prior use of norethisterone</td> </tr> <tr> <td class=\"indent1\">Prior abdominal irradiation</td> </tr> <tr> <td class=\"indent1\">Use of total parenteral nutrition within 30 days before HCT</td> </tr> <tr> <td class=\"indent1\">High dose cytoreductive therapy</td> </tr> <tr> <td class=\"indent1\">Conditioning regimen containing busulfan with or without cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Conditioning regimen containing fludarabine</td> </tr> <tr> <td class=\"indent1\">Conditioning regimen containing melphalan</td> </tr> <tr> <td class=\"indent1\">Total body irradiation</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease prophylaxis with cyclosporin with or without methotrexate</td> </tr> <tr> <td class=\"indent1\">Use of sirolimus</td> </tr> <tr> <td class=\"indent1\">Use of tranexamic acid</td> </tr> <tr> <td class=\"indent1\">Platelet transfusion containing ABO-incompatible plasma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; HCT: hematopoietic cell transplantation.</div><div class=\"graphic_reference\">Modified with permission from: Cheuk DK. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies. World J Transplant 2012; 2:27. Copyright © 2012 Baishideng Publishing Group Co., Limited.</div><div id=\"graphicVersion\">Graphic 91604 Version 1.0</div></div></div>"},"91605":{"type":"graphic_waveform","displayName":"ECG SSS with sinus arrest","title":"Single-lead electrocardiogram (ECG) showing manifestations of sick sinus syndrome (SSS) with sinus arrest","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing manifestations of sick sinus syndrome (SSS) with sinus arrest</div><div class=\"cntnt\"><img style=\"width:550px; height:100px;\" src=\"images/CARD/91605_ECG_SSS_sinus_arrest.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of sick sinus syndrome (SSS). In this example, sinus arrest is seen with a junctional escape beat, a premature atrial complex, and eventual resumption of sinus activity.</div><div class=\"graphic_reference\">Courtesy of Alan Cheng, MD, FACC, FAHA, FHRS.</div><div id=\"graphicVersion\">Graphic 91605 Version 1.0</div></div></div>"},"91606":{"type":"graphic_waveform","displayName":"ECG SSS with ectopic atrial and junctional beats","title":"Single lead electrocardiogram (ECG) showing sick sinus syndrome (SSS) with ectopic atrial and junctional beats","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing sick sinus syndrome (SSS) with ectopic atrial and junctional beats</div><div class=\"cntnt\"><img style=\"width:485px; height:44px;\" src=\"images/CARD/91606_ECG_SSS_ectop_atrl_jnc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of sick sinus syndrome (SSS). In this example, sinus rhythm abruptly pauses, followed by two ectopic atrial beats, a junctional escape beat, and resumption of sinus activity.</div><div class=\"graphic_reference\">Courtesy of Alan Cheng, MD, FACC, FAHA, FHRS.</div><div id=\"graphicVersion\">Graphic 91606 Version 1.0</div></div></div>"},"91611":{"type":"graphic_table","displayName":"Pediatric donor management goals","title":"Pediatric donor management goals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric donor management goals</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Hemodynamic support</td> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Blood pressure (mmHg)</td> </tr> <tr> <td class=\"subtitle2\">Systolic*</td> <td class=\"subtitle2\">Diastolic</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"> <ul> <li>Normalization of blood pressure <ul> <li>Systolic blood pressure appropriate for age </li> <li><em>NOTE: Lower systolic blood pressures may be acceptable if biomarkers such as lactate are normal</em></li> </ul> </li> <li>CVP &#60;12 <em>(if measured)</em> </li> <li>Dopamine &#60;10 mcg/kg/min </li> <li>Normal serum lactate </li> </ul> </td> <td><strong>Neonate</strong></td> <td class=\"centered\">60-90</td> <td class=\"centered\">35-60</td> </tr> <tr> <td><strong>Infants</strong><br /> (6 months)</td> <td class=\"centered\">80-95</td> <td class=\"centered\">50-65</td> </tr> <tr> <td><strong>Toddler</strong><br /> (2 years)</td> <td class=\"centered\">85-100</td> <td class=\"centered\">50-65</td> </tr> <tr> <td><strong>School age</strong><br /> (7 years)</td> <td class=\"centered\">90-115</td> <td class=\"centered\">60-70</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Adolescent</strong><br /> (15 years)</td> <td class=\"centered\">110-130</td> <td class=\"centered\">65-80</td> </tr> <tr> <td class=\"subtitle1\">Oxygenation and ventilation</td> <td class=\"subtitle1\" colspan=\"3\">Fluids and electrolytes</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Maintain PaO<sub>2</sub> &#62;100 mmHg </li> <li>FiO<sub>2</sub> 0.40 </li> <li>Normalize PaCO<sub>2</sub> 35-45 mmHg </li> <li>Arterial pH 7.30-7.45 </li> <li>Tidal volumes 8-10 cc/kg </li> <li>PEEP 5 cm H<sub>2</sub>O </li> </ul> </td> <td colspan=\"3\"> <ul> <li>Serum Na<sup>+</sup> 130-150 mEq/L </li> <li>Serum K<sup>+</sup> 3-5 mEq/L </li> <li>Serum glucose 60-150 mg/dL </li> <li>Ionized Ca<sup>++</sup> <em>(if measured)</em> 0.8-1.2 mmol/L </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Thermal regulation</td> </tr> <tr> <td class=\"centered\" colspan=\"4\">Core body temperature 36-38&#176;C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CVP: central venous pressure; PaO<sub>2</sub>: arterial oxygen tension; PaCO<sub>2</sub>: arterial carbon dioxide tension; FiO<sub>2</sub>: fraction of inspired oxygen; PEEP: positive end-expiratory pressure.<br />* Normal systolic blood pressure = 80 + (age in years x 2).</div><div class=\"graphic_reference\">Reproduced with permission from: Nakagawa TA. Updated Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. Copyright &copy; 2008 NATCO.</div><div id=\"graphicVersion\">Graphic 91611 Version 2.0</div></div></div>"},"91612":{"type":"graphic_picture","displayName":"Inflammatory fibroid polyp","title":"Inflammatory fibroid polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory fibroid polyp</div><div class=\"cntnt\"><img style=\"width:377px; height:372px;\" src=\"images/GAST/91612_Inflamm_fibroid_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic view of an inflammatory fibroid polyp in the antrum showing a firm, well-circumscribed submucosal lesion.<br />(B) Histologically, a flattened, often eroded, gastric epithelium lines a compact aggregate of fibrous tissue mixed with inflammatory cells.<br />(C) Vessels usually are surrounded by a characteristic circumferential deposition of fibroblasts (onion skin), and the stroma contains myriad eosinophils.</div><div class=\"graphic_reference\">Reproduced from: Shaib YH, Rugge M, Graham DY, Genta RM. Management of gastric polyps: An endoscopy-based approach. Clin Gastroenterol Hepatol 2013; 11:1374. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91612 Version 1.0</div></div></div>"},"91618":{"type":"graphic_table","displayName":"Guidelines expert groups posttreatment surveil colorectal cancer","title":"Summary of professional guidelines regarding posttreatment surveillance for resected colon and rectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of professional guidelines regarding posttreatment surveillance for resected colon and rectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organization</td> <td class=\"subtitle1\">History and physical examination</td> <td class=\"subtitle1\">CEA testing</td> <td class=\"subtitle1\">CT scanning</td> <td class=\"subtitle1\">Endoscopic surveillance</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>ASCO<sup>[1]</sup> and CCO<sup>[2]</sup></td> <td>Every&nbsp;3 to&nbsp;6 months for 5 years</td> <td>Every 3 to 6 months for 5 years</td> <td>Abdomen and chest annually for 3 years; pelvis: rectal cancer only, annually for 3 to 5 years</td> <td>Colonoscopy at&nbsp;1 year*; subsequent studies dictated by prior findings. If negative, every&nbsp;5 years. Proctosigmoidoscopy every 6 months for 2 to 5 years if rectal cancer and no pelvic RT.</td> <td>Posttreatment surveillance strategy guided by the estimated risk of recurrence and functional status. These recommendations are for resected stage II and III colon and rectal cancer. Recommendations not provided for resected stage I or IV disease due to lack of data to guide recommendation.</td> </tr> <tr class=\"divider_bottom\"> <td>American Cancer Society<sup>[8]</sup></td> <td>Every 3 to 6 months for the first&nbsp;2 years, then every 6 months&nbsp;to&nbsp;5 years.</td> <td>Every 3 to 6 months for the first&nbsp;2 years, then every 6 months&nbsp;to&nbsp;5 years if the patient is a potential candidate for further intervention.</td> <td>Abdomen/pelvis and chest every 12 months for&nbsp;5 years for stage III and high-risk&nbsp;stage I/II disease.&nbsp;</td> <td>Colonoscopy in year 1; if advanced adenoma, repeat in&nbsp;1 year; otherwise, repeat in&nbsp;3 years.&nbsp;If no advanced adenoma in year 4, repeat every&nbsp;5 years. </td> <td>High-risk stage&nbsp;I/II disease not defined. &nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>NCCN<sup>[3]</sup></td> <td>Every 3 to 6 months for 2 years, then every 6 months for 3 years</td> <td>Every 3 to 6 months for 2 years for &#8805;T2 disease, then every 6 months for 3 years. For resected metastatic disease, every 3 to 6 months for 2 years, then every 6 months for 3 to 5 years.</td> <td> <p>Colon: Abdomen/pelvis and chest&nbsp;every 6 to 12 months&nbsp;for up to 5 years for those at high risk of recurrence<sup>&#165;</sup>. For rectal cancer,&nbsp;CT chest/abdomen and pelvis every 3 to 6 months for&nbsp;2 years, then every 6 to 12 months for up to 5 years for those at high risk of recurrence<sup>&#165;</sup>.&nbsp;For resected metastatic disease, CT abdomen/pelvis and chest every 3 to 6 months for 2 years, then every 6 to 12 months up to a&nbsp;total of 5 years</p> </td> <td> <p>Colonoscopy at 1 year<sup>&#182;</sup>; subsequent studies dictated by prior findings. If no advanced adenoma, repeat at 3 years, then every 5 years; if advanced adenoma at&nbsp;1 year, repeat at&nbsp;1 year. </p> <p>Flexible sigmoidoscopy with EUS or MRI every 3 to 6 months for&nbsp;2 years,&nbsp;then every 6 months to complete&nbsp;5 years for patients with rectal cancer undergoing transanal excision only. </p> </td> <td>Recommendations&nbsp;apply to&nbsp;stage II, III, and resected stage IV colon cancer, and for stage I,II, III, or resected stage IV rectal cancer.</td> </tr> <tr class=\"divider_bottom\"> <td>ESMO colon cancer<sup>[4]</sup></td> <td>Every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years</td> <td>Every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years</td> <td>Abdomen and chest every 6 to 12 months for 3 years; CEUS can substitute for abdominal CT</td> <td>Colonoscopy at&nbsp;1 year; every&nbsp;3 to&nbsp;5 years thereafter.</td> <td>Guidelines are for localized colon cancer; do not state if applicable to resected stage I disease. CTs recommended for patients at \"higher\" risk of recurrence.</td> </tr> <tr class=\"divider_bottom\"> <td>ESMO rectal cancer<sup>[5]</sup></td> <td>Every 6 months for 2 years<sup>&#916;</sup></td> <td>Every 6 months for the first 3 years</td> <td>A minimum of two CT scans of the chest, abdomen, and pelvis in the first&nbsp;3 years</td> <td>Colonoscopy every 5 years up to age 75.</td> <td>High-risk patients (eg, circumferential resection margin+) may merit more proactive surveillance for local recurrence.</td> </tr> <tr class=\"divider_bottom\"> <td>New Zealand<sup>[6]</sup></td> <td>Clinical assessment<sup>&#9674; </sup>stratified according to risk of recurrence: <ul class=\"decimal_heading\"> <li><em>High-risk cancer (stage IIB, III):</em> Every 6 to 12 months for 3 years, then annually for 2 years </li> <li><em>Lower risk (stage I, IIA), or with comorbidities restricting future surgery:</em> Annual review for 5 years or when symptoms occur </li> </ul> </td> <td> <p><em>For high-risk cancer (stage IIB, III):</em> Every 6 to 12 months for 3 years, then annually for 2 years</p> <em>For lower risk (stage I, IIA), or with comorbidities restricting future surgery:</em> Annually for 5 years</td> <td>All individuals with stages I to III colorectal cancer should have liver imaging between years 1 and 3</td> <td> <p>Colonoscopy at 1 year<sup>&#167;</sup>; colonoscopy every 6 to 12 months for 3 years for high-risk patients (stages IIB, III), then annually for at least 5 years.</p> For low-risk patients, colonoscopy every 3 to 5 years. For rectal cancer, proctoscopy or sigmoidoscopy at 3, 6, 12, and 24 months postsurgery; colonoscopy at 3 to 5 year intervals thereafter.</td> <td>Recommendations cover stages I, II, and III colorectal cancer.</td> </tr> <tr> <td>US Multi-Society Task Force on Colorectal Cancer<sup>[9]</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Colonoscopy&nbsp;1 year after surgery (or&nbsp;1 year after the clearing perioperative colonoscopy). The interval to the next colonoscopy should be&nbsp;3 years, and then&nbsp;5 years. If neoplastic polyps are detected, the intervals between colonoscopies should be shorter and in accordance with published guidelines for polyp surveillance intervals<sup>[10]</sup>. These intervals do not apply to patients with Lynch syndrome.</p> <p>For rectal cancer, flexible sigmoidoscopy or endoscopic ultrasound every 3 to 6 months for the first 2 to 3 years after surgery for patients at high risk for local recurrence (see text).</p> </td> <td>&nbsp;</td> </tr> <tr> <td>British Columbia Medical Association<sup>[7]</sup></td> <td>Every 3 to 6 months for 2 years, then every 6 months for 3 years</td> <td>Every 3 months for 3 years, then every 6 months for 2 years</td> <td>Liver ultrasound or CT scans (preferred) every 6 months for 3 years, then annually for 2 years. Annual chest CT for 3 years.</td> <td>Colonoscopy at 1 year; if normal, repeat 3 years later and, if normal, every 5 years thereafter.</td> <td>These guidelines are for resected stage II and III colon and rectal cancer. Patients with significant comorbidities, very advanced age, or limited 5-year life expectancy are not routinely offered surveillance.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CEA: carcinoembryonic antigen; CT: computed tomography; ASCO: American Society of Clinical Oncology; CCO: Cancer Care Ontario; RT: radiation therapy; NCCN: National Comprehensive Cancer Network; EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; ESMO: European Society for Medical Oncology; CEUS: contrast enhancement transabdominal ultrasound.<br />* Except if no preoperative colonoscopy because of obstructing lesion; do as soon as possible after completion of adjuvant chemotherapy rather than waiting until one year.<br />¶&nbsp;Except if no preoperative colonoscopy because of obstructing lesion; recommend at&nbsp;three to&nbsp;six months rather than waiting until one year.<br />Δ&nbsp;Minimum provisional recommendation.<br />◊&nbsp;Clinical assessment for patients with colon cancer includes physical examination, CEA, chest/abdominal and pelvic CT scans, colonoscopy, and liver ultrasound. Clinical assessment for rectal cancer patients includes physical examination, CEA, chest/abdominal and pelvic CT scans, colonoscopy, and proctoscopy or sigmoidoscopy.<br />§&nbsp;If no complete colonoscopy before surgery, perform colonoscopy within&nbsp;six months.<br />¥ Features suggesting a high risk of recurrence: poorly differentiated histology, lymphatic or venous&nbsp;invasion. </div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 2013; 31:4465.</LI>&#xD;&#xA;<LI>Cancer Care Ontario. <A href=\"http://www.cancercare.on.ca/\" target=_blank>www.cancercare.on.ca</A>.</LI>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Available at: <A href=\"http://www.nccn.org/\" target=_blank>www.nccn.org</A>.</LI>&#xD;&#xA;<LI>Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi64.</LI>&#xD;&#xA;<LI>Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (suppl 4):iv22.</LI>&#xD;&#xA;<LI>Guidance on Surveillance for People at Increased Risk of Colorectal Cancer. Published by the New Zealand Guidelines Group for the Ministry of Health PO Box 10 665, Wellington 6143, New Zealand. Available at: <A href=\"http://www.health.govt.nz/publication/guidance-surveillance-people-increased-risk-colorectal-cancer\" target=_blank>http://www.health.govt.nz/publication/guidance-surveillance-people-increased-risk-colorectal-cancer</A>.</LI>&#xD;&#xA;<LI>British Columbia Medial Association. Follow-up of Colorectal Polyps or Cancer (2013). <A href=\"http://www.bcguidelines.ca/pdf/colorectal_followup.pdf\" target=_blank>http://www.bcguidelines.ca/pdf/colorectal_followup.pdf</A>.</LI>&#xD;&#xA;<LI>American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015; 65:427.</LI>&#xD;&#xA;<LI>Colonoscopy surveillance after colorectal cancer resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer (American Gastroenterological Association, American College of Gastroenterology, American Society for Gastrointestinal Endoscopy). Gastroenterology 2016; 150:758.</LI>&#xD;&#xA;<LI>Guidelines for colonoscopy surveillance after screening and polypectomy from the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 20121; 143:844.</LI></OL></div><div id=\"graphicVersion\">Graphic 91618 Version 15.0</div></div></div>"},"91622":{"type":"graphic_diagnosticimage","displayName":"Coal workers pneumoconiosis radiograph and CT","title":"Images and histopathology from a patient with coal worker’s pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Images and histopathology from a patient with coal worker’s pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:545px; height:164px;\" src=\"images/PULM/91622_Coal_wrk_pneu_radio_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph from a patient with coal worker's pneumoconiosis shows bilateral upper lobe conglomerate shadows and cephalad retraction of hilar regions.<BR>(B) Chest computed tomogram (CT) confirms the dorsal, upper lobe location of conglomerate masses. Needle aspiration biopsy yielded alveolar macrophages filled with black coal dust.</div><div id=\"graphicVersion\">Graphic 91622 Version 1.0</div></div></div>"},"91623":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph conglomerate silicosis","title":"Chest radiograph showing conglomerate silicosis in a foundry worker","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing conglomerate silicosis in a foundry worker</div><div class=\"cntnt\"><img style=\"width:430px; height:464px;\" src=\"images/PULM/91623_Chst_radi_conglom_silicsis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a foundry worker with a prior right upper lobectomy who now has a left upper lobe conglomerate mass due to silica exposure.</div><div id=\"graphicVersion\">Graphic 91623 Version 1.0</div></div></div>"},"91624":{"type":"graphic_diagnosticimage","displayName":"Conglomerate mass in foundry worker","title":"Computed tomography of conglomerate mass in foundry worker with anthracosilicosis, initially suspected of representing a bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of conglomerate mass in foundry worker with anthracosilicosis, initially suspected of representing a bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:429px; height:362px;\" src=\"images/PULM/91624_Conglom_mass_fnd_work.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomogram (CT) from a foundry worker with anthracosilicosis, who was status post remote right upper lobe lobectomy. Image taken at the level of the tracheal bifurcation demonstrates a conglomerate mass encasing the left upper lobe bronchus. Biopsy of the left upper lobe mass yielded coal-filled alveolar macrophages.</div><div id=\"graphicVersion\">Graphic 91624 Version 2.0</div></div></div>"},"91625":{"type":"graphic_diagnosticimage","displayName":"Chronic beryllium lung disease","title":"Chest radiograph and computed tomography of chronic beryllium lung disease","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and computed tomography of chronic beryllium lung disease</div><div class=\"cntnt\"><img style=\"width:513px; height:219px;\" src=\"images/PULM/91625_Chron_berylli_lung_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph and computed tomogram (CT)&nbsp;from a patient with advanced beryllium lung disease show a right upper lobe conglomerate mass&nbsp;with heavy calcification as well as scarring and loss of volume in both upper lobes. The CT scan also shows several calcified subpleural nodules, consistent with beryllium.</div><div id=\"graphicVersion\">Graphic 91625 Version 1.0</div></div></div>"},"91626":{"type":"graphic_diagnosticimage","displayName":"CT scan of calcified pleural plaques","title":"Chest computed tomogram in a patient with pleural calcifications due to asbestos exposure","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Chest computed tomogram in a patient with pleural calcifications due to asbestos exposure</div><div class=\"cntnt\"><img style=\"width:530px; height:183px;\" src=\"images/PULM/91626_CT_calcif_pleural_plaq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram (CT) with calcified pleural plaques forming a so-called table mountain or mesa configuration.</div><div id=\"graphicVersion\">Graphic 91626 Version 1.0</div></div></div>"},"91627":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaques due to asbestos","title":"Calcified pleural plaques with \"table mountain\" pleural thickening due to asbestos","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Calcified pleural plaques with \"table mountain\" pleural thickening due to asbestos</div><div class=\"cntnt\"><img style=\"width:474px; height:186px;\" src=\"images/PULM/91627_Calcif_plr_plaq_asbest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography (CT) showing calcified pleural plaques with \"table mountain\" pleural thickening due to asbestos.</div><div id=\"graphicVersion\">Graphic 91627 Version 2.0</div></div></div>"},"91628":{"type":"graphic_diagnosticimage","displayName":"Asbestosis chest CT features","title":"Computed tomographic features of asbestosis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Computed tomographic features of asbestosis</div><div class=\"cntnt\"><img style=\"width:511px; height:685px;\" src=\"images/PULM/91628_Asbestos_chest_CT_feat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Series of computed tomograms (CT) showing features of asbestosis: (A) parenchymal band in right middle lobe; (B) prone image with subpleural curvilinear line in left lower lobe; (C) reticular opacities in right lower lobe; (D) retractile pleuritis; (E) prone image with honeycombing R&gt;L lower lobe.</div><div class=\"graphic_reference\">Courtesy of HG Hieckel, MD.</div><div id=\"graphicVersion\">Graphic 91628 Version 1.0</div></div></div>"},"91629":{"type":"graphic_diagnosticimage","displayName":"Asbestosis with right lower lobe lung cancer","title":"Asbestosis with right lower lobe lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestosis with right lower lobe lung cancer</div><div class=\"cntnt\"><img style=\"width:408px; height:399px;\" src=\"images/PULM/91629_Asbst_r_low_lob_lung_canc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with asbestosis showing bilateral pleural plaques and a large, poorly marginated right lower lobe mass.</div><div id=\"graphicVersion\">Graphic 91629 Version 1.0</div></div></div>"},"91630":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaques and lung cancer","title":"Chest radiograph of calcified pleural plaques and left apical lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of calcified pleural plaques and left apical lung cancer</div><div class=\"cntnt\"><img style=\"width:430px; height:461px;\" src=\"images/PULM/91630_Calcifi_pleur_plq_lng_canc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph from a patient with asbestos exposure shows calcified pleural plaques with rolled edges seen on face. A left apical mass with a caudal convex border was determined to be bronchogenic carcinoma.</div><div id=\"graphicVersion\">Graphic 91630 Version 1.0</div></div></div>"},"91631":{"type":"graphic_diagnosticimage","displayName":"CT scan in acute hypersensitivity pneumonia","title":"Chest CT scan in patient with acute hypersensitivity pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest CT scan in patient with acute hypersensitivity pneumonia</div><div class=\"cntnt\"><img style=\"width:207px; height:224px;\" src=\"images/PULM/91631_CT_acute_hypersensit_pneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram in patient with acute hypersensitivity pneumonia demonstrating so-called \"head cheese\" pattern with mixture of ground-glass, consolidation, and air-trapping in adjoining secondary pulmonary lobules.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91631 Version 2.0</div></div></div>"},"91632":{"type":"graphic_diagnosticimage","displayName":"Chest CT scan chronic hypersensitivity pneumonia","title":"Chest computed tomography of chronic hypersensitivity pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest computed tomography of chronic hypersensitivity pneumonia</div><div class=\"cntnt\"><img style=\"width:243px; height:175px;\" src=\"images/PULM/91632_Chst_CT_chron_hyprsns_pneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomogram in a patient with chronic hypersensitivity pneumonia demonstrating fibrosis of the axial and parenchymal interstitium with accompanying traction bronchiectases.</div><div id=\"graphicVersion\">Graphic 91632 Version 1.0</div></div></div>"},"91633":{"type":"graphic_table","displayName":"Typical radiographic characteristics of pneumoconioses","title":"Typical radiographic characteristics of pneumoconioses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical radiographic characteristics of pneumoconioses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent/occupation</td> <td class=\"subtitle1\">Chest radiograph</td> <td class=\"subtitle1\">Computed tomography</td> </tr> <tr class=\"divider_bottom\"> <td>Asbestos <p class=\"sublist1\">Asbestos mining, insulation work, brakes, shipbuilding, construction</p> </td> <td>Pleural <p class=\"sublist1\">Plaques, calcified plaques, effusion, diffuse thickening, malignant mesothelioma</p> Lung parenchyma <p class=\"sublist1\">Lower lung predominant, peripheral, fine or coarse, reticular opacities with or without honeycombing. Lower lobe bronchogenic carcinoma.</p> </td> <td>Pleural <p class=\"sublist1\">Pleural plaques linear or punctate calcifications, or&nbsp;band-like, nodular, or raised appearance. In malignant mesothelioma, circumferential pleural thickening may be nodular.</p> Lung parenchyma <p class=\"sublist1\">Lower lung zone, subpleural fibrosis with parenchymal bands, subpleural curvilinear lines, interlobular and intralobular septal thickening, traction bronchiectasis, and honeycombing</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Beryllium <p class=\"sublist1\">Used in fluorescent light, dental, computer, and aerospace industries</p> </td> <td>Multiple small rounded opacities that can calcify; upper lobe scarring, volume loss and bullae</td> <td>Ground-glass opacities early; small nodules in perilymphatic distribution in the interlobular septa and in subpleural location; upper lobe scarring with volume loss and bullae as late manifestations</td> </tr> <tr class=\"divider_bottom\"> <td>Coal dust <p class=\"sublist1\">Coal miners</p> </td> <td>Upper lobe predominant, small, rounded, nodular opacities, less than 1 cm in diameter. Progressive massive fibrosis with cavitation when admixed with silica.</td> <td>Simple <p class=\"sublist1\">Small, rounded centrilobular, and perilymphatic nodules with upper lung zone predominance</p> Complicated <p class=\"sublist1\">Coalescence of nodules into large masses with distortion and volume loss creating progressive massive fibrosis</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Hard metal (cobalt) <p class=\"sublist1\">Diamond polishing, cobalt mining</p> </td> <td>Small nodular and reticular opacities and small cystic spaces</td> <td>Ground-glass opacities, consolidation, reticular opacities, and traction bronchiectasis</td> </tr> <tr class=\"divider_bottom\"> <td>Inert dust pneumoconiosis <p class=\"sublist1\">Welding</p> </td> <td>High attenuation micronodules and reticular opacities</td> <td>Centrilobular high attenuation nodules</td> </tr> <tr class=\"divider_bottom\"> <td>Silica <p class=\"sublist1\">Mining, quarrying, drilling, and sandblasting</p> </td> <td>Simple <p class=\"sublist1\">Innumerable, sharply marginated, small rounded opacities with upper lung zone predominance</p> Complicated <p class=\"sublist1\">Conglomerate masses that may have \"angel wings\" appearance</p> Acute <p class=\"sublist1\">Diffuse ground glass and consolidative opacities with appearance similar to pulmonary alveolar proteinosis</p> </td> <td>Simple <p class=\"sublist1\">Multiple small nodules that are subpleural and perilymphatic with upper lobe predominance and sharp margins. Nodules can calcify.</p> Complicated <p class=\"sublist1\">Coalescence of nodules leads to progressive massive fibrosis or conglomerate masses &#62;1 cm; pericicatricial emphysema; punctate or eggshell calcifications in hilar and mediastinal lymph nodes</p> Acute <p class=\"sublist1\">Diffuse ground glass opacities, consolidation, and intralobular septal thickening</p> </td> </tr> <tr> <td>Talc <p class=\"sublist1\">Ceramics, plastics, rubber, paint, and cosmetic industries</p> </td> <td>Upper lobe predominant, small, rounded opacities</td> <td>Small centrilobular and subpleural nodules and conglomerated masses containing focal areas of high attenuation; focal ground glass opacities; relative sparing lung base.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91633 Version 1.0</div></div></div>"},"91634":{"type":"graphic_picture","displayName":"Soft mist inhaler","title":"Soft mist inhaler","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Soft mist inhaler</div><div class=\"cntnt\"><img style=\"width:534px; height:704px;\" src=\"images/PULM/91634_SoftmistinhalerPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2018 Boehringer Ingelheim GmbH. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91634 Version 3.0</div></div></div>"},"91636":{"type":"graphic_table","displayName":"Factors that may affect FENO interpretation","title":"Factors that may affect FENO interpretation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that may affect FENO interpretation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors that increase&nbsp;FE<sub>NO</sub></td> <td class=\"subtitle1\">Factors that decrease FE<sub>NO</sub></td> </tr> <tr> <td>Age over 12 years</td> <td>Alcohol, caffeine ingestion</td> </tr> <tr> <td>Asthma</td> <td>Bronchiectasis</td> </tr> <tr> <td>Atopy</td> <td>Cigarette smoking, environmental tobacco smoke</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> <td class=\"sublist1_start\">Chemical exposure</td> </tr> <tr> <td class=\"sublist1\">Enalapril</td> <td class=\"sublist1\">Water vapor</td> </tr> <tr> <td>Exacerbation of COPD</td> <td class=\"sublist1\">Nitrous oxide</td> </tr> <tr> <td>Air pollution exposure</td> <td class=\"sublist1\">Heptane</td> </tr> <tr> <td>Ingestion of arginine or nitrite/nitrate rich foods</td> <td class=\"sublist1\">100 percent oxygen</td> </tr> <tr> <td class=\"sublist1_start\">Chemical exposure</td> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Chlorine dioxide</td> <td class=\"sublist1\">Antileukotriene agents</td> </tr> <tr> <td class=\"sublist1\">Fluoride</td> <td class=\"sublist1\">Glucocorticoids</td> </tr> <tr> <td class=\"sublist1\">Formaldehyde</td> <td class=\"sublist1\">Oxymetazoline</td> </tr> <tr> <td class=\"sublist1\">Latex</td> <td class=\"sublist1\">NOS inhibitors</td> </tr> <tr> <td class=\"sublist1\">Ozone</td> <td>Exercise</td> </tr> <tr> <td>Nonasthmatic eosinophilic bronchitis</td> <td>Hypothermia</td> </tr> <tr> <td rowspan=\"4\">Upper respiratory tract infections</td> <td>Menses</td> </tr> <tr> <td>Moderate altitude</td> </tr> <tr> <td>Repeated spirometry</td> </tr> <tr> <td>Sputum induction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FE<SUB>NO</SUB>: fractional exhaled nitric oxide; NO: nitric oxide.</div><div id=\"graphicVersion\">Graphic 91636 Version 1.0</div></div></div>"},"91637":{"type":"graphic_table","displayName":"Prevalence of cardiovascular disease risk factors","title":"Prevalence of cardiovascular disease risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of cardiovascular disease risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factors</td> <td class=\"subtitle1\" rowspan=\"2\">Definitions</td> <td class=\"subtitle1\" colspan=\"2\">Framingham Heart Study</td> <td class=\"subtitle1\" colspan=\"2\">NHANES III*</td> </tr> <tr> <td class=\"subtitle2\">Men<br /> (n = 3418)</td> <td class=\"subtitle2\">Women<br /> (n = 3973)</td> <td class=\"subtitle2\">Men<br /> (n = 681)</td> <td class=\"subtitle2\">Women<br /> (n = 807)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Blood pressure, percent</td> </tr> <tr> <td class=\"indent1\">High</td> <td>Systolic &#8805;140 mmHg, diastolic &#8805;90 mmHg, or treatment for hypertension</td> <td class=\"centered\">38</td> <td class=\"centered\">33</td> <td class=\"centered\">26</td> <td class=\"centered\">25</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serum LDL cholesterol level, percent</td> </tr> <tr> <td class=\"indent1\">High</td> <td>4.12 mmol/L (&#62;159 mg/dL)</td> <td class=\"centered\">26</td> <td class=\"centered\">27</td> <td class=\"centered\">26</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serum HDL cholesterol level, percent</td> </tr> <tr> <td class=\"indent1\">Low</td> <td>&#60;1.04 mmol/L (&#60;40 mg/dL)</td> <td class=\"centered\">36</td> <td class=\"centered\">10</td> <td class=\"centered\">40</td> <td class=\"centered\">13</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Diabetes mellitus or glucose intolerance, percent</td> </tr> <tr> <td class=\"indent1\">High</td> <td>Known diabetes or fasting glucose level &#62;6.94 mmol/L (&#60;125 mg/dL) or 2-h glucose level &#62;11.04 mmol/L (&#62;199 mg/dL)</td> <td class=\"centered\">6</td> <td class=\"centered\">4</td> <td class=\"centered\">8</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Smoking, percent</td> </tr> <tr> <td class=\"indent1\">High</td> <td>Current</td> <td class=\"centered\">35</td> <td class=\"centered\">33</td> <td class=\"centered\">28</td> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; LDL: low-density lipoprotein; NHANES III: Third National Health and Nutrition Examination Survey.<br />* Data for 1488 eligible non-Hispanic white persons who were 35 to 74 years of age and had no vascular disease in their medical history. There were 10,507 non-Hispanic white persons in the NHANES III sample (out of 33,199 for all ethnicities). Persons &lt;35 years of age (n = 4825), persons &gt;74 years of age (n = 1658), those who fasted less than nine hours (n = 1841), those with a history of vascular disease (n = 262), and those with missing risk factor data (n = 433) were excluded.</div><div class=\"graphic_reference\">Data from: Vasan RS, Sullivan LM, Wilson PF, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:396.</div><div id=\"graphicVersion\">Graphic 91637 Version 1.0</div></div></div>"},"91638":{"type":"graphic_table","displayName":"Prevalence of borderline cardiovascular disease risk factors","title":"Prevalence of borderline cardiovascular disease risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of borderline cardiovascular disease risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factors</td> <td class=\"subtitle1\" rowspan=\"2\">Definitions</td> <td class=\"subtitle1\" colspan=\"2\">Framingham Heart Study</td> <td class=\"subtitle1\" colspan=\"2\">NHANES III*</td> </tr> <tr> <td class=\"subtitle2\">Men<br /> (n = 3418)</td> <td class=\"subtitle2\">Women<br /> (n = 3973)</td> <td class=\"subtitle2\">Men<br /> (n = 681)</td> <td class=\"subtitle2\">Women<br /> (n = 807)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Blood pressure, percent</td> </tr> <tr> <td class=\"indent1\">Borderline</td> <td>Systolic 120 to 139 mmHg or diastolic 80 to 89 mmHg</td> <td class=\"centered\">43</td> <td class=\"centered\">36</td> <td class=\"centered\">43</td> <td class=\"centered\">27</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serum LDL cholesterol level, percent</td> </tr> <tr> <td class=\"indent1\">Borderline</td> <td>2.59 to 4.12 mmol/L (100 to 159 mg/dL)</td> <td class=\"centered\">62</td> <td class=\"centered\">57</td> <td class=\"centered\">60</td> <td class=\"centered\">58</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serum HDL cholesterol level, percent</td> </tr> <tr> <td class=\"indent1\">Borderline</td> <td>1.04 to 1.53 mmol/L (40 to 59 mg/dL)</td> <td class=\"centered\">53</td> <td class=\"centered\">49</td> <td class=\"centered\">50</td> <td class=\"centered\">53</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Glucose intolerance, percent</td> </tr> <tr> <td class=\"indent1\">Borderline</td> <td>Fasting glucose level 6.11 to 6.94 mmol/L (110 to 125 mg/dL) or 2-h glucose level 7.77 to 11.04 mmol/L (140 to 199 mg/dL)</td> <td class=\"centered\">13</td> <td class=\"centered\">6</td> <td class=\"centered\">10</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Smoking, percent</td> </tr> <tr> <td class=\"indent1\">Borderline</td> <td>Former</td> <td class=\"centered\">39</td> <td class=\"centered\">25</td> <td class=\"centered\">42</td> <td class=\"centered\">30</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; LDL: low-density lipoprotein; NHANES III: Third National Health and Nutrition Examination Survey.<br />* Data for 1488 eligible non-Hispanic white persons who were 35 to 74 years of age and had no vascular disease in their medical history. There were 10,507 non-Hispanic white persons in the NHANES III sample (out of 33,199 for all ethnicities). Persons &lt;35 years of age (n = 4825), persons &gt;74 years of age (n = 1658), those who fasted less than nine hours (n = 1841), those with a history of vascular disease (n = 262), and those with missing risk factor data (n = 433) were excluded.</div><div class=\"graphic_reference\">Data from: Vasan RS, Sullivan LM, Wilson PF, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:396.</div><div id=\"graphicVersion\">Graphic 91638 Version 2.0</div></div></div>"},"91641":{"type":"graphic_diagnosticimage","displayName":"Low output bile leak treated with surgical drain ","title":"Surgical drain for treatment of a low output bile leak","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Surgical drain for treatment of a low output bile leak</div><div class=\"cntnt\"><img style=\"width:492px; height:598px;\" src=\"images/RADIOL/91641_Lw_out_bil_trt_surg_dn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a HIDA scan in the early post operative period following laparoscopic cholecystectomy&nbsp;and shows a small subhepatic bile leak (arrow).<BR>Image B is an ERCP and shows a small leak from a minor duct emptying into the post operative bed (arrow). The subhepatic drain remained in place until bile drainage reduced. A stent was not inserted.<BR>Image C is a HIDA scan performed 11 days later and shows resolution of the bile leak.</div><div class=\"graphic_footnotes\">HIDA: hepatobiliary iminodiacetic acid; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91641 Version 2.0</div></div></div>"},"91642":{"type":"graphic_diagnosticimage","displayName":"Biliary stent and percutaneous drain to treat biloma","title":"Biloma treated with stent and percutaneous drain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biloma treated with stent and percutaneous drain</div><div class=\"cntnt\"><img style=\"width:421px; height:434px;\" src=\"images/RADIOL/91642_Bili_stnt_percut_bilom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ERCP following laparoscopic cholecystectomy (A) shows a bile leak into the gallbladder fossa from a minor duct (double arrow). A pigtail catheter is in place (arrowhead).<br />Image B shows a plastic stent in the bile duct (arrow).<br />Image C is a CT scan through the upper abdomen and shows a complex biloma with air bubbles (arrow).<br />Image D shows a percutaneous catheter in the biloma (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 91642 Version 3.0</div></div></div>"},"91643":{"type":"graphic_diagnosticimage","displayName":"Biloma on CT and fluoroscopy ","title":"Computed tomography scan and fluoroscopy showing biloma ","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Computed tomography scan and fluoroscopy showing biloma </div><div class=\"cntnt\"><img style=\"width:597px; height:466px;\" src=\"images/RADIOL/91643_Biloma_CT_fluoroscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reconstructed in the coronal plane (A) shows a large biloma in the gallbladder fossa (arrow) following laparoscopic cholecystectomy. Image B shows a plastic stent (arrowhead) in the bile duct and a percutaneously placed pigtail in the biloma (arrow). Image C is a fluoroscopic image of the biloma (arrow) after contrast injection.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91643 Version 2.0</div></div></div>"},"91644":{"type":"graphic_diagnosticimage","displayName":"Type II bipartite patella xray","title":"Type II bipartite patella on plain x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Type II bipartite patella on plain x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:332px;\" src=\"images/RADIOL/91644_X_bipartite_patella_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P x-ray of the right knee (A) shows a type 2 bipartite patella with a small lateral segment&nbsp;(arrow) separated from the larger segment by a vertical cleft. A sunrise view of the right knee shows the bipartite patella with the smaller fragment on the lateral aspect of the patella (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 91644 Version 3.0</div></div></div>"},"91645":{"type":"graphic_diagnosticimage","displayName":"MRI bone bruise tibia ","title":"Bone bruise of the tibia on MRI","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Bone bruise of the tibia on MRI</div><div class=\"cntnt\"><img style=\"width:599px; height:312px;\" src=\"images/RADIOL/91645_MRI_bone_bruise_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal view of the right knee (A) on a T1 weighted MRI shows a low intensity bone bruise (between arrows). Image B is a proton density fat saturated sequence and shows correlating high intensity edema (between arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91645 Version 1.0</div></div></div>"},"91649":{"type":"graphic_picture","displayName":"Central centrifugal cicatricial alopecia early stage","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/91649_Cen_centrif_cica_alop_early.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduced hair density on the crown of the scalp in a patient with early central centrifugal cicatricial alopecia.</div><div id=\"graphicVersion\">Graphic 91649 Version 1.0</div></div></div>"},"91650":{"type":"graphic_picture","displayName":"Central centrifugal cicatricial alopecia patch","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:556px; height:576px;\" src=\"images/DERM/91650_Cen_centrif_cica_alop_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scalp hair loss is most severe in the center of an involved area in central centrifugal cicatricial alopecia.</div><div id=\"graphicVersion\">Graphic 91650 Version 1.0</div></div></div>"},"91651":{"type":"graphic_picture","displayName":"Inflammatory central centrifugal cicatricial alopecia","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:451px; height:576px;\" src=\"images/DERM/91651_Inflam_centrif_cicatri_alop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory central centrifugal cicatricial alopecia demonstrating hair loss on the crown of the scalp, inflamed papules, pustules, and scarring.</div><div id=\"graphicVersion\">Graphic 91651 Version 1.0</div></div></div>"},"91652":{"type":"graphic_picture","displayName":"Central centrifugal cicatricial alopecia severe","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:576px; height:555px;\" src=\"images/DERM/91652_Cen_centrif_cica_alop_sever.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe central centrifugal cicatricial alopecia demonstrating hypopigmentation, hyperpigmentation, and extensive scarring.</div><div id=\"graphicVersion\">Graphic 91652 Version 1.0</div></div></div>"},"91662":{"type":"graphic_table","displayName":"Diagnostic criteria for logopenic variant PPA","title":"Diagnostic criteria for logopenic variant PPA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for logopenic variant PPA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Clinical diagnosis of logopenic variant PPA</td> </tr> <tr> <td class=\"indent1\"><strong>Both of the following core features must be present:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"decimal_heading\"> <li>Impaired single-word retrieval in spontaneous speech and naming </li> <li>Impaired repetition of sentences and phrases </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>At least 3 of the following other features must be present:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"decimal_heading\"> <li>Speech (phonologic) errors in spontaneous speech and naming </li> <li>Spared single-word comprehension and object knowledge </li> <li>Spared motor speech </li> <li>Absence of frank agrammatism </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Imaging-supported diagnosis of logopenic variant PPA</td> </tr> <tr> <td class=\"indent1\"><strong>Both criteria must be present:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"decimal_heading\"> <li>Clinical diagnosis of logopenic variant PPA </li> <li>Imaging must show at least one of the following results:<br /> a. Predominant left posterior perisylvian or parietal atrophy on MRI<br /> b. Predominant left posterior perisylvian or parietal hypoperfusion or hypometabolism on SPECT or PET </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">III. Logopenic variant PPA with definite pathology</td> </tr> <tr> <td class=\"indent1\"><strong>Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present:</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"decimal_heading\"> <li>Clinical diagnosis of logopenic variant PPA </li> <li>Histopathologic evidence of a specific neurodegenerative pathology (eg, AD, FTLD-tau, FTLD-TDP, other) </li> <li>Presence of a known pathogenic mutation </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: Alzheimer disease; FTLD: frontotemporal lobar degeneration; PPA: primary progressive aphasia.</div><div class=\"graphic_reference\">From: Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/76/11/1006.abstract\" target=_blank>10.1212/WNL.0b013e31821103e6</A>. Copyright © 2011 American Academy of Neurology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91662 Version 5.0</div></div></div>"},"91666":{"type":"graphic_table","displayName":"Revised PTEN hamartoma tumor syndrome clinical DX criteria","title":"Revised <em>PTEN</em> hamartoma tumor syndrome clinical diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised <em>PTEN</em> hamartoma tumor syndrome clinical diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> </tr> <tr> <td class=\"indent1\">Endometrial cancer (epithelial)</td> </tr> <tr> <td class=\"indent1\">Thyroid cancer (follicular)</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal hamartomas (including ganglioneuromas, but excluding hyperplastic polyps; &#8805;3)</td> </tr> <tr> <td class=\"indent1\">Lhermitte-Duclos disease (adult)</td> </tr> <tr> <td class=\"indent1\">Macrocephaly (&#8805;97 percentile: 58 cm for females, 60 cm for males)</td> </tr> <tr> <td class=\"indent1\">Macular pigmentation of the glans penis</td> </tr> <tr> <td class=\"indent1\">Multiple mucocutaneous lesions (any of the following):</td> </tr> <tr> <td class=\"indent2\">Multiple trichilemmomas (&#8805;3, at least one biopsy proven)</td> </tr> <tr> <td class=\"indent2\">Acral keratoses (&#8805;3 palmoplantar keratotic pits and/or acral hyperkeratotic papules)</td> </tr> <tr> <td class=\"indent2\">Mucocutaneous neuromas (&#8805;3)</td> </tr> <tr> <td class=\"indent2\">Oral papillomas (particularly on tongue and gingiva), multiple (&#8805;3)</td> </tr> <tr> <td class=\"indent2\">OR biopsy proven OR dermatologist diagnosed</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Autism spectrum disorder</td> </tr> <tr> <td class=\"indent1\">Colon cancer</td> </tr> <tr> <td class=\"indent1\">Esophageal glycogenic acanthosis (&#8805;3)</td> </tr> <tr> <td class=\"indent1\">Lipomas (&#8805;3)</td> </tr> <tr> <td class=\"indent1\">Mental retardation (ie, IQ &#8804;75)</td> </tr> <tr> <td class=\"indent1\">Renal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Testicular lipomatosis</td> </tr> <tr> <td class=\"indent1\">Thyroid cancer (papillary or follicular variant of papillary)</td> </tr> <tr> <td class=\"indent1\">Thyroid structural lesions (eg, adenoma, multinodular goiter)</td> </tr> <tr> <td class=\"indent1\">Vascular anomalies (including multiple intracranial developmental venous anomalies)</td> </tr> <tr> <td class=\"subtitle1_single\">Operational diagnosis in an individual (either of the following)</td> </tr> <tr> <td class=\"indent1\">1. Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos disease, or gastrointestinal hamartomas; or</td> </tr> <tr> <td class=\"indent1\">2. Two major and three minor criteria.</td> </tr> <tr> <td class=\"subtitle1_single\">Operational diagnosis in a family where one individual meets revised <em>PTEN</em> hamartoma tumor syndrome clinical diagnostic criteria or has a <em>PTEN</em> mutation:</td> </tr> <tr> <td class=\"indent1\">1. Any two major criteria with or without minor criteria; or</td> </tr> <tr> <td class=\"indent1\">2. One major and two minor criteria; or</td> </tr> <tr> <td class=\"indent1\">3. Three minor criteria.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Pilarski R, Burt R, Kohlman W, et al. Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. J Natl Cancer Inst 2013; 105:1607. By permission of the National Cancer Institute. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91666 Version 9.0</div></div></div>"},"91667":{"type":"graphic_movie","displayName":"Intraventricular chemotherapy administration technique","title":"Intraventricular chemotherapy administration technique","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Intraventricular chemotherapy administration technique</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/91667_Ommayaaccesstechniqvideo.mp4\" style=\"width:528px;height:320px\"></div><img style=\"width:576px; height:432px;\" src=\"images/NEURO/91667_Ommayaaccesstechniqimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91667 Version 2.0</div></div></div>"},"91669":{"type":"graphic_diagnosticimage","displayName":"CXR situs inversus and atrial isomerism","title":"Chest radiograph in a patient with situs inversus and atrial isomerism","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a patient with situs inversus and atrial isomerism</div><div class=\"cntnt\"><img style=\"width:590px; height:433px;\" src=\"images/PEDS/91669_CXRsitusinveratrialiso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior view of a chest radiograph of a patient with situs inversus and atrial isomerism: The apex of the heart is rightward, consistent with dextrocardia. The obtuse angle right mainstem bronchus (RMSB) and liver are leftward, while the stomach bubble and acute angle left mainstem bronchus (LMSB) are rightward, all consistent with situs inversus. Note that the left diaphragm is slightly higher due to the presence of the left-sided liver, while the trachea is shifted leftward due to the presence of a right aortic arch, which is to the right of the trachea and arches over the LMSB.</div><div id=\"graphicVersion\">Graphic 91669 Version 2.0</div></div></div>"},"91671":{"type":"graphic_table","displayName":"Antidepressant side effects 2 PI","title":"Chance of side effects with certain antidepressant medicines, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chance of side effects with certain antidepressant medicines, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name<br /> </td> <td class=\"subtitle1\">US brand name</td> <td class=\"subtitle1\">Dry mouth<br /> Blurred vision<br /> Trouble urinating<br /> Constipation<br /> Dizziness</td> <td class=\"subtitle1\">Drowsiness</td> <td class=\"subtitle1\">Trouble sleeping<br /> Jitteriness</td> <td class=\"subtitle1\">Nausea<br /> Vomiting<br /> Diarrhea</td> <td class=\"subtitle1\">Weight gain</td> <td class=\"subtitle1\">Sexual problems</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Tricyclic and tetracyclic antidepressants (TCAs)</td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>Elavil</td> <td>High</td> <td>High</td> <td>None</td> <td>Very low</td> <td>High</td> <td>Moderate to high</td> </tr> <tr> <td class=\"indent1\">Amoxapine</td> <td>Asendin (only sold as generic in US)</td> <td>Low</td> <td>Low</td> <td>Low</td> <td>None</td> <td>Low</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>Anafranil</td> <td>High</td> <td>High</td> <td>Very low</td> <td>Very low</td> <td>High</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>Norpramin</td> <td>Very low</td> <td>High</td> <td>Very low</td> <td>None</td> <td>Very low</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Doxepin</td> <td>Silenor, Sinequan</td> <td>Moderate</td> <td>Moderate</td> <td>None</td> <td>None</td> <td>High</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>Tofranil</td> <td>Moderate</td> <td>Moderate</td> <td>Very low</td> <td>Very low</td> <td>High</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Maprotiline</td> <td>Ludiomil (only sold as generic in US)</td> <td>Low</td> <td>Moderate</td> <td>None</td> <td>None</td> <td>Low</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td>Pamelor</td> <td>Low</td> <td>Low</td> <td>None</td> <td>None</td> <td>Very low</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Protriptyline</td> <td>Vivactil (only sold as generic in US)</td> <td>Low</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> <td>Moderate to high</td> </tr> <tr> <td class=\"indent1\">Trimipramine</td> <td>Surmontil</td> <td>High</td> <td>High</td> <td>Very low</td> <td>None</td> <td>High</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Monoamine oxidase inhibitors</td> </tr> <tr> <td class=\"indent1\">Isocarboxazid</td> <td>Marplan</td> <td>Very low</td> <td>Very low</td> <td>Low</td> <td>Very low</td> <td>Very low</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Phenelzine</td> <td>Nardil</td> <td>Very low</td> <td>Low</td> <td>Very low</td> <td>Very low</td> <td>Low</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Selegiline</td> <td>Eldepryl, Emsam, others</td> <td>Very low</td> <td>None</td> <td>Very low</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td class=\"indent1\">Tranylcypromine</td> <td>Parnate</td> <td>Very low</td> <td>Very low</td> <td>Low</td> <td>Very low</td> <td>Very low</td> <td>High</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Many of these medicines can affect your blood pressure&nbsp;and make you feel light headed when you stand up. This could increase your risk of falling. </div><div class=\"graphic_reference\">Created with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nelson JC. Tricyclic and tetracyclic drugs. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg AF, Nemeroff CB (Ed), American Psychiatric Publishing, Washington, DC 2009. p.263. </LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved. </LI>&#xD;&#xA;<LI>Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric disease. Clin Pharm Ther 2011; 89:142-7. </LI></OL></div><div id=\"graphicVersion\">Graphic 91671 Version 9.0</div></div></div>"},"91672":{"type":"graphic_table","displayName":"Geriatric-8 questionnaire","title":"The Geriatric-8 questionnaire for screening of older patients with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Geriatric-8 questionnaire for screening of older patients with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Items</td> <td class=\"subtitle1\">Possible responses (score)</td> </tr> <tr class=\"divider_bottom\"> <td>Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties?</td> <td> <p>0 = Severe decrease in food intake</p> <p>1 = Moderate decrease in food intake</p> 2 = No decrease in food intake</td> </tr> <tr class=\"divider_bottom\"> <td>Weight loss during the last 3 months?</td> <td> <p>0 = Weight loss &#62;3 kg</p> <p>1 = Does not know</p> <p>2 = Weight loss between 1 and 3 kg</p> 3 = No weight loss</td> </tr> <tr class=\"divider_bottom\"> <td>Mobility?</td> <td> <p>0 = Bed or chair bound</p> <p>1 = Able to get out of bed/chair but does not go out</p> 2 = Goes out</td> </tr> <tr class=\"divider_bottom\"> <td>Neuropsychological problems?</td> <td> <p>0 = Severe dementia or depression</p> <p>1 = Mild dementia</p> 2 = No psychological problems</td> </tr> <tr class=\"divider_bottom\"> <td>BMI?</td> <td> <p>0 = BMI &#60;19</p> <p>1 = BMI 19 to &#60;21</p> <p>2 = BMI 21 to &#60;23</p> 3 = BMI &#8805;23</td> </tr> <tr class=\"divider_bottom\"> <td>Takes more than three prescription drugs per day?</td> <td> <p>0 = Yes</p> 1 = No</td> </tr> <tr class=\"divider_bottom\"> <td>In comparison with other people of the same age, how does the patient consider his/her health status?</td> <td> <p>0.0 = Not as good</p> <p>0.5 = Does not know</p> <p>1.0 = As good</p> 2.0 = Better</td> </tr> <tr class=\"divider_bottom\"> <td>Age</td> <td> <p>0: &#62;85</p> <p>1: 80-85</p> 2: &#60;80</td> </tr> <tr class=\"highlight_gray_text\"> <td>&nbsp;</td> <td><strong>Total score: 0-17</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index = weight (kg)/height (m<SUP>2</SUP>).</div><div class=\"graphic_reference\">From: Bellera CA, Rainfray M, Mathoulin-P&eacute;lissier S. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012; 23:2166. By permission of the European Society of Medical Oncology. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91672 Version 5.0</div></div></div>"},"91674":{"type":"graphic_table","displayName":"Drugs linked to telogen effluvium","title":"Drugs and drug classes* linked to telogen effluvium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and drug classes* linked to telogen effluvium</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Allopurinol</td> </tr> <tr> <td>Androgens</td> </tr> <tr> <td>Anticholesterol agents (statins)</td> </tr> <tr> <td>Anticoagulants</td> </tr> <tr> <td>Anticonvulsants</td> </tr> <tr> <td>Antifungals</td> </tr> <tr> <td>Antihistamines (H2)</td> </tr> <tr> <td>Antiinflammatory agents</td> </tr> <tr> <td>Antimitotic agents</td> </tr> <tr> <td>Antithyroid agents</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Dopa</td> </tr> <tr> <td>Ergots</td> </tr> <tr> <td>Heavy metals</td> </tr> <tr> <td>Hormones (oral contraceptives, hormone replacement therapy)</td> </tr> <tr> <td>Immunomodulators</td> </tr> <tr> <td>Retinoids</td> </tr> <tr> <td>Psychotropics</td> </tr> <tr> <td>Minoxidil</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td>Selective estrogen receptor modulators and phytoestrogen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not all drugs within the classes described have been linked to telogen effluvium.</div><div id=\"graphicVersion\">Graphic 91674 Version 1.0</div></div></div>"},"91675":{"type":"graphic_figure","displayName":"Course of acute and chronic telogen effluvium","title":"Course of acute and chronic telogen effluvium","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Course of acute and chronic telogen effluvium</div><div class=\"cntnt\"><img style=\"width:593px; height:308px;\" src=\"images/DERM/91675_Cour_acu_chron_telogn_efflv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute telogen effluvium is characterized by a single episode of hair shedding that exceeds an individual's normal rate of hair loss (50 to 150 hairs per day). Chronic telogen effluvium may occur when triggers for hair loss persist or recur.</div><div id=\"graphicVersion\">Graphic 91675 Version 1.0</div></div></div>"},"91679":{"type":"graphic_picture","displayName":"Giardia lamblia histology","title":"Giardia lamblia histology","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Giardia lamblia histology</div><div class=\"cntnt\"><img style=\"width:513px; height:400px;\" src=\"images/GAST/91679_Giardiasis_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low power view of a random biopsy specimen from the second portion of the duodenum shows a normal villous architecture in a patient with&nbsp;Giardia lamblia infection.&nbsp;The cellular elements of the lamina propria, lymphocytes and plasma cells, are at the upper limit of normal. <br />(B) Medium power and (C) and high power views demonstrate the flattened or pear shape trophozoites of Giardia lamblia. The organisms are both intraluminal (arrow and circle) and attached to the glycocalyx of the enterocyte (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 91679 Version 1.0</div></div></div>"},"91680":{"type":"graphic_picture","displayName":"Celiac disease endoscopy","title":"Celiac disease","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Celiac disease</div><div class=\"cntnt\"><img style=\"width:725px; height:317px;\" src=\"images/GAST/91680_Celiac_disease_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 50-year-old female presented for the evaluation of a one-year history of abdominal pain and diarrhea. Of interest, the patient had a recent diagnosis of dermatitis herpetiformis. An upper endoscopy was performed and revealed scalloped (arrow) and flattened duodenal folds (arrowhead); multiple biopsies were obtained from the second and third portion. The diagnosis was celiac sprue.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 91680 Version 1.0</div></div></div>"},"91681":{"type":"graphic_picture","displayName":"Celiac disease histology high power","title":"Celiac disease histology","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Celiac disease histology</div><div class=\"cntnt\"><img style=\"width:711px; height:530px;\" src=\"images/GAST/91681_Celiac_disease_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of the duodenal biopsy reveals a marked increase in intraepithelial lymphocytes. The expanded lamina propria contains an increase in lymphocytes, plasma cells, and eosinophils.</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 91681 Version 1.0</div></div></div>"},"91682":{"type":"graphic_picture","displayName":"Gastric heterotopia endoscopy","title":"Gastric heterotopia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastric heterotopia</div><div class=\"cntnt\"><img style=\"width:504px; height:393px;\" src=\"images/GAST/91682_Gast_heterotopia_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a benign-appearing 10 by 15 mm sessile polyp in the duodenal bulb&nbsp;(oval). Biopsies were consistent with gastric heterotopia in the duodenum.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 91682 Version 1.0</div></div></div>"},"91683":{"type":"graphic_picture","displayName":"Gastric heterotopia histology","title":"Gastric heterotopia ","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Gastric heterotopia </div><div class=\"cntnt\"><img style=\"width:514px; height:193px;\" src=\"images/GAST/91683_Gastric_heteroto_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Medium power view of a biopsy specimen from the duodenal bulb shows foveolar epithelium (oval) and a central area of basophilic glands highly suggestive for gastric heterotopia (dashed oval).<br />(B) High power view of a biopsy specimen from the duodenal bulb demonstrates mainly chief cells and occasional parietal cells diagnostic of gastric heterotopia.</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 91683 Version 1.0</div></div></div>"},"91684":{"type":"graphic_picture","displayName":"Duodenal carcinoid tumor endoscopy","title":"Duodenal carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Duodenal carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:513px; height:266px;\" src=\"images/GAST/91684_Duodena_carc_tum_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view&nbsp;of&nbsp;an 8 mm polyp in the second portion of the duodenum (panels A and B). Snare polypectomy was performed with complete removal of the lesion. The&nbsp;histology&nbsp;was consistent with a&nbsp;duodenal carcinoid.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 91684 Version 1.0</div></div></div>"},"91685":{"type":"graphic_picture","displayName":"Duodenal carcinoid tumor histology","title":"Duodenal carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Duodenal carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:515px; height:195px;\" src=\"images/GAST/91685_Duod_carcin_tumr_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low power view of a duodenal polyp biopsy specimen demonstrating replacement of the glandular compartment by an infiltrate of small blue cells.<br />(B) High power view of the same duodenal polyp reveals solid nests of uniform cells with basophilic cytoplasm. No mitosis identified. The features are characteristic of a duodenal neuroendocrine tumor (carcinoid tumor). Immunohistochemical stains may be helpful to categorize these tumors, which are positive on staining with antibodies to synaptophysin and chromogranin.</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 91685 Version 1.0</div></div></div>"},"91686":{"type":"graphic_picture","displayName":"Duodenal polyps with dysplasia endoscopy","title":"Duodenal polyps with dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal polyps with dysplasia</div><div class=\"cntnt\"><img style=\"width:392px; height:411px;\" src=\"images/GAST/91686_Duod_polyps_dyspl_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the duodenum in a patient with familial adenomatous polyposis shows multiple small polyps of various sizes (arrows) that on histology were consistent&nbsp;with high-grade dysplasia.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 91686 Version 1.0</div></div></div>"},"91687":{"type":"graphic_picture","displayName":"Duodenal polyps with dysplasia histology","title":"Duodenal polyp with high-grade dysplasia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Duodenal polyp with high-grade dysplasia</div><div class=\"cntnt\"><img style=\"width:516px; height:198px;\" src=\"images/GAST/91687_Duod_polyps_dysp_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Medium power view of one of the duodenal&nbsp;polyps contains straight tubular glands lined by hyperchromatic stratified epithelial cells replacing the normal duodenal mucosa.<br />(B) High power view of the same duodenal&nbsp;polyp shows evidence of high-grade dysplasia characterized by nuclear enlargement (arrow) and loss of polarity. In low-grade dysplasia, the nuclei are long and thin, while in high-grade dysplasia, the nuclei enlarge, round up, and become displaced towards the surface.</div><div class=\"graphic_reference\">Courtesy of Edward Uhlemann, MD.</div><div id=\"graphicVersion\">Graphic 91687 Version 1.0</div></div></div>"},"91689":{"type":"graphic_picture","displayName":"Instinct hemoclip","title":"Instinct Endoscopic Hemoclip","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Instinct Endoscopic Hemoclip</div><div class=\"cntnt\"><img style=\"width:626px; height:470px;\" src=\"images/GAST/91689_Instinct_hemoclip_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Instinct Endoscopic Hemoclip opens to a width of 16 mm and allows for 360 degree bidirectional rotation. In addition, the jaws can be reopened to reposition the clip.</div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 91689 Version 1.0</div></div></div>"},"91691":{"type":"graphic_waveform","displayName":"ECG ventricular premature beats from RVOT","title":"ECG ventricular premature beats from RVOT","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">ECG ventricular premature beats from RVOT</div><div class=\"cntnt\"><img style=\"width:601px; height:343px;\" src=\"images/CARD/91691_ECG_vent_prm_bts_RVOT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twelve-lead electrocardiogram (ECG) showing sinus rhythm with frequent ventricular premature beats (VPBs) in a pattern of ventricular bigeminy. The VPBs have a left bundle branch block (LBBB) morphology and an inferior axis, suggesting origin in the right ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 91691 Version 1.0</div></div></div>"},"91692":{"type":"graphic_waveform","displayName":"ECG ventricular premature beats from left ventricle","title":"12-lead electrocardiogram (ECG) showing ventricular premature beats (VPBs) originating from the left ventricle (LV)","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing ventricular premature beats (VPBs) originating from the left ventricle (LV)</div><div class=\"cntnt\"><img style=\"width:596px; height:373px;\" src=\"images/CARD/91692_ECG_ventr_prem_bts_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twelve-lead electrocardiogram (ECG) showing sinus rhythm with frequent ventricular premature beats (VPBs) in a pattern of ventricular bigeminy. The VPBs have a right bundle branch block&nbsp;morphology, suggesting origin in the left ventricle.</div><div id=\"graphicVersion\">Graphic 91692 Version 2.0</div></div></div>"},"91699":{"type":"graphic_table","displayName":"Colonoscopy guidelines after CRC","title":"Surveillance colonoscopy guidelines for patients with a history of colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surveillance colonoscopy guidelines for patients with a history of colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organization</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Endoscopic surveillance</td> </tr> <tr class=\"divider_bottom\"> <td>ASCO<sup>[1]</sup> and CCO<sup>[2]</sup></td> <td class=\"centered\">2013</td> <td>Colonoscopy at 1 year*; subsequent studies dictated by prior findings. If negative, every 5 years. Proctosigmoidoscopy every 6 months for 2 to 5 years if rectal cancer and no pelvic RT.</td> </tr> <tr class=\"divider_bottom\"> <td>NCCN<sup>[3]</sup></td> <td class=\"centered\">2013</td> <td>Colonoscopy at 1 year<sup>&#182;</sup>; subsequent studies dictated by prior findings. If no advanced adenoma, repeat at 3 years, then every 5 years; if advanced adenoma at 1 year, repeat at 1 year. Proctoscopy every 6 months for 3 to 5 years for rectal cancer if status post low anterior resection of transanal excision.</td> </tr> <tr class=\"divider_bottom\"> <td>American Cancer Society and US Multi-Specialty Task Force on Colorectal Cancer<sup>[4]</sup></td> <td class=\"centered\">2006</td> <td>After clearance for synchronous disease, perform colonoscopy at 1 year. If normal, repeat colonoscopy in 3 years; if normal repeat at 5 years. Shorter intervals (every 3 years) may be indicated for findings of advanced adenoma (three or more adenomas, high-grade dysplasia, villous features or at least one adenoma &#62;1 cm in size), or if the patient's age, family history, or tumor testing indicate definite or probable hereditary nonpolyposis syndrome. For rectal cancer undergoing low anterior resection: endoscopic ultrasound or flexible sigmoidoscopy at 3- to 6-month intervals for the first 2 years.</td> </tr> <tr class=\"divider_bottom\"> <td>ESMO colon cancer<sup>[5]</sup></td> <td class=\"centered\">2013</td> <td>Colonoscopy at 1 year; every 3 to 5 years thereafter.</td> </tr> <tr class=\"divider_bottom\"> <td>ESMO rectal cancer<sup>[6]</sup></td> <td class=\"centered\">2013</td> <td>Colonoscopy every 5 years.</td> </tr> <tr class=\"divider_bottom\"> <td>New Zealand<sup>[7]</sup></td> <td class=\"centered\">2012</td> <td> <p>Colonoscopy at 1 year<sup>&#916;</sup>; colonoscopy every 6 to 12 months for 3 years for high-risk patients (stages IIB, III) then annually for at least 5 years.</p> <p>For low-risk patients, colonoscopy every 3 to 5 years. </p> <p>For rectal cancer: Proctoscopy or sigmoidoscopy at 3, 6, 12, and 24 months postsurgery; colonoscopy at 3- to 5-year intervals thereafter.</p> </td> </tr> <tr class=\"divider_bottom\"> <td>British Columbia Medical Association<sup>[8]</sup></td> <td class=\"centered\">2013</td> <td>Colonoscopy at 1 year; if normal, repeat 3 years later, and if normal, every 5 years thereafter.</td> </tr> <tr> <td>Australia<sup>[9]</sup></td> <td class=\"centered\">2011</td> <td>Colonoscopy 1 year after resection of a sporadic cancer, unless a complete postoperative colonoscopy was performed sooner. If either study shows advanced adenoma (three or more adenomatous polyps, at least one &#62;10 mm, or villous or tubulovillous histology or high-grade dysplasia), repeat at 3 years. Otherwise, the next colonoscopy in 5 years. Patients with Lynch syndrome should have annual surveillance colonoscopy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASCO: American Society of Clinical Oncology; CCO: Cancer Care Ontario; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; RT: radiation therapy.<br />* Except if no preoperative colonoscopy because of obstructing lesion; do as soon as possible after completion of adjuvant chemotherapy rather than waiting until one year.<br />¶ Except if no preoperative colonoscopy because of obstructing lesion; recommend at three to six months rather than waiting until one year.<br />Δ If no complete colonoscopy before surgery, perform colonoscopy within six months.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 2013; [Epub ahead of print].</LI>&#xD;&#xA;<LI>Cancer Care Ontario. <A href=\"http://www.cancercare.on.ca/\" target=_blank>www.cancercare.on.ca</A>.</LI>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Available at: <A href=\"http://www.nccn.org/\" target=_blank>www.nccn.org</A>.</LI>&#xD;&#xA;<LI>Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on colorectal cancer. Available at: <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.3322/canjclin.56.3.160/full\" target=_blank>http://onlinelibrary.wiley.com/doi/10.3322/canjclin.56.3.160/full</A>.</LI>&#xD;&#xA;<LI>Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi81.</LI>&#xD;&#xA;<LI>Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi64.</LI>&#xD;&#xA;<LI>Guidance on surveillance for people at increased risk of colorectal Cancer. Published by the New Zealand Guidelines Group for the Ministry of Health PO Box 10 665, Wellington 6143, New Zealand. Available at: <A href=\"http://www.health.govt.nz/publication/guidance-surveillance-people-increased-risk-colorectal-cancer\" target=_blank>http://www.health.govt.nz/publication/guidance-surveillance-people-increased-risk-colorectal-cancer</A>.</LI>&#xD;&#xA;<LI>British Columbia Medial Association. Follow-up of colorectal polyps or cancer (2013). <A href=\"http://www.bcguidelines.ca/pdf/colorectal_followup.pdf\" target=_blank>http://www.bcguidelines.ca/pdf/colorectal_followup.pdf</A>.</LI>&#xD;&#xA;<LI>Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical Practice Guidelines for Surveillance Colonoscopy – in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Cancer Council Australia, Sydney (December 2011). <A href=\"http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ext0008_colonoscopy_guideline_120314.pdf\" target=_blank>http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ext0008_colonoscopy_guideline_120314.pdf</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 91699 Version 3.0</div></div></div>"},"91701":{"type":"graphic_picture","displayName":"Superficial basal cell carcinoma single lesion","title":"Superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91701_Sup_basal_cell_carc_single.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slightly shiny erythematous macule with minimal scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91701 Version 1.0</div></div></div>"},"91702":{"type":"graphic_picture","displayName":"Superficial basal cell carcinomas","title":"Superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/91702_Superfic_basal_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two erythematous patches with peripheral pearly papules and slight scale. Spotty brown pigment is also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91702 Version 1.0</div></div></div>"},"91703":{"type":"graphic_picture","displayName":"Large superficial basal cell carcinoma","title":"Superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91703_Large_sup_basal_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial basal cell carcinoma manifesting as an erythematous patch measuring several centimeters in diameter on the abdomen. Subtle, small pearly papules are present peripherally. A small second lesion also is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91703 Version 1.0</div></div></div>"},"91704":{"type":"graphic_picture","displayName":"Multiple superficial basal cell carcinomas","title":"Superficial basal cell carcinomas","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinomas</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91704_Mult_super_basal_cell_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules consistent with superficial basal cell carcinomas on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91704 Version 1.0</div></div></div>"},"91706":{"type":"graphic_diagnosticimage","displayName":"Imaging osteomyelitis spine after AAA repair","title":"Osteomyelitis lumbar spine s/p AAA repair","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis lumbar spine s/p AAA repair</div><div class=\"cntnt\"><img style=\"width:552px; height:521px;\" src=\"images/RADIOL/91706_Img_osteomy_spine_sp_AAA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral examination of the lumbar spine (A) shows erosive scalloping of the L2 and L3 vertebral bodies (arrows). Image B is a magnified view of an abscess (arrow) surrounding the aortic graft (arrowhead) and eroding into the vertebral body (dashed arrow). Image C is a bone window of L3 that shows destruction of the vertebral body by the perigraft abscess.</div><div class=\"graphic_footnotes\">s/p: status post; AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 91706 Version 1.0</div></div></div>"},"91707":{"type":"graphic_diagnosticimage","displayName":"MRI discitis and epidural abscess","title":"Discitis lumbar spine and epidural abscess on T2-weighted MRI","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Discitis&nbsp;lumbar spine and epidural abscess on T2-weighted MRI</div><div class=\"cntnt\"><img style=\"width:597px; height:362px;\" src=\"images/RADIOL/91707_T2_MRI_osteomy_epid_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T2-weighted image of the lumbar spine (A) shows an epidural abscess (arrow) extending from the abnormal disc space between L1 and L2 (arrowhead). There is increased signal in the disc. Image B is a magnified view and shows the epidural abscess (arrow) and an abnormal, high intensity disc (arrowhead). The patient received an epidural injection&nbsp;two weeks prior to presentation.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91707 Version 4.0</div></div></div>"},"91708":{"type":"graphic_diagnosticimage","displayName":"CT vertebral osteomyelitis psoas abscess","title":"Vertebral osteomyelitis causing a psoas abscess on CT","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Vertebral osteomyelitis causing a psoas abscess on CT</div><div class=\"cntnt\"><img style=\"width:484px; height:587px;\" src=\"images/RADIOL/91708_CT_verte_osteomy_psoas_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan through the lower abdomen and shows bony destruction of a lumbar vertebral body (arrow) with a swollen right psoas muscle (arrowhead). Image B is a CT scan through the upper pelvis and shows an abscess in the right psoas muscle (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91708 Version 1.0</div></div></div>"},"91709":{"type":"graphic_diagnosticimage","displayName":"Imaging cervical osteomyelitis","title":"Cervical osteomyelitis on radiograph and MRI","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Cervical osteomyelitis on radiograph and MRI</div><div class=\"cntnt\"><img style=\"width:598px; height:362px;\" src=\"images/RADIOL/91709_Imag_cervical_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph of the cervical spine shows bony destruction of C4 (arrow) and C5 (arrowhead)&nbsp;with kyphosis. Image B is a T1-weighted MRI sequence with fat saturation following gadolinium and shows enhancement of C4 and C5 (arrows) and their posterior elements (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91709 Version 2.0</div></div></div>"},"91710":{"type":"graphic_diagnosticimage","displayName":"CT vertebral osteomyelitis","title":"Vertebral osteomyelitis on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Vertebral osteomyelitis on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:385px;\" src=\"images/RADIOL/91710_CT_vertebral_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal reconstruction of the lumbar spine shows disc space widening (arrow) and subtle destruction of the opposing endplates not appreciated on plain radiograph. Image B shows more advanced destruction of bone on either side of the joint space (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91710 Version 2.0</div></div></div>"},"91711":{"type":"graphic_diagnosticimage","displayName":"CT vertebral osteomyelitis paravertebral abscess","title":"Vertebral osteomyelitis and paravertebral abscess on CT","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Vertebral osteomyelitis and paravertebral abscess on CT</div><div class=\"cntnt\"><img style=\"width:456px; height:673px;\" src=\"images/RADIOL/91711_CT_vert_osteo_paravert_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT through the mid-chest shows destruction of the vertebral body (arrow) with a paravertebral abscess (arrowhead). In image B, the paravertebral abscess is overlaid in orange.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91711 Version 2.0</div></div></div>"},"91712":{"type":"graphic_diagnosticimage","displayName":"CT guided aspiration paravertebral abscess","title":"Aspiration of a paravertebral abscess under CT guidance","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Aspiration of a paravertebral abscess under CT guidance</div><div class=\"cntnt\"><img style=\"width:598px; height:348px;\" src=\"images/RADIOL/91712_CT_guided_aspir_paraver_abs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan with the patient in left decubitus position and shows a right-sided paravertebral abscess. Image B shows the tip of the needle as it advances toward the abscess.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91712 Version 1.0</div></div></div>"},"91713":{"type":"graphic_diagnosticimage","displayName":"T1 weighted MRI of lumbar osteomyelitis","title":"Osteomyelitis lumbar spine on T1-weighted MRI","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis lumbar spine on T1-weighted MRI</div><div class=\"cntnt\"><img style=\"width:596px; height:446px;\" src=\"images/RADIOL/91713_T1_weight_MRI_lumbar_osteom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1-weighted image of the lumbar spine (A) shows decreased signal intensity of the vertebral bodies (arrows) and loss of endplate definition (arrowhead). Image B is a magnified view of the ill-defined low intensity disc (arrowhead). There is poor definition of the disc with the low intensity end plates (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91713 Version 2.0</div></div></div>"},"91714":{"type":"graphic_diagnosticimage","displayName":"MRI contrast enhanced lumbar osteomyelitis","title":"Osteomyelitis lumbar spine on T1 contrast-enhanced MRI","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis lumbar spine on T1 contrast-enhanced MRI</div><div class=\"cntnt\"><img style=\"width:598px; height:379px;\" src=\"images/RADIOL/91714_MRI_contrast_lumbar_osteomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast-enhanced MRI of the lumbar spine (A) shows enhancement of the end plates and the vertebral bodies (arrows). Image B is a magnified view of the lumbar spine showing enhancement of the opposing endplates and vertebral bodies (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91714 Version 2.0</div></div></div>"},"91715":{"type":"graphic_table","displayName":"Dose modifications for hematologic side effects","title":"Peginterferon and ribavirin dose reductions for hematologic abnormalities during treatment for chronic hepatitis C virus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peginterferon and ribavirin dose reductions for hematologic abnormalities during treatment for chronic hepatitis C virus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Value</td> <td class=\"subtitle1\">Peginterferon alfa-2a<br /> (starting dose 180 micrograms)</td> <td class=\"subtitle1\">Peginterferon alfa-2b<br /> (starting dose 1.5 micrograms/kg)</td> <td class=\"subtitle1\">Ribavirin<br /> (starting daily dose ranges from 800 to 1400 mg)</td> <td class=\"subtitle1\">Direct acting antiviral</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Hemoglobin</strong>*</td> <td>&#8805;10 g/dL</td> <td>No change</td> <td>No change</td> <td>No change</td> <td>No change</td> </tr> <tr> <td>&#60;10 to 8.5 g/dL<sup>&#916;</sup></td> <td>No change</td> <td>No change</td> <td>Reduce dose:<br /> <ul> <li>by 200 mg total daily dose each week if starting dose &#60;1400 mg </li> <li>by 400 mg total daily dose initially then 200 mg each week if starting dose 1400 mg </li> <li>to 600 mg total daily dose if also using a direct acting antiviral </li> </ul> </td> <td>No change</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;8.5 g/dL</td> <td>No change</td> <td>No change</td> <td>Hold ribavirin for one week, then restart at 600 mg daily dose</td> <td>No change</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Absolute neutrophil count</strong></td> <td>&#8805;500/microL</td> <td>No change</td> <td>No change</td> <td>No change</td> <td>No change</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;500/microL</td> <td>Reduce to 135 micrograms</td> <td>Reduce by 50 percent</td> <td>No change</td> <td>No change</td> </tr> <tr> <td rowspan=\"3\"><strong>Platelets</strong></td> <td>&#8805;50,000/microL</td> <td>No change</td> <td>No change</td> <td>No change</td> <td>No change</td> </tr> <tr> <td>&#60;50,000 to 25,000/microL</td> <td>Reduce to 90 micrograms</td> <td>Reduce by 50 percent</td> <td>No change</td> <td>No change</td> </tr> <tr> <td>&#60;25,000/microL</td> <td>Discontinue</td> <td>Discontinue</td> <td>Discontinue</td> <td>Discontinue</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Ribavirin dose reductions at higher hemoglobin thresholds may be appropriate for patients with comorbidities that make them less likely to tolerate mild to moderate anemia (such as ischemic heart disease).<br />&Delta; Erythropoietic growth factors may be useful for patients who continue to have hemoglobin &lt;10 g/dL despite ribavirin dose reduction as an attempt to avoid ribavirin discontinuation.</div><div id=\"graphicVersion\">Graphic 91715 Version 1.0</div></div></div>"},"91717":{"type":"graphic_diagnosticimage","displayName":"Stented mesenteric bypass graft","title":"Stented mesenteric bypass graft","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Stented mesenteric bypass graft</div><div class=\"cntnt\"><img style=\"width:601px; height:301px;\" src=\"images/RADIOL/91717_Stent_mesent_bypa_grft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CTA of the abdominal aorta (A) in sagittal projection shows a patent celiac axis stent (short arrow), with collateral supply (dashed arrow), bypassing an occluded SMA stent (arrow) to the distal SMA (arrowhead). The IMA is occluded. Image B shows a subsequently placed aortomesenteric graft (dashed arrow). Image C shows occlusion of the graft (dashed arrow) with distal reconstitution (short arrow). Image D is a sagittal reconstruction without contrast and shows stents in the aortomesenteric graft, in the celiac axis (short arrow), SMA (arrow), and common iliac artery (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; CTA: computed tomography angiography; SMA: superior mesenteric artery; IMA: inferior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 91717 Version 2.0</div></div></div>"},"91731":{"type":"graphic_table","displayName":"Emergent and urgent care asthma clinical score - PRAM","title":"Pediatric respiratory assessment measure (PRAM) - Emergent and urgent care asthma clinical score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric respiratory assessment measure (PRAM) - Emergent and urgent care asthma clinical score</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Signs</td> <td class=\"subtitle1\">0</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">3</td> </tr> <tr> <td>Suprasternal indrawing</td> <td>Absent</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Scalene retractions</td> <td>Absent</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Wheezing</td> <td>Absent</td> <td>Expiratory only</td> <td>Inspiratory and expiratory</td> <td>Audible without stethoscope/silent chest with minimal air entry</td> </tr> <tr> <td>Air entry</td> <td>Normal</td> <td>Decreased at bases</td> <td>Widespread decrease</td> <td>Absent/minimal</td> </tr> <tr class=\"divider_bottom\"> <td>Oxygen saturation on room air</td> <td>&#62;93 percent</td> <td>90 percent to 93 percent</td> <td>&#60;90 percent</td> <td>&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Severity classification</td> <td class=\"subtitle1\">PRAM clinical score</td> </tr> <tr> <td class=\"centered\">Mild</td> <td class=\"centered\">0 to 4</td> </tr> <tr> <td class=\"centered\">Moderate</td> <td class=\"centered\">5 to 8</td> </tr> <tr> <td class=\"centered\">Severe</td> <td class=\"centered\">9 to 12</td> </tr> <tr> <td class=\"centered\">Impending respiratory failure</td> <td class=\"centered\">12+ following lethargy, cyanosis, decreasing respiratory effort, and/or rising pCO<sub>2</sub></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">pCO2: partial pressure of carbon dioxide.</div><div class=\"graphic_reference\">Reproduced from: Chalut DS, Ducharme FM, Davis GM. The Preschool Respiratory Assessment Measure (PRAM): a responsive index of acute asthma severity. J Pediatr 2000; 137:762. Original figure modified for this publication. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91731 Version 2.0</div></div></div>"},"91732":{"type":"graphic_table","displayName":"Inpatient asthma clinical score - modified PRAM","title":"Modified pediatric respiratory assessment measure (modified PRAM): Inpatient asthma clinical score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified pediatric respiratory assessment measure (modified PRAM): Inpatient asthma clinical score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Signs</td> <td class=\"subtitle1\">0</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">3</td> </tr> <tr> <td>Suprasternal indrawing</td> <td>Absent</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Scalene retractions</td> <td>Absent</td> <td>&nbsp;</td> <td>Present</td> <td>&nbsp;</td> </tr> <tr> <td>Wheezing</td> <td>Absent</td> <td>Expiratory only</td> <td>Inspiratory and expiratory</td> <td>Audible without stethoscope/silent chest</td> </tr> <tr> <td>Air entry</td> <td>Normal</td> <td>Decreased at bases</td> <td>Widespread decrease</td> <td>Absent/minimal</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Phase change criteria:</STRONG> Score of &lt;3 at routine assessment or&nbsp;clinician order on reassessment in Phase I or Phase II (all phase changes require verbal or written&nbsp;clinician order).<br /><STRONG>For beta<SUB>2</SUB> -agonist assessment:</STRONG> If score ≥3 give beta<SUB>2</SUB> -agonist, if &lt;3 no beta<SUB>2</SUB> -agonist.<br /><STRONG>For any assessment score ≥6:</STRONG> Give beta<SUB>2</SUB> -agonist and notify clinician. If in Phase II or Phase III, move back to previous phase. If in Phase I, consider further investigations, reassess therapy (beta<SUB>2</SUB> -agonist frequency, IV, oxygen, etc) and consider ICU consultation if not responding to treatment.</div><div class=\"graphic_footnotes\">IV: intravenous; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: Chalut DS, Ducharme FM, Davis GM. The Preschool Respiratory Assessment Measure (PRAM):&nbsp;A responsive index of acute asthma severity. J Pediatr 2000; 137:762. Original figure modified for this publication. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91732 Version 2.0</div></div></div>"},"91735":{"type":"graphic_diagnosticimage","displayName":"Carotid artery ultrasound with IMT measurement","title":"Carotid artery ultrasound with measurement of intimal-media thickness (IMT)","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Carotid artery ultrasound with measurement of intimal-media thickness (IMT)</div><div class=\"cntnt\"><img style=\"width:598px; height:267px;\" src=\"images/CARD/91735_Carotid_US_IMT_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular ultrasound imaging is highly accessible, reproducible, safe, and validated as a surrogate endpoint for atherosclerosis. Noninvasive carotid ultrasound (both cross-sectional and longitudinal) is highly suitable for human cardiovascular health assessment in those at risk, as well as for the efficacy assessment of therapeutic and preventive measures. The figure shows B-mode ultrasound images of the carotid artery of a 35-year-old male with type 1 diabetes mellitus without symptomatic cardiovascular disease.<br />(A) In the overview image the sonographer selects a region of interest of the carotid artery.<br />(B) The expanded high-resolution 1.2 x 1.2 cm image is used for the carotid intima-media thickness (c-IMT) measurement. The distance between lumen&ndash;intima interface and the media&ndash;adventitia interface, as depicted by the arrows, shows an increased c-IMT of 1.12 mm in this high at risk subject (reference common c-IMT for gender and age 0.55 to 0.65 mm).</div><div id=\"graphicVersion\">Graphic 91735 Version 1.0</div></div></div>"},"91736":{"type":"graphic_diagnosticimage","displayName":"Carotid artery MRI","title":"Magnetic resonance imaging (MRI) of the carotid artery","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) of the carotid artery</div><div class=\"cntnt\"><img style=\"width:482px; height:656px;\" src=\"images/CARD/91736_Carotid_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery magnetic resonance images (3.0 Tesla) of different stages of atherosclerosis and different atherosclerotic plaque phenotypes. The left column shows the original images, and the right shows the analyzed images.<br />(A) Carotid artery of a young healthy subject without atherosclerosis.<br />(B) Early stage of atherosclerosis in an older healthy subject, with thickening of the vessel wall.<br />(C) Calcified plaque.<br />(D) Fibrous plaque.<br />(E) Plaque with a lipid rich necrotic core.</div><div class=\"graphic_footnotes\">Red line = lumen - wall boundary.<br />Green line = wall - perivascular tissue boundary.<br />Orange = plaque calcification.<br />Yellow = lipid rich necrotic core.</div><div class=\"graphic_reference\">Courtesy of Aart Nederveen, PhD.</div><div id=\"graphicVersion\">Graphic 91736 Version 2.0</div></div></div>"},"91737":{"type":"graphic_figure","displayName":"Interferon gamma intracellular signaling pathway","title":"Intracellular events following engagement of interferon-gamma with its heterodimeric receptor  ","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Intracellular events following engagement of interferon-gamma with its heterodimeric receptor  </div><div class=\"cntnt\"><img style=\"width:513px; height:448px;\" src=\"images/ALLRG/91737_Interferon_gamma_intracellular_signaling_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All four receptor chains (two IFNγR1 and two IFNγR2) approximate and form docking sites for JAKs, which are transphosphorylated, leading to recruitment of STAT1s from the cytosol. STAT1s become transactivated and phosphorylated. Once phosphorylated, STAT1s homodimerize and form GAF. GAF translocates to the nucleus and binds to GAS, initiating transcription of response genes.</div><div class=\"graphic_footnotes\">IFNγR1: interferon-gamma receptor chain 1; IFNγR2: interferon-gamma receptor chain 2; JAK: Janus kinase; STAT1: signal transducer and activator of transcription 1; GAF: interferon-gamma activation factor; GAS: interferon-gamma activated sequence.</div><div id=\"graphicVersion\">Graphic 91737 Version 2.0</div></div></div>"},"91738":{"type":"graphic_table","displayName":"Strategies for patients with Ehlers-Danlos syndrome","title":"Strategies for enhancement of function and prevention of injuries for patients with Ehlers-Danlos syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for enhancement of function and prevention of injuries for patients with Ehlers-Danlos syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>\"Pain is NO gain.\" STOP immediately and do not \"push through\" joint discomfort for sport or work. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Try to soak for 10 to 15 minutes in a hot bath in the evening and in the morning to reduce morning stiffness and aching and nighttime joint pain. Seek a heated pool for swimming. </li> </ul> </td> </tr> <tr> <td> <ul> <li>When a joint \"pops\" in and out (subluxation), use ice immediately to reduce swelling, then apply heat or warm compresses that night. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Minimize running, stair climbing, step aerobics, and stretching yoga to protect hips, knees, and ankles. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Consider tai chi exercises for improving balance, body control, and posture, and for the prevention or worsening of scoliosis and pectus excavatum. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Do not chew gum, hard rolls, or ice, or bite into hard fruit, as this may help prevent temporomandibular (TMJ) pain disorder. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Take breaks during dental work to close your mouth, and remind the dentist that your healing may be delayed and bleeding may be greater than expected. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Participate in a physical therapy program for strengthening and stabilization of joints; use prescribed braces as needed for added stability. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Warn massage therapists against deep tissue massage, which may cause muscle damage. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Choose musical instruments which take advantage of small joint hypermobility (eg, violin, viola, or piano), rather than reeded wind or brass instruments, to help prevent pneumothorax (lung collapse). </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91738 Version 1.0</div></div></div>"},"91784":{"type":"graphic_diagnosticimage","displayName":"CT hemorrhage collecting system post renal biopsy","title":"Hemorrhage into collecting system post renal biopsy on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Hemorrhage into collecting system post renal biopsy on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:337px;\" src=\"images/RADIOL/91784_CT_hemorrh_collecting_syst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan following a renal biopsy (A) shows high density blood in the perinephric space (arrow) and in the collecting system (arrowhead). Image B is a coronal reconstruction and shows high density blood in the renal pelvis (arrowhead) and&nbsp;perinephric space (arrow) with a large amount of&nbsp;layering in the bladder (asterisk).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91784 Version 1.0</div></div></div>"},"91786":{"type":"graphic_figure","displayName":"Recommendations for therapy for management of stage C HFrEF","title":"Recommendations for pharmacological therapy for management of stage C HF<em>r</em>EF","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Recommendations for pharmacological therapy for management of stage C HF<em>r</em>EF</div><div class=\"cntnt\"><img style=\"width:595px; height:838px;\" src=\"images/CARD/91786_Recom_therapy_stage_C_HFrEF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; AF: atrial fibrillation; ARB: angiotensin-receptor blocker; COR: Class of Recommendation; DM: diabetes mellitus; GDMT: guideline-directed medical therapy; HF: heart failure; HF<em>p</em>EF: heart failure with preserved ejection fraction; HF<em>r</em>EF: heart failure with reduced ejection fraction; LOE: Level of Evidence; LVEF: left ventricular ejection fraction; MI: myocardial infarction; N/A: not available; NYHA: New York Heart Association; PUFA: polyunsaturated fatty acids.<br />* In the absence of contraindications to anticoagulation.</div><div class=\"graphic_reference\">Original figure modified for this publication. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91786 Version 2.0</div></div></div>"},"91787":{"type":"graphic_picture","displayName":"Premature desquamation of the inner root sheath","title":"Premature desquamation of the inner root sheath in central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Premature desquamation of the inner root sheath in central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:502px; height:377px;\" src=\"images/DERM/91787_Prem_desqum_in_rt_shth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The follicle on the right side shows premature desquamation of the inner root sheath in a patient with central centrifugal cicatricial alopecia. Compare with the normal follicle on the left.</div><div id=\"graphicVersion\">Graphic 91787 Version 1.0</div></div></div>"},"91788":{"type":"graphic_picture","displayName":"Pathology of central centrifugal cicatricial alopecia","title":"Perifollicular concentric lamellar fibroplasia and perifollicular lymphocytic inflammation in central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Perifollicular concentric lamellar fibroplasia and perifollicular lymphocytic inflammation in central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:502px; height:376px;\" src=\"images/DERM/91788_Pth_cnt_cicatricial_alopec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eccentric epithelial atrophy, concentric lamellar fibroplasia, and perifollicular lymphocytic inflammation in central centrifugal cicatricial alopecia.</div><div id=\"graphicVersion\">Graphic 91788 Version 1.0</div></div></div>"},"91789":{"type":"graphic_picture","displayName":"Pathology of central centrifugal cicatricial alopecia infiltrate","title":"Destructive perifollicular inflammation in central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Destructive perifollicular inflammation in central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:502px; height:480px;\" src=\"images/DERM/91789_Pth_cent_cicat_alop_infilt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note eccentric epithelial atrophy (thinning), concentric lamellar fibroplasia, and perifollicular lymphocytic inflammation. The follicular epithelium surrounding the hair shaft in the right upper portion of the image has been completely destroyed, resulting in a \"naked\" hair shaft.</div><div id=\"graphicVersion\">Graphic 91789 Version 1.0</div></div></div>"},"91790":{"type":"graphic_picture","displayName":"Pathology of central centrifugal cicatricial alopecia scar","title":"Follicular scar in central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Follicular scar in central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:502px; height:377px;\" src=\"images/DERM/91790_Path_centr_cicat_alop_scar.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 91790 Version 1.0</div></div></div>"},"91797":{"type":"graphic_figure","displayName":"Prescription label PI","title":"Prescription medicine label","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Prescription medicine label</div><div class=\"cntnt\"><img style=\"width:593px; height:549px;\" src=\"images/PI/91797_Prescription_label_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whenever you get a new prescription, read the entire label and any other information that comes with the medicine carefully. Make sure you understand all the instructions. If you have any questions about the medicine, ask your pharmacist, doctor, or nurse.</div><div id=\"graphicVersion\">Graphic 91797 Version 1.0</div></div></div>"},"91799":{"type":"graphic_diagnosticimage","displayName":"US physiological hydronephrosis of pregnancy ","title":"Physiological hydronephrosis of pregnancy on US","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Physiological hydronephrosis of pregnancy on US</div><div class=\"cntnt\"><img style=\"width:598px; height:236px;\" src=\"images/RADIOL/91799_US_phys_hydroneph_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ultrasound performed on a 22-week pregnancy shows moderate hydronephrosis (arrowhead) and hydroureter (arrow). Image B is a Doppler study of the bladder and shows a right ureteral jet (arrow).</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91799 Version 1.0</div></div></div>"},"91800":{"type":"graphic_diagnosticimage","displayName":"US ureterolithiais and hydronephrosis in pregnancy","title":"Ureterolithiais and hydronephrosis in pregnancy on US","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ureterolithiais and hydronephrosis in pregnancy on US</div><div class=\"cntnt\"><img style=\"width:598px; height:193px;\" src=\"images/RADIOL/91800_US_uretero_hydron_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sagittal US of the right kidney shows moderate hydronephrosis (asterisks) and perirenal extravasation (arrow). Image B shows a left-sided ureteral jet (arrow). The right jet is absent.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91800 Version 1.0</div></div></div>"},"91801":{"type":"graphic_diagnosticimage","displayName":"US UVJ stone and hydronephrosis in pregnancy","title":"UVJ stone and hydronephrosis in pregnancy on US","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">UVJ stone and hydronephrosis in pregnancy on US</div><div class=\"cntnt\"><img style=\"width:542px; height:453px;\" src=\"images/RADIOL/91801_US_UVJ_stone_hydr_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal ultrasound of the left kidney (A) shows hydronephrosis (asterisks). Image B shows an echogenic distal left UVJ stone (arrow) with posterior shadowing (between arrowheads). The stone is impacted in the left ureteral orifice. Image C is an ultrasound performed six weeks later, after the patient had passed a stone, and shows resolution of the hydronephrosis and a left-sided ureteral jet (arrow image D).</div><div class=\"graphic_footnotes\">UVJ: ureteropelvic junction; US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91801 Version 2.0</div></div></div>"},"91802":{"type":"graphic_diagnosticimage","displayName":"MRI ureterolithiais and hydronephrosis in pregnancy","title":"Ureterolithiais and hydronephrosis in pregnancy on MRI","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ureterolithiais and hydronephrosis in pregnancy on MRI</div><div class=\"cntnt\"><img style=\"width:598px; height:219px;\" src=\"images/RADIOL/91802_MRI_ureter_hydron_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial fat saturated T2 weighted image of the kidney (A) shows moderate hydronephrosis of the right kidney (arrow) with perinephric extravasation (arrowhead). Image B shows periureteric extravasation (arrow) at the pelvic inlet.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91802 Version 2.0</div></div></div>"},"91803":{"type":"graphic_diagnosticimage","displayName":"X-ray abnormal popliteal fossa","title":"Popliteal fossa disease on x-ray","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Popliteal fossa disease on x-ray</div><div class=\"cntnt\"><img style=\"width:597px; height:447px;\" src=\"images/RADIOL/91803_X_abnor_popliteal_foss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral examination of the knee (A) shows a vague soft tissue density (between arrowheads). A popliteal cyst was subsequently confirmed. Image B shows a calcified popliteal aneurysm (between arrowheads). Severe tricompartmental degenerative disease dominant in the patellofemoral joint (arrow) is present.</div><div id=\"graphicVersion\">Graphic 91803 Version 1.0</div></div></div>"},"91804":{"type":"graphic_diagnosticimage","displayName":"US small popliteal cyst","title":"Small popliteal cyst on ultrasound imaging","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Small popliteal cyst on ultrasound imaging</div><div class=\"cntnt\"><img style=\"width:588px; height:277px;\" src=\"images/RADIOL/91804_US_sm_popliteal_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">US in transverse projection shows a popliteal cyst (arrow) that measures 1.1 cm by .75 cm.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91804 Version 2.0</div></div></div>"},"91805":{"type":"graphic_diagnosticimage","displayName":"US popliteal cysts and aneurysm","title":"Popliteal cysts and aneurysm on ultrasound imaging","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Popliteal cysts and aneurysm on ultrasound imaging</div><div class=\"cntnt\"><img style=\"width:658px; height:514px;\" src=\"images/RADIOL/91805_US_popliteal_cysts_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Doppler&nbsp;US of the popliteal fossa shows an anechoic popliteal cyst (arrow). Image B shows a septation in a popliteal cyst (arrow). Image C shows echogenic material (arrows) within a popliteal cyst. Image D is a popliteal aneurysm compressing the popliteal vein (arrowhead). The lumen of the aneurysm (asterisk) is surrounded by thrombus (arrow) within the aneurysm.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91805 Version 2.0</div></div></div>"},"91806":{"type":"graphic_diagnosticimage","displayName":"US ruptured popliteal cyst","title":"Ruptured popliteal cyst on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ruptured popliteal cyst on ultrasound</div><div class=\"cntnt\"><img style=\"width:598px; height:338px;\" src=\"images/RADIOL/91806_US_ruptured_popliteal_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">US through the popliteal fossa (A) in transverse projection shows a decompressed popliteal cyst (arrow). Image B is a longitudinal view inferior to the popliteal fossa and shows fluid dissecting through the muscle planes (arrow).</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 91806 Version 2.0</div></div></div>"},"91807":{"type":"graphic_diagnosticimage","displayName":"MRI and CT of ruptured dissecting popliteal cysts","title":"Ruptured and dissecting popliteal cysts on magnetic resonance imaging and computed tomography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ruptured and dissecting popliteal cysts on magnetic resonance imaging and computed tomography</div><div class=\"cntnt\"><img style=\"width:598px; height:318px;\" src=\"images/RADIOL/91807_Img_rupt_dissect_popl_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal MRI of the knee (A) using a fat saturated proton density sequence shows a popliteal cyst (asterisk) with a thin layer of fluid dissecting in the muscle planes. Image B is a CT and shows a decompressed popliteal cyst (asterisk) with multi-centric regions of thick-walled dissecting fluid collections (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 91807 Version 2.0</div></div></div>"},"91808":{"type":"graphic_diagnosticimage","displayName":"MR arthrogram popliteal cyst","title":"Popliteal cyst on magnetic resonance (MR) arthrogram","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Popliteal cyst on magnetic resonance (MR) arthrogram</div><div class=\"cntnt\"><img style=\"width:569px; height:510px;\" src=\"images/RADIOL/91808_MR_arthrogram_popliteal_cys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 54-year-old woman presents with pain and a prior history of meniscal surgery. Image A is a cross-table lateral examination of the knee following injection of contrast into the joint under fluoroscopic guidance, and it shows a popliteal cyst (arrow). Image B is a sagittal projection using a fat-saturated T1 sequence, and shows the contrast-filled popliteal cyst (arrow). Image C is an axial projection using fat-saturated T1 sequence, and shows the popliteal cyst (arrow) communicating with the knee joint (arrowhead).</div><div id=\"graphicVersion\">Graphic 91808 Version 2.0</div></div></div>"},"91809":{"type":"graphic_diagnosticimage","displayName":"US-guided popliteal cyst aspiration","title":"Popliteal cyst aspiration under ultrasound guidance","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Popliteal cyst aspiration under ultrasound guidance</div><div class=\"cntnt\"><img style=\"width:651px; height:486px;\" src=\"images/RADIOL/91809_US_guided_poplit_cyst_aspir.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI in the axial plane through the knee (A) using a fat-suppressed proton density sequence shows a septated popliteal cyst (arrow). Image B is an ultrasound and shows an anechoic septated cyst. Image C shows a needle tip (arrowhead) in the decompressed cyst (arrow). Eight ccs of thick gelatinous fluid were aspirated.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 91809 Version 3.0</div></div></div>"},"91810":{"type":"graphic_figure","displayName":"Computed tomogram of rounded atelectasis","title":"Computed tomogram of rounded atelectasis","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Computed tomogram of rounded atelectasis</div><div class=\"cntnt\"><img style=\"width:594px; height:425px;\" src=\"images/PULM/91810_Comp_tomo_rnd_atelect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest computed tomogram shows two examples of rounded atelectasis. The&nbsp;upper panel&nbsp;shows a right lower lobe subpleural mass with loss of volume, an adjacent pleural plaque, and a \"comet tail\". The lower panel shows rounded atelectasis originating from the posterobasal segment of the&nbsp;left lower lobe. A subpleural mass with accompanying loss of volume, pleural thickening, and a so-called comet tail connecting the mass to the hilar structures are characteristic for this diagnosis.<br />(B) Graphic representation of rounded atelectasis. A cleft-like invagination of visceral pleura isolates a subsegment of lung that forms a subpleural mass. The bronchi and vessels that connect the mass to hilar structures are pulled into the area of atelectasis and form a so-called comet tail.</div><div class=\"graphic_reference\">Panel B: Courtesy of HE Stark, MD, PhD.</div><div id=\"graphicVersion\">Graphic 91810 Version 1.0</div></div></div>"},"91811":{"type":"graphic_table","displayName":"NCI CTCAE v5 agitation, confusion, delirium","title":"NCI CTCAE v5.0 agitation, confusion, delirium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 agitation, confusion, delirium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Agitation</td> <td>Mild mood alteration</td> <td>Moderate mood alteration</td> <td>Severe agitation; hospitalization not indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Confusion</td> <td>Mild disorientation</td> <td>Moderate disorientation; limiting instrumental ADL*</td> <td>Severe disorientation; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>&nbsp;</td> </tr> <tr> <td>Delirium</td> <td>Mild acute confusional state</td> <td>Moderate and acute confusional state; limiting instrumental ADL*</td> <td>Severe and acute confusional state; limiting self-care ADL*; urgent intervention indicated; new onset</td> <td>Life-threatening consequences, threats of harm to self or others; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Agitation is characterized by a state of restlessness associated with unpleasant feelings of irritability and tension. Confusion is characterized by a lack of clear and orderly thought and behavior. Delirium is characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations; it is usually a reversible condition.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing, using the toilet, taking medications.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 91811 Version 5.0</div></div></div>"},"91821":{"type":"graphic_table","displayName":"Maintaining hemodynamic stability in the pediatric organ donor","title":"Maintaining hemodynamic stability in the pediatric organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maintaining hemodynamic stability in the pediatric organ donor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamically stable</td> <td class=\"subtitle1\">Hemodynamically unstable</td> </tr> <tr> <td> <ul> <li>Methylprednisolone</li> <li>Levothyroxine <strong>OR</strong> triiodothyronine administration should be considered in this patient population</li> <li>Diabetes insipidus<br /> a. Desmopressin*<br /> <p class=\"indent1\">1. Continuous infusion (preferred)<br /> 2. Intermittent dose</p> <p class=\"indent2\"><strong>OR</strong></p> b. Vasopressin administered by continuous infusion</li> </ul> </td> <td> <ul> <li>Volume loading with crystalloid or colloid</li> <li>Inotropic support <ul> <li>Dopamine</li> <li>Dobutamine</li> <li>Epinephrine</li> <li>Phenylephrine</li> <li>Norepinephrine</li> </ul> </li> <li>Methylprednisolone</li> <li>Bolus dose of levothyroxine followed by continuous infusion <strong>OR</strong> triiodothyronine infusion</li> <li>Diabetes insipidus <ul> <li>Vasopressin administered by continuous infusion</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Desmopressin has a longer&nbsp;<FONT size=3 face=calibri>half-</FONT>life than vasopressin.&nbsp;If desmopressin is used, it&nbsp;can be&nbsp;discontinued&nbsp;two to&nbsp;three hours prior to organ recovery, to allow for its metabolism prior&nbsp;to the transplant procedure. Consultation with pediatric intensivists and transplant surgeons should occur to discuss preferences in pharmacologic agents used to maintain hemodynamic stability.</div><div class=\"graphic_reference\">Reproduced with permission from: Nakagawa TA. Updated Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. Copyright &copy; 2008 NATCO.</div><div id=\"graphicVersion\">Graphic 91821 Version 1.0</div></div></div>"},"91822":{"type":"graphic_table","displayName":"Causes of cough related to advanced cancer","title":"Causes of cough related to advanced cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cough related to advanced cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Direct effect of the tumor</td> </tr> <tr> <td class=\"indent1\">Extrinsic or intrinsic airway obstruction</td> </tr> <tr> <td class=\"indent1\">Atelectasis</td> </tr> <tr> <td class=\"indent1\">Esophagorespiratory fistula</td> </tr> <tr> <td class=\"indent1\">Superior vena cava syndrome</td> </tr> <tr> <td class=\"indent1\">Lymphangitic carcinomatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Indirect effect of the tumor</td> </tr> <tr> <td class=\"indent1\">Pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pericardial effusion</td> </tr> <tr> <td class=\"indent1\">Treatment-induced (radiotherapy, chemotherapy [especially bleomycin]) pneumonitis</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Aspiration</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol 2004; 2:523. Copyright &copy; 2004 Frontline Medical Communications LLC.</div><div id=\"graphicVersion\">Graphic 91822 Version 1.0</div></div></div>"},"91823":{"type":"graphic_table","displayName":"Causes of cough in palliative care non-malignant conditions","title":"Non-malignant causes of cough in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-malignant causes of cough in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute (&#60;3 weeks)</td> </tr> <tr> <td class=\"indent1\">Common cold</td> </tr> <tr> <td class=\"indent1\">Acute laryngitis or bronchitis</td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> </tr> <tr> <td class=\"indent1\">Bacterial sinusitis</td> </tr> <tr> <td class=\"indent1\">COPD exacerbations</td> </tr> <tr> <td class=\"indent1\">Pertussis</td> </tr> <tr> <td class=\"indent1\">Environmental irritant</td> </tr> <tr> <td class=\"indent1\">Aspiration</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic (&#62;3 weeks)</td> </tr> <tr> <td class=\"indent1\">PNDS</td> </tr> <tr> <td class=\"indent1\">Cough-variant asthma</td> </tr> <tr> <td class=\"indent1\">GERD</td> </tr> <tr> <td class=\"indent1\">Chronic bronchitis</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Post-infection cough</td> </tr> <tr> <td class=\"indent1\">ACE inhibitors</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Pleural disease</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; PNDS: post-nasal drip syndrome; GERD: gastroesophageal reflux disease; ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Modified with permission from: Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol 2004; 2:523. Copyright © 2004 Frontline Medical Communications LLC.</div><div id=\"graphicVersion\">Graphic 91823 Version 1.0</div></div></div>"},"91827":{"type":"graphic_table","displayName":"Common indoor exposures and variables","title":"Common exposures/variables in nonindustrial indoor environments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common exposures/variables in nonindustrial indoor environments</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Allergens</td> </tr> <tr> <td class=\"indent1\">Molds and fungal spores</td> </tr> <tr> <td class=\"indent1\">Dust mite excreta</td> </tr> <tr> <td class=\"indent1\">Cockroach and other insect antigens</td> </tr> <tr> <td class=\"indent1\">Animal dander and excreta</td> </tr> <tr> <td class=\"indent2\">Domestic animals</td> </tr> <tr> <td class=\"indent2\">Rodents</td> </tr> <tr> <td class=\"indent2\">Other laboratory animals</td> </tr> <tr> <td class=\"indent1\">Pollen</td> </tr> <tr> <td class=\"subtitle1_single\">Gases and \"criteria\" air pollutants</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Nitrogen dioxide</td> </tr> <tr> <td class=\"indent1\">Ozone</td> </tr> <tr> <td class=\"indent1\">Sulfur dioxide</td> </tr> <tr> <td class=\"indent1\">Particulate matter</td> </tr> <tr> <td class=\"subtitle1_single\">Volatile organic compounds</td> </tr> <tr> <td class=\"indent1\">Formaldehyde</td> </tr> <tr> <td class=\"indent1\">Solvents</td> </tr> <tr> <td class=\"indent1\">Paints and resins</td> </tr> <tr> <td class=\"indent1\">Printer and photocopier emissions</td> </tr> <tr> <td class=\"subtitle1_single\">Chemicals found in cleaning products</td> </tr> <tr> <td class=\"indent1\">Ammonia and other solvents</td> </tr> <tr> <td class=\"indent1\">Bleach and other alkalis</td> </tr> <tr> <td class=\"indent1\">Glutaraldehyde</td> </tr> <tr> <td class=\"indent1\">Quaternary ammonia compounds</td> </tr> <tr> <td class=\"indent1\">Alcohols</td> </tr> <tr> <td class=\"indent1\">Acetic acid</td> </tr> <tr> <td class=\"indent1\">Phosphoric acid</td> </tr> <tr> <td class=\"indent1\">Hydrochloric acid</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious agents and bioaerosols</td> </tr> <tr> <td class=\"indent1\">Viruses</td> </tr> <tr> <td class=\"indent1\">Bacteria and mycobacteria</td> </tr> <tr> <td class=\"indent1\">Molds and fungi</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Secondhand smoke</td> </tr> <tr> <td class=\"indent1\">Pesticides</td> </tr> <tr> <td class=\"indent1\">Perfumes</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Temperature</td> </tr> <tr> <td class=\"indent1\">Relative humidity</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91827 Version 1.0</div></div></div>"},"91830":{"type":"graphic_table","displayName":"Well-defined building-related illnesses","title":"Defined disorders that may be attributable to indoor environments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Defined disorders that may be attributable to indoor environments</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Allergic</td> </tr> <tr> <td class=\"indent1\">Allergic contact dermatitis</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis (eczema)</td> </tr> <tr> <td class=\"indent1\">Allergic conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Rhinitis</td> </tr> <tr> <td class=\"indent1\">Eosinophilic bronchitis</td> </tr> <tr> <td class=\"indent1\">Asthma (work related or work exacerbated)</td> </tr> <tr> <td class=\"subtitle1_single\">Irritant</td> </tr> <tr> <td class=\"indent1\">Irritant dermatitis</td> </tr> <tr> <td class=\"indent1\">Dry eyes</td> </tr> <tr> <td class=\"indent1\">Inflammatory conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Upper respiratory tract irritation</td> </tr> <tr> <td class=\"indent1\">Lower respiratory tract irritation</td> </tr> <tr> <td class=\"indent1\">Work-exacerbated asthma</td> </tr> <tr> <td class=\"indent1\">Irritant-induced asthma (including RADS)</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Legionnaires' disease and Pontiac fever</td> </tr> <tr> <td class=\"indent1\">Flu-like illnesses and the common cold</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"indent1\">Pneumoconioses</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide poisoning</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The disorders listed in the table are examples of well-defined (or specific) building-related illnesses.</div><div class=\"graphic_footnotes\">RADS: reactive airways dysfunction syndrome.</div><div id=\"graphicVersion\">Graphic 91830 Version 3.0</div></div></div>"},"91833":{"type":"graphic_algorithm","displayName":"WHO screen and treat protocol","title":"WHO cervical cancer screen and treat protocol","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">WHO cervical cancer screen and treat protocol</div><div class=\"cntnt\"><img style=\"width:449px; height:396px;\" src=\"images/ONC/91833_WHO_screen_treat_protocol.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; LEEP: loop electrosurgical excision procedure; VIA: visual inspection with acetic acid.</div><div class=\"graphic_reference\">Reproduced with permission from: WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, World Health Organization, 2013:XV. Copyright © 2013 World Health Organization. Available at: <A spellcheck=true href=\"http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf\" target=_blank>http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf</A>. (Accessed on October 7, 2014).</div><div id=\"graphicVersion\">Graphic 91833 Version 2.0</div></div></div>"},"91835":{"type":"graphic_table","displayName":"Approach to IT testing in children","title":"Suggested approach to testing for inherited thrombophilia (IT) in pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested approach to testing for inherited thrombophilia (IT) in pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient who has had a venous thromboembolism (VTE)</td> <td class=\"subtitle1\">Recommendation about IT testing</td> <td class=\"subtitle1\">Rationale/comments</td> </tr> <tr> <td>CVC-related, first episode</td> <td>Not recommended</td> <td>IT test results do not alter management. The CVC is the primary risk factor. Possible exceptions are children with a strong family history of VTE.*</td> </tr> <tr> <td>Not CVC-related (with or without other risk factors<sup>&#182;</sup>)</td> <td>Strongly considered</td> <td>Prevalence of IT is higher in this group as compared with children with CVC-associated VTE. Identification of strong thombophilias or combined defect may impact treatment duration or future thromboprophylaxis; counsel/test other family members.</td> </tr> <tr> <td>Recurrent (with or without CVC or other risk factors)</td> <td>Strongly considered</td> <td>These patients are more likely to have an underlying thrombophilia as compared with children with a single episode of VTE. Identification of strong thombophilias or combined defect may impact treatment duration or future thromboprophylaxis; counsel/test other family members.</td> </tr> <tr> <td class=\"subtitle1\">Patient who has NOT had a VTE</td> <td class=\"subtitle1\">Recommendation about IT testing</td> <td class=\"subtitle1\">Rationale/comments</td> </tr> <tr> <td>Healthy children, with a strong family history of IT or VTE*</td> <td>Considered on an individual basis<sup>&#916;</sup></td> <td>Counsel adolescent females about the risk of estrogen (eg, estrogen-containing contraceptives); thromboprophylaxis in high-risk situations. Encourage families to delay IT testing until the child is older.</td> </tr> <tr> <td>Children with acquired risk factors for VTE<sup>&#182;</sup></td> <td>Not recommended</td> <td>Most patients will not develop VTE, not cost effective.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IT: inherited thrombophilia; VTE: venous thromboembolism; CVC: central venous catheter.<br />* VTE developing in a first-degree relative &lt;40 years of age would be considered a strong family history of VTE.<br />¶ Patient-specific risk factors for VTE include estrogen, cancer, central venous catheter [CVC], trauma, or major surgery.<br />Δ When IT testing is undertaken in healthy children who have a family history of thrombosis, we suggest testing only for the well-established genetic thrombophilias, including factor V Leiden mutation, prothrombin 20210 mutation, and deficiencies of antithrombin, protein C, and protein S.</div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 91835 Version 3.0</div></div></div>"},"91838":{"type":"graphic_table","displayName":"Pregnancy heparin dosing","title":"Use of heparins during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of heparins during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Heparin</td> <td class=\"subtitle1\">Dose level</td> <td class=\"subtitle1\">Dosage</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">LMW heparin</td> <td rowspan=\"2\">Prophylactic*</td> <td>Enoxaparin 40 mg SC once daily</td> </tr> <tr> <td>Dalteparin 5000 units SC once daily</td> </tr> <tr> <td rowspan=\"2\">Intermediate<sup>&#182;</sup></td> <td>Enoxaparin 40 mg SC once daily, increase as pregnancy progresses to 1 mg/kg once daily</td> </tr> <tr> <td>Dalteparin 5000 units once daily, increase as pregnancy progresses to 100 units/kg once daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Therapeutic</td> <td>Enoxaparin 1 mg/kg every 12 hours</td> </tr> <tr> <td class=\"divider_bottom\">Dalteparin 100 units/kg every 12 hours</td> </tr> <tr> <td rowspan=\"5\">Unfractionated heparin</td> <td>Prophylactic</td> <td>5000 units SC twice daily</td> </tr> <tr> <td rowspan=\"3\">Intermediate<sup>&#182;</sup></td> <td>First trimester: 5000 to 7500 units every 12 hours</td> </tr> <tr> <td>Second trimester: 7500 to 10,000 units every 12 hours</td> </tr> <tr> <td>Third trimester: 10,000 units every 12 hours</td> </tr> <tr> <td>Therapeutic</td> <td>Dose every 12 hours to keep aPTT at 1.5 to 2.5 times control or patient's baseline six hours after dose</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses apply to pregnant women receiving heparin for venous thromboembolism prophylaxis. Therapeutic dose level refers to doses used both for prophylaxis in individuals at especially high risk and for treatment of venous thromboembolism. This dosing table should <strong>not</strong> be used in women with prosthetic heart valves. Refer to the UpToDate topic on anticoagulant use in pregnancy for details of administration and monitoring. Refer to UpToDate topics on specific pregnant patient populations for other dosing recommendations (eg, prosthetic heart valve, atrial fibrillation, treatment of deep vein thrombosis or pulmonary embolism).</div><div class=\"graphic_footnotes\">LMW: low molecular weight; SC: subcutaneously; aPTT: activated partial thromboplastin time.<br />* Prophylactic dosing may require modifications for extremes of body weight; refer to the UpToDate table on LMW heparin dosing in obesity for details.<br />¶ Our \"intermediate\" dose level differs from that used in society guidelines (eg, ACCP, ACOG).</div><div id=\"graphicVersion\">Graphic 91838 Version 4.0</div></div></div>"},"91839":{"type":"graphic_figure","displayName":"Friedman tongue position","title":"Friedman tongue position","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Friedman tongue position</div><div class=\"cntnt\"><img style=\"width:727px; height:245px;\" src=\"images/NEURO/91839_Friedman_tongue_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) FTP I allows visualization of the entire uvula and tonsils/pillars.<br />(B) FTP IIa allows visualization of most of the uvula, but the tonsils/pillars are absent.<br />(C) FTP IIb allows visualization of the entire soft plate to the base of the uvula.<br />(D) In FTP III some of the soft palate is visualized but the distal structures are absent.<br />(E) FTP IV allows visualization of the hard palate only.<br />Note that tongue should be relaxed within the mouth, not protruded.</div><div class=\"graphic_reference\">Reproduced from: Friedman M. Friedman tongue position and the staging of obstructive sleep apnea/hypopnea syndrome. In: Sleep Apnea and Snoring: Surgical and Nonsurgical Therapy, Scheidt S, Clansey N (Eds), Philadelphia, Elsevier 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91839 Version 2.0</div></div></div>"},"91840":{"type":"graphic_figure","displayName":"Genomic alterations in adult diffuse gliomas","title":"Genomic alterations in adult diffuse gliomas","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Genomic alterations in adult diffuse gliomas</div><div class=\"cntnt\"><img style=\"width:457px; height:427px;\" src=\"images/NEURO/91840_Genomic_alterations_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Suva ML, Louis DN. Next-generation molecular genetics of brain tumours. Curr Opin Neurol 2013; 26:681. DOI: <A href=\"http://journals.lww.com/co-neurology/pages/articleviewer.aspx?year=2013&amp;issue=12000&amp;article=00015&amp;type=abstract\" target=_blank>10.1097/WCO.0000000000000027</A>. Copyright © 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91840 Version 3.0</div></div></div>"},"91841":{"type":"graphic_figure","displayName":"Genomic alterations in pediatric diffuse gliomas","title":"Genomic alterations in pediatric diffuse gliomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genomic alterations in pediatric diffuse gliomas</div><div class=\"cntnt\"><img style=\"width:421px; height:275px;\" src=\"images/NEURO/91841_Genomic_alterations_childr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Suva ML, Louis DN. Next-generation molecular genetics of brain tumours. Curr Opin Neurol 2013; 26:681. DOI: <a href=\"http://journals.lww.com/co-neurology/pages/articleviewer.aspx?year=2013&amp;issue=12000&amp;article=00015&amp;type=abstract\" target=\"_blank\">10.1097/WCO.0000000000000027</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 91841 Version 3.0</div></div></div>"},"91842":{"type":"graphic_picture","displayName":"Calf stretch exercise","title":"Calf stretch exercise","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Calf stretch exercise</div><div class=\"cntnt\"><img style=\"width:525px; height:300px;\" src=\"images/RHEUM/91842_Calf_stretch_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sit with your legs straight and loop a towel around your foot. Then pull the top part of your foot towards you. Hold it like that for 10 to 30 seconds. Repeat this five times each session and do two sessions a day. You can also push the ball of your foot against the towel. This exercises and strengthens the muscles in your foot.</div><div id=\"graphicVersion\">Graphic 91842 Version 1.0</div></div></div>"},"91843":{"type":"graphic_picture","displayName":"Foot ankle circles exercise","title":"Foot ankle circles exercise","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Foot ankle circles exercise</div><div class=\"cntnt\"><img style=\"width:515px; height:452px;\" src=\"images/RHEUM/91843_Foot_ankle_circles_exrcse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With your leg resting against something and your foot in the air, point and flex your foot. Then make circles with your foot by rotating your ankle.</div><div id=\"graphicVersion\">Graphic 91843 Version 1.0</div></div></div>"},"91844":{"type":"graphic_picture","displayName":"Toe curls exercise","title":"Toe curls exercise","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Toe curls exercise</div><div class=\"cntnt\"><img style=\"width:483px; height:367px;\" src=\"images/RHEUM/91844_Toe_curls_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curl your toes around the edge of a book. Then straighten them. Do this over and over again for two minutes, twice a day.</div><div id=\"graphicVersion\">Graphic 91844 Version 1.0</div></div></div>"},"91845":{"type":"graphic_picture","displayName":"Toe towel curls exercise","title":"Toe towel curls exercise","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Toe towel curls exercise</div><div class=\"cntnt\"><img style=\"width:521px; height:308px;\" src=\"images/RHEUM/91845_Toe_towel_curls_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curl your toes around a towel. Then grip and release the towel over and over again for one to two minutes, twice a day.</div><div id=\"graphicVersion\">Graphic 91845 Version 1.0</div></div></div>"},"91846":{"type":"graphic_figure","displayName":"PMR pain distribution","title":"PMR: Distribution of symptoms","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">PMR: Distribution of symptoms</div><div class=\"cntnt\"><img style=\"width:459px; height:672px;\" src=\"images/RHEUM/91846_PMR_pain_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded areas demonstrate the typical sites of aching and stiffness&nbsp;in patients with PMR, including the shoulders and upper arms, posterior neck, and pelvic girdle.</div><div class=\"graphic_footnotes\">PMR: polymyalgia rheumatica.</div><div id=\"graphicVersion\">Graphic 91846 Version 3.0</div></div></div>"},"91851":{"type":"graphic_table","displayName":"Clinical features of androgen insensitivity syndromes","title":"Clinical features and genetics of androgen insensitivity syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features and genetics of androgen insensitivity syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Complete AIS</td> <td class=\"subtitle1\">Partial AIS/female</td> <td class=\"subtitle1\">Partial AIS/male</td> <td class=\"subtitle1\">Minimal AIS</td> </tr> <tr> <td>Gender</td> <td>Female</td> <td>Female</td> <td>Male</td> <td>Male</td> </tr> <tr> <td>Genital appearance</td> <td>Completely female external genitalia, short vagina</td> <td>Clitoromegaly, narrow vagina, variable fusion of labia minora</td> <td>Hypospadias, variable scrotum bifidum</td> <td>Unambiguous male</td> </tr> <tr> <td>Location of gonads</td> <td>Mostly abdominal or inguinal</td> <td>Mostly inguinal</td> <td>Mostly scrotal</td> <td>Scrotal</td> </tr> <tr> <td>Pubertal development</td> <td>Feminization</td> <td>Breast development and slight virilization</td> <td>Persistent gynecomastia and slight virilization</td> <td>Gynecomastia and virilization</td> </tr> <tr> <td>Secondary sexual hair</td> <td>Sparse to absent</td> <td>Sparse</td> <td>Slightly diminished</td> <td>Slightly diminished</td> </tr> <tr> <td>Spermatogenesis</td> <td>Absent</td> <td>Absent</td> <td>Absent to severely impaired</td> <td>Mostly severely impaired</td> </tr> <tr> <td>AR gene mutations</td> <td>Located throughout AR gene</td> <td>Mostly DNA-binding and hormone-binding domain</td> <td>Mostly DNA-binding and hormone-binding domain</td> <td>Located throughout AR gene, in case of spino-bulbar muscular atrophy: within CAG repeat region of N-terminal region</td> </tr> <tr> <td>Timing of gonadectomy</td> <td>Post-pubertal gonadectomy favored</td> <td>Pre-pubertal gonadectomy favored</td> <td>No gonadectomy, but surveillance recommended</td> <td>No gonadectomy, but surveillance recommended</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIS: androgen insensitivity syndrome; AR: androgen receptor.</div><div id=\"graphicVersion\">Graphic 91851 Version 3.0</div></div></div>"},"91858":{"type":"graphic_picture","displayName":"Plantar wart PI","title":"Plantar warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Plantar warts</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/DERM/91858_Plantar_wart_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91858 Version 1.0</div></div></div>"},"91859":{"type":"graphic_picture","displayName":"Flat warts on forehead PI","title":"Flat warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Flat warts</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91859_Flat_warts_on_forehead_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91859 Version 1.0</div></div></div>"},"91860":{"type":"graphic_picture","displayName":"Flat warts forehead PI","title":"Flat warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Flat warts</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/91860_Flat_warts_forehead_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 91860 Version 1.0</div></div></div>"},"91862":{"type":"graphic_picture","displayName":"Areas of palpation of Achilles tendon","title":"Areas of palpation of the Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Areas of palpation of the Achilles tendon</div><div class=\"cntnt\"><img style=\"width:240px; height:515px;\" src=\"images/EM/91862_Area_palp_achill_tend.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different regions of the Achilles tendon are palpated to help identify different pathology. In the photograph above, the superimposed rectangle is the location of Achilles tendinopathy, the arrows indicate the site of subtendinous (or retrocalcaneal) bursitis, and the area of the oval indicates the site of enthesopathy or subcutaneous bursitis. Refer to the text for details.</div><div class=\"graphic_reference\">Courtesy of Peter Ham, MD and Karen Maughan, MD.</div><div id=\"graphicVersion\">Graphic 91862 Version 1.0</div></div></div>"},"91863":{"type":"graphic_diagnosticimage","displayName":"Subtendinous bursitis deep to Achilles tendon","title":"Subtendinous (retrocalcaneal) bursitis deep to Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Subtendinous (retrocalcaneal) bursitis deep to Achilles tendon</div><div class=\"cntnt\"><img style=\"width:537px; height:295px;\" src=\"images/EM/91863_Subtd_burs_achill_tend.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse ultrasound image shows a normal Achilles tendon (arrowhead) and deep to the tendon the hypoechoic (ie, black-appearing)&nbsp;subtendinous (ie, retrocalcaneal)&nbsp;bursa (arrow). The bursa&nbsp;is swollen with fluid, a finding&nbsp;consistent with bursitis.</div><div class=\"graphic_reference\">Courtesy of Bert Fields, MD.</div><div id=\"graphicVersion\">Graphic 91863 Version 1.0</div></div></div>"},"91866":{"type":"graphic_table","displayName":"Types of dissociative amnesia","title":"Types of dissociative amnesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of dissociative amnesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Localized amnesia:</strong> Inability to remember a specific period of time, or a specific event, such as a suicide attempt, or a circumscribed period of time, such as before age 12, all of 2nd and 3rd grade, etc</td> </tr> <tr> <td><strong>Selective amnesia:</strong> Inability to remember some, but not all, of the events during a circumscribed period of time, such as parts of a combat experience, a sexual assault, etc</td> </tr> <tr> <td><strong>Systematized amnesia:</strong> Inability to remember certain categories of memory, such as no recall of one&rsquo;s home-life during 3rd grade, but recalling being at school; or inability to recall a particular person, eg, a reportedly abusive brother</td> </tr> <tr> <td><strong>Continuous amnesia:</strong> Inability to remember successive events as they occur, ie, anterograde dissociative amnesia; may present as dissociative pseudo-delirium, pseudo-dementia, or pseudo-amnestic-confabulatory syndrome</td> </tr> <tr> <td><strong>Generalized (global) amnesia:</strong> Failure to recall the whole life of the person</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91866 Version 2.0</div></div></div>"},"91868":{"type":"graphic_table","displayName":"Differential diagnosis of dissociative amnesia","title":"Differential diagnosis of dissociative amnesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of dissociative amnesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ordinary forgetting</td> </tr> <tr> <td class=\"indent1\">Age-related cognitive decline</td> </tr> <tr> <td class=\"indent1\">Normal autobiographical memory problems</td> </tr> <tr> <td class=\"subtitle1_single\">Non-pathological forms of amnesia</td> </tr> <tr> <td class=\"indent1\">Infantile and childhood amnesia</td> </tr> <tr> <td class=\"indent1\">Amnesia for sleep and dreaming</td> </tr> <tr> <td class=\"indent1\">Hypnotic amnesia</td> </tr> <tr> <td class=\"subtitle1_single\">Dementia</td> </tr> <tr> <td class=\"subtitle1_single\">Delirium</td> </tr> <tr> <td class=\"subtitle1_single\">Amnestic disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Neurological disorders with discrete memory loss episodes</td> </tr> <tr> <td class=\"indent1\">Posttraumatic amnesia</td> </tr> <tr> <td class=\"indent1\">Transient global amnesia</td> </tr> <tr> <td class=\"indent1\">Amnesia related to seizure disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Substance-related amnesia</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Sedative-hypnotics</td> </tr> <tr> <td class=\"indent1\">Anticholinergic agents</td> </tr> <tr> <td class=\"indent1\">Steroids</td> </tr> <tr> <td class=\"indent1\">Marijauna</td> </tr> <tr> <td class=\"indent1\">Narcotic analgesics</td> </tr> <tr> <td class=\"indent1\">Psychedelics</td> </tr> <tr> <td class=\"indent1\">Phencyclidine</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Pentazocine</td> </tr> <tr> <td class=\"indent1\">Hypoglycemic agents</td> </tr> <tr> <td class=\"indent1\">&#946;-blockers</td> </tr> <tr> <td class=\"indent1\">Lithium carbonate</td> </tr> <tr> <td class=\"indent1\">Many others</td> </tr> <tr> <td class=\"subtitle1_single\">Other dissociative disorders</td> </tr> <tr> <td class=\"indent1\">Dissociative fugue</td> </tr> <tr> <td class=\"indent1\">Dissociative identity disorder</td> </tr> <tr> <td class=\"indent1\">Dissociative disorder nos</td> </tr> <tr> <td class=\"subtitle1_single\">Acute stress disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Posttraumatic stress disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Somatization disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Psychotic episode</td> </tr> <tr> <td class=\"indent1\">Lack of memory for psychotic episode when returns to non-psychotic state</td> </tr> <tr> <td class=\"subtitle1_single\">Mood disorder episode</td> </tr> <tr> <td class=\"indent1\">Lack of memory for aspects of episode of mania when depressed and vice versa, or of either when euthymic</td> </tr> <tr> <td class=\"subtitle1_single\">Factitious disorder</td> </tr> <tr> <td class=\"subtitle1_single\">Malingering</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91868 Version 1.0</div></div></div>"},"91871":{"type":"graphic_table","displayName":"Causes of hemoptysis in palliative care patients","title":"Causes of hemoptysis in palliative care patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hemoptysis in palliative care patients</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Coagulopathy</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia, platelet dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Lung abscess</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Necrotizing pneumonia</td> </tr> <tr> <td class=\"indent1\">Parasitic infection</td> </tr> <tr> <td class=\"indent1\">Fungal infection (eg, mycetoma)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Viral infection</td> </tr> <tr> <td class=\"indent1\">Septic pulmonary emboli</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Bronchogenic carcinoma</td> </tr> <tr> <td class=\"indent1\">Metastatic cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic diseases</td> </tr> <tr> <td class=\"indent1\">Goodpasture's syndrome</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Bullous emphysema</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic from diagnostic or therapeutic procedure</td> </tr> <tr> <td class=\"indent1\">Bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Swan Ganz catheter-induced infarction</td> </tr> <tr> <td class=\"indent1\">Pulmonary artery rupture</td> </tr> <tr> <td class=\"indent1\">Transtracheal aspiration</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs or toxins</td> </tr> <tr> <td class=\"indent1\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Aspirin</td> </tr> <tr> <td class=\"indent1\">Thrombolytic agents</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. Clin Chest Med 1994; 15:147.</div><div id=\"graphicVersion\">Graphic 91871 Version 2.0</div></div></div>"},"91872":{"type":"graphic_table","displayName":"Causes of inadequate milk intake","title":"Causes of inadequate milk intake","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of inadequate milk intake</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Comments/explanation/examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Maternal</td> </tr> <tr> <td class=\"indent1\">Breast surgery</td> <td> <p>Breast augmentation in women in whom there was a periareolar incision and/or loss of nipple sensation</p> <p>Breast reduction using the free nipple technique, in which the nipple was completely removed during surgery</p> Biopsy</td> </tr> <tr> <td class=\"indent1\">Nipple conditions</td> <td>Sore nipples may decrease milk supply by infrequent feeds or inadequate emptying</td> </tr> <tr> <td class=\"indent1\">Medications associated with decreased milk production*</td> <td> <p>Combination oral contraceptive pills with high estrogen content</p> <p>Pseudoephedrine</p> <p>Nicotine</p> <p>Diuretics</p> <p>Ethanol: excessive use may decrease milk supply, whereas a small amount may improve breast milk let down</p> Antihistamines in high doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hormonal</td> <td> <p>Pituitary insufficiency</p> <p>Retained placenta</p> <p>Polycystic ovary syndrome</p> Insufficient glandular tissue due to congenital decreased glandular development</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Infant</strong></td> <td> <p>Malformations of the lip and palate, including cleft lip and/or palate</p> <p>Sucking and swallowing disorders</p> <p>Neuromotor delay</p> Premature infants</td> </tr> <tr> <td><strong>Mother and infant dyad</strong></td> <td> <p>Separation of mother and infant dyad</p> Poor latch</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* See LactMed for information on specific medications (<a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\" target=\"_blank\">http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT</a>).</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Reilly S, Reid J, Skeat J, Academy of Breastfeeding Medicine Clinical Protocol Committee. ABM clinical protocol #17: Guidelines for breastfeeding infants with cleft lip, cleft palate, or cleft lip and palate. Breastfeed Med 2007; 2:243.</li>&#xD;&#xA;    <li>Thomas J, Marinelli KA, Hennessy M, Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #16: Breastfeeding the hypotonic infant. Breastfeed Med 2007; 2:112.</li>&#xD;&#xA;    <li>Academy of Breastfeeding Medicine. ABM clinical protocol #10: Breastfeeding the late preterm infant (34(0/7) to 36(6/7) weeks gestation) (first revision June 2011). Breastfeed Med 2011; 6:151.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 91872 Version 1.0</div></div></div>"},"91874":{"type":"graphic_diagnosticimage","displayName":"MRI right UPJ obstruction","title":"MRI demonstrating right ureteropelvic junction obstruction","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">MRI demonstrating right ureteropelvic junction obstruction</div><div class=\"cntnt\"><img style=\"width:513px; height:258px;\" src=\"images/PEDS/91874_MRI_r_UPJ_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI (magnetic resonance imaging) showing ureteropelvic junction obstruction of the right kidney demonstrated by&nbsp;dilation of the&nbsp;renal collecting system&nbsp;(arrows). <br />(A) Coronal view.<br />(B) Transverse view.</div><div class=\"graphic_footnotes\">UPJ: ureteropelvic junction.</div><div id=\"graphicVersion\">Graphic 91874 Version 1.0</div></div></div>"},"91875":{"type":"graphic_diagnosticimage","displayName":"Hydronephrosis due to ureteral polyp","title":"Hydronephrosis due to ureteral polyp","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Hydronephrosis due to ureteral polyp</div><div class=\"cntnt\"><img style=\"width:513px; height:189px;\" src=\"images/PEDS/91875_Hydronephr_urtrl_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography demonstrating hydronephrosis in panel B (arrowheads) caused by a ureteral polyp seen in panel A (arrow).</div><div id=\"graphicVersion\">Graphic 91875 Version 1.0</div></div></div>"},"91876":{"type":"graphic_figure","displayName":"Pathogenesis of infective endocarditis","title":"Pathogenesis of infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of infective endocarditis</div><div class=\"cntnt\"><img style=\"width:612px; height:521px;\" src=\"images/ID/91876_Pathogen_infective_endocard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pathogens gain (transient) access to the bloodstream as a result of healthcare procedures, via a dentogen pathway, or by intravenous drug use.<br />(B) Pathogens can rapidly (within minutes) adhere via platelet fibrin deposition (\"nonbacterial thrombotic endocarditis\") to a mechanically injured valve surface (pre-existing valvular disease) or to an inflamed valve surface (without pre-existing valve disease).<br />(C) Some pathogen species, such as <EM>Staphylococcus aureus</EM>, obtain intracellular access to the valve endothelium, which adds to inflammation and aggressive tissue destruction by the pathogens.<br />(D) Proliferation of the pathogens on and in the endothelium leads to maturation of the vegetation on the valve.<br />(E) Consequently, embolization of vegetation particles and systemic haematogenous spreading of the pathogens often occurs, leading to complications such as ischaemic stroke, cerebral haemorrhage, meningitis or meningeal reaction, brain abscess, and mycotic aneurysm.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cardiology. Werdan K, Dietz S, L&ouml;ffler B, et al. Mechanisms of infective endocarditis: pathogen&ndash;host interaction and risk states. Nat Rev Cardiol 2014; 11:35. <a href=\"http://www.nature.com/nrcardio\" target=\"_blank\">www.nature.com/nrcardio</a>.</div><div id=\"graphicVersion\">Graphic 91876 Version 2.0</div></div></div>"},"91877":{"type":"graphic_figure","displayName":"Mechanisms of infective endocarditis","title":"Mechanisms of infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Mechanisms of infective endocarditis</div><div class=\"cntnt\"><img style=\"width:600px; height:491px;\" src=\"images/ID/91877_Mechan_infective_endocardit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Valve colonization as a consequence of mechanical injury. (1) Nonbacterial thrombotic endocarditis. (2) Bacteria bind to coagulum and colonize it during transient bacteraemia. Adhered monocytes release tissue factor and cytokines. (3) More platelets are attracted and become activated, and the vegetation grows. (4) Endothelial cells are infected and can be lysed by bacterial products or bacteria can persist inside the cells by changing phenotype into small colony variants.<br />(B) Valve colonization as a consequence of an inflammatory endothelial lesion. (1) Activated endothelial cells express integrins that promote the local deposition of fibronectin; bacteria such as <EM>Staphylococcus aureus</EM> adhere to this protein. (2) Bacteria are internalized, and endothelial cells release tissue factor and cytokines, causing blood clotting and promoting the extension of inflammation and vegetation formation. (3) Infected endothelial cells can be lysed by bacterial products or bacteria can persist inside the cells by changing phenotype into small colony variants.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cardiology. Werdan K, Dietz S, L&ouml;ffler B, et al. Mechanisms of infective endocarditis: pathogen&ndash;host interaction and risk states. Nat Rev Cardiol 2014; 11:35. <a href=\"http://www.nature.com/nrcardio\" target=\"_blank\">www.nature.com/nrcardio</a>.</div><div id=\"graphicVersion\">Graphic 91877 Version 2.0</div></div></div>"},"91880":{"type":"graphic_algorithm","displayName":"Traumatic diaphragmatic injury algorithm","title":"Traumatic diaphragmatic injury algorithm","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Traumatic diaphragmatic injury algorithm</div><div class=\"cntnt\"><img style=\"width:692px; height:636px;\" src=\"images/SURG/91880_Trmtc_dphrgmtc_inry_alg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TDI: traumatic diaphragmatic injury; ATLS: advanced trauma life support; CT: computed tomography; MRI: magnetic resonance imaging.<br />* Consider MRI in pregnant patients.<br />&para; Same signs as suspicion for TDI above.<br />&Delta; There are cases of isolated TDI with subtle presentation. Laparoscopy is appropriate in a hemodynamically stable patient with an equivocal CT scan and appropriate mechanism for TDI.<br /><span class=\"lozenge\">&loz;</span> When TDI occurs more centrally, repair may be needed in the first look phase to effectively exclude the abdominal compartment from the thoracic compartment and prevent herniation.<br />&sect; Typical left-sided posterior diaphragmatic injuries.<br />&yen; The need to place mesh in the setting of associated organ injury should prompt careful evaluation to rule out bowel injury and ensure control of all other injuries. A second look should be considered.</div><div id=\"graphicVersion\">Graphic 91880 Version 4.0</div></div></div>"},"91881":{"type":"graphic_table","displayName":"Vaccines cancer patients","title":"Vaccination of patients with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccination of patients with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Prior to or during chemotherapy</td> <td class=\"subtitle1\" colspan=\"2\">Starting &#8805;3 months postchemotherapy and &#8805;6 months post anti-B cell antibodies for inactivated vaccines; see each live vaccine for interval</td> </tr> <tr> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> </tr> <tr> <td><em>Haemophilus influenzae</em> b conjugate</td> <td>U*</td> <td>Weak, low</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Hepatitis A</td> <td>U*</td> <td>Weak, low</td> <td>U</td> <td>Strong, very low</td> </tr> <tr> <td>Hepatitis B</td> <td>U*</td> <td>Weak, low</td> <td> <p>U</p> R: adults</td> <td> <p>Strong, moderate</p> Strong, very low</td> </tr> <tr> <td>Diphtheria toxoid, tetanus toxoid, acellular pertussis; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis</td> <td>U*</td> <td>Weak, low</td> <td> <p>U: age 0 to 18 years</p> R: adults with acute lymphoblastic leukemia or lymphoma</td> <td> <p>Strong, moderate</p> Weak, very low</td> </tr> <tr> <td>Human papillomavirus</td> <td>U: age 11 to 26 years*</td> <td>Weak, very low</td> <td>U</td> <td>Strong, very low</td> </tr> <tr> <td>Influenza-inactivated (inactivated influenza vaccine)</td> <td>U*</td> <td>Strong, low-moderate*</td> <td>U<sup>&#182;</sup></td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza-live attenuated (live attenuated influenza vaccine)</td> <td>X</td> <td>Weak, very low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Measles, mumps, and rubella-live</td> <td>X<sup>&#916;</sup></td> <td>Strong, moderate</td> <td>Starting at 3 months: U<sup></sup></td> <td>Strong, low</td> </tr> <tr> <td>Measles, mumps, and rubella-varicella-live</td> <td>X<sup>&#916;</sup></td> <td>Strong, moderate</td> <td>Starting at 3 months: U</td> <td>Weak, very low</td> </tr> <tr> <td>Meningococcal conjugate</td> <td>U*</td> <td>Weak, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Pneumococcal conjugate-13 (PCV13)</td> <td> <p>R: age &#60;6 years</p> R: age &#8805;6 years<sup>&#9674;</sup></td> <td> <p>Strong, low</p> Strong, very low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Pneumococcal polysaccharide (PPSV23)</td> <td>R: age &#8805;2 years</td> <td>Strong, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Polio-inactivated (inactivated poliovirus vaccine)</td> <td>U*</td> <td>Weak, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Rotavirus-live</td> <td>X</td> <td>Strong, very low</td> <td>Not applicable</td> <td>&nbsp;</td> </tr> <tr> <td>Varicella-live</td> <td>X<sup>&#916;</sup></td> <td>Strong, moderate</td> <td>Starting at 3 months: U<sup>&#167;</sup></td> <td>Weak, very low</td> </tr> <tr> <td>Zoster-live</td> <td>X<sup>&#916;</sup></td> <td>Strong, very low</td> <td>Starting at 3 months: U<sup>&#167;</sup></td> <td>Weak, very low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">R: recommended - administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection; U: usual - administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories; X: contraindicated.<br />* Administer inactivated influenza vaccine (IIV) annually to patients with hematological malignancies (strong, moderate) or solid tumor malignancies (strong, low) except those receiving anti-B-cell antibodies such as rituximab or alemtuzumab (weak, low). The Infectious Diseases Society of America also suggests that IIV be avoided in patients receiving intensive chemotherapy such as for induction or consolidation therapy for acute leukemia (weak, low). However, we favor giving an inactivated influenza vaccine to such patients given the need for annual administration to protect against circulating seasonal strains of influenza. Administration of inactivated vaccines other than IIV, which are routinely recommended for healthy children in the annually updated United States Centers for Disease Control and Prevention (CDC) recommendations, can be considered for children with malignancies who are receiving maintenance chemotherapy (weak, low). However, vaccines administered while receiving cancer chemotherapy should not be considered valid doses (strong, low). Administration of indicated inactivated vaccines 2 or more weeks prior to chemotherapy is preferred.<br />&para; IIV can be administered &le;3 months after chemotherapy, but response rate may be low.<br />&Delta; These live vaccines should not be administered unless the vaccine is otherwise indicated based on the annually updated CDC recommendations AND the patient is not immunosuppressed AND there will be an interval of &ge;4 weeks prior to initiation of chemotherapy.<br /><span class=\"lozenge\">&loz;</span> For patients aged &ge;19 years who have received PPSV23, PCV13 should be administered after an interval of &ge;1 year after the last PPSV23 dose (weak, low).<br />&sect; Although measles, mumps, and rubella vaccine has been given safely three months after completion of chemotherapy, data on the safety, immunogenicity, and efficacy of varicella or zoster vaccine after completion of chemotherapy are not available.</div><div class=\"graphic_reference\">Adapted from: Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58:e44. By permission of the Infectious Disease Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91881 Version 11.0</div></div></div>"},"91882":{"type":"graphic_table","displayName":"Vaccines HCT recipients","title":"Vaccinations prior to or after allogeneic or autologous hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccinations prior to or after allogeneic or autologous hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"32%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Pre-HCT</td> <td class=\"subtitle1\" colspan=\"2\">Post-HCT</td> </tr> <tr> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> <td class=\"subtitle2\">Recommendation; earliest time posttransplant; number of doses</td> <td class=\"subtitle2\">Strength, evidence quality</td> </tr> <tr> <td><em>Haemophilus influenzae</em> b conjugate</td> <td>U</td> <td>Strong, moderate</td> <td>R;&nbsp;six months;&nbsp;three doses</td> <td>Strong, moderate</td> </tr> <tr> <td>Hepatitis A</td> <td>U</td> <td>Strong, very low</td> <td>R; six months;&nbsp;two doses</td> <td>Weak, low</td> </tr> <tr> <td>Hepatitis B</td> <td>U</td> <td>Strong, low</td> <td>R; six months;&nbsp;three doses</td> <td>Strong, moderate</td> </tr> <tr> <td rowspan=\"2\">DTaP, DT, Td, Tdap</td> <td rowspan=\"2\">U</td> <td rowspan=\"2\">Strong, low</td> <td>R; age &#60;7 years: DTaP;&nbsp;six months;&nbsp;three doses</td> <td>Strong, low</td> </tr> <tr> <td> <p>R; age &#8805;7 years: DTaP*; six months;&nbsp;three doses</p> <p>OR</p> one&nbsp;dose Tdap, then&nbsp;two doses DT* or Td;&nbsp;six months</td> <td> <p>Weak, very low</p> <p>DTaP: weak, moderate</p> DT, Td: weak, low</td> </tr> <tr> <td>Human papillomavirus</td> <td>U: 11 to 26 years</td> <td>Strong, very low</td> <td>U;&nbsp;six months;&nbsp;three doses</td> <td>Weak, very low</td> </tr> <tr> <td>Influenza-inactivated (inactivated influenza vaccine)</td> <td>U</td> <td>Strong, low</td> <td>R;&nbsp;four months</td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza-live attenuated (live attenuated influenza vaccine)</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Measles, mumps, and rubella-live</td> <td>U<sup>&#182;</sup></td> <td>Strong, very low</td> <td>X<sup>&#916;</sup></td> <td>Strong, low</td> </tr> <tr> <td>Measles, mumps, and rubella-varicella-live</td> <td>U<sup>&#182;</sup></td> <td>Weak, very low</td> <td>X</td> <td>Strong, very low</td> </tr> <tr> <td>Meningococcal conjugate</td> <td>U</td> <td>Strong, very low</td> <td>R; age 11 to 18 years;&nbsp;six months;&nbsp;two doses</td> <td>Strong, low</td> </tr> <tr> <td>Pneumococcal conjugate (PCV13)</td> <td>R<sup>&#9674;</sup></td> <td>Strong, low</td> <td>R;&nbsp;three months;&nbsp;three doses</td> <td>Strong, low</td> </tr> <tr> <td>Pneumococcal polysaccharide (PPSV23)</td> <td>R<sup>&#9674;</sup></td> <td>Strong, very low</td> <td>R; &#8805;12 months post if no GVHD</td> <td>Strong, low</td> </tr> <tr> <td>Polio-inactivated (inactivated poliovirus vaccine)</td> <td>U</td> <td>Strong, very low</td> <td>R;&nbsp;three months;&nbsp;three doses</td> <td>Strong, moderate</td> </tr> <tr> <td>Rotavirus-live</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Varicella-live</td> <td>U<sup>&#182;</sup></td> <td>Strong, low</td> <td>X<sup>&#167;</sup></td> <td>Strong, low</td> </tr> <tr> <td rowspan=\"2\">Zoster-live</td> <td>R<sup>&#182;</sup><sup>&#165;</sup>: age 50 to 59 years*</td> <td>Weak, very low</td> <td>X</td> <td>Strong, low</td> </tr> <tr> <td>U<sup>&#182;</sup>: age &#8805;60 years</td> <td>Strong, low</td> <td>X</td> <td>Strong, low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplant; U: usual&nbsp;– administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories; R: recommended – administer if not previously administered or current; such patients may be at increased risk for this vaccine-preventable infection;&nbsp;DT: diphtheria toxoid, tetanus toxoid; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis; Td: tetanus toxoid, reduced diphtheria toxoid; Tdap: tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; X: contraindicated; GVHD: graft-versus-host disease.<br />* Indicates recommendation for a course of action that deviates from recommendations of the Advisory Committee on Immunization Practices, United States Centers for Disease Control and Prevention (CDC).<br />¶ These live vaccines should not be administered unless the vaccine is otherwise indicated based on the annually updated CDC recommendations AND the patient is not immunosuppressed AND there will be an interval of ≥4 weeks prior to transplant.<br />Δ Administer to adolescents and adults (strong, low) and to children (strong, moderate) if measles seronegative, the timing is ≥24 months after transplant, no GVHD is present, and the patient is not receiving immunosuppressive medication. Two doses should be administered.<br /><FONT class=lozenge>◊</FONT> If not previously administered.<br />§ Administer if varicella seronegative, the timing is ≥24 months after transplant, no GVHD is present, and the patient is not receiving immunosuppressive medication. Two doses should be administered (strong, low).<br />¥ Consider if the patient is not severely immunosuppressed AND the patient is varicella immune as defined by documentation of age-appropriate varicella vaccination, serologic evidence of immunity, documentation of varicella or zoster infection, or birth in the United States before 1980<SUP>[1]</SUP> AND there will be an interval of ≥4 weeks prior to transplant.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</LI></OL>Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.</LI></OL>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58:e44. By permission of the Infectious Disease Society of America. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91882 Version 15.0</div></div></div>"},"91883":{"type":"graphic_table","displayName":"Vaccines SOT recipients","title":"Vaccinations prior to or after solid organ transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccinations prior to or after solid organ transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Pretransplant</td> <td class=\"subtitle1\" colspan=\"2\">Starting 2 to 6 months posttransplant</td> </tr> <tr> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> </tr> <tr> <td><em>Haemophilus influenzae</em> b conjugate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Hepatitis A</td> <td> <p>U: age 12 to 23 months</p> R: age &#8805;2 years</td> <td> <p>Strong, moderate</p> Strong, moderate</td> <td>R, if not completed pretransplant</td> <td>Strong, moderate</td> </tr> <tr> <td>Hepatitis B</td> <td> <p>U: age 1 to 18 years</p> R: age &#8805;18 years</td> <td> <p>Strong, moderate</p> Strong, moderate</td> <td>R, if not completed pretransplant*</td> <td>Strong, moderate</td> </tr> <tr> <td>Diphtheria toxoid, tetanus toxoid, acellular pertussis; tetanus toxoid, reduced diphtheria toxoid; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis</td> <td>U</td> <td>Strong, moderate</td> <td>U, if not completed pretransplant</td> <td>Strong, moderate</td> </tr> <tr> <td>Human papillomavirus</td> <td> <p>U: females 11 to 26 years</p> U: males 11 to 26 years</td> <td> <p>Strong, moderate</p> Strong, low</td> <td> <p>U: females 11 to 26 years</p> U: males 11 to 26 years</td> <td> <p>Strong, moderate</p> Strong, low</td> </tr> <tr> <td>Influenza-inactivated (inactivated influenza vaccine)</td> <td>U</td> <td>Strong, moderate</td> <td>U<sup>&#182;</sup></td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza-live attenuated (live attenuated influenza vaccine)</td> <td>X</td> <td>Weak, low</td> <td>X</td> <td>Weak, low</td> </tr> <tr> <td>Measles, mumps, and rubella-live</td> <td> <p>R<sup>&#916;</sup>: age 6 to 11 months</p> U<sup>&#9674;</sup>: age &#8805;12 months</td> <td> <p>Weak, very low</p> Strong, moderate</td> <td>X</td> <td>Strong, low</td> </tr> <tr> <td>Measles, mumps, and rubella-varicella-live</td> <td>U<sup>&#9674;</sup></td> <td>Strong, moderate</td> <td>X</td> <td>Strong, low</td> </tr> <tr> <td>Meningococcal conjugate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Pneumococcal conjugate (PCV13)</td> <td> <p>U: age &#8804;5 years</p> R: age &#8805;6 years<sup>&#167;</sup></td> <td> <p>Strong, moderate</p> Strong, very low</td> <td> <p>U: age 2 to 5 years</p> R: age &#8805;6 years if not administered pretransplant<sup>&#167;</sup></td> <td> <p>Strong, moderate</p> Strong, very low</td> </tr> <tr> <td>Pneumococcal polysaccharide (PPSV23)</td> <td>R: age &#8805;2 years</td> <td>Strong, moderate</td> <td>R: age &#8805;2 years, if not administered pretransplant</td> <td>Strong, moderate</td> </tr> <tr> <td>Polio-inactivated (inactivated poliovirus vaccine)</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Rotavirus-live</td> <td>U<sup>&#916;</sup></td> <td>Strong, moderate</td> <td>X</td> <td>Strong, low</td> </tr> <tr> <td>Varicella-live</td> <td> <p>R<sup>&#165;</sup>: age 6 to 11 months</p> U<sup>&#9674;</sup></td> <td> <p>Weak, very low</p> Strong, low</td> <td>X<sup>&#135;</sup></td> <td>Strong, low</td> </tr> <tr> <td>Zoster-live</td> <td> <p>R<sup>&#134;</sup>: age 50 to 59 years</p> U**: age &#8805;60 years</td> <td> <p>Weak, low</p> Strong, moderate</td> <td>X</td> <td>Strong, low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">R: recommended - administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection; U: usual - administer if patient not current with annually updated United States Centers for Disease Control and Prevention (CDC) recommendations for immunocompetent persons in risk and age categories; X: contraindicated.<br />* Consider hepatitis B vaccine for hepatitis B-infected liver transplant patients (weak, low).<br />¶&nbsp;Inactivated influenza vaccine may be administered to solid organ transplant recipients despite intensive immunosuppression (eg, during the immediate posttransplant period), particularly in an outbreak situation (weak, low).<br />Δ Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant.<br /><FONT class=lozenge>◊</FONT> Administer only if patient is nonimmune, not severely immunosuppressed, and the timing is ≥4 weeks prior to transplant.<br />§ For patients aged ≥19 years who have received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose (weak, low).<br />¥ Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant. This recommendation deviates from recommendations of the Advisory Committee on Immunization Practices, CDC.<br />‡ Selected seronegative patients with renal or liver transplant have been safely vaccinated. This recommendation deviates from recommendations of the Advisory Committee on Immunization Practices, CDC.<br />† Administer only if patient is not severely immunosuppressed, the timing is ≥4 weeks prior to transplant, and the patient is varicella immune as defined by documentation of age-appropriate varicella vaccination, serologic evidence of immunity, documentation of varicella or zoster infection, or birth in the United States before 1980<SUP>[1,2]</SUP>. This recommendation deviates from recommendations of the Advisory Committee on Immunization Practices, CDC.<br />** Administer only if patient is not severely immunosuppressed and the timing is ≥4 weeks prior to transplant.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</LI>&#xD;&#xA;<LI>Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009; 9 (Suppl 4):S273.<br /></LI></OL>From: Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58:e44. By permission of the Infectious Disease Society of America. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91883 Version 10.0</div></div></div>"},"91884":{"type":"graphic_table","displayName":"Vaccines inflammatory diseases","title":"Vaccination of persons with chronic inflammatory diseases on immunosuppressive medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccination of persons with chronic inflammatory diseases on immunosuppressive medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Planned immunosuppression</td> <td class=\"subtitle1\" colspan=\"2\">Low-level immunosuppression*</td> <td class=\"subtitle1\" colspan=\"2\">High-level immunosuppression*</td> </tr> <tr> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> </tr> <tr> <td><em>Haemophilus influenzae</em> b conjugate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Hepatitis A</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Hepatitis B</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Diphtheria toxoid, tetanus toxoid, acellular pertussis; tetanus toxoid, reduced diphtheria toxoid; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Human papillomavirus</td> <td>U: 11 to 26 years</td> <td>Strong, moderate</td> <td>U: 11 to 26 years</td> <td>Strong, low</td> <td>U: 11 to 26 years</td> <td>Strong, very low</td> </tr> <tr> <td>Influenza-inactivated (inactivated influenza vaccine)</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza live-attenuated (live-attenuated influenza vaccine)</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Measles, mumps, and rubella-live</td> <td>U<sup>&#182;</sup></td> <td>Strong, moderate</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Measles, mumps, and rubella-varicella-live</td> <td>U<sup>&#182;</sup></td> <td>Strong, low</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Strong, very low</td> </tr> <tr> <td>Meningococcal conjugate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Pneumococcal conjugate (PCV13)</td> <td>R<sup>&#916;</sup></td> <td>Strong, moderate</td> <td>U: &#60;6 years<br /> R: &#8805;6 years<sup>&#916;</sup></td> <td>Strong, low<br /> Strong, very low</td> <td>U: &#60;6 years<br /> R: &#8805;6 years<sup>&#916;</sup></td> <td>Strong, low<br /> Strong, very low</td> </tr> <tr> <td>Pneumococcal polysaccharide (PPSV23)</td> <td>R: age &#8805;2 years</td> <td>Strong, low</td> <td>R: age &#8805;2 years</td> <td>Strong, low</td> <td>R: age &#8805;2 years</td> <td>Strong, very low</td> </tr> <tr> <td>Polio-inactivated (inactivated poliovirus vaccine)</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, moderate</td> <td>U</td> <td>Strong, low</td> </tr> <tr> <td>Rotavirus-live</td> <td>U</td> <td>Strong, moderate</td> <td>X</td> <td>Weak, very low</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Varicella-live</td> <td>U<sup>&#182;</sup></td> <td>Strong, moderate</td> <td>X<sup>&#9674;</sup></td> <td>Weak, very low</td> <td>X</td> <td>Strong, moderate</td> </tr> <tr> <td>Zoster-live</td> <td>R: age 50 to 59 years<sup>&#167;</sup><br /> U: age &#8805;60 years</td> <td>Weak, low<br /> Strong, low</td> <td>R: age 50 to 59 years<sup>&#167;</sup><br /> U: age &#8805;60 years</td> <td>Weak, very low<br /> Strong, very low</td> <td>X</td> <td>Weak, very low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">U: usual - administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories; X: contraindicated; R: recommended - administer if not previously administered or not current (such patients may be at increased risk for this vaccine-preventable infection); ACIP: Advisory Committee on Immunization Practices; CDC: United States Centers for Disease Control and Prevention.<br />* Low-level immunosuppression includes treatment with &lt;20 mg/day prednisone equivalents (or &lt;2 mg/kg per day for patients who weigh &lt;10 kg) for &lt;14 days, methotrexate ≤0.4 mg/kg per week, azathioprine ≤3 mg/kg per day, or 6-mercaptopurine ≤1.5 mg/kg per day. High-level immunosuppression regimens include treatment with doses higher than those listed for low-dose immunosuppression and biologic agents such as tumor necrosis factor-alpha antagonists or rituximab.<br />¶ Administer only if patient is nonimmune, not severely immunosuppressed, and the timing is ≥4 weeks prior to initiation of immunosuppressive medications.<br />Δ For patients aged ≥19 years who have received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose (weak, low).<br /><FONT class=lozenge>◊</FONT> Administration of varicella vaccine can be considered for non-varicella-immune patients treated for chronic inflammatory disease who are receiving long-term low-dose immunosuppression (weak, very low). This recommendation deviates from recommendations of the ACIP,&nbsp;CDC.<br />§ This recommendation deviates from recommendations of the ACIP, CDC<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1&ndash;30.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58:e44. By permission of the Infectious Disease Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91884 Version 16.0</div></div></div>"},"91885":{"type":"graphic_table","displayName":"Vaccines asplenia or sickle cell disease","title":"Vaccination of persons with asplenia or sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccination of persons with asplenia or sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Asplenia or sickle cell disease</td> </tr> <tr> <td class=\"subtitle2\">Recommendation</td> <td class=\"subtitle2\">Strength, evidence quality</td> </tr> <tr> <td rowspan=\"2\"><em>Haemophilus influenzae</em> b conjugate</td> <td>U: age &#60;5 years</td> <td>Strong, moderate</td> </tr> <tr> <td>R: age &#8805;5 years</td> <td>Weak, low</td> </tr> <tr> <td>Hepatitis A</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Hepatitis B</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Diphtheria toxoid, tetanus toxoid, acellular pertussis; tetanus toxoid, reduced diphtheria toxoid; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Human papillomavirus</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza-inactivated (inactivated influenza vaccine)</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Influenza-live attenuated (live attenuated influenza vaccine)</td> <td>X</td> <td>Weak, very low</td> </tr> <tr> <td>Measles, mumps, and rubella-live</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Measles, mumps, and rubella-varicella-live</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Meningococcal conjugate*</td> <td>R<sup>&#182;</sup></td> <td>Strong, low</td> </tr> <tr> <td>Meningococcal serogroup B</td> <td>R if age &#8805;10 years<sup>&#916;</sup></td> <td>Strong, low</td> </tr> <tr> <td rowspan=\"2\">Pneumococcal conjugate (PCV13)</td> <td>U: age &#60;6 years<sup>&#9674;</sup></td> <td>Strong, moderate</td> </tr> <tr> <td>R: age &#8805;6 years<sup>&#167;</sup></td> <td>Strong, very low</td> </tr> <tr> <td>Pneumococcal polysaccharide (PPSV23)</td> <td>R: age &#8805;2 years<sup>&#165;</sup></td> <td>Strong, low</td> </tr> <tr> <td>Polio-inactivated (inactivated poliovirus vaccine)</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Rotavirus-live</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Varicella-live</td> <td>U</td> <td>Strong, moderate</td> </tr> <tr> <td>Zoster-live</td> <td>U</td> <td>Strong, moderate</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to related UpToDate content for immunization schedules and additional details. </div><div class=\"graphic_footnotes\">R: recommended—administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection; U: usual—administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories; X: contraindicated.<br />* Only the quadrivalent meningococcal polysaccharide vaccine (Menomune, MPSV4) has been approved by the US Food and Drug Administration for individuals ≥56 years of age; however, this vaccine was discontinued in 2017. In addition, a quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) is preferred by the United States Advisory Committee on Immunization Practices (ACIP) for individuals in this age group who are expected to require revaccination since limited data demonstrate a higher antibody response after a subsequent dose of a quadrivalent meningococcal conjugate vaccine compared with a subsequent dose of the quadrivalent meningococcal polysaccharide vaccine.<br />¶ A two-dose primary series should be administered with an additional dose every five years.<br />Δ A meningococcal serogroup B vaccine should be administered as either a two-dose series of Bexsero or a three-dose series of Trumenba.<br />◊ Two doses of PCV13 for children aged two to five years who have not received doses of PCV or received &lt;3 doses of PCV7.<br />§&nbsp;If PCV13 has not been administered. For patients aged ≥19 years who have received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose (weak, low).<br />¥&nbsp;Administer eight or more weeks after indicated dose(s) of PCV13 with a single revaccination with PPSV23 five years after the initial dose (strong, moderate).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</LI>&#xD;&#xA;<LI>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 2013; 58:e44.</LI>&#xD;&#xA;<LI>Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup&nbsp;B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608.</LI>&#xD;&#xA;<LI>Kim DK, Riley LE, Harriman KH, et al. Recommended Immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med 2017; 166:209.</LI></OL>Adapted from: Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58:e44. By permission of the Infectious Disease Society of America. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 91885 Version 15.0</div></div></div>"},"91891":{"type":"graphic_table","displayName":"Ov tub perit ca immunohist gene mutat","title":"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Common immunohistochemical profiles and gene mutations in histologic subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Common immunohistochemical profiles and gene mutations in histologic subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Common immunoprofile</td> <td class=\"subtitle1\">Common gene mutations</td> </tr> <tr> <td><strong>High-grade serous</strong></td> <td> <p>P53+</p> <p>WT1+</p> <p>Pax8+</p> High Ki67</td> <td> <p><em>TP53</em></p> <em>BRCA1,2</em></td> </tr> <tr> <td><strong>Low-grade serous</strong></td> <td> <p>WT1+</p> <p>Pax8+</p> <p>p53 wild type</p> Low Ki67</td> <td> <p><em>BRAF</em></p> <em>KRAS</em></td> </tr> <tr> <td><strong>Endometrioid</strong></td> <td> <p>Estrogen receptor (ER)+</p> <p>Pax8+</p> <p>Vimentin+</p> <p>WT1-</p> p53 wild type</td> <td> <p><em>PTEN</em></p> <em>CTNNB-1</em> (beta-catenin)</td> </tr> <tr> <td><strong>Clear cell</strong></td> <td> <p>HNF beta+</p> <p>WT1-</p> ER-</td> <td> <p><em>KRAS</em></p> <p><em>PTEN</em></p> <em>PIK3CA</em></td> </tr> <tr> <td><strong>Mucinous</strong></td> <td> <p>CK20+</p> <p>cdx2+</p> <p>CK7+</p> <p>ER-</p> WT1-</td> <td><em>KRAS</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91891 Version 1.0</div></div></div>"},"91893":{"type":"graphic_table","displayName":"Adult PCOS phenotypes","title":"Polycystic ovary syndrome adult phenotypes, in order of decreasing clinical severity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polycystic ovary syndrome adult phenotypes, in order of decreasing clinical severity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"75%\"></colgroup><colgroup span=\"5\" width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Phenotype 1 (classic PCOS)</td> <td style=\"vertical-align: middle;\" class=\"highlight_red_text centered\" rowspan=\"13\"><strong>Rotterdam criteria, 2003<sup>[1]</sup>&nbsp;</strong></td> <td style=\"vertical-align: middle;\" class=\"highlight_blue_text centered divider_bottom\" rowspan=\"10\"><strong>AES criteria, 2006<sup>[2]</sup>&nbsp;</strong></td> <td style=\"vertical-align: middle;\" class=\"highlight_green_text centered divider_bottom\" rowspan=\"7\"><strong>NIH criteria, 1992<sup>[3]</sup></strong>&nbsp;</td> <td style=\"vertical-align: middle;\" class=\"highlight_yellow_text centered divider_bottom\" rowspan=\"4\"><strong>Classic PCOS<sup>[4]</sup>&nbsp;</strong></td> </tr> <tr> <td class=\"indent1\">Clinical and/or biochemical evidence of hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">Evidence of oligo-anovulation</td> </tr> <tr> <td class=\"indent1\">Ultrasonographic evidence of a polycystic ovary</td> </tr> <tr> <td class=\"subtitle1_single\">Phenotype 2 (hyperandrogenic anovulation)</td> </tr> <tr> <td class=\"indent1\">Clinical and/or biochemical evidence of hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">Evidence of oligo-anovulation</td> </tr> <tr> <td class=\"subtitle1_single\">Phenotype 3 (ovulatory PCOS)</td> </tr> <tr> <td class=\"indent1\">Clinical and/or biochemical evidence of hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">Ultrasonographic evidence of a polycystic ovary</td> </tr> <tr> <td class=\"subtitle1_single\">Phenotype 4 (non-hyperandrogenic PCOS)</td> </tr> <tr> <td class=\"indent1\">Evidence of oligo-anovulation</td> </tr> <tr> <td class=\"indent1\">Ultrasonographic evidence of a polycystic ovary</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Specification of phenotype was proposed in a workshop convened by the National Institutes of Health (NIH) in 2012.<SUP>[5]</SUP> The four phenotypes are listed here in order of decreasing diagnostic specificity. The specificity of the two least severe phenotypes is successively less. Each set of diagnostic criteria requires exclusion of other causes of hyperandrogenism and anovulation.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; AES:&nbsp;Androgen&nbsp;Excess Society;&nbsp;NIH: National Institutes of Health.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;<li>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19.</li>&#xD;&#xA;<li>Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91:4237.</li>&#xD;&#xA;<li>Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Dunaif A, Givens JR, Haseltine FP, Merriam GE (Eds), Blackwell Scientific Inc., Boston 1992. p.377.</li>&#xD;&#xA;<li>Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.</li>&#xD;&#xA;<li>Johnson TRB, Kaplan LK, Ouyang P, Rizza RA. Evidence-based methodology workshop on polycystic ovary syndrome, 2012. Executive Summary. Available at: http://prevention.nih.gov/workshops/2012/pcos/docs/FinalReport.pdf (Accessed on December 24, 2013).</li></ol></div><div id=\"graphicVersion\">Graphic 91893 Version 2.0</div></div></div>"},"91894":{"type":"graphic_table","displayName":"Differential diagnosis of hyperandrogenism in adolescents","title":"Differential diagnosis of hyperandrogenism in adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hyperandrogenism in adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiologic adolescent anovulation&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Functional gonadal hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">PCOS: primary functional ovarian hyperandrogenism (common form of polycystic ovary syndrome)</td> </tr> <tr> <td class=\"sublist2_start\">Secondary functional ovarian hyperandrogenism</td> </tr> <tr> <td class=\"sublist2\">Virilizing congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"sublist2\">Adrenal rests of the ovary&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Syndromes of severe insulin resistance</td> </tr> <tr> <td class=\"sublist2\">Acromegaly</td> </tr> <tr> <td class=\"sublist2\">Epilepsy &#177; valproic acid therapy</td> </tr> <tr> <td class=\"indent1\">Ovarian steroidogenic blocks</td> </tr> <tr> <td class=\"indent1\">Disorders of sex development</td> </tr> <tr> <td class=\"indent1\">Pregnancy-related hyperandrogenism</td> </tr> <tr> <td class=\"subtitle1_single\">Functional adrenal hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">PCOS: primary functional adrenal hyperandrogenism (uncommon form of polycystic ovary syndrome)</td> </tr> <tr> <td class=\"indent1\">Virilizing congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"sublist2_start\">Other glucocorticoid-suppressible functional adrenal hyperandrogenism</td> </tr> <tr> <td class=\"sublist2\">Prolactin excess</td> </tr> <tr> <td class=\"sublist2\">Cortisone reductase deficiency (and apparent cortisone reductase deficiency)</td> </tr> <tr> <td class=\"sublist2\">Dehydroepiandrosterone sulfotransferase deficiency, apparent&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Glucocorticoid-nonsuppressible functional adrenal hyperandrogenism&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Cushing syndrome&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Glucocorticoid resistance&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Peripheral androgen overproduction</td> </tr> <tr> <td class=\"indent1\">Obesity </td> </tr> <tr> <td class=\"indent1\">Idiopathic hyperandrogenism </td> </tr> <tr> <td class=\"indent1\">Portohepatic shunting</td> </tr> <tr> <td class=\"subtitle1_single\">Virilizing tumors (adrenal or ovarian)</td> </tr> <tr> <td class=\"subtitle1_single\">Androgenic drugs (eg, exogenous androgenic steroids or valproic acid)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div class=\"graphic_reference\">Original figure modified for this publication. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677. Illustration used with the permission of Elsevier Inc. All rights reserved.<br />Updates reflected in the version published in: ​Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136:1154.</div><div id=\"graphicVersion\">Graphic 91894 Version 6.0</div></div></div>"},"91907":{"type":"graphic_table","displayName":"Factors governing O2 supply and demand in myocardial ischemia","title":"Myocardial ischemia: Factors governing O<sub>2</sub> supply and demand","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myocardial ischemia: Factors governing O<sub>2</sub> supply and demand</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Factors that &#8595; O<sub>2</sub> supply</td> </tr> <tr> <td class=\"indent1\">&#8593; Heart rate*</td> </tr> <tr> <td class=\"indent1\">&#8595; Arterial O<sub>2</sub> content</td> </tr> <tr> <td class=\"indent2\">&#8595; Hemoglobin</td> </tr> <tr> <td class=\"indent2\">&#8595; <span style=\"color: black;\">SaO<sub>2</sub></span></td> </tr> <tr> <td class=\"indent1\">&#8595; Coronary blood flow</td> </tr> <tr> <td class=\"indent2\">&#8595; Coronary perfusion pressure (CPP) = DBP - LVEDP</td> </tr> <tr> <td class=\"indent3\">&#8595; Diastolic blood pressure (DBP)</td> </tr> <tr> <td class=\"indent3\">&#8593; Left ventricular end-diastolic pressure (LVEDP)</td> </tr> <tr> <td class=\"indent2\">&#8593; Coronary vascular resistance</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Factors that &#8593; O<sub>2</sub> demand</td> </tr> <tr> <td class=\"indent1\">&#8593; Heart rate*</td> </tr> <tr> <td class=\"indent1\">&#8593; LV systolic wall stress (LV afterload)</td> </tr> <tr> <td class=\"indent2\"><strong>&#8593;</strong> systolic blood pressure (SBP)</td> </tr> <tr> <td class=\"indent2\"><strong>&#8593;</strong> LV chamber size (&#8593; LV end-diastolic volume [LVEDV])</td> </tr> <tr> <td class=\"indent2\">&#8595; LV wall thickness</td> </tr> <tr> <td class=\"indent1\">&#8593; Contractility</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>A number of clinical conclusions should be drawn from this table. First, increased heart rate (tachycardia) is harmful because it both decreases oxygen supply and increases oxygen demand. Second, severe anemia or severe hypoxemia is harmful because of reduced supply. Third, increases in LVEDV and LVEDP, which often (but not always) occur together, are harmful because of both decreased supply (decreased coronary perfusion pressure [CPP]) and increased demand (afterload). Fourth, the ideal blood pressure is patient-dependent, but severe hypotension is likely to reduce supply (diastolic blood pressure [DBP]) more than its beneficial effect on demand (SBP). But, conversely, severe hypertension typically increases demand (afterload) more than it improves supply (DBP).</LI>&#xD;&#xA;<LI>Left ventricular (LV) afterload is best defined as LV systolic wall stress. Based on Laplace's law, LV systolic wall stress = (LV systolic pressure x LV end-diastolic radius) / 2 x LV wall thickness. Therefore, factors that increase LV afterload include increased systolic blood pressure (SBP) and/or increased LV radius or left ventricular end-diastolic volume (LVEDV). Note that the normal (chronic) compensatory response to these hemodynamic changes is for the LV walls to thicken or hypertrophy, which works to normalize systolic wall stress, but requires months or years for change to occur. Therefore, of the hemodynamic variables that often change during the perioperative period, increases in SBP or LVEDV are harmful, owing to their deleterious effects on LV afterload.</LI></UL></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: <FONT color=black>oxygen; <SPAN style=\"COLOR: black\">SaO<SUB>2</SUB></SPAN>: oxygen saturation <SPAN style=\"COLOR: black\">of arterial blood</SPAN>;</FONT> DBP: diastolic blood pressure; LVEDP: left ventricular end-diastolic pressure; LV: left ventricular; SBP: systolic blood pressure; LVEDV: left ventricular end-diastolic volume.<br />* Affects both supply and demand.</div><div class=\"graphic_reference\">Original figure modified for this publication. Royster RL, Butterworth JF IV, Groban L, et al. Cardiovascular Pharmacology. In: Essentials of Cardiac Anesthesia. Kaplan JA (Ed), Saunders Elsevier, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 91907 Version 6.0</div></div></div>"},"91917":{"type":"graphic_table","displayName":"Patient factors affecting pain treatment in older adults","title":"Patient factors affecting pain treatment in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient factors affecting pain treatment in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient factors</td> <td class=\"subtitle1\">Considerations when prescribing analgesic medication</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Medical comorbidities</td> </tr> <tr> <td class=\"indent1\">Constipation</td> <td>For most patients, prescribe a stimulant laxative (eg, senna) when opioids are initiated.</td> </tr> <tr> <td class=\"indent1\">Lower extremity edema, hypertension, congestive heart failure, peptic ulcer disease, renal insufficiency</td> <td>These conditions may be exacerbated by nonsteroidal antiinflammatory drugs. Gabapentin and pregabalin can contribute to lower extremity edema. Renal insufficiency may influence use of and dosing of various analgesics.</td> </tr> <tr> <td class=\"indent1\">Obesity</td> <td>Some medications (eg, gabapentin, pregabalin, tricyclic antidepressants) may contribute to weight gain. </td> </tr> <tr> <td class=\"indent1\">Sleep disturbance</td> <td>Pain may disrupt sleep. Opioids are associated with disruption in sleep architecture.</td> </tr> <tr> <td class=\"indent1\">Difficulty walking/falls</td> <td>Pain may contribute to weakness, difficulty walking, and falls. Patients with underlying mobility problems should be monitored carefully when medications that may cause balance and mobility problems (eg, opioids, pregabalin, gabapentin, tricyclic antidepressants) are prescribed. Ongoing ascertainment of benefit and risk is critical.</td> </tr> <tr> <td class=\"indent1\">Memory loss</td> <td>Pain may contribute to poorer neuropsychological performance. Although effective pain treatment may improve memory, some pain medications (eg, opioids, pregabalin, gabapentin, tricyclic antidepressants) may contribute to confusion. Ongoing assessment of benefits and risks is critical.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychological factors</td> </tr> <tr> <td class=\"indent1\">Depression, anxiety</td> <td>Underlying depression and/or anxiety can impair neuropsychological performance. These issues should be treated as part of pain treatment.</td> </tr> <tr> <td class=\"indent1\">Coping skills</td> <td>Poor coping skills (eg, tendency to catastrophize) can inhibit the efficacy of pain treatment. Patients who do not cope well with chronic pain may benefit from cognitive behavioral therapy (CBT) as part of pain treatment.</td> </tr> <tr> <td class=\"indent1\">Fear of movement (fear-avoidance beliefs)</td> <td>Patients with a history of falls may fear recurrent falls and thus may be reluctant to be mobile. Fear avoidance beliefs (ie, fear of moving because of concerns about exacerbating pain) can be reduced by physical therapy. Referral to a pain psychologist also may be helpful.</td> </tr> <tr> <td class=\"indent1\">Treatment expectancy</td> <td>Patients who believe that treatment will work will likely improve (placebo effect); those who believe that treatment will not work tend not to improve (nocebo effect).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Social factors</td> </tr> <tr> <td class=\"indent1\">Social/caregiver support</td> <td>Social isolation can interfere with the older adult's ability to distract themselves from their pain and thus intensify the pain experience. This may be especially problematic for the older adult with dementia.</td> </tr> <tr> <td class=\"indent1\">Financial status</td> <td>Patients without the financial resources to access recommended treatments will not use them.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 91917 Version 2.0</div></div></div>"},"91921":{"type":"graphic_table","displayName":"CATCH rule ","title":"Canadian Assessment of Tomography for Childhood Head injury (CATCH) rule ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian Assessment of Tomography for Childhood Head injury (CATCH)&nbsp;rule </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">CT of the head is required only for children with minor head injury* and any one of the following findings:</td> </tr> <tr> <td class=\"subtitle2_left\">High risk (need for neurologic intervention)</td> </tr> <tr> <td class=\"indent1\">1. Glasgow Coma Scale score &#60;15 at two hours after injury</td> </tr> <tr> <td class=\"indent1\">2. Suspected open or depressed skull fracture</td> </tr> <tr> <td class=\"indent1\">3. History of worsening headache</td> </tr> <tr> <td class=\"indent1\">4. Irritability on examination</td> </tr> <tr> <td class=\"subtitle2_left\">Medium risk (brain injury on CT scan)</td> </tr> <tr> <td class=\"indent1\">5. Any sign of basal skull fracture (eg, hemotympanum, \"raccoon\" eyes, otorrhea or rhinorrhea of the cerebrospinal fluid, Battle's sign)</td> </tr> <tr> <td class=\"indent1\">6. Large, boggy hematoma of the scalp</td> </tr> <tr> <td class=\"indent1\">7. Dangerous mechanism of injury (eg, motor vehicle crash, fall from elevation &#8805;3 ft [&#8805;91 cm] or 5 stairs, fall from bicycle with no helmet)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Minor head injury is defined as injury within the past 24 hours associated with witnessed loss of consciousness, definite amnesia, witnessed disorientation, persistent vomiting (more than one episode) or persistent irritability (in a child under two years of age) in a patient with a Glasgow Coma Scale score of 13-15.</div><div class=\"graphic_reference\">Reproduced with permission from: Osmond MH, Klassen TP, Welss GA, et al. CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ 2010; 182:341. Copyright © 2010 Canadian Medical Association. All rights reserved. This work is protected by copyright and the making of this copy was with the permission of Access Copyright. Any alteration of its content or further copying in any form whatsoever is strictly prohibited unless otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 91921 Version 2.0</div></div></div>"},"91922":{"type":"graphic_table","displayName":"CHALICE rule","title":"The children's head injury algorithm for the prediction of important clinical events (CHALICE) rule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The children's head injury algorithm for the prediction of important clinical events (CHALICE)&nbsp;rule</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1_single\">Computed tomography of the head is required if any of the following criteria are present.</td> </tr> <tr> <td class=\"subtitle2_single\">History</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Witnessed loss of consciousness of &#62;5 min duration </li> <li>History of amnesia (either antegrade or retrograde) of &#62;5 min duration </li> <li>Abnormal drowsiness (defined as drowsiness in excess of that expected by the examining doctor) </li> <li>&#8805;3 vomits after head injury (a vomit is defined as a single discrete episode of vomiting) </li> <li>Suspicion of non-accidental injury (NAI, defined as any suspicion of NAI by the examining doctor) </li> <li>Seizure after head injury in a patient who has no history of epilepsy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Examination</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Glasgow Coma Score (GCS) &#60;14, or GCS &#60;15 if &#60;1 year old </li> <li>Suspicion of penetrating or depressed skull injury or tense fontanelle </li> <li>Signs of a basal skull fracture (defined as evidence of blood or cerebrospinal fluid from ear or nose, panda eyes, Battles sign, haemotympanum, facial crepitus or serious facial injury) </li> <li>Positive focal neurology (defined as any focal neurology, including motor, sensory, coordination or reflex abnormality) </li> <li>Presence of bruise, swelling or laceration &#62;5 cm if &#60;1 year old </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Mechanism</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>High-speed road traffic accident either as pedestrian, cyclist or occupant (defined as accident with speed &#62;40 m/h) </li> <li>Fall of &#62;3 m in height </li> <li>High-speed injury from a projectile or an object </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">If none of the above variables are present, the patient is at low risk of intracranial pathology.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from Archives of Disease in Childhood, Dunning J, Daly JP, Lomas J-P, et al, volume 91, pages 885-891, copyright © 2006, with permission from BMJ Publishing Group Ltd and Dr. Joel Dunning.</div><div id=\"graphicVersion\">Graphic 91922 Version 3.0</div></div></div>"}};